Dubai Final-v20.indd - World Allergy Organization
Dubai Final-v20.indd - World Allergy Organization
Dubai Final-v20.indd - World Allergy Organization
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Final</strong> Program<br />
5–8 December 2010 • WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
<strong>Dubai</strong>, UAE<br />
Asthma and Co-morbid Conditions:<br />
Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
A <strong>World</strong> Federation of <strong>Allergy</strong>, Asthma<br />
& Clinical Immunology Societies<br />
www.worldallergy.org
CANCÚN, MÉXI<br />
<strong>World</strong> <strong>Allergy</strong> Congress<br />
Registration<br />
Open!<br />
Register between now and January 1, 2011 to<br />
receive 10% off of your registration rate!<br />
Just enter the code: WISC2010<br />
when prompted during the<br />
registration process.<br />
http://www.worldallergy.org/<br />
wac2011/registration/<br />
OOOOORR<br />
The <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO) holds its <strong>World</strong> <strong>Allergy</strong><br />
Congress (WAC) every two years. Each Congress attracts over<br />
4,000 professionals working and interested in the field<br />
of allergy, asthma, and clinical immunology and<br />
WORLD ALLERGY<br />
HOTEL ACCOMMODATIONS<br />
CANCÚN, MÉXICO<br />
www.worldallergy.org/wac 20 1 1<br />
Hotels, Travel, and Social<br />
Program Information<br />
other related fields.<br />
WAO will offer a variety of discounted hotel accommodations for attendees. Cancún offers some<br />
of the most comfortable hotels with easy access to the Convention Center.<br />
TRAVEL<br />
The Cancún International Airport (CUN) is served by a large number of international airline<br />
carriers that provide direct service from several major cities, making Cancún one of the easiest<br />
and most affordable destinations to visit.<br />
SOCIAL PROGRAM<br />
Following in the tradition of previous <strong>World</strong> <strong>Allergy</strong> Congresses, an exciting social program is<br />
being planned by members of the Congress Organizing and Local Organizing Committees.<br />
Events will include the Opening Ceremony, Welcome Reception and All Congress Event. Optional<br />
tours will also be available for delegates and accompanying persons.
CO<br />
COImportant Dates<br />
30 June 2011 Early Registration Deadline<br />
30 June 2011 Abstract Submission Deadline<br />
15 July 2011 Late-Breaking Abstract Submission Deadline<br />
31 October 2011 Late Registration Deadline<br />
3 December 2011 On-Site Registration Begins<br />
4-8 December 2011 2011 <strong>World</strong> <strong>Allergy</strong> Congress<br />
CONGRESS<br />
CONGRESS 2011 2011<br />
4-8 4-8 DECEMBER DECEMBER 2011 2011<br />
ICO ICO<br />
Scientific Program<br />
The <strong>World</strong> <strong>Allergy</strong> Congress 2011will feature<br />
a variety of topics and session types<br />
TOPIC SESSION TYPE<br />
Asthma & co-morbid conditions Breakfast Symposia<br />
Debates Plenary Sessions<br />
Drug allergy Meet the Experts<br />
Immunetherapy Hands-On Workshops<br />
Pediatric allergy & asthma New Horizon Sessions<br />
Primary & secondary immunedeficiencies<br />
and allergic diseases<br />
For a full listing and more information about the Scientific Program visit the WAC2011 website.<br />
You may start submitting abstracts to be a part of the program, starting in February 2011!<br />
Keep checking http://www.worldallergy.org/wac2011/abstracts for more information.<br />
A meeting of the<br />
In collaboration with<br />
WAO-1010--417
WElCOmE lEttErs<br />
ruby Pawankar<br />
President Elect, WAO<br />
Conference Organizing<br />
Chair<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
Dear Colleagues,<br />
Welcome to <strong>Dubai</strong> and the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong>’s 1st international scientific Conference!<br />
the theme of this Conference, “Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care,” is<br />
one that, as President of the WAO, i have promised to promote through research and education. As a member of the worldwide<br />
specialty of allergy, asthma and clinical immunology, i would like to encourage a culture in which allergists/immunologists are first<br />
knowledgeable primary care physicians, internists, and pediatricians, and then specialists. Physicians trained in this way should<br />
be able to provide patients with more complete, cost-effective care for asthma and allied allergic and immunologic diseases. they<br />
should be able to diagnose and treat co-morbid conditions. thus, the theme of this Conference is to capture and reflect this vision.<br />
Your participation in this inaugural event will help transform this vision of how we manage allergic diseases into everyday practice.<br />
i wish you a most successful Conference.<br />
richard F. lockey<br />
President, <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO)<br />
On behalf of the WAO Board of Directors<br />
Dear Friends,<br />
We join richard lockey in warmly welcoming you to this meeting. it has been a most rewarding experience organizing this Conference<br />
and developing its scientific program. We are confident that as a participant your experience will be equally energizing for you. the<br />
scientific and educational program is designed to provide a forum for the latest research, reviews of current theory and practice, and<br />
importantly, “hands-on” problem-based learning. it is our hope, that as practitioners, educators, and researchers, you will take away<br />
from this Conference valuable insight into the most effective advances in the diagnosis and management of asthma and its comorbidities<br />
as well as broader aspects of related allergic disorders to meet the challenges of the global unmet needs in this area.<br />
We want to take this opportunity also to thank the exceptionally skilled and committed faculty who are a truly international and<br />
versatile group. A majority of the faculty is presenting more than once covering different session-types and several co-morbidities<br />
– demonstrating in this range the true meaning of the theme of this Conference: “Asthma and Co-morbid Conditions: Expanding the<br />
Practice of <strong>Allergy</strong> for Optimal Patient Care”.<br />
An equally important part of learning occurs outside the sessions when we have the important opportunity to meet up with<br />
colleagues to exchange ideas, make new connections and continue old conversations. We hope you will do plenty of all this. Please<br />
share with us your feedback and ideas so that we can continue to promote excellence in the field of allergy and asthma.<br />
Once again: Welcome!<br />
sincerely,<br />
g. Walter Canonica<br />
Past President, WAO<br />
Executive Chair,<br />
scientific Program<br />
Committee<br />
Eric Bateman<br />
Co-Chair,<br />
scientific Program<br />
Committee<br />
Stephen T. Holgate<br />
member-at-large,<br />
WAO Board<br />
Co-Chair,<br />
scientific Program<br />
Committee<br />
robert lemanske<br />
Co-Chair,<br />
scientific Program<br />
Committee<br />
www.worldallergy.org 2<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
On behalf of the <strong>Dubai</strong> Health Authority, i would like to welcome you to the <strong>World</strong> <strong>Allergy</strong> Organisation’s (WAO’s) inaugural<br />
international scientific Conference that is taking place in <strong>Dubai</strong> from the 5th to the 8th of December, 2010 at the <strong>Dubai</strong> international<br />
Convention and Exhibition Centre<br />
As a strategic and principle health authority for the Emirate of <strong>Dubai</strong>, the DHA is responsible for securing and policing the very best<br />
healthcare standards in <strong>Dubai</strong> and is also responsible for developing the future direction of health policy here in <strong>Dubai</strong>.<br />
Hosting, attending and speaking at congresses such as this are an important part of our vision as we continue to develop<br />
healthcare policies that meet the requirements of our population, now and in the future.<br />
the Conference programme highlights a range of issues and areas of interests that will be explored over the next few days. this<br />
is reflected in the number of eminent healthcare professionals from around the world who will be joining and speaking at the<br />
Conference.<br />
this is a platform where international and local eminent speakers will get an opportunity to discuss and understand the latest in the<br />
diagnosis and management of asthma and its co-morbidities.<br />
the forum shall help healthcare professionals interact with colleagues, regional leaders and world experts in the field, thus updating<br />
their knowledge.<br />
With this, i wish you all the best and i hope you enjoy the Conference.<br />
His Excellency Qadhi saeed Al murooshid<br />
Director general of the <strong>Dubai</strong> Health Authority<br />
www.worldallergy.org 3<br />
FinAl PrOgrAm
tABlE OF COntEnts<br />
About the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO) . . . . . . . . . . . . 5-6<br />
WAO member societies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7<br />
Welcome to <strong>Dubai</strong>!. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9<br />
general information, A-Z . . . . . . . . . . . . . . . . . . . . . . . . 10-11<br />
Conference information, A-Z . . . . . . . . . . . . . . . . . . . . . 13-16<br />
<strong>Dubai</strong> international Convention and<br />
Exhibition Centre Floorplans. . . . . . . . . . . . . . . . . . . . . . 16-17<br />
Hotels map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19<br />
Optional tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20<br />
Exhibition Floorplan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22<br />
Exhibitor Directory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23-26<br />
Program-at-a-glance. . . . . . . . . . . . . . . . . . . . . . . . . . . 29-32<br />
scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33-52<br />
Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54-76<br />
Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78-162<br />
speaker and Chairperson index . . . . . . . . . . . . . . . . . 163-164<br />
Poster Author index . . . . . . . . . . . . . . . . . . . . . . . . . . 165-169<br />
sponsors & Partners . . . . . . . . . . . . . . . . . . . . . . . Back Cover<br />
<strong>World</strong> allergy organization (Wao) Secretariat<br />
555 E. Wells st., suite 1100<br />
milwaukee, Wi 53202 UsA<br />
Phone: +1 414 276 1791<br />
Fax: +1 414 276 3349<br />
E-mail: info@worldallergy.org<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
COmmittEEs<br />
WAO BOArD OF DirECtOrs 2010-2011<br />
richard F. lockey, President<br />
mario sanchez Borges, treasurer<br />
lanny J. rosenwasser, secretary-general<br />
ruby Pawankar, President-Elect<br />
g. Walter Canonica, Past-President<br />
michael A. Kaliner, Historian<br />
ignacio Ansotegui<br />
michael Blaiss<br />
thomas B. Casale<br />
motohiro Ebisawa<br />
Yehia El-gamal<br />
sandra gonzalez-Diaz<br />
tari Haahtela<br />
stephen t. Holgate<br />
Juan Carlos ivancevich<br />
marek l. Kowalski<br />
Hae-sim Park<br />
Paul C. Potter<br />
tatiana slavyanskaya<br />
myron Zitt<br />
2010 WAO intErnAtiOnAl sCiEntiFiC COnFErEnCE<br />
OrgAniZing COmmittEEs<br />
Conference President<br />
richard F. lockey<br />
Conference organizing<br />
Chair<br />
ruby Pawankar<br />
Scientific Program<br />
Executive Committee<br />
g. Walter Canonica, Executive<br />
Chair<br />
Eric Bateman, Co-Chair<br />
stephen t. Holgate, Co-Chair<br />
robert lemanske, Co-Chair<br />
local organizing<br />
Committee<br />
ruby Pawankar, Chair<br />
Bassam mahboub, Co-Chair<br />
mona Al Ahmad, Co-Chair<br />
suleiman Al Hammadi<br />
saleh Al muhsen<br />
salem Al tamemi<br />
Abdulla ibrahim<br />
regional advisor<br />
Yehia El-gamal<br />
regional advisory Committee<br />
Hani Ababneh<br />
malek Abdulalim<br />
Yousef Abdulrazzaq<br />
Abdulrahman Al Frayh<br />
Harb Al Harfi<br />
Jamil Al mughales<br />
mirza Al sayegh<br />
Adel Al Wahadneh<br />
shirina Al souwaidi<br />
Zeinab Awad<br />
Zeina Baz<br />
Abdenour Benyounes<br />
Habib Douagui<br />
mohamad Ehlayel<br />
Ahmed Elbousify<br />
Youness El gueddari<br />
Kamal Hanna<br />
syed Hasnain<br />
Elham Hossny<br />
lubna Hwejeh<br />
Omer Kalayci<br />
Ali Ben Kheder<br />
Andreas liveris<br />
Yousser mohamed<br />
mostafa moin<br />
mohammad reza masjedi<br />
menachem rottem<br />
Fadhel saleh<br />
Zineb sayah<br />
Arzu Yorgancioglu<br />
Fares Zaitoun<br />
www.worldallergy.org 4<br />
FinAl PrOgrAm
ABOUt WAO<br />
the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO) is a global federation<br />
of 84 regional and national allergy, asthma and clinical<br />
immunology societies. through collaboration with its member<br />
societies, WAO provides a wide range of educational and<br />
outreach programs to WAO individual members around the<br />
globe. these programs, relating to the clinical practice of<br />
allergy and asthma, allergy and asthma service provision, and<br />
physician training in allergy and asthma help better understand<br />
and address the challenges facing allergists worldwide.<br />
missiOn<br />
WAO’s mission is to be a global resource and advocate in the<br />
field of allergy, advancing excellence in clinical care through<br />
education, research and training as a worldwide alliance of<br />
allergy, asthma and clinical immunology societies.<br />
mEEtings<br />
<strong>World</strong> allergy Congress (WaC)<br />
WAO hosts the <strong>World</strong> <strong>Allergy</strong> Congress (WAC) – its main<br />
scientific meeting – biennially in different regions of the world.<br />
Please join us in Cancún, méxico in 2011, rome, italy in 2013<br />
and seoul, Korea in 2015. For more details on WAC 2011 in<br />
Cancún, please visit www.worldallergy.org/wac2011<br />
Wao international Scientific Conference<br />
WAO is excited to launch its theme-based scientific Conference,<br />
alternating with and complementing WAO’s biennial Congress.<br />
it is with great pleasure that we welcome you to the 1st WAO<br />
international scientific Conference on Asthma and Co-morbid<br />
Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient<br />
Care in <strong>Dubai</strong>, UAE, 5-8 December 2010.<br />
WAO WEBsitE<br />
www.worldallergy.org<br />
As a leading global online destination for allergy, asthma and<br />
clinical immunology, www.worldallergy.org supports and<br />
enhances all WAO educational activities and provides materials<br />
specifically designed for continued medical training. Popular<br />
resources include the specially commissioned educational<br />
synopses on major topics posted in the Allergic Diseases<br />
Resource Center, interactive case studies that challenge<br />
allergists to diagnose unusual cases, an archive of webinars<br />
recorded at major meetings, and audio recordings of interviews<br />
with key opinion leaders around the world. the WAO website is<br />
now HOncode certified.<br />
tHE WOrlD AllErgY OrgAniZAtiOn JOUrnAl<br />
www.waojournal.org<br />
The <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> Journal (WAO Journal) is the<br />
official publication of WAO and underscores WAO’s commitment<br />
to raising awareness and advancing excellence in clinical care,<br />
education, research and training. this international, peerreviewed<br />
journal covers a broad spectrum of the interdisciplinary<br />
fields of allergy and clinical immunology. As an online-only<br />
journal, the publication process of the WAO Journal is efficient<br />
and quick, with articles posted each month on schedule. All WAO<br />
members have free access to the WAO Journal.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
the primary goals of the WAO Journal are:<br />
• to be a premier journal of original scientific and clinically<br />
relevant information for practicing allergists/immunologists<br />
and other physicians concerned with the practice of allergy<br />
and clinical immunology<br />
• to publish state-of-the-art review articles and editorials on<br />
translational and clinical medicine in the field of allergy and<br />
immunology<br />
• to present a forum for scientific interaction between<br />
allergists and immunologists worldwide<br />
WAO PrOgrAms FOr EDUCAtiOn,<br />
rEsEArCH AnD PAtiEnt CArE<br />
global resources in allergy (gloria)<br />
glOriA promotes best practices in the management of allergic<br />
disease through didactic programs developed by international<br />
experts. glOriA is presented at national and regional allergy<br />
society meetings throughout the world and also at regional,<br />
state and local society meetings within the United states. All<br />
current glOriA modules are available for free download at<br />
www.worldallergy.org/gloria<br />
<strong>World</strong> allergy Forum ® (WaF)<br />
WAF brings cutting edge symposia to major allergy meetings<br />
throughout the world. Developed by international expert<br />
advisory panels, the symposia provide up-to-the minute<br />
presentations on scientific and clinical developments in the<br />
field of allergic disease. WAF placements attract up to 1,000<br />
attendees. WAF is supported by an unrestricted educational<br />
grant from novartis. View presentations for free at<br />
www.worldallergy.org/waf<br />
Emerging Societies Program (ESP)<br />
EsP advances the WAO mission by supporting developments<br />
that enable allergists to better serve patients now and in the<br />
future. EsP aims to disseminate information on and share<br />
experiences about new treatments for allergic disease and<br />
about new indications for available therapies. All EsP meetings<br />
and training schools are conducted with the help and support<br />
of WAO member societies. the American College of <strong>Allergy</strong>,<br />
Asthma and immunology (ACAAi) partners with WAO on EsP.<br />
View all EsP activities at www.worldallergy.org/esp<br />
WAO PrOJECts AnD PUBliCAtiOns<br />
www.worldallergy.org/publications<br />
anaphylaxis:<br />
• “Epinephrine: the drug of choice for anaphylaxis.” Kemp<br />
st, lockey rF, simons FEr, was published in 2008 (<strong>Allergy</strong>,<br />
2008, 63:1061-1070), and reproduced as an e-supplement<br />
to the WAO Journal. Available at www.waojournal.org<br />
• “Epinephrine auto-injectors: first-aid treatment still out of<br />
reach for many at risk of anaphylaxis in the community.”<br />
simons FEr, et al, for the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong>. (Ann<br />
<strong>Allergy</strong> Asthma Immunol, 2009, 102: 403-409)<br />
• “global availability of medications, supplies and equipment<br />
for the assessment and management of anaphylaxis by<br />
physicians in healthcare settings.” simons, FEr, for <strong>World</strong><br />
<strong>Allergy</strong> <strong>Organization</strong>, in preparation, 2010<br />
www.worldallergy.org 5<br />
FinAl PrOgrAm
ABOUt WAO<br />
Cow’s milk allergy: “the evidence-based WAO global<br />
guidelines on the Diagnosis & rationale for Action Against<br />
Cow’s milk <strong>Allergy</strong>,” authored by the WAO Food <strong>Allergy</strong> special<br />
Committee. (WAO Journal. 2010;3(4):57-161)<br />
immunotherapy: “sub-lingual immunotherapy (slit) -<br />
WAO Position Paper 2009.” slit is an exciting therapeutic<br />
strategy on the delivery of immunotherapy and is gradually<br />
being adopted by allergy communities throughout the world.<br />
Following a first meeting in genoa in november 2008 to review<br />
experience of Us trials of slit, WAO hosted a meeting in Paris<br />
in January 2009 to develop the first global consensus on slit.<br />
All WAO regional & Affiliate member societies were invited to<br />
send representative delegates to this meeting and the majority<br />
were represented. they were joined by delegates representing<br />
non-member organizations including niH, gA2lEn, EFA, iCPrg,<br />
and AriA. A WAO Position Paper based on the Paris meeting was<br />
published in the WAO Journal, and in <strong>Allergy</strong>. (WAO Journal.<br />
2009;2(11):223-281)<br />
the first State of <strong>World</strong> allergy report (SoWar) appeared in<br />
the WAO Journal in June 2008. sOWAr stresses the importance<br />
of providing national allergy services for the burgeoning<br />
numbers of allergy patients in the world. this downloadable,<br />
on-line report is a useful resource for allergists and allergy<br />
societies wishing to make the case for improved local allergy<br />
service provision. Available at: www.waojournal.org. (WAO<br />
Journal. 2008;1(6):51-517)<br />
WAO Position Papers support and promote the specialty of<br />
allergy and help set standards for clinical practice and training:<br />
• “What is an allergist? A position statement of the WAO<br />
specialty and training Council.” 2008 Available at: www.<br />
waojournal.org<br />
• “requirements for physician competencies in allergy: Key<br />
clinical competencies appropriate for the care of patients<br />
with allergic or immunologic diseases—a position statement<br />
of the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong>.” 2008 Available at: www.<br />
waojournal.org<br />
• “recommendations for competency in allergy training<br />
for undergraduates qualifying as medical practitioners –<br />
A position paper of the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong>.” 2009<br />
Available at: www.waojournal.org<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
Wao White Book on allergy is being prepared for launch in<br />
2011. the Executive summary to the WAO White Book is being<br />
launched during the Conference in <strong>Dubai</strong>. the WAO White Book<br />
will be an important resource to help individual allergists and<br />
allergy/immunology societies promote allergic diseases as a<br />
major global public health issue.<br />
WAO mEmBEr sOCiEtY sUrVEYs<br />
WAO’s federal structure provides a unique network to conduct<br />
effective global surveys about allergy and asthma. A number of<br />
projects have taken place over the last two years:<br />
• the WAO specialty and training Council conducted surveys<br />
on general/adult and pediatric clinical allergy services and<br />
training to obtain global information on current and future<br />
allergy service provision.<br />
• Building on the WAO’s 2007 international survey on the<br />
availability of epinephrine auto-injectors worldwide, in 2008<br />
the WAO special Committee on Anaphylaxis conducted<br />
a survey of member societies to gather data on how<br />
anaphylaxis is diagnosed and treated in healthcare settings<br />
in their respective countries. the combined results of<br />
these surveys will form the basis of the WAO international<br />
guidelines for the assessment and management of<br />
anaphylaxis, which was introduced at WAC 2009 and will<br />
launch in 2010.<br />
• the Asthma special Committee conducted a survey of<br />
member societies to find out about the major allergens<br />
involved in exacerbations of severe and chronic asthma,<br />
and to learn whether national definitions of severe asthma<br />
exist. the information obtained will form a WAO educational<br />
program based on the 2009 <strong>World</strong> Health <strong>Organization</strong>’s<br />
definition of severe Asthma.<br />
• the Drug <strong>Allergy</strong> special Committee conducted a survey on<br />
in-vivo methods used in the diagnosis of allergic reactions<br />
to major drug classes. the information obtained will be the<br />
first step to reaching a global consensus about the best way<br />
to diagnose drug hypersensitivity reactions, and to sharing<br />
expertise on this clinical problem.<br />
• the Evidence Based medicine and methodology special<br />
Committee developed a survey to establish allergists’<br />
educational needs in evidence-based medicine.<br />
<strong>World</strong> allergy organization<br />
555 E. Wells st., suite 1100<br />
milwaukee, Wi 53202-3823 UsA<br />
Phone: +1 414 276 1791<br />
Fax: +1 414 276 3349<br />
E-mail: info@worldallergy.org<br />
www.worldallergy.org<br />
www.worldallergy.org 6<br />
FinAl PrOgrAm
WAO mEmBEr sOCiEtiEs<br />
Albanian society of Allergology and Clinical immunology<br />
American Academy of <strong>Allergy</strong>, Asthma and immunology<br />
American College of <strong>Allergy</strong>, Asthma and immunology<br />
Argentine Association of <strong>Allergy</strong> and Clinical immunology<br />
Argentine society of <strong>Allergy</strong> and immunopathology<br />
Australasian society of Clinical immunology and <strong>Allergy</strong><br />
Austrian society of Allergology and immunology<br />
Azerbaijan society for Asthma, <strong>Allergy</strong> and Clinical immunology<br />
Bangladesh society of <strong>Allergy</strong> and immunology<br />
Belgian society of <strong>Allergy</strong> and Clinical immunology<br />
Brazilian society of <strong>Allergy</strong> and immunopathology<br />
British society for <strong>Allergy</strong> and Clinical immunology<br />
Bulgarian society of Allergology<br />
Canadian society of <strong>Allergy</strong> and Clinical immunology<br />
Chilean society of <strong>Allergy</strong> and immunology<br />
Chinese society of Allergology<br />
(Chinese) Hong Kong institute of <strong>Allergy</strong><br />
Colombian <strong>Allergy</strong>, Asthma, and immunology Association<br />
Croatian society of Allergology and Clinical immunology<br />
Cuban society of Allergology<br />
Czech society of Allergology and Clinical immunology<br />
Danish society of Allergology<br />
Egyptian society of <strong>Allergy</strong> and Clinical immunology<br />
Egyptian society of Pediatric <strong>Allergy</strong> and immunology<br />
Finnish society of Allergology and Clinical immunology<br />
French society of Allergology<br />
georgian Association of Allergology and Clinical immunology<br />
german society for Allergology and Clinical immunology<br />
Hellenic society of Allergology and Clinical immunology<br />
Honduran society of <strong>Allergy</strong> and Clinical immunology<br />
Hungarian society of Allergology and Clinical immunology<br />
icelandic society of <strong>Allergy</strong> and immunology<br />
indian College of <strong>Allergy</strong>, Asthma and Applied immunology<br />
indonesian society for <strong>Allergy</strong> and immunology<br />
israel Association of <strong>Allergy</strong> and Clinical immunology<br />
italian Association of territorial and Hospital Allergists<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO), a world federation of allergy, asthma and clinical immunology societies, consists of<br />
84 member societies.<br />
All active members of dues-paying member societies are individual members of the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO).<br />
AssOCiAtE mEmBEr sOCiEtiEs<br />
national Association for Private Algerian<br />
Allergists<br />
Ecuadorian society of <strong>Allergy</strong> and<br />
immunology<br />
Ecuadorian society of Allergology and<br />
Affiliated sciences<br />
Jordanian society for <strong>Allergy</strong> and Clinical<br />
immunology<br />
Kuwait society of <strong>Allergy</strong> and Clinical<br />
immunology<br />
moroccan society of Allergology and<br />
Clinical immunology<br />
swedish Association for Allergology<br />
rEgiOnAl OrgAniZAtiOns<br />
Asia Pacific Association of <strong>Allergy</strong>, Asthma<br />
and Clinical immunology<br />
Commonwealth of independent states<br />
society of immunology and Allergology<br />
European Academy of <strong>Allergy</strong> and Clinical<br />
immunology<br />
latin American society of <strong>Allergy</strong> and<br />
immunology<br />
italian society of <strong>Allergy</strong> and Clinical immunology<br />
Japanese society of Allergology<br />
Korean Academy of <strong>Allergy</strong>, Asthma and Clinical immunology<br />
latvian Association of Allergists<br />
lebanese society of <strong>Allergy</strong> and immunology<br />
malaysian society of <strong>Allergy</strong> and immunology<br />
mexican College of Clinical immunology and <strong>Allergy</strong><br />
mexican College of Pediatricians specialized in <strong>Allergy</strong> and<br />
Clinical immunology<br />
mongolian society of Allergology<br />
netherlands society of Allergology<br />
norwegian society of Allergology and immunopathology<br />
Panamanian Association of Allergology and Clinical immunology<br />
Paraguayan society of immunology and <strong>Allergy</strong><br />
Peruvian society of <strong>Allergy</strong> and immunology<br />
Philippine society of <strong>Allergy</strong>, Asthma and immunology<br />
Polish society of Allergology<br />
Portuguese society of Allergology and Clinical immunology<br />
romanian society of Allergology and Clinical immunology<br />
russian Association of Allergology and Clinical immunology<br />
serbian Association of Allergologists & Clinical immunologists<br />
<strong>Allergy</strong> and Clinical immunology society (singapore)<br />
slovenian Association for Allergology and Clinical immunology<br />
<strong>Allergy</strong> society of south Africa<br />
spanish society of Allergology and Clinical immunology<br />
<strong>Allergy</strong> & immunology society of sri lanka<br />
swiss society for Allergology and immunology<br />
<strong>Allergy</strong>, Asthma and immunology society of thailand<br />
turkish national society of <strong>Allergy</strong> and Clinical immunology<br />
Ukrainian Association of Allergologists and Clinical<br />
immunologists<br />
Uruguayan society of Allergology<br />
Venezuelan society of <strong>Allergy</strong> and immunology<br />
Vietnam Association of <strong>Allergy</strong>, Asthma and Clinical immunology<br />
Zimbabwe <strong>Allergy</strong> society<br />
AFFiliAtE OrgAniZAtiOns<br />
gA²lEn (global <strong>Allergy</strong> and Asthma<br />
European network)<br />
international Association of Asthmology<br />
international Primary Care respiratory<br />
group<br />
southern European <strong>Allergy</strong> societies<br />
Apply for your national <strong>Allergy</strong> society to become a WAO member society at www.worldallergy.org/wao_societies/apply.php<br />
www.worldallergy.org 7<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
WElComE To THE WorlD allErgY organiZaTion (Wao)<br />
inTErnaTional SCiEnTiFiC ConFErEnCE!<br />
5–8 DECEmBEr 2010<br />
VEnUE<br />
the venue for the Conference is the <strong>Dubai</strong> international<br />
Convention and Exhibition Centre (DiCEC). the DiCEC<br />
offers world class exhibition and convention facilities and<br />
is centrally located.<br />
<strong>Dubai</strong> international Convention and Exhibition Centre<br />
(DiCEC)<br />
sheikh Zayed road<br />
PO Box 9292<br />
<strong>Dubai</strong><br />
United Arab Emirates<br />
tel: +971 4 332 1000<br />
Fax: +971 4 318 8741<br />
Website: www.dwtc.com<br />
WElComE To DUBai, UaE!<br />
<strong>Dubai</strong> is the second largest of the seven emirates that make up the United Arab Emirates. located on the southern shore<br />
of the beautiful Arabian gulf, <strong>Dubai</strong> is a city-state, replete with clean, sandy beaches and clear, blue-green waters. it has<br />
an ancient islamic heritage that survives amidst the skyscrapers and highways of a modern, cosmopolitan city of almost<br />
1.4 million people. this ‘Pearl of the Arabian gulf,’ concentrated mainly on its exquisite Creek, the fi nest natural shelter in<br />
1600 km (1000 miles) of coastline, ranks as the United Arab Emirates’ most important port and commercial center.<br />
With great underwater visibility and lots of sea life, snorkeling is a popular pastime in <strong>Dubai</strong>, as is quad biking in the<br />
desert, camel riding, and deep-sea fi shing and windsurfi ng. With a number of challenging golf courses, some with<br />
gorgeous views of the Creek, and the desert, there is plenty of choice in <strong>Dubai</strong> for the avid golfer.<br />
the several large shopping malls in <strong>Dubai</strong> provide an exciting variety of shops to choose from. shoppers can fi nd the best<br />
in designer labels and some fantastic bargains. there are local souks for those who do not wish to go to the malls, which<br />
offer local merchandise ranging from clothes and fabrics to regional food and fruit, woodcarvings and handicrafts.<br />
www.worldallergy.org 9<br />
FinAl PrOgrAm
gEnErAl inFOrmAtiOn, A-Z<br />
BAnKs/Atm (AUtOmAtiC tEllEr mACHinEs):<br />
HOW DO YOU PAY?<br />
many international banks are represented by branches in <strong>Dubai</strong>.<br />
Bank hours vary but in general are 08:00 to 14:00, sunday to<br />
thursday and 08:00 to 12:00, saturday.<br />
Credit cards (American Express, Diners Club, master Card and<br />
Visa) and debit cards (Visa Electron) are widely accepted in all<br />
the shopping malls, supermarkets and many of the stand-alone<br />
shops. However, most of the smaller grocery stores and shops<br />
in the souks generally take cash. should you need to convert<br />
foreign currency into local currency, there are money exchanges<br />
and banks all over the city and in hotels. Atms are also located<br />
in most hotels and malls.<br />
Emirates Bank international ltd and national Bank of <strong>Dubai</strong> are<br />
located within the <strong>Dubai</strong> international Convention and Exhibition<br />
Centre (DiCEC), hours are 08:00 to 13:00 for Emirates Bank and<br />
national Bank of <strong>Dubai</strong>, daily except Fridays. Atm machines can<br />
be found on Concourses 1 and 2.<br />
BArgAining<br />
Bargaining is expected in the souk (market) and is quite usual<br />
elsewhere. Vendors will usually drop the price and often quite<br />
substantially, particularly for a cash sale.<br />
BUsinEss HOUrs<br />
Business: 08:00-13:00 and 16:00-19:30, sunday to thursday.<br />
most of the multinational companies work from 09:00-18:00<br />
with a one-hour lunch break.<br />
Government offices: 07:30-14:30, sunday to thursday.<br />
Exchange houses: 10:00-22:00.<br />
Shopping malls: 10:00-22:00, sunday to Wednesday and<br />
10:00-00:00, thursday and Friday.<br />
ClimAtE<br />
<strong>Dubai</strong> has a sub-tropical, arid climate. sunny, blue skies can be<br />
expected most of the year. rainfall is infrequent and irregular,<br />
falling mainly in winter. temperatures range from a low of about<br />
10.5°C/50°F to a high of 48°C/118°F.<br />
COmmUniCAtiOns<br />
the international dialing code for in-coming calls is +9714.<br />
Calls to and from land-lines within <strong>Dubai</strong> are free of charge<br />
and direct dialing is possible to more than 170 countries.<br />
gPrs and WAP services are also available. A gsm international<br />
roaming service for mobile phones is available for more than<br />
60 countries. if your country isn’t one of them, then a service<br />
known as “Wasel” is available. Bring your phone or buy it here<br />
and purchase a sim card (available at most supermarkets,<br />
petrol stations and hotels), which enables you to make and<br />
receive calls from the UAE. internet services are also available<br />
for nonsubscribers from regular phone lines.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
CUrrEnCY<br />
the currency in <strong>Dubai</strong> is the UAE Dirham (AED). notes are in<br />
denominations of AED 1,000, 500, 200, 100, 50, 20, 10 and 5.<br />
Coins are in denominations of AED 1, and 50, 25, 10 and 5 fils.<br />
Exchange rates, as of October 2010:<br />
£1.00 = AED 5.78<br />
$1.00 = AED 3.67<br />
€1.00 = AED 5.13<br />
ElECtriCitY<br />
the voltage in the United Arab Emirates is 220 / 240 volts A / C<br />
at 50 cycles.<br />
lAngUAgE<br />
Arabic is the official language of <strong>Dubai</strong>, although English,<br />
malayalam, Hindi, Urdu, Bengali, tamil, Persian, tagalog,<br />
Chinese and other languages are also spoken.<br />
rEstAUrAnts<br />
there are many restaurants/cafés located in the DiCEC<br />
including:<br />
• loop Café: Exhibition Hall 8, Concourse 2<br />
(opposite Emirates bank)<br />
Hours: 07:00 to 18:00 - saturday to thursday<br />
• Hub: Opposite Hall 6, Concourse 2, in between both sheikh<br />
rashid Hall’s entrances<br />
Hours: 08:00 to 18:00 - saturday to thursday<br />
• Za’abeel Bistro & Za’abeel Café: Za’abeel Hall<br />
Hours: 08:00 to 17:00 - saturday to thursday<br />
• round table Pizza: Exhibition Hall 2, Concourse 1<br />
Hours: 07:00 to 23:00 - saturday to Friday<br />
• tea leaf & Coffee bean: Exhibition Hall 1, Concourse 1<br />
Hours: 07:00 to 23:00 - saturday to Friday<br />
• Café nero: trade Centre Plaza<br />
Hours: 06:00 to 19:00 - saturday to Friday<br />
• Japengo: trade Centre Plaza<br />
Hours: 09:00 to 22:00 - saturday to Friday<br />
• Pizza Express: trade Centre Plaza (Opening soon)<br />
Hours: 10:00 to 01:00 - saturday to Friday<br />
refreshment carts serving a variety of lebanese, Chinese<br />
and indian food as well as sandwiches are available in the<br />
concourse.<br />
For a complete listing of restaurants in <strong>Dubai</strong> city with location,<br />
phone and type of cuisine, please visit the <strong>Dubai</strong> Convention<br />
bureau’s web site:<br />
http://www.definitelydubai.com/im-visiting/where-do-i-eat/<br />
restaurants-dubai<br />
trAVEl<br />
the city is served by <strong>Dubai</strong> international Airport (DXB)—host<br />
to the world’s largest duty free shopping area—situated in the<br />
north central part of the city. <strong>Dubai</strong> international Airport provides<br />
regular flights to and from the UK, Australia, America, Asia and<br />
Europe. more than 80 airlines take advantage of <strong>Dubai</strong>’s open<br />
skies policy, and operate to and from <strong>Dubai</strong> international Airport<br />
to more than 130 destinations, making it one of the world’s<br />
busiest airports.<br />
www.worldallergy.org 10<br />
FinAl PrOgrAm
gEnErAl inFOrmAtiOn, A-Z<br />
tiPPing AnD grAtUitiEs<br />
tipping practices are similar to most other parts of the world.<br />
most restaurants include a 10 percent service charge, but<br />
tipping in general is at the customer’s discretion.<br />
tOUrist inFOrmAtiOn<br />
Please visit the <strong>Dubai</strong> Department of tourism and Commerce<br />
marketing in the Exhibit Hall, sheikh rashid F. they can answer<br />
questions about <strong>Dubai</strong>.<br />
Website: http://www.dubaitourism.ae<br />
trAnsPOrtAtiOn WitHin tHE CitY<br />
to experience this spectacular city to the fullest, you’ll want to<br />
explore. the advanced public transport system means you and<br />
your party can transition effortlessly from business to leisure.<br />
<strong>Dubai</strong> has an advanced public transport system including a<br />
new state-of-the-art metro system, buses and taxis on their<br />
WAO Small Airways Working Group Steering Committee<br />
Lanny J. Rosenwasser, Chair – USA<br />
Monica Kraft, Vice Chair – USA<br />
Leif Bjermer – Sweden<br />
Thomas B. Casale – USA<br />
Leonardo Fabbri – Italy<br />
Qutayba Hamid – Canada<br />
Peter H. Howarth – United Kingdom<br />
Charles Irvin – USA<br />
J. Christian Virchow – Germany<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
multi-lane highways. the newly opened <strong>Dubai</strong> metro will be the<br />
longest fully automated rail network in the world when it is fully<br />
completed in 2010. the red line ‘trade Centre station’ serves<br />
DiCEC, delivering maximum convenience to millions of visitors.<br />
Bus services operate on 62 routes linking various residential<br />
and industrial areas with the two central business districts.<br />
there are fi ve major taxi companies - <strong>Dubai</strong> transport, Cars<br />
taxis, national taxis, metro taxis and Arabia taxis, all equipped<br />
with the latest gPs systems.<br />
About 150 Abras (traditional boats made of wood), transport<br />
people across the <strong>Dubai</strong> Creek seating around 20 passengers<br />
each. they transport approximately 15 million passengers every<br />
year. For yet another option of travel, choose the waterbus<br />
system, a collection of comfortable and stylish boats stopping<br />
at all major tourist attractions along the <strong>Dubai</strong> Creek.<br />
www.worldallergy.org/small_airways_group<br />
Small Airways Disease<br />
Working Group<br />
Search a database of scientific literature<br />
Stay informed with announcements of upcoming live events<br />
Expand your knowledge base with educational resources<br />
on all aspects of small airways disease<br />
www.worldallergy.org 11<br />
FinAl PrOgrAm<br />
WAO-1110-385
ONBREZ ® BREEZHALER ®<br />
Important note: Before prescribing, consult full prescribing information. Presentation: Inhalation powder hard capsules containing indacaterol maleate equivalent to 150 microgram<br />
(mcg) indacaterol; inhalation powder hard capsules containing indacaterol maleate equivalent to 300 mcg indacaterol. Indications: ONBREZ ® BREEZHALER ® is a long-acting beta2-agonist<br />
indicated for longterm, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Dosage: Adults:<br />
recommended dosage is the once-daily inhalation of the content of one 150 mcg capsule using the ONBREZ BREEZHALER inhaler. The dosage should only be increased on medical<br />
advice. Once-daily inhalation of the content of one 300 mcg capsule using the ONBREZ BREEZHALER inhaler, has been shown to provide additional clinical benefit to some patients,<br />
e.g. with regard to breathlessness, particularly for patients with severe COPD. The maximum dose is 300 mcg once-daily. Children (
COnFErEnCE inFOrmAtiOn, A-Z<br />
ABstrACts<br />
Abstracts for the WAO international scientific Conference were<br />
submitted under a variety of different topics related to the theme<br />
of the Conference. All accepted abstracts have been placed in<br />
Poster sessions on 6, 7 and 8 December and are printed in the<br />
back of this <strong>Final</strong> Program. Poster numbers are listed in the<br />
‘Posters’ section of the <strong>Final</strong> Program (pages 54-76). this Poster<br />
number also corresponds to the abstract, which is printed in the<br />
‘Abstract’ section (pages 78-162) of the <strong>Final</strong> Program. For more<br />
information, see “Poster sessions” section.<br />
BADgEs<br />
Each participant will receive a name badge upon check-in at the<br />
registration Desk. the badge will be the official meeting document<br />
and should be worn at all times in order to gain entry to the<br />
Conference rooms. Please note that access to any of the Conference<br />
areas or events will not be possible without an official badge.<br />
in order to comply with security requirements, participants<br />
are expected to wear their badges at all times in all areas.<br />
if you lose your badge, a new one can be purchased at the<br />
registration Desk for $50 UsD with photo identification.<br />
BUsinEss CEntEr<br />
the DiCEC offers a business center, spectrum-Digital Print, for<br />
various business needs. it offers a range of services including printing<br />
and internet access along with internet cards for WiFi access.<br />
Spectrum – Digital Print<br />
DWtC <strong>Dubai</strong> <strong>World</strong> trade Centre<br />
Concourse 1, Between Hall 2 & 3<br />
tel: +971 4 327 5900<br />
Fax: +971 4 327 5166<br />
Email: dwtc@spectrumdubai.com<br />
www.spectrumdubai<br />
Hours: 08:30 to 19:30 - saturday to thursday<br />
CErtiFiCAtE OF AttEnDAnCE<br />
Certificates of Attendance will be available on 7th and 8th<br />
December at the registration Desk. After the Conference is<br />
over, you may request a Certificate of Attendance by emailing a<br />
request to lori@actionreg.com. Your request should include your<br />
name badge number.<br />
COntinUing mEDiCAl EDUCAtiOn (CmE) CrEDits<br />
the WAO international scientific Conference is accredited by<br />
the European Accreditation Council for Continuing medical<br />
Education (EAAACmE) and the Faculty of medicine & Health<br />
sciences (FmHs) at the UAE University. All CmE Certificates will<br />
be distributed by email after the Conference. Please be sure to<br />
fill out the CmE self-reporter with your correct email address,<br />
which is included in your registration bag.<br />
European accreditation Council for Continuing medical<br />
Education (EaaCmE)<br />
the WAO international scientific Conference is accredited by<br />
the European Accreditation Council for Continuing medical<br />
Education (EAACmE) to provide a CmE activity for medical<br />
specialists attending the Conference. the goal of a CmE system<br />
is to assure a high level of theoretic and clinical competence<br />
throughout the working life of medical specialists.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
the WAO international scientific Conference has been<br />
designated for a maximum of 24 hours of European external<br />
CmE credits.<br />
Division of CmE Credits:<br />
sunday, 5 December: 6 hours<br />
monday, 6 December: 6 hours<br />
tuesday, 7 December: 6 hours<br />
Wednesday, 8 December: 6 hours<br />
EACCmE credits are recognized by the American medical<br />
Association (AmA) toward the Physician’s recognition Award.<br />
to convert EACCmE to AmA PrA category 1 credit, contact the<br />
AmA, telephone 1-800-621-8335 or 1-312-464-4941. Us<br />
doctors do not automatically earn CmE credits unless they<br />
contact the AmA.<br />
noTE: in order to receive your CmE certificate by email, please<br />
fill out the CmE self-reporter Form that is included in your<br />
Conference bag. CmE self-reporter Forms should be returned<br />
to the registration Desk, located outside sheikh rashid E.<br />
United arab Emirates Continuing medical Education Credits<br />
UAE CmE will be provided by the Faculty of medicine & Health<br />
sciences (FmHs), UAE University.<br />
FmHs accredits CmE events for CmE providers in the UAE.<br />
these are recognized by all the medical bodies in the UAE.<br />
the WAO international scientific Conference has been<br />
designated for a maximum of 33 hours of UAE CmE.<br />
Division of CmE Credits:<br />
sunday, 5 December: 7 hours<br />
monday, 6 December: 9.5 hours<br />
tuesday, 7 December: 9 hours<br />
Wednesday, 8 December: 7.5 hours<br />
noTE: in order to receive your CmE certificate by email, please<br />
fill out the CmE self-reporter Form that is included in your<br />
Conference bag. CmE self-reporter Forms should be returned<br />
to the registration Desk, located outside sheikh rashid E.<br />
COAt/PACKAgE CHECK<br />
the cloakroom is located near the Convention gate Entrance.<br />
Hours<br />
sunday, 5 December: 07:00 – 22:00<br />
monday, 6 December: 07:00 – 18:30<br />
tuesday, 7 December: 07:00 – 18:30<br />
Wednesday, 8 December: 07:00 – 16:00<br />
Price<br />
AED 20.00 per item<br />
no item should be left in the luggage room overnight. Any items<br />
not collected within the opening hours will be kept overnight at<br />
the DWtC lost & Found Office at an additional charge of AED<br />
50.00 per day per item.<br />
COFFEE BrEAKs<br />
Coffee breaks are included in the registration fee for Delegates,<br />
students, nurses and Accompanying Persons. morning and<br />
afternoon coffee breaks will take place in the 1 st floor foyer on<br />
5 December and in sheikh rashid F on 6, 7, and 8 December.<br />
www.worldallergy.org 13<br />
FinAl PrOgrAm
COnFErEnCE inFOrmAtiOn, A-Z<br />
DisClAimEr<br />
WAO will not be held liable for personal injuries or for loss<br />
or damage to property incurred by participants or guests at<br />
the WAO international scientific Conference, including those<br />
participating in tours and social events. Participants and guests<br />
are encouraged to purchase insurance to cover loss incurred<br />
in the event of cancellation, medical expenses or damage to<br />
or loss of personal effects when traveling outside of their own<br />
countries.<br />
WAO cannot be held liable for any hindrance to or disruption of<br />
the international scientific Conference proceedings arising from<br />
natural, political, social or economic events or other unforeseen<br />
incidents beyond its control. registration of a participant implies<br />
acceptance of this condition.<br />
the materials presented at this continuing medical education<br />
activity are made available for educational purposes only. the<br />
materials are not intended to represent the only, nor necessarily<br />
best, methods or procedures appropriate for the medical<br />
situations discussed, but rather are intended to present an<br />
approach, view, statement, or opinion of the faculty that may be<br />
helpful to others who face similar situations.<br />
DrEss<br />
Dress for the Conference is business casual.<br />
EmErging sOCiEtiEs PrOgrAm-WOrlD AllErgY<br />
trAining sCHOOl (EsP-WAts) lEVEl 2<br />
the Emerging societies Program (EsP), a joint initiative of<br />
the WAO and the American College of <strong>Allergy</strong>, Asthma and<br />
immunology (ACAAi), is hosting a level 2 <strong>World</strong> <strong>Allergy</strong> training<br />
school (WAts) Course at the WAO international scientific<br />
Conference on 5 December 2010. this WAts level 2 is a<br />
follow-up to the very successful WAts level 1 held in <strong>Dubai</strong><br />
in march 2009. the EsP Council has identified specific<br />
Postgraduate Courses as WAts level 2 Courses. these courses<br />
are denoted in the preliminary program with “WAts 2.”<br />
the objectives of the WAts are the following:<br />
• to educate and update young physicians in the practice<br />
of allergic diseases by disseminating state-of-the-art<br />
knowledge on the basic and clinical aspects of allergic<br />
diseases and enhancing practical knowledge and skills in the<br />
diagnosis and treatment of allergic diseases<br />
• to help in capacity building by training representatives<br />
from various countries in the diagnosis and management of<br />
allergic diseases<br />
• to provide a platform where world class experts can lecture<br />
and interact with young physicians<br />
• to stimulate interest in young physicians to pursue the<br />
specialty of allergy and thus increase the number of allergists<br />
WAts Postgraduate Courses are available to all registered<br />
delegates.<br />
EVAlUAtiOns<br />
Conference evaluation forms are included in the registration bag.<br />
Your feedback is very important to us and we encourage you to<br />
complete your evaluation. Please fill out your form and return it to<br />
the registration Desk, located outside sheikh rashid E.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
EXHiBitiOn<br />
A commercial exhibition will take place on the following dates<br />
and times in sheikh rashid F:<br />
sunday, 5 December: 20:00 - 22:00<br />
monday, 6 December: 09:00 - 18:30<br />
tuesday, 7 December: 09:00 - 17:00<br />
Wednesday, 8 December: 09:00 - 13:30<br />
the Exhibit Hall map and Directory are listed on pages 22-26 of<br />
the <strong>Final</strong> Program.<br />
Admittance into the Exhibit Hall is included in the registration rate<br />
for Delegates, nurses, students and Accompanying Persons. An<br />
official badge is required for entry into the Exhibit Hall.<br />
intErnEt<br />
Please visit the DiCEC Business Centre for internet access or to<br />
purchase Wi-Fi internet cards. see “Business Centre” for more<br />
information.<br />
lAngUAgE<br />
the official language of the Conference is English.<br />
lOst AnD FOUnD<br />
the lost and Found office is located next to the cloakroom, near<br />
the Convention gate Entrance. Please see the detailed map of<br />
the DiCEC on page 17 for exact location. Please call +971 4<br />
308 4600 if the office is closed.<br />
lUnCH<br />
lunch boxes are included in the registration fee for Delegates,<br />
students, nurses and Accompanying Persons. lunch boxes<br />
will be distributed in Al multaqua on 5 December and in sheikh<br />
rashid C & D on 6, 7, and 8 December.<br />
Delegates are encouraged to pick up their lunches in sheikh<br />
rashid C & D on 6, 7 and 8 December and bring the lunch into<br />
sheikh rashid E to attend the Keynote lunch symposium.<br />
mEDiCAl HElP & PHArmACY<br />
Emergency and first-aid office is located near the Exhibition<br />
gate reception between Halls 4 and 5. For emergencies, please<br />
call +971 4 306 4040.<br />
<strong>Dubai</strong> life Pharmacy is located in Concourse 2, between Halls<br />
5 and 6.<br />
mEEting POint<br />
the Conference meeting Point is the registration Area outside<br />
sheikh rashid E.<br />
mOBilE PHOnEs<br />
Use of mobile phones is strictly prohibited within the scientific<br />
session rooms. Please ensure that you have your mobile phone<br />
silenced while attending sessions.<br />
PArKing – FrEE<br />
Free outdoor parking is available at Car Park B, C & D.<br />
PHOtOgrAPHing<br />
Kindly respect that taking photos in the session rooms is strictly<br />
forbidden.<br />
www.worldallergy.org 14<br />
FinAl PrOgrAm
COnFErEnCE inFOrmAtiOn, A-Z<br />
POstEr sEssiOns<br />
All accepted abstracts will be presented as posters in Poster<br />
sessions on 6, 7, and 8 December in the Exhibition Hall (sheikh<br />
rashid F). Each Poster session will focus on posters in 3-4<br />
topic categories. Chairpersons are assigned to each category<br />
and will stimulate discussion between the audience and<br />
Presenting Authors. Presenting Authors will stand next to their<br />
posters, answer questions and discuss their research.<br />
Poster Session 1<br />
Includes networking session with faculty and WAO leadership<br />
monday, 6 December<br />
17:00 – 18:30<br />
Allergens and risk factors<br />
Asthma education and management<br />
Asthma epidemiology and mechanisms<br />
rhinitis, rhinosinusitis and conjunctivitis<br />
Poster Session 2<br />
Includes Outstanding Poster Awards announcement<br />
tuesday, 7 December<br />
13:00 – 14:15<br />
Clinical immunology<br />
Drug and food allergy<br />
skin and other diseases<br />
Poster Session 3<br />
Wednesday, 8 December<br />
09:30 – 10:30<br />
immune mechanisms of allergy<br />
immunotherapy<br />
Pediatric allergies<br />
Posters must be set up on monday, 6 December between<br />
09:00 – 16:00. Posters will remain on display throughout the<br />
Conference, and must be dismantled between 10:30 – 13:00 on<br />
Wednesday, 8 December. Posters not dismantled by 13:00 on<br />
Wednesday, 8 December will be discarded.<br />
Poster numbers are listed in the ‘Posters’ section of the <strong>Final</strong><br />
Program (pages 54-76). this Poster number also corresponds<br />
to the abstract number, which is printed in the ‘Abstracts’<br />
section (pages 78-162) of the <strong>Final</strong> Program. All posters will<br />
remain on display throughout the conference.<br />
outstanding Poster awards<br />
Abstracts that scored highly in the review process and have<br />
exceptional posters will be given WAO Outstanding Poster<br />
Awards. Awards will be announced at the beginning of Poster<br />
session 2 on tuesday, 7 December. Posters that receive this<br />
award will have a ribbon displayed on the poster board.<br />
POstgrADUAtE COUrsEs – 5 DECEmBEr<br />
Postgraduate Courses will take place on 5 December in the<br />
DiCEC in the 1st and 2nd floor meeting rooms. Please refer to the<br />
DiCEC floorplan on page 17 for exact locations.<br />
since attendance is limited, all Postgraduate Courses require<br />
pre-registration. At the time of check in at the registration<br />
Desk, all pre-registered attendees will be provided with a ticket<br />
for each registered session.<br />
All attendees must provide a ticket to gain entry to a<br />
Postgraduate Course.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
rEgistrAtiOn<br />
the registration Desk will be located outside sheikh rashid E<br />
and will be open during the following hours:<br />
saturday, 4 December: 16:00 – 19:00<br />
sunday, 5 December: 07:00 – 20:00<br />
monday, 6 December: 07:00 – 18:30<br />
tuesday, 7 December: 07:00 – 18:30<br />
Wednesday, 8 December: 07:00 – 16:00<br />
if you lose your badge, a new one can be purchased at the<br />
registration Desk for $50 UsD with photo identification.<br />
The registration fee for Delegates, nurses and Students<br />
includes:<br />
* Admission to all scientific sessions<br />
* Conference bag and meeting materials<br />
* Free access to exhibition area<br />
* Certificate of attendance<br />
* CmE<br />
* invitation to social events<br />
* Keynote lunch lectures<br />
The registration fee for accompanying Persons includes:<br />
* Free access to exhibition area<br />
* invitation to social events<br />
* Keynote lunch lectures<br />
Registration for Accompanying Persons does not include:<br />
Admission to the scientific sessions or conference bag and<br />
meeting materials<br />
smOKing POliCY<br />
smoking is not permitted during any meeting activity or event in<br />
the DiCEC.<br />
sOCiAl EVEnts:<br />
Name badges are strictly required for all Social Events<br />
opening Ceremony and Welcome reception<br />
sunday, 5 December 2010<br />
19:00 – 22:00<br />
DiCEC, sheikh rashid E & F<br />
Join fellow delegates, faculty and the WAO leadership in<br />
sheikh rashid E for the Opening Ceremony to launch the<br />
Conference. Following the Opening Ceremony, we will move to<br />
a hosted reception in the Exhibit Hall, sheikh rashid F, featuring<br />
hors d’oeuvres, and the opportunity to network with colleagues<br />
and friends.<br />
Included in registration fee for Delegates, Students, Nurses and<br />
Accompanying Persons.<br />
Poster Session 1 and networking with Faculty and Wao<br />
leadership<br />
monday, 6 December 2010<br />
17:00 – 18:30<br />
DiCEC, sheikh rashid F<br />
Junior delegates will have the opportunity to discuss and<br />
view posters in an informal setting, as well as network with<br />
Conference faculty and the WAO leadership. light refreshments<br />
will be served.<br />
Included in registration fee for Delegates, Students, Nurses and<br />
Accompanying Persons.<br />
www.worldallergy.org 15<br />
FinAl PrOgrAm
COnFErEnCE inFOrmAtiOn, A-Z<br />
sPEAKErs’ PrEViEW rOOm<br />
the speakers’ Preview room is located in Ajman A, on the<br />
1st floor of the sheikh rashid area. speakers are requested to<br />
check-in, drop off and finalize their slide presentations here.<br />
it is requested that speakers visit the Preview room at least<br />
3 hours before the beginning of their session. speakers making<br />
presentations in the early morning sessions should ensure that<br />
they have checked in the previous day.<br />
the speakers’ Preview room will be open during the following<br />
hours:<br />
saturday, 4 December: 10:00 – 17:00<br />
sunday, 5 December: 07:00 – 21:00<br />
monday, 6 December: 06:30 – 18:30<br />
tuesday, 7 December: 07:00 – 18:30<br />
Wednesday, 8 December: 07:00 – 16:00<br />
C - Location Map<br />
Sheikh rashid area<br />
Trade<br />
Centre<br />
Tower<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
DUBAi intErnAtiOnAl COnVEntiOn AnD EXHiBitiOn CEntrE<br />
Venue Map<br />
Za’abeel park<br />
F<br />
Trade Centre<br />
Roundabout<br />
Parking<br />
A<br />
312 Road<br />
Za'abeel Hall<br />
Hall<br />
1 2 3 4<br />
Convention<br />
Tower<br />
Sheikh Saeed Halls<br />
Arena<br />
3 2 1<br />
D<br />
Hall 8<br />
7<br />
6<br />
5<br />
D C<br />
A Za’abeel Entrance<br />
B Convention Gate Entrance<br />
VEnUE<br />
the venue for the Conference is the <strong>Dubai</strong> international<br />
Convention and Exhibition Centre (DiCEC). the DiCEC offers<br />
world class exhibition and convention facilities and is centrally<br />
located.<br />
<strong>Dubai</strong> international Convention and Exhibition Centre (DiCEC)<br />
sheikh Zayed road<br />
PO Box 9292<br />
<strong>Dubai</strong><br />
United Arab Emirates<br />
tel: +971 4 332 1000<br />
Fax: +971 4 318 8741<br />
Website: www.dwtc.com<br />
www.worldallergy.org 16<br />
FinAl PrOgrAm<br />
B<br />
Novotel<br />
Hotel<br />
Ibis Hotel<br />
B C<br />
<strong>Dubai</strong> Trade Centre Hotel Apartments<br />
Metro<br />
Sheikh<br />
Maktoum<br />
Hall<br />
Block A<br />
Sheikh<br />
Rashid<br />
Hall<br />
Sheikh Zayed Road (E11) Abu Dhabi ><br />
Multi-storey car park<br />
Block B<br />
C Plaza Entrance<br />
D Arena Entrance<br />
<strong>Dubai</strong> Trade Centre<br />
District<br />
Block C<br />
E<br />
NORTH<br />
Emirates<br />
Towers
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
DUBAi intErnAtiOnAl COnVEntiOn AnD EXHiBitiOn CEntrE<br />
SHEiKH raSHiD arEa<br />
Floor Color Key:<br />
ground Floor<br />
al multaqua<br />
Ballroom<br />
1st Floor<br />
2nd Floor<br />
speakers’ Preview room<br />
Ajman A<br />
Postgraduate Courses<br />
Sharjah D<br />
Postgraduate Courses<br />
Sharjah A<br />
lunch on<br />
5 December<br />
to Free Car Park<br />
Convention gate Entrance<br />
Exhibition gate Entrance<br />
to taxi stations<br />
LIFT LIFT<br />
-<br />
registration<br />
Area<br />
www.worldallergy.org 17<br />
FinAl PrOgrAm<br />
-<br />
-<br />
-<br />
A<br />
-<br />
Cloakroom and lost & Found Offi ce<br />
A B<br />
F<br />
E<br />
Sheikh rashid Hall<br />
D C<br />
lunch<br />
Boxes<br />
Postgraduate Courses<br />
Abu Dhabi A<br />
Postgraduate Courses<br />
Abu Dhabi B<br />
Postgraduate Courses<br />
Ras Al Khaimah<br />
Postgraduate Courses<br />
Umm Al Qwain<br />
LIFT<br />
-<br />
- - -<br />
- -<br />
-<br />
-<br />
-<br />
symposia<br />
Plenary sessions<br />
Opening<br />
Ceremony<br />
Exhibition Hall &<br />
Poster sessions<br />
Welcome reception<br />
Coffee Breaks
Helping to control asthma<br />
throughout the year 1<br />
<br />
SINGULAIR is indicated in the treatment of asthma<br />
as add-on therapy in those patients with mild to<br />
moderate persistent asthma who are inadequately<br />
controlled on inhaled corticosteroids and in whom “as<br />
needed” short-acting Beta-agonists provide inadequate<br />
clinical control of asthma. In those asthmatic<br />
patients in whom SINGULAIR is indicated in asthma,<br />
SINGULAIR can also provide symptomatic relief of<br />
seasonal allergic rhinitis.<br />
SINGULAIR is also indicated in the prophylaxis of asthma<br />
in which the predominant component is exercise-induced<br />
bronchoconstriction.<br />
SINGULAIR is contraindicated in patients with hypersensitivity<br />
to the active substance or to any of the excipients.<br />
Patients should be advised to continue taking SINGULAIR<br />
even if their asthma is under control, as well as during<br />
periods of worsening asthma.<br />
In clinical studies in asthmatic patients 15 years of age and<br />
older, the following drug-related adverse reactions, abdominal<br />
t y p e i s f r u t i g e r b l a c k i t a l i c<br />
pain and headache, were reported commonly (≥1/100 to
HOtEls mAP<br />
7<br />
7<br />
5<br />
1<br />
2<br />
3<br />
4<br />
5<br />
6<br />
6<br />
4<br />
3<br />
4<br />
3<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2<br />
<strong>Dubai</strong> International Convention & Exhibition Centre<br />
Grand Hyatt <strong>Dubai</strong><br />
Al Gharoud, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 317 1234, Fax: +971 4 317 1235<br />
Novotel <strong>World</strong> Trade Center<br />
Zabeel Road 2nd, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 3320000, Fax: +971 4 3320001<br />
Ibis <strong>World</strong> Trade Center<br />
Sheikh Zayed Road, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 3324444, Fax: +971 4 3311220<br />
Fairmont <strong>Dubai</strong><br />
Sheikh Zayed Road, <strong>Dubai</strong>, United Arab Emirates<br />
Tel +971 332 5555, Fax +971 4 332 4555<br />
HOtEl inFOrmAtiOn<br />
mCi middle East, the local Professional Congress Organizer<br />
for the Conference will be handling all hotels on-site. For hotel<br />
information, please visit the Hotels & tours Desk, which is<br />
located in the registration Area outside sheikh rashid E.<br />
2<br />
www.worldallergy.org 19<br />
FinAl PrOgrAm<br />
5<br />
6<br />
7<br />
1<br />
Towers Rotana Hotel<br />
Sheikh Zayed Road, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 343 8000, Fax: +971 4 343 5111<br />
Rose Rayhaan by Rotana<br />
Sheikh Zayed Road, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 323 0111, Fax: +971 4 323 0222<br />
Shangri-La <strong>Dubai</strong><br />
Sheikh Zayed Road, <strong>Dubai</strong>, United Arab Emirates<br />
Tel: +971 4 343 8888, Fax: +971 4 343 8886<br />
1
OPtiOnAl tOUrs<br />
CitY OF COntrAsts - sHArJAH CUltUrAl tOUr<br />
35 USD Per Person<br />
Sunday, 5 December 9:00 – 13:00<br />
Tuesday, 7 December 10:30 – 14:30<br />
sharjah was crowned by UnEsCO Cultural Capital of the Arab<br />
<strong>World</strong> in 1998. With a reputation for artistic excellence, the<br />
emirate boasts over 15 museums, an aquarium and a center for<br />
Arabian wildlife.<br />
Anyone who has an interest in local history, culture and<br />
architecture will enjoy exploring sharjah’s old city. A visit to souq<br />
Al Arsah, sharjah’s oldest market, is a must.<br />
the next stop is the sharjah Heritage museum, beginning a<br />
journey of discovery through sharjah’s rich and diverse heritage<br />
with handcrafted works of art and<br />
objects that date back to a time<br />
when local people relied solely on<br />
fi shing and pearling. Discover the<br />
traditional skills and crafts relating<br />
to jewelry, costumes, and herbal<br />
medicines, music and folklore.<br />
CitY OF mErCHAnts - DUBAi OriEntAtiOn tOUr<br />
35 USD Per Person<br />
Sunday, 5 December 14:30 – 18:00<br />
monday, 6 December 14:30 – 18:00<br />
Tueday, 7 December 14:30 – 18:00<br />
Wednesday, 8 December 14:30 – 18:00<br />
Experience the historic sites and lively multi-ethnic life of <strong>Dubai</strong>.<br />
From the famous Burj Al Arab to the gold souk, you’ll see all the<br />
famous sights of <strong>Dubai</strong> on this leisurely tour.<br />
Your excursion begins with a drive on sheikh Zayed road to<br />
view the city’s skyscrapers with a photo stop at <strong>Dubai</strong>’s most<br />
famous landmark and tallest tower in the world - Burj Khalifa. the<br />
tour proceeds to Jumeirah, where we can witness the worldrenowned<br />
luxury hotel Burj Al Arab – with the unique billowing<br />
sail design. the hotel is a must see for all visitors to <strong>Dubai</strong>.<br />
see some of the palaces of the royal Family and residential areas<br />
with a stop at the eminent Jumeirah mosque and a drive by the<br />
palace of the ruler of <strong>Dubai</strong>. We<br />
then proceed to<br />
Al Bastakiya, <strong>Dubai</strong>’s atmospheric<br />
old quarter by the Creek. then it’s<br />
all aboard the Abra (water taxi) to<br />
cross the Creek to the spice souk.<br />
You’ll then have time to shop in<br />
another famous <strong>Dubai</strong> landmark,<br />
the glittering gold souk.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
mCi middle East, the local Professional Congress Organizer for the Conference, will be handling all local tours for the 2010 WAO<br />
international scientifi c Conference. You can purchase tickets on-site at the Hotel & Tours Desk located in the registration<br />
area outside Sheikh rashid E.<br />
important Tour information:<br />
1. All tours are conducted in English.<br />
2. tours’ duration and date of operation are subject to change. the tour can be cancelled if a minimum number of participants is<br />
not achieved.<br />
3. For all tours, the pick up and drop off point is the Hotels & tours Desk located in the registration Area outside sheikh rashid E.<br />
Kindly report to the pick up point 15 minutes prior to the start of the tour.<br />
DEsErt sAFAri WitH BBQ DinnEr<br />
90 USD Per Person<br />
Tuesday, 7 December 15:00 – 20:00<br />
this tour departs in the afternoon by four-wheel drive vehicles<br />
across the desert of <strong>Dubai</strong> with several photo stops. A camel<br />
farm is the fi rst destination of this exciting dune drive. the drive<br />
continues across the desert, stopping to watch the beautiful<br />
sunset before reaching the campsite where you have the<br />
opportunity for a camel ride, sand boarding and trying out a<br />
henna design on your hands or feet. Enjoy a delicious barbecue<br />
dinner and shisha (the famous Arabic water pipe). Before<br />
returning to <strong>Dubai</strong>, watch our belly dancer performing her show<br />
around the campfi re by starlight.<br />
sUnsEt CrUisE<br />
45 USD Per Person<br />
Wednesday, 8 December 16:00 – 18:00<br />
What could be more enchanting than to marvel at the sunset<br />
aboard a dhow as it slips silently along <strong>Dubai</strong> Creek? Your cruise<br />
aboard traditional wooden vessels offers an intriguingly different<br />
view of this amazing city – a portrait of the true character of<br />
<strong>Dubai</strong>, the intertwining of the traditional and modern.<br />
see old wooden dhows, luxury yachts and spectacular modern<br />
architecture. Offering a selection of two select beverages, this<br />
tour refl ects a delicious taste of true Arabian hospitality.<br />
CAmEl riDing & sAnDBOArDing sAFAri<br />
75 USD Per Person<br />
Tuesday, 7 December 10:30 – 14:30<br />
travel with our experienced safari guides in four-wheel drive<br />
vehicles to the desert for a thrilling journey over the rolling dunes.<br />
After an exhilarating drive, enjoy a camel ride just like the<br />
nomadic Bedouin have<br />
done for centuries. Abandon<br />
tradition for a breathtaking<br />
mode of transport:<br />
strapping on a sand board<br />
for an exhilarating ride<br />
down the steep-sided<br />
dunes to the valley fl oor<br />
below.<br />
www.worldallergy.org 20<br />
FinAl PrOgrAm
Online Learning Content<br />
for Practitioners — and Trainees<br />
Webinar Archive<br />
Asthma and Co-Morbid Conditions<br />
Risk Assessment in Anaphylaxis<br />
Respiratory Syncytial Virus Illness: A Gateway to Asthma?<br />
Gastroesophageal Reflux Disease (GERD) and Asthma<br />
Dedicated to Reaching Allergists Everywhere<br />
Symposia and<br />
Training Schools<br />
Materials and schedules<br />
free to download<br />
Educational Resources<br />
Major Medical Journal Article Summaries<br />
Medical Book Reviews<br />
Allergic Disease Resource Center, Synopses<br />
Interactive Teaching Case Reports<br />
Conversations with Experts<br />
Clinical <strong>Allergy</strong> Tips<br />
Passport to expert resources in allergy, asthma<br />
and clinical immunology<br />
Continuing Education<br />
www.worldallergy.org/educational _programs/online_learning.php<br />
Asthma and Allergic Rhinitis Online Lecture Series<br />
Drug <strong>Allergy</strong> Interactive Module<br />
Immunology Online Lecture Series<br />
Food <strong>Allergy</strong> Interactive Module<br />
Small Airways Disease Working Group<br />
www.worldallergy.org/small_airways_group<br />
Podcasts, Case Studies, Clinical Pearls and more…<br />
http://www.worldallergy.org/educational_programs/<br />
www.worldallergy.org<br />
Member Resources<br />
<strong>World</strong>wide <strong>Allergy</strong> Meetings, Interactive Calendar<br />
Global <strong>Allergy</strong> Web Links<br />
Research and Training Resources<br />
WAO News & Notes Monthly Electronic Newsletters<br />
<strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> Journal<br />
www.worldallergy.org<br />
WAO-1110-385
EXHiBitiOn FlOOrPlAn<br />
sHEiKH rAsHiD F<br />
Poster Board Poster Board Poster Board<br />
EXHiBit HAll HOUrs<br />
sunday, 5 December: 20:00 - 22:00<br />
monday, 6 December: 09:00 - 18:30<br />
tuesday, 7 December: 09:00 - 17:00<br />
Wednesday, 8 December: 09:00 - 13:30<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
Coffee Break<br />
19<br />
Future<br />
meetings<br />
table<br />
20<br />
Cis<br />
21 16<br />
<strong>Dubai</strong> Bedfont<br />
Convention scientific<br />
Bureau limited<br />
22 14<br />
mEAAAiC lg life<br />
sciences<br />
slAAi<br />
EAACi<br />
<strong>World</strong> <strong>Allergy</strong><br />
<strong>Organization</strong><br />
2011 <strong>World</strong><br />
<strong>Allergy</strong> Congress<br />
Coffee Break<br />
sheikh rashid Hall F<br />
Entrance<br />
www.worldallergy.org 22<br />
FinAl PrOgrAm<br />
23<br />
24<br />
18<br />
<strong>Dubai</strong><br />
Health<br />
Authority<br />
17<br />
nycomed<br />
13<br />
HAE: learn<br />
About it, talk<br />
About it<br />
6<br />
<strong>Allergy</strong> Julphar<br />
therapeutics<br />
7<br />
First Defense<br />
nasal screen<br />
Corp<br />
8<br />
HVD<br />
sanofi-<br />
Aventis<br />
9<br />
10<br />
novartis<br />
msD<br />
5<br />
4<br />
stallergenes<br />
CiPlA -<br />
ntPE<br />
3<br />
2<br />
Omron<br />
Healthcare<br />
12<br />
gsK<br />
1
EXHiBitOr DirECtOrY<br />
allergy Therapeutics Booth 6<br />
Dominion Way<br />
Worthing, West sussex Bn14 8sA<br />
United Kingdom<br />
Phone: +44 1903 844 700<br />
Website: www.allergytherapeutics.com<br />
<strong>Allergy</strong> therapeutics is a fully integrated specialty pharmaceutical<br />
company with a profitable core business and a patent protected<br />
development pipeline of allergy vaccines with the potential to<br />
transform allergy treatment.<br />
Bedfont Scientific Booth 16<br />
105 laker road<br />
rochester<br />
Kent mE1 3QX<br />
United Kingdom<br />
Phone: +44 1634 673 720<br />
Fax: +44 1634 673 721<br />
Website: www.bedfont.com<br />
Bedfont scientific ltd is a world leader in developing innovative,<br />
non-invasive breath analysis monitors for a number of medical<br />
applications. their newest innovation is the nObreath FEnO<br />
monitor, a breakthrough in providing portable airway inflammation<br />
management for asthmatics. measuring FEnO enables the<br />
health professional to prescribe and measure steroid response<br />
as an alternative harsh or invasive testing such as blood tests or<br />
spirometry, demonstrating Bedfont’s commitment to their company<br />
slogan: “breath analysis is the new blood test”.<br />
CiPla-nTPE Booth 3<br />
PO Box 3139<br />
ntDE House<br />
street 9 Umm ramool<br />
Phone: +9714 285 2222<br />
Fax: +9714 222 2900<br />
CiPlA is the largest pharmaceutical manufacturer in india (ims-<br />
Org ’10 report), exporting its 1200 formulations in 65 therapeutic<br />
categories to 180 countries in the world including UsA, UK, germany,<br />
Australia, south Africa, gCC etc. CiPlA has manufacturing facilities<br />
approved by UsFDA, UK mHrA, tgA Australia, PiC germany etc.<br />
CiPlA’s innovative patented respiratory devices like Zerostat spacer,<br />
transparent DP halers; revolizer, etc are distributed in UAE by their<br />
agents national trading & Pharmaceutical Est. (ntPE).<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
CiS - Commonwealth of independent<br />
States Society of immunology and allergology Booth 20<br />
<strong>World</strong> immunopathology <strong>Organization</strong><br />
4 Ostrovityanova street<br />
117513 moscow<br />
russia<br />
Phone: +7 (495) 735-1414<br />
Fax: +7 (495) 735-1441<br />
E-mail: info@wipocis.org<br />
Please join us for the following meetings:<br />
Cis society of Allergology and immunology<br />
iV <strong>World</strong> Asthma and COPD Forum<br />
Paris, France<br />
may 1-3,2011<br />
www.wipocis.org<br />
Vi <strong>World</strong> Congress on immunopathology & respiratory allergy<br />
moscow, russia<br />
september 15-18,2011<br />
<strong>Dubai</strong> Convention Bureau Booth 21<br />
PO Box 594<br />
<strong>Dubai</strong><br />
UAE<br />
Phone: + 0097 1420 10220<br />
Website: www.dcb.ae<br />
the <strong>Dubai</strong> Convention Bureau is a division of the Department of<br />
tourism and Commerce marketing, a non-profit government funded<br />
organization, whose aim is to further develop and increase <strong>Dubai</strong>’s<br />
share of the international miCE and special events markets, whilst<br />
maximizing the economic prospects of <strong>Dubai</strong>. the DCB is dedicated<br />
to pursue and win events through national and international<br />
promotions to advance the position of the Emirate as a leading<br />
business tourism destination.<br />
<strong>Dubai</strong> Health authority Booth 18<br />
the <strong>Dubai</strong> Health Authority (DHA) was created in June 2007, by<br />
law 13 issued by His Highness sheikh mohammed bin rashid Al<br />
maktoum, Vice President and Prime minister of the UAE, ruler of<br />
<strong>Dubai</strong>. As the strategic health authority for the Emirate of <strong>Dubai</strong>, the<br />
DHA is empowered to set policies and strategies for health and to<br />
assure the application of those health policies and strategies. His<br />
Excellency Qadhi saeed Al murooshid is the Director general of the<br />
<strong>Dubai</strong> Health Authority (DHA).<br />
the DHA’s aim in <strong>Dubai</strong> is to provide an accessible, effective and<br />
integrated healthcare system, protect public health and improve<br />
the quality of life within the Emirate. this is a direct translation of<br />
the objectives of the <strong>Dubai</strong> strategic Plan 2015 launched by His<br />
Highness sheikh mohammed bin rashid Al maktoum. Keeping the<br />
strategic plan in mind, the DHA’s mission is to ensure access to<br />
health services, maintain and improve the quality of these services,<br />
improve the health status of nationals, residents and visitors and<br />
oversee a dynamic, efficient and innovative health sector.<br />
www.worldallergy.org 23<br />
FinAl PrOgrAm
EXHiBitOr DirECtOrY<br />
EaaCi - European academy of<br />
allergy and Clinical immunology Booth 24<br />
genferstrasse 21<br />
Zurich 8002<br />
switzerland<br />
Phone: +41 44 205 55 33<br />
Fax: +41 44 205 55 39<br />
Website: www.eaaci.net<br />
Email: info@eaaci.net<br />
the European Academy of <strong>Allergy</strong> and Clinical immunology is a<br />
non-profit organization active in the field of allergic and immunologic<br />
diseases such as asthma, rhinitis, eczema, occupational allergy, food<br />
and drug allergy and anaphylaxis. EAACi was founded in 1956 in<br />
Florence and has become the largest medical association in Europe<br />
in the field of allergy and clinical immunology. it includes 6,100<br />
individual members from 107 countries as well as 41 national <strong>Allergy</strong><br />
societies.<br />
First Defense nasal Screen Corp Booth 7<br />
7143 state rd 54, #117<br />
new Port richey, Fl 34653<br />
UsA<br />
Phone: 877.mY.Air.09<br />
Fax: 800.616.0258<br />
Email: customerservice@nasalscreens.com<br />
Website: http://www.filteryourlife.com/contact.htm<br />
Our product is the first ever invented light weight, almost non visible,<br />
non inserted allergy nasal screen that is a self adhesive, hypo<br />
allergenic, latex free, nasal screen that reduces the inhalation of<br />
allergens by up to 99% by completely and individually sealing each<br />
nasal passage and can be worn for extended periods of time and has<br />
no side effects.<br />
Future meetings Table Booth 19<br />
glaxoSmithKline Booth 1<br />
gulf & near East<br />
P.O. Box 50199<br />
United Arab Emirates<br />
Website: www.gsk.com<br />
gsK is one of the world’s leading producers of prescription<br />
medicines, vaccines and consumer healthcare products leading the<br />
way in respiratory , anti-viral medications, anti-infectives, <strong>Allergy</strong>,<br />
rhinitis and Cns diseases. the spirit of gsK is to improve the quality<br />
of human life by enabling people to do more, feel better and live<br />
longer through its’ responsibility to improve access to medicines,<br />
contributing to community programs around the world and supporting<br />
improvement in science education.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
HaE: learn about it, Talk about it Booth 13<br />
730 stockton Drive<br />
Exton, PA<br />
UsA<br />
Phone: +1 610 321 2333<br />
Fax: +1 610 321 3868<br />
Website: www.viropharma.com<br />
‘HAE: learn About it, talk About it’ is a peer-driven campaign<br />
designed to foster communication between physicians on the front<br />
lines of the diagnosis and treatment of hereditary angioedema<br />
(HAE), a rare and potentially fatal swelling disease. the program<br />
is led by the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO), the American<br />
College of Asthma, <strong>Allergy</strong> & immunology (ACAAi) and the American<br />
gastroenterological Association (AgA) institute, and supported by<br />
ViroPharma incorporated.<br />
HVD life Sciences Booth 8<br />
16, Vouliagmenis Avenue<br />
glyfada gr-16610<br />
greece<br />
Phone: +30 210 9600 687<br />
Fax: +30 210 9600 693<br />
Website: www.hvdlifesciences.com<br />
Email: office@hvdgmbh.com<br />
HVD lifesciences is a marketing and distribution company<br />
representing PHADiA, with 8 offices and over 45 partner companies<br />
in middle East, Africa, latin America and Europe we provide top<br />
quality service. Phadia develops, manufactures and markets blood<br />
test systems for clinical diagnosis and monitoring of allergy, asthma<br />
and autoimmune diseases to more than 3,000 laboratories in<br />
60 countries. supplying seven out of ten allergy laboratory tests<br />
worldwide, the company is world leader for 25 years.<br />
Julphar Booth 5<br />
P.O. Box 997,<br />
ras Al Khaimah<br />
Degdaga - Airport road<br />
United Arab Emirates,<br />
Phone: +971 7 2461461<br />
Fax: +971 7 2462462<br />
E-mail: Julphar@emirates.net.ae / info@Julphar.net<br />
since gulf Pharmaceutical industries (JUlPHAr) has been<br />
established in 1980 as the first UAE company specialized in<br />
pharmaceuticals manufacturing in the region, it has worked on<br />
strengthening its leading and distinguished role and adopted the<br />
method of renewal and innovation depending on the application<br />
of the highest quality standards and international standards in all<br />
pharmaceutical manufacturing aspects. As a result of the company’s<br />
commitment to strict quality and benefits, it has been able to have a<br />
distinct presence in more than 50 countries around the world.<br />
latin american Society of allergy<br />
and immunology (Slaai) Booth 23<br />
Jose Benitez 2704 (302)<br />
Col. Obispado<br />
monterrey, n.l. 64060<br />
méxico<br />
Phone: +52 (81) 834 824 59<br />
Fax: +52 (81) 834 824 59<br />
Website: www.slaai.org<br />
www.worldallergy.org 24<br />
FinAl PrOgrAm
EXHiBitOr DirECtOrY<br />
lg life Sciences, ltd Booth 14<br />
20 lg twin towers<br />
Yoido-Dong<br />
Youngdungpo-gu<br />
seoul 150-721<br />
south Korea<br />
Phone: +82 2 3773 7296<br />
Fax: +82 2 3773 7329<br />
Website: www.lgls.com<br />
in a bid to find the next-generation diagnostic methodologies, lgls<br />
is developing seminal technology and products related to automated<br />
allergy system for screening, DnA analysis and lab-on-a-chip<br />
technology, which can be used to simultaneously find multiple<br />
disease markers in a short time. We will continue our efforts to<br />
emerge as a top global brand in the diagnostic field.<br />
<strong>Allergy</strong> screening Products<br />
test items intended Use<br />
Alloscreen screening of 42 kinds of specific allergen<br />
Alloscan 2.0 strip scanner for Alloscreen kit<br />
Allostation s Fully automated allergy system for screening<br />
for Alloscreen kit<br />
mEaaaiC - middle East asia allergy, asthma<br />
and immunology Congress Booth 22<br />
middle East Asia <strong>Allergy</strong> Asthma immunology Congress (mEAAAiC) is<br />
a regional congress that presents a valuable and unique<br />
opportunity for both specialists and general physicians, to update<br />
their knowledge and advance their skills. mEAAAiC generally<br />
attracts key opinion leaders from the region as well as world<br />
renowned international faculty. the 1st mEAAAiC in march 2009 was<br />
held in collaboration with international organizations like the WAO,<br />
EAACi, AAAAi and ACAAi. the congress attracted around 1,500<br />
participants from over 43 countries. With the resounding success<br />
in 2009, mEAAAiC is now an established biennial congress with the<br />
next edition to be held in April 2011. For more information, please<br />
visit www.meaaaic.org<br />
merck Booth 12<br />
1 merck Drive<br />
Whitehouse station, nJ 08889-3497<br />
UsA<br />
Phone: (908) 423-1000<br />
Website: www.msd.com<br />
today’s msD is a global healthcare leader working to help the world<br />
be well. msD is a tradename of merck & Co., inc., with headquarters<br />
in Whitehouse station, n.J., U.s.A. through our prescription<br />
medicines, vaccines, biologic therapies, and consumer care and<br />
animal health products, we work with customers and operate in<br />
more than 140 countries to deliver innovative health solutions. We<br />
also demonstrate our commitment to increasing access to healthcare<br />
through far-reaching policies, programs and partnerships. msD. Be<br />
well. For more information, visit www.msd.com.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
novartis Booth 10<br />
novartis international Ag<br />
CH-4002 Basel<br />
switzerland<br />
Phone: +41 61 324 11 11<br />
Fax: +41 61 324 80 01<br />
Website: www.novartis.com<br />
At novartis Booth, there will be a display of videos discussing:<br />
• the quality of life of patients living with severe allergic asthma<br />
• the impact Xolair has on changing the way patients live with<br />
severe allergic asthma<br />
• the mode of action of Xolair<br />
As well, novartis will distribute at the booth some booklets about real<br />
adults case studies treated with Xolair.<br />
to insure that visiting physicians get all the inquiries answered, at<br />
the booth we’ll have product specialists that can answer physician<br />
questions or record their queries in order to answer them at a later<br />
time.<br />
All this aside from other promotional activities that abide by the<br />
Pharma Code of Conduct.<br />
nycomed Booth 17<br />
<strong>Dubai</strong> Healthcare City<br />
PO Box 1586<br />
<strong>Dubai</strong><br />
UAE<br />
Phone: +0097 1438 34207<br />
Fax: +0097 1435 72839<br />
Website: www.nycomed.com<br />
Email: sheriff.hassan@nycomed.ae<br />
Alvesco:<br />
o Has a novel mechanism of action for exceptional balance of safety<br />
and efficacy.<br />
o Efficacy comparable with the leading iCs.<br />
o safety and tolerability comparable with placebo.<br />
o Once-daily dosing helps to improve compliance.<br />
Alvesco is:<br />
lUng tArgEtED<br />
• smaller particle size for greater lung deposition and less oral<br />
exposure.<br />
• greater than 50% of the inhaled dose is delivered directly to the<br />
lung.<br />
lUng ACtiVAtED<br />
• Converted to its active form by esterases in the lung.<br />
• lipid conjugation for prolonged anti-inflammatory effects and<br />
once-daily dosing.<br />
lUng limitED<br />
• High protein binding for systemic safety.<br />
• Only 1% is available for systemic exposure.<br />
• Quickly metabolized in the liver for first-pass inactivation.<br />
www.worldallergy.org 25<br />
FinAl PrOgrAm
EXHiBitOr DirECtOrY<br />
omron Healthcare Europe B.V. Booth 2<br />
Kruisweg 577<br />
Hoofddrop 2132 nA<br />
netherlands<br />
Phone: +31 20 354 8200<br />
Fax: +31 20 354 8201<br />
Website: www.omrom-healthcare.com<br />
Email: info.omronhealthcare@eu.omron.com<br />
Omron Healthcare, an innovative global medical devices company,<br />
develops and manufactures high quality products for respiratory care.<br />
Omron’s further product line is dedicated to preventing, monitoring<br />
and treating lifestyle-related diseases such as cardiovascular,<br />
hypertension, diabetes and obesity.<br />
Sanofi-aventis Booth 9<br />
182 Avenue de France<br />
Paris 75013<br />
France<br />
Phone: +33 1 55 71 51 76<br />
Fax: +33 1 55 71 51 80<br />
Website: www.sanofi-aventis.com<br />
telfast®/Allegra® (fexofenadine hydrochloride) is a selective,<br />
non-sedating, H1-receptor antagonist indicated in seasonal Allergic<br />
rhinitis and Chronic idiopathic Urticaria in children and adults. it does<br />
not cross the blood-brain barrier.<br />
nasacort® AQ (triamcinolone acetonide) nasal spray is indicated<br />
for the treatment of the nasal symptoms of seasonal and Perennial<br />
Allergic rhinitis in adults and children 2 years of age and older.<br />
Formulated with no fragrance and no alcohol.<br />
Before prescribing the product always refer to the prescribing<br />
information available in your country.<br />
Stallergenes Booth 4<br />
6 rue Alexis de tocqueville<br />
Antony 92183<br />
France<br />
Phone: +33 1 55 59 20 00<br />
Fax: +33 1 55 59 21 29<br />
Website: www.stallergenes.com<br />
Email: contact@stallergenes.com<br />
stallergenes is a European biopharmaceutical company dedicated to<br />
allergen immunotherapy for the prevention and treatment of allergyrelated<br />
respiratory diseases, e.g. allergic rhinitis, rhinoconjunctivitis<br />
and asthma.<br />
leader in sublingual immunotherapy treatments, stallergenes<br />
reached a turnover of 193 million euros in 2009 (24%, being devoted<br />
to research and Development) and is actively involved in the<br />
development of sublingual immunotherapy tablets.<br />
stallergenes markets its products in 50 countries via 10 subsidiaries<br />
throughout Europe and distribution and partnership agreements<br />
around the globe.<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
<strong>World</strong> allergy organization (Wao)<br />
555 East Wells street, suite 1100<br />
milwaukee, Wi 53202<br />
UsA<br />
Phone: +1 414 276 1791<br />
Fax: +1 414 276 3349<br />
Email: info@worldallergy.org<br />
Website: www.worldallergy.org<br />
Please visit the WAO Exhibit to learn more about WAO: Educational<br />
Programs, Online learning, and the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong><br />
Journal (WAOJ)<br />
2011 <strong>World</strong> allergy Congress (WaC)<br />
555 East Wells street, suite 1100<br />
milwaukee, Wi 53202<br />
UsA<br />
Phone: +1 414 276 1791<br />
Fax: +1 414 276 3349<br />
Email: WAC2011@worldallergy.org<br />
Website: www.worldallergy.org/wac2011<br />
Please visit the WAC Exhibit to learn more about the 2011 <strong>World</strong> <strong>Allergy</strong><br />
Congress from 4 – 8 December in Cancún, méxico and receive a<br />
special registration discount code for use by 1 January 2011.<br />
www.worldallergy.org 26<br />
FinAl PrOgrAm
PrOgrAm-At-A-glAnCE<br />
registration<br />
Outside Sheikh Rashid E<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sUnDAY, 5 DECEmBEr 2010<br />
<strong>Dubai</strong> international Convention and Exhibition Centre<br />
07:00<br />
07:15<br />
07:30<br />
07:45<br />
08:00<br />
08:15<br />
08:30<br />
08:45<br />
09:00 Pg1:<br />
Pg2:<br />
Pg3:<br />
09:15<br />
spirometry Exhaled nO and managing smoking<br />
09:30<br />
Sharjah A other markers of cessation clinics<br />
09:45<br />
10:00<br />
10:15<br />
infl ammation<br />
WAts2<br />
Sharjah D<br />
Umm Al Qwain<br />
10:30 Coffee Break<br />
1st 10:45<br />
Floor Foyer<br />
11:00 Pg7:<br />
Pg8:<br />
Pg9:<br />
11:15<br />
inhalation devices investigating and Asthma self-<br />
11:30<br />
Sharjah A managing upper management plans<br />
11:45<br />
12:00<br />
12:15<br />
12:30<br />
airway disorders<br />
Sharjah D<br />
WAts2<br />
Umm Al Qwain<br />
12:45<br />
lunch Break<br />
13:00<br />
13:15<br />
Al Multaqua<br />
13:30 Pg13:<br />
Pg14:<br />
Pg15:<br />
13:45<br />
Practical aspects of role of bone Asthma control<br />
14:00<br />
managing rhinitis and scanning in asthma measures in<br />
14:15<br />
14:30<br />
14:45<br />
asthma in children<br />
WAts2<br />
Sharjah A<br />
and osteoporosis<br />
Sharjah D<br />
research and clinical<br />
practice<br />
Umm Al Qwain<br />
15:00 Coffee Break<br />
1st 15:15<br />
Floor Foyer<br />
15:30 Pg19:<br />
Pg20:<br />
Pg21:<br />
15:45<br />
When and how to Bronchial Asthma education<br />
16:00<br />
use epinephrine provocation tests in Umm Al Qwain<br />
16:15<br />
16:30<br />
16:45<br />
17:00<br />
/ treatment of<br />
anaphylaxis<br />
Sharjah A<br />
adults and children<br />
Sharjah D<br />
17:15 Special Session:<br />
17:30<br />
Hereditary Angioedema (HAE):<br />
17:45<br />
spotlight on the latest advances in diagnosis and treatment<br />
18:00<br />
18:15<br />
18:30<br />
18:45<br />
19:00<br />
Abu Dhabi B<br />
19:15<br />
opening Ceremony<br />
19:30<br />
19:45<br />
20:00<br />
20:15<br />
20:30<br />
Sheikh Rashid E<br />
20:45<br />
Welcome reception<br />
21:00<br />
21:15<br />
21:30<br />
21:45<br />
22:00<br />
Sheikh Rashid F<br />
Exhibition<br />
Sheikh Rashid F<br />
Pg4:<br />
nasal endoscopy<br />
and challenge tests<br />
WAts2<br />
Abu Dhabi A<br />
Pg10:<br />
CPAP and sleep<br />
disorders<br />
WAts2<br />
Abu Dhabi A<br />
Pg16:<br />
Food allergy:<br />
Diagnosis and<br />
treatment<br />
WAts2<br />
Abu Dhabi A<br />
Pg22:<br />
skin testing: theory<br />
and practice<br />
Abu Dhabi A<br />
Pg5:<br />
Aspirin<br />
desensitization<br />
WAts2<br />
Abu Dhabi B<br />
Pg11:<br />
Clinical methods for<br />
distinguishing COPD<br />
and asthma<br />
WAts2<br />
Abu Dhabi B<br />
Pg17:<br />
managing chronic<br />
cough<br />
Abu Dhabi B<br />
Pg23:<br />
Practical aspects of<br />
immunotherapy<br />
WAts2<br />
Abu Dhabi B<br />
Pg6:<br />
sputum analysis/<br />
BAl analysis<br />
Ras Al Khaimah<br />
Pg12:<br />
Dietary factors and<br />
weight management<br />
Ras Al Khaimah<br />
Pg18:<br />
Optimizing asthma<br />
management &<br />
treatment through<br />
behavior modifi cation<br />
WAts2<br />
Ras Al Khaimah<br />
Pg24:<br />
Preventing asthma<br />
exacerbations<br />
WAts2<br />
Ras Al Khaimah<br />
KEY<br />
Css Company sponsored symposium<br />
Kn Keynote lunch symposium<br />
Pg Postgraduate Course<br />
Ps Plenary session<br />
sY symposium<br />
www.worldallergy.org 29<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
WisC 2010 PrOgrAm-At-A-glAnCE<br />
mOnDAY, 6 DECEmBEr 2010<br />
<strong>Dubai</strong> international Convention and Exhibition Centre<br />
06:30<br />
06:45<br />
07:00<br />
07:15<br />
07:30<br />
07:45<br />
08:00 PS 1:<br />
08:15<br />
08:30<br />
08:45<br />
09:00<br />
09:15<br />
09:30<br />
09:45<br />
10:00 Coffee Break<br />
Sheikh Rashid F<br />
10:15<br />
10:30 SY1:<br />
10:45<br />
11:00<br />
11:15<br />
11:30<br />
11:45<br />
registration<br />
Outside Sheikh Rashid E<br />
Exhibition<br />
Sheikh Rashid F<br />
Update on asthma and lower airway co-morbidities<br />
Sheikh Rashid E<br />
Update on asthma research and clinical<br />
practice<br />
Sheikh Rashid A<br />
SY2:<br />
Asthma and co-morbidities<br />
Sheikh Rashid B<br />
12:00 lunch Break<br />
12:15<br />
Sheikh Rashid C&D<br />
12:30 Kn1: Presidential Keynote lunch symposium: Asthma and co-morbid conditions<br />
12:45<br />
Sheikh Rashid E<br />
13:00 PS2:<br />
13:15<br />
13:30<br />
13:45<br />
14:00<br />
14:15<br />
14:30<br />
14:45<br />
15:00 Coffee Break<br />
Sheikh Rashid F<br />
15:15<br />
15:30 SY4:<br />
15:45<br />
16:00<br />
16:15<br />
16:30<br />
16:45<br />
Asthma & upper airway co-morbidities<br />
Sheikh Rashid E<br />
Asthma in the elderly<br />
Sheikh Rashid A<br />
17:00 Poster Session 1:<br />
17:15<br />
17:30<br />
17:45<br />
18:00<br />
18:15<br />
18:30<br />
18:45<br />
19:00<br />
19:15<br />
19:30<br />
19:45<br />
20:00<br />
20:15<br />
20:30<br />
20:45<br />
21:00<br />
Poster session and networking with<br />
Faculty and WAO leadership<br />
Sheikh Rashid F<br />
SY5:<br />
mEAAAiC: Asthma and upper airway comorbidities<br />
in the gulf and near East<br />
Sheikh Rashid B<br />
SY3:<br />
Asthma and upper airway co-morbidities:<br />
research and clinical practice updates<br />
Sheikh Rashid E<br />
SY6:<br />
Asthma and upper airway co-morbidities:<br />
looking ahead<br />
Sheikh Rashid E<br />
KEY<br />
Css Company sponsored symposium<br />
Kn Keynote lunch symposium<br />
Pg Postgraduate Course<br />
Ps Plenary session<br />
sY symposium<br />
www.worldallergy.org 30<br />
FinAl PrOgrAm
PrOgrAm-At-A-glAnCE<br />
registration<br />
Outside Sheikh Rashid E<br />
Exhibition<br />
Sheikh Rashid F<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
tUEsDAY, 7 DECEmBEr 2010<br />
<strong>Dubai</strong> international Convention and Exhibition Centre<br />
07:00<br />
07:15<br />
07:30<br />
07:45<br />
08:00 PS3:<br />
08:15<br />
Asthma and endocrine co-morbidities<br />
08:30<br />
08:45<br />
09:00<br />
09:15<br />
09:30<br />
09:45<br />
Sheikh Rashid E<br />
10:00 Coffee Break<br />
10:15<br />
Sheikh Rashid F<br />
10:30 SY7:<br />
SY8:<br />
SY9:<br />
10:45<br />
An overview of pediatric asthma Asthma, endocrine disorders and new concepts in severe asthma<br />
11:00<br />
Sheikh Rashid A<br />
iatrogenesis<br />
Sheikh Rashid E<br />
11:15<br />
11:30<br />
11:45<br />
Sheikh Rashid B<br />
12:00 lunch Break<br />
12:15<br />
Sheikh Rashid C&D<br />
12:30 Kn2: Use of antimicrobials to treat acute exacerbations of chronic bronchitis, asthma and COPD<br />
12:45<br />
Sheikh Rashid E<br />
13:00 Poster Session 2: outstanding Poster awards<br />
CSS:<br />
13:15<br />
Sheikh Rashid F<br />
sanofi Aventis:<br />
13:30<br />
Allergic airways diseases: From the<br />
13:45<br />
14:00<br />
14:15<br />
evidence to clinical practice<br />
Sheikh Rashid B<br />
14:30 PS4:<br />
14:45<br />
Asthma and COPD: Present and future therapies<br />
15:00<br />
15:15<br />
15:30<br />
15:45<br />
16:00<br />
16:15<br />
Sheikh Rashid E<br />
16:30 Coffee Break<br />
16:45<br />
Sheikh Rashid F<br />
17:00 SY10:<br />
SY11:<br />
SY12:<br />
17:15<br />
immunotherapy and immune modulators in EAACi: the multiple faces of asthma Asthma and COPD<br />
17:30<br />
asthma and allergic rhinitis<br />
Sheikh Rashid B<br />
Sheikh Rashid E<br />
17:45<br />
18:00<br />
18:15<br />
18:30<br />
18:45<br />
19:00<br />
19:15<br />
19:30<br />
19:45<br />
20:00<br />
Sheikh Rashid A<br />
20:15<br />
20:30<br />
KEY<br />
20:45<br />
21:00<br />
Css Company sponsored symposium<br />
Kn Keynote lunch symposium<br />
Pg Postgraduate Course<br />
Ps Plenary session<br />
sY symposium<br />
www.worldallergy.org 31<br />
FinAl PrOgrAm
PrOgrAm-At-A-glAnCE<br />
registration<br />
Outside Sheikh Rashid E<br />
Exhibition<br />
Sheikh Rashid F<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
WEDnEsDAY, 8 DECEmBEr 2010<br />
<strong>Dubai</strong> international Convention and Exhibition Centre<br />
07:00<br />
07:15<br />
07:30<br />
07:45<br />
08:00 PS5:<br />
08:15<br />
Asthma and atopic eczema, food allergy, anaphylaxis<br />
08:30<br />
08:45<br />
09:00<br />
09:15<br />
Sheikh Rashid E<br />
09:30 Poster Session 3:<br />
09:45<br />
10:00<br />
10:15<br />
Sheikh Rashid F<br />
10:30 Coffee Break<br />
10:45<br />
Sheikh Rashid F<br />
11:00 SY14:<br />
SY15:<br />
11:15<br />
Asthma and viral infections<br />
Asthma and chest co-morbidities<br />
11:30<br />
Sheikh Rashid A<br />
in the middle East<br />
11:45<br />
12:00<br />
12:15<br />
12:30<br />
Sheikh Rashid B<br />
12:45 lunch Break<br />
13:00<br />
Sheikh Rashid C&D<br />
13:15 Kn3: Asthma and immunotherapy: Past, present and future<br />
13:30<br />
13:45<br />
Sheikh Rashid E<br />
14:00 PS6:<br />
14:15<br />
Psychological and societal dimensions of asthma<br />
14:30<br />
14:45<br />
15:00<br />
15:15<br />
15:30<br />
15:45<br />
16:00<br />
16:15<br />
16:30<br />
16:45<br />
17:00<br />
Sheikh Rashid E<br />
SY13:<br />
Asthma and ocular allergy co-morbidity<br />
Sheikh Rashid A<br />
SY16:<br />
Asthma and concomitant chest diseases<br />
Sheikh Rashid E<br />
KEY<br />
Css Company sponsored symposium<br />
Kn Keynote lunch symposium<br />
Pg Postgraduate Course<br />
Ps Plenary session<br />
sY symposium<br />
www.worldallergy.org 32<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010<br />
POstgrADUAtE COUrsEs<br />
since attendance is limited, all Postgraduate Courses require pre-registration. At the time of check in at the registration Desk, all<br />
pre-registered attendees will be provided with a ticket for each registered session.<br />
Please provide your ticket to gain entry to a Postgraduate Course.<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 1 Sharjah a<br />
Spirometry<br />
learning objectives:<br />
• to define what constitutes accurate and adequate spirometric assessment<br />
• to discuss how spirometry performance and interpretation differ depending on age<br />
• to review how pulmonary-function assessment compares with other outcome measures in asthma<br />
Speakers: Omar Al rawas<br />
thomas B. Casale<br />
stephen Peters<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 2 Sharjah D<br />
Exhaled no and other markers of inflammation - WaTS2*<br />
learning objectives:<br />
• to highlight the importance of monitoring airway inflammation for improved asthma control<br />
• to show how exhaled nitric oxide serves as a biomarker for airway inflammation<br />
• to review the clinical applications of measuring exhaled nitric oxide<br />
Speaker: myron Zitt<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 3 Umm al Qwain<br />
managing smoking cessation clinics<br />
learning objectives:<br />
• to review best practices on how and where to set up such clinics<br />
• to discuss what management approaches work best and why<br />
• to discuss effective ways to ensure adherence to non-smoking<br />
Speakers: Bassam mahboub<br />
riccardo Polosa<br />
giovanni Viegi<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 4 abu Dhabi a<br />
nasal endoscopy and challenge tests - WaTS2*<br />
learning objectives:<br />
• to demonstrate how to use these practical procedures to yield reproducible results<br />
• to show how to assess the outcomes of these tests and best use them in the clinic<br />
• to explain when to opt for a challenge test<br />
Speakers: Abdulla ibrahim<br />
Dennis ledford<br />
ruby Pawankar<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 5 abu Dhabi B<br />
aspirin desensitization - WaTS2*<br />
learning objectives:<br />
• to understand the principles of aspirin desensitization<br />
• to demonstrate how to assess correctly when it is indicated<br />
• to review the mechanisms of aspirin desensitization and what are its short and long-term outcomes<br />
Speakers: marek l. Kowalski<br />
Hae-sim Park<br />
*<strong>World</strong> allergy Training School 2<br />
www.worldallergy.org 33<br />
FinAl PrOgrAm<br />
sUnDAY, 5 DECEmBEr 2010
sUnDAY, 5 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010<br />
09:00 – 10:30 PoSTgraDUaTE CoUrSE 6 ras al Khaimah<br />
Sputum analysis/Bal analysis<br />
learning objectives:<br />
• to explain the advantages and disadvantages of sputum versus BAl analyses<br />
• to present data regarding what biomarkers in either sputum or BAl may be useful for clinical monitoring<br />
• to discuss the age groups in which sputum induction can be performed and interpreted<br />
Speakers: neil Barnes<br />
louis-Philippe Boulet<br />
Paul O’Byrne<br />
10:30 – 11:00 CoFFEE BrEaK 1st Floor Foyer<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 7 Sharjah a<br />
inhalation devices<br />
learning objectives:<br />
• to review various asthma medication delivery systems relevant to age<br />
• to show how HFA propellants may affect drug delivery from mDis<br />
• to provide insight into spacers and their importance in drug delivery<br />
Speakers: suleiman Al Hammadi<br />
sandra gonzález-Díaz<br />
Pramod Kelkar<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 8 Sharjah D<br />
investigating and managing upper airway disorders<br />
learning objectives:<br />
• to demonstrate examination techniques, including rhinolaryngoscopy, for upper airway disorders<br />
• to illustrate common pathologies, including the causes of sleep-disordered breathing of upper airway disorders<br />
Speakers: g. Walter Canonica<br />
Omer Kalayci<br />
michael A. Kaliner<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 9 Umm al Qwain<br />
asthma self-management (Sm) plans - WaTS2*<br />
learning objectives:<br />
• to emphasize the importance of patient self-management plans for asthma<br />
• to provide examples of sm plans for use in children, adolescents and adults in different practice settings<br />
• to review the impact of illiteracy, resource limitation and other barriers to self-management<br />
Speakers: ignacio J. Ansotegui<br />
tari Haahtela<br />
nizar Kherallah<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 10 abu Dhabi a<br />
CPaP and sleep disorders - WaTS2*<br />
learning objectives:<br />
• to explain better the physiology and pathophysiology of obstructive sleep apnea and its consequences<br />
• to emphasize the magnitude of the clinical problem<br />
• to make familiar the practical aspects of treatment techniques<br />
• to identify unmet needs<br />
Speaker: Fulvio Braido<br />
*<strong>World</strong> allergy Training School 2<br />
www.worldallergy.org 34<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 11 abu Dhabi B<br />
Clinical methods for distinguishing CoPD and asthma - WaTS2*<br />
learning objectives:<br />
• to review different methods for distinguishing asthma from COPD in different practice settings, including the role of screening<br />
questionnaires, and lung function and allergy tests<br />
• to review and discuss the role of clinical trials of therapy and monitoring of outcomes in asthma/COPD<br />
Speakers: Hatem Al Ameri<br />
stephen Peters<br />
Eric Bateman<br />
11:00 – 12:30 PoSTgraDUaTE CoUrSE 12 ras al Khaimah<br />
Dietary factors and weight management<br />
learning objectives:<br />
• to review appropriate dietary management in preschool children<br />
• to provide updates on the use of probiotics in disease prevention<br />
• to present information regarding what dietary and/or behavioral interventions are most successful in achieving appropriate weight<br />
control<br />
Speakers: michael s. Blaiss<br />
Paul greenberger<br />
12:30 – 13:30 lUnCH BrEaK al multaqua<br />
Beginning at 12:30, lunch boxes may be picked up in al multaqua.<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 13 Sharjah a<br />
Practical aspects of managing rhinitis and asthma in children - WaTS2*<br />
learning objectives:<br />
• to explain the process of diagnosis of rhinitis and asthma in children<br />
• to make familiar the specifics of treatment of rhinitis and asthma in children, especially in relation to safety, efficacy and easy<br />
administration toward better compliance<br />
• to identify specifics of disease that may be related to region<br />
Speakers: salem Al tamemi<br />
Carlos E. Baena-Cagnani<br />
michael s. Blaiss<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 14 Sharjah D<br />
role of bone scanning in asthma and osteoporosis<br />
learning objectives:<br />
• to review the different methods used to assess bone density<br />
• to review the risks and benefits of bone density assessments<br />
Speakers: Dennis ledford<br />
richard F. lockey<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 15 Umm al Qwain<br />
asthma control measures in research and clinical practice<br />
learning objectives:<br />
• to review and compare validated measures for assessing asthma control<br />
• to provide practical advice on their use in clinical research and in various clinical care settings<br />
• to show the relationship between current control and “future” risk and its implications for care and setting treatment goals<br />
Speakers: sergio Bonini<br />
Paul O’Byrne<br />
*<strong>World</strong> allergy Training School 2<br />
www.worldallergy.org 35<br />
FinAl PrOgrAm<br />
sUnDAY, 5 DECEmBEr 2010
sUnDAY, 5 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 16 abu Dhabi a<br />
Food allergy: Diagnosis and treatment - WaTS2*<br />
learning objectives:<br />
• to provide insight into diagnosing food allergy (igE testing and food challenge)<br />
• to explain how to cope with allergic reactions (including anaphylaxis) induced by food allergy<br />
• to understand the role of “oral immunotherapy” for food allergy<br />
Speakers: sami Bahna<br />
motohiro Ebisawa<br />
Alessandro Fiocchi<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 17 abu Dhabi B<br />
managing chronic cough<br />
learning objective:<br />
• to demonstrate the combined diagnostic/therapeutic approach to chronic cough<br />
Speakers: Pramod Kelkar<br />
riccardo Polosa<br />
13:30 – 15:00 PoSTgraDUaTE CoUrSE 18 ras al Khaimah<br />
optimizing asthma management & treatment through behavior modification - WaTS2*<br />
learning objectives:<br />
• to provide insight into reasons for non-compliance in asthma therapy, including patient fears<br />
• to review effective ways of enhancing treatment compliance at different ages<br />
Speakers: Fulvio Braido<br />
Harold nelson<br />
mario sanchez-Borges<br />
15:00 – 15:30 CoFFEE BrEaK 1st Floor Foyer<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 19 Sharjah a<br />
When and how to use epinephrine / Treatment of anaphylaxis<br />
learning objectives:<br />
• to review the mechanisms by which epinephrine reduces the symptoms of anaphylaxis<br />
• to present appropriate dosing and route of administration of epinephrine<br />
• to discuss when epinephrine should or should not be given to school children with a history of “anaphylaxis”<br />
Speakers: richard F. lockey<br />
myron Zitt<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 20 Sharjah D<br />
Bronchial provocation tests in adults and children<br />
learning objectives:<br />
• to describe different forms of bronchial provocation tests and their uses<br />
• to provide practical advice on their selection and conduct<br />
• to review the safety and interpretation of bronchial provocation tests<br />
Speakers: Omer Kalayci<br />
lanny rosenwasser<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 21 Umm al Qwain<br />
asthma education<br />
learning objectives:<br />
• to review the definitions of asthma severity and control<br />
• to reinforce the concept of current asthma impairment versus future asthma risk<br />
• to identify communication barriers that impair both short and long term asthma education<br />
Speakers: tari Haahtela<br />
michael A. Kaliner<br />
tatiana slavyanskaya<br />
*<strong>World</strong> allergy Training School 2<br />
www.worldallergy.org 36<br />
FinAl PrOgrAm
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—sUnDAY, 5 DECEmBEr 2010<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 22 abu Dhabi a<br />
Skin testing: Theory and practice<br />
learning objectives:<br />
• to review the use of skin testing for allergy<br />
• to review the approved methods of skin testing<br />
• to discuss ways to improve skin testing<br />
Speakers: sami Bahna<br />
sandra gonzález-Díaz<br />
Fares Zaitoun<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 23 abu Dhabi B<br />
Practical aspects of immunotherapy - WaTS2*<br />
learning objectives:<br />
• to review the process of how to select patients for immunotherapy<br />
• to explain the methodology of immunotherapy and who should administer it to the patient<br />
• to review the risks and benefits of the different types of immunotherapy<br />
Speakers: g. Walter Canonica<br />
Harold nelson<br />
15:30 – 17:00 PoSTgraDUaTE CoUrSE 24 ras al Khaimah<br />
Preventing asthma exacerbations - WaTS2*<br />
learning objectives:<br />
• to address the question: What defines an asthma exacerbation versus loss of asthma control?<br />
• to discuss which patients may be at increased risk for exacerbations<br />
• to review why reducing exacerbation frequency may be important in terms of long term consequences (i.e., loss of lung function)<br />
Speakers: thomas B. Casale<br />
nizar Kherallah<br />
marek l. Kowalski<br />
17:15 – 18:15 Special Session abu Dhabi B<br />
Hereditary angioedema (HaE): Spotlight on the latest advances in diagnosis and treatment<br />
Chairperson: lanny rosenwasser<br />
17:15 Welcoming remarks<br />
17:20 Clinical presentation and differential diagnosis |
mOnDAY, 6 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010<br />
8:00 – 10:00 PlEnarY SESSion 1 Sheikh rashid E<br />
Update on asthma and lower airway co-morbidities<br />
learning objectives:<br />
• to provide an overview of recent advances in asthma pathophysiology and treatment<br />
• to show the relationship of lower airway co-morbidities to asthma severity and control<br />
• to review new approaches to treatments directed toward lower airway co-morbidities<br />
Chairpersons: Hassan Alrayes<br />
Ali Ben Kheder<br />
Ashok shah<br />
08:00 Welcoming remarks<br />
08:05 Epidemiology and risk factors for asthma and CoPD |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010<br />
11:15 asthma exacerbation and reducing emergency room visits |
mOnDAY, 6 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010<br />
11:15 asthma and nasal polyps |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010<br />
15:00 – 15:30 CoFFEE BrEaK Sheikh rashid F<br />
15:30 – 17:00 SYmPoSiUm 4 Sheikh rashid a<br />
asthma in the elderly<br />
learning objectives:<br />
• to recognize the importance and high prevalence of asthma in the elderly<br />
• to consider clinical presentations and management issues of asthma in the elderly<br />
• to consider diagnostic challenges presented by co-morbid conditions<br />
Chairpersons: Young-Koo Jee<br />
Yousser mohamed<br />
Fadhel saleh<br />
15:30 Welcoming remarks<br />
15:35 asthma and co-morbidities in the elderly |
mOnDAY, 6 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—mOnDAY, 6 DECEmBEr 2010<br />
15:30 – 17:00 SYmPoSiUm 6 Sheikh rashid E<br />
asthma and upper airway co-morbidities: looking ahead<br />
learning objectives:<br />
• to review functional upper airway disorders and their relationship with asthma<br />
• to investigate the contribution of gErD to asthma morbidity<br />
• to evaluate the relationship(s) between obstructive sleep apnea and asthma<br />
Chairpersons: Carla irani<br />
Ho Joo Yoon<br />
15:30 Welcoming remarks<br />
15:35 asthma and vocal cord dysfunction |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
08:00 – 10:00 PlEnarY SESSion 3 Sheikh rashid E<br />
asthma and endocrine co-morbidities<br />
learning objectives:<br />
• to describe endocrine factors related to obesity that may contribute to asthma pathophysiology<br />
• to review how weight gain or loss may influence asthma severity and/or control<br />
• to consider the effects of pregnancy on asthma control and approaches to treatment<br />
Chairpersons: Abdulrahman Al Frayh<br />
Waleed Al-Herz<br />
Young Joo Cho<br />
08:00 Welcoming remarks<br />
08:05 Dietary factors, obesity and pediatric asthma |
tUEsDAY, 7 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
11:15 Prevention of pediatric asthma and allergies |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
11:15 Small airways disease in asthma<br />
Wao Small airways Diseases Working group lecture* |
tUEsDAY, 7 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
13:00 – 14:30 ComPanY SPonSorED SYmPoSiUm Sheikh rashid B<br />
Sanofi-aventis Symposium – allergic airways diseases: From the evidence to clinical practice<br />
Chairperson: mario sanchez-Borges<br />
13:00 Welcoming remarks<br />
13:05 Burden of allergic diseases in middle East countries |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
17:00 – 18:30 SYmPoiSUm 10 Sheikh rashid a<br />
immunotherapy and immune modulators in asthma and allergic rhinitis<br />
learning objectives:<br />
• to explain the mechanisms of and indications for immunotherapy<br />
• to review the available immunotherapy approaches<br />
• to review when and how to use immunotherapy and assess its success<br />
Chairpersons: Ahmed Elbousify<br />
nagata makoto<br />
17:00 Welcoming remarks<br />
17:05 Subcutaneous immunotherapy |
tUEsDAY, 7 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—tUEsDAY, 7 DECEmBEr 2010<br />
17:00 – 18:45 SYmPoiSUm 12 Sheikh rashid E<br />
asthma and CoPD<br />
learning objectives:<br />
• to provide insight into how disordered cell and molecular processes in these diseases can be used as diagnostic and prognostic tests<br />
• to provide updates on new methods that help in diagnosis of lung diseases<br />
• to review allergen avoidance strategies: those that work and those that do not<br />
Chairpersons: Hasan Al-Dhekri<br />
Kamal Hanna<br />
17:00 Welcoming remarks<br />
17:05 Biomarkers in the assessment of asthma and CoPD |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—WEDnEsDAY, 8 DECEmBEr 2010<br />
08:00 – 9:30 PlEnarY SESSion 5 Sheikh rashid E<br />
asthma and atopic eczema, food allergy, anaphylaxis<br />
learning objectives:<br />
• to explain the clinical presentation of atopic dermatitis and its management<br />
• to present information regarding the natural history of food allergy<br />
• to review the management of anaphylaxis in the asthmatic patient<br />
Chairpersons: Hani Ababneh<br />
mK Agarwal<br />
08:00 Welcoming remarks<br />
08:05 atopic eczema and respiratory allergy |
WEDnEsDAY, 8 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—WEDnEsDAY, 8 DECEmBEr 2010<br />
09:55 asthma and rhinoconjunctivitis co-morbidity and quality-of-life |
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—WEDnEsDAY, 8 DECEmBEr 2010<br />
11:45 The impact of olive pollens on allergy and asthma in Jordan |
WEDnEsDAY, 8 DECEmBEr 2010<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
sCiEntiFiC PrOgrAm—WEDnEsDAY, 8 DECEmBEr 2010<br />
14:00 – 16:00 Plenary Session 6 Sheikh rashid E<br />
Psychological and societal dimensions of asthma<br />
learning objectives:<br />
• to highlight the links between the mind and body in asthma<br />
• to identify the impact of psychological factors upon attitudes regarding compliance and the implications for treatment<br />
• to describe the influence of socioeconomic factors on the prevalence and management of asthma<br />
• to consider special behavioral and developmental issues affecting children with asthma<br />
Chairpersons: mirza Al-sayegh<br />
noel rodriguez-Perez<br />
14:00 Welcoming remarks<br />
14:05 Developmental and behavioral problems in children and adolescents |
30 th Congress of the<br />
European Academy of<br />
<strong>Allergy</strong> and Clinical Immunology<br />
11 – 15 June 2011<br />
Istanbul, Turkey<br />
EAACI Congress 2011<br />
www.eaaci2011.com<br />
Bridging Science and Culture<br />
Abstract<br />
Submission<br />
Deadline:<br />
18 January<br />
2011
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
POstEr sEssiOns<br />
All accepted abstracts will be presented as posters in Poster sessions on 6, 7, and 8 December in the Exhibition Hall (sheikh rashid<br />
F). Each Poster session will focus on posters in 3-4 topic categories. Chairpersons are assigned to each category and will stimulate<br />
discussion between the audience and Presenting Authors. Presenting Authors will stand next to their posters, answer questions and<br />
discuss their research.<br />
Posters must be set up on monday, 6 December between 09:00 – 16:00. Posters will remain on display throughout the Conference,<br />
and must be dismantled between 10:30 – 13:00 on Wednesday, 8 December. Posters not dismantled by 13:00 on Wednesday,<br />
8 December will be discarded.<br />
the Poster number listed above the abstract title corresponds to the abstract number, which is printed in the ‘Abstracts’ section<br />
(pages 78-162) of this program. it also corresponds to the Poster Board number, placed on the boards in the Exhibition Hall (sheikh<br />
rashid F).<br />
All posters will remain on display throughout the conference.<br />
monday, 6 December 2010 – Poster Session 1<br />
Poster Session and networking with Faculty and Wao leadership<br />
Junior delegates will have the opportunity to discuss and view posters in an informal setting, as well as network with Conference<br />
faculty and the WAO leadership. light refreshments will be served.<br />
included in the registration fee for Delegates, students, nurses and Accompanying Persons.<br />
17:00 - 18:30 PO1-1: Allergens and risk factors sheikh rashid F<br />
To view full abstracts from this session, please reference pages 78-87 of the ‘Abstracts’ section in this program.<br />
Chairpersons: syed m. Hasnain<br />
noel rodriguez-Perez<br />
1100<br />
allErgiC aSTHma in SYrian aDUlTS<br />
A. Khoury, m. merrawi and A. H. Joukaj<br />
Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria.<br />
1101<br />
oCCUPaTional aSTHma in PETroCHEmiSTrY WorKErS WiTH PErSiSTanT EXPoSUrE<br />
A. Eatemadi<br />
Immunology & Infectious disease, Ahvaz University of Medical Sciences, Ahvaz, Iran.<br />
1102<br />
SPECiFiC igE SEnSiTiZaTion To CEPHaloSPorinS in HoSPiTal PErSonnEl<br />
J. E. Kim, s. H. Kim, H. J. Jin, J. H. Kim, Y. m. Ye and H. s. Park<br />
Department of <strong>Allergy</strong> & Rheumatology, Ajou University School of Medicine, Suwon, South Korea.<br />
1103<br />
HoUSE DUST miTE allErgY – inDian PErSPECTiVE<br />
g. K. saha, Professor<br />
Zoology, Department of Zoology, University of Calcutta, Kolkata, India.<br />
1104<br />
SEnSiTiZaTion raTE anD riSK FaCTorS For SEnSiTiZaTion To DigESTiVE EnZYmES in HoSPiTal PErSonnEl<br />
J. E. Kim, H. J. Jin, J. H. Kim, Y. m. Ye and H. s. Park<br />
Department of <strong>Allergy</strong> & Rheumatology, Ajou University School of Medicine, Suwon, South Korea.<br />
1105<br />
SKin TEST rEaCTiViTY in THE EaSTErn ProVinCE oF SaUDi araBia<br />
r. KHOUQEEr<br />
<strong>Allergy</strong> and Immunology, Saad Specialist Hospital, Alkhobar, Saudi Arabia.<br />
www.worldallergy.org 54<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1106<br />
QUanTiFiCaTion oF a 24 KD maJor allErgEn oF CULEX QUINQUEFASCIATUS WHolE BoDY EXTraCT BY immUnologiCal<br />
TECHniQUES<br />
m. A. Kausar, Ph.D. 1 , V. Vijayan, Ph.D. 2 , s. Bansal, Ph.D. 3 , m. Vermani, Ph.D. 4 , W. siddiqui, Ph.D. 5 and m. Agarwal, Ph.D. 6<br />
1 Departments of Respiratory <strong>Allergy</strong> and Applied Immunology, VP Chest Institute, University of Delhi, New Delhi, India. 2 Department<br />
of Respiratory Medicine, V.P. Chest Institute, Delhi, India. 3 Department of Biochemistry, V.P. Chest Institute, Delhi, India. 4 Department<br />
of Respiratory <strong>Allergy</strong> and Applied Immunology, V.P. Chest Institute, Delhi, India. 5 Department of Biochemistry, Jamia Hamdard,, New<br />
Delhi, India. 6 Department of Respiratory <strong>Allergy</strong> and Applied Immunology, Formerly at V.P. Chest Institute, Delhi, India.<br />
1107<br />
PrEValEnCE oF aSTHma in ElEmEnTarY SCHool STUDEnTS aFTEr an oil lEaK in THE WESTErn CoaST oF KorEa<br />
Y. K. Jee, mD, PhD 1 , K. m. Kim 1 , D. H. Kim 1 , Y. s. Kim 1 , J. s. Park 1 , W. C. Jeong 2 , J. i. Hur 2 , s. C. Jung, mD 3 and s. C. roh, mD, mPH,<br />
PhD 3<br />
1 Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea. 2 Taean Institute of Environmental Health, Taean,<br />
South Korea. 3 Occupational and Environmental Medicine, Dankook University College of Medicine, Cheonan, South Korea.<br />
1108<br />
PrEValEnCE oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE anD iTS aSSoCiaTion WiTH ToBaCCo SmoKing anD<br />
EnVironmEnTal ToBaCCo SmoKE EXPoSUrE among rUral PoPUlaTion<br />
P. B g 1 , n. Huliraj 2 , P. K. s P 1 , r. B m 1 , g. Dr 1 , r. m. n r 1 and s. B. C r 3<br />
1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 2 Department of Thoracic<br />
Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 3 Department of Radiology, Kempegowda Institute of Medical<br />
Sciences, Bangalore, India.<br />
1109<br />
aSSESSmEnT oF lUna-air oaSiS air PUriFiErS in PrEVEnTing inHalanT allErgiES in DogS BY rEDUCing<br />
aEroallErgEnS anD VoCS<br />
n. ghosh, Ph.D. 1 , A. Aranda, Bs 1 , J. Bennert, Ph.D., Ctn 2 , J. Chudasama, Bs 2 , A. B. Das, D.sc. 3 and C. saadeh, mD, FACP, FACr 4<br />
1 Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX. 2 Air Oasis, Amarillo. 3 Dept. of Agricultural<br />
Biotechnology, College of Agriculture, Orissa University of Agricultutre & Technology, India. 4 <strong>Allergy</strong> A.R.T.S., Amarillo, TX.<br />
1110<br />
EFFECT oF mUlTiWallED CarBon nanoTUBE in oVa-inDUCED aSTHma moDEl<br />
i. s. Yun, mD 1 , J. Y. Kim, PhD 2 , i. H. Choi, PhD 3 , C. s. Hong, mD, PhD 1 and J. W. Park, mD, PhD 4<br />
1 Division of <strong>Allergy</strong> & Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.<br />
2 Institute of <strong>Allergy</strong> Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 3 Department<br />
of Microbiology, Yonsei University College of Medicine, South Korea. 4 Division of <strong>Allergy</strong> & Immunology Department of Internal<br />
Medicine, Yonsei University College of Medicine, Seoul.<br />
1111<br />
PollEn CoUnTS ProFilE in gEorgia EValUaTED BY THE BUrKHarD PollEn TraP<br />
m. V. Chikhladze 1 and r. i. sepiashvili 2<br />
1 National Institute of Allergology, Asthma & Clinical Immunology, Georgian Academy of Sciences, Tskhaltubo, Georgia. 2 Department<br />
of Allergology and Clinical Immunology, Institute of Immunophysiology, Moscow, Russia.<br />
1112<br />
air PUriFiEr THaT USES PHoTo CaTalYTiC oXiDaTion rEDUCED THE PoPUlaTion oF mrSa<br />
n. ghosh, Ph.D. 1 , C. Pratt, Bs 1 , J. Bennert, Ph.D., Ctn 2 , J. Chudasama, Bs 2 and A. B. Das, D.sc. 3<br />
1 Life, Earth and Environmental Sciences, West Texas A&M University, Canyon, TX. 2 Air Oasis, Amarillo. 3 Dept. of Agricultural<br />
Biotechnology, College of Agriculture, Orissa University of Agriculture & Technology, India.<br />
1113<br />
inCrEaSing oF allErgY PoTEnCY oF PollEn grainS in HElianTHUS annUUS l. UnDEr BEnZo(Á) PYrEnE (BaP)<br />
EXPoSUrE<br />
Z. Baghali 1 , A. majd 2 , A. Chehregani 3 , Z. Pourpak 4 and m. Vatanchian 3<br />
1 Dept. of Biology, Tarbiat Moallem University, Hamedan, Iran. 2 Dept. of Biology, Tarbiat Moallem University, Tehran, Iran. 3 Dept. of<br />
Biology, Bu-Ali Sina University, Hamedan, Iran. 4 Immunology, Asthma and <strong>Allergy</strong> Research Institute, Tehran University, Tehran, Iran.<br />
www.worldallergy.org 55<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1114<br />
rElaTionSHiP BETWEEn ToTal SErUm igE anD BoDY maSS inDEX in PaTiEnTS WiTH nonaToPiC rESPiraTorY allErgY<br />
s. H. Kim, W. Y. lee, s. J. Yong, K. C. shin, s. n. lee, s. J. lee and m. K. lee<br />
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea.<br />
1115<br />
PollEn STUDY in inDonESia<br />
i. rengganis<br />
Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.<br />
1116<br />
inHalanT allErgEnS SEnSiTiZaTion in PaTiEnTS WiTH aSTHma anD allErgiC rHiniTiS; rEViEW oF SKin TEST rESUlTS<br />
oVEr TWo YEarS PErioD aT SUlTan QaBooS UniVErSiTY HoSPiTal, mUSCaT – oman<br />
s. W. sharef, mD. and s. H. Al-tamemi, mD., FrCPC.<br />
Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.<br />
1117<br />
SKin PriCK TEST in CHilDrEn rESiDing in a rUral CommUniTY in BanDUng, WEST JaVa, inDonESia<br />
g. sapartini 1 , C. B.Kartasasmita 1 , B. setiabudiawan 1 , r. g. D. majangsari 1 , W. saptaputra 2 and n. irwan 2<br />
1 Department of Child Health, School of Medicine Padjadjaran University, Bandung, Indonesia. 2 Health Research Unit, School of<br />
Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia.<br />
1118<br />
ProTEin EXPrESSion ProFilE oF inDigEnoUS anD CommErCial EXTraCTS oF amaranTHUS PollEn in allErgY<br />
PaTiEnTS<br />
s. m. Hasnain, PhD, FACAAi, FAAAAi 1 , H. Al sini 1 , A. Al-Qassim 1 , A. Al Frayh, prof., allergy/pulmonology 2 , m. O. gad-El-rab 3 and A.<br />
Alaiya 1<br />
1 Biological and Medical Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 2 king saud University<br />
&King Khalid Hospital Riadh K S ARiyadh, Riyadh. 3 College of Medicine, King Saud University.<br />
1119<br />
naTUral rUBBEr laTEX-rElaTED oCCUPaTional aSTHma: SUCCESSFUl SUBlingUal DESEnSiTiZaTion<br />
D. schiavino<br />
<strong>Allergy</strong> Department, Catholic University, Rome, Italy.<br />
1120<br />
ToTal igE SEnSiTiViTY ComParED WiTH SPECiFiC igE rESUlTS againST miTES anD molDS For THE SCrEEning oF TYPE<br />
1 allErgY in WorKErS oF a PoliCE inSTiTUTE in CaraCaS, VEnEZUEla<br />
n. A. silva, Esp., C. monterrey, n. Camacho and g. nirsen<br />
Laboratory of Production and Quality Control, Corpodiagnostica, Caracas, Venezuela.<br />
17:00 - 18:30 PO 1-2: Asthma education and management sheikh rashid F<br />
To view full abstracts from this session, please reference pages 87-98 of the ‘Abstracts’ section in this program.<br />
Chairpersons: Eric Bateman<br />
mohammed nizam iqbal<br />
1200<br />
omaliZUmaB ProVing To BE EFFECTiVE in PaTiEnTS WiTH normal igE lEVElS & rEFraCTorY aSTHma,<br />
B. mahboub, Head, of, Pulmonary, medicine1 , r. mohamed, Pulmonologist2 and n. mohamed, Pulmonologist3 1 2 ,Rashid hospital, <strong>Dubai</strong>, United Arab Emirates. Department of Pulmonary Medicine, Rashid hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
3 ,Department of Pulmonary medicine ,Rashid hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
1201<br />
From TEmPEramEnT To PErSonaliTY: DoES aSTHma aFFECT DEVEloPmEnT?<br />
C. grønnerød, Dr.psychol.<br />
Department of Psychology, University of Oslo, Oslo, Norway.<br />
www.worldallergy.org 56<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1202<br />
THE TrEaTmEnT oF PaTiEnTS WiTH BronCHial aSTHma anD arTErial HYPErTEnSion<br />
E. A. latysheva1 , O. m. Kurbacheva1 and g. E. gendlin2 1 2 Allergology and Clinical Immunology, Institute of Immunology FMBA Russia, Moscow, Russia. Cardiology, Russian Medical<br />
University.<br />
1203<br />
aDUlT aToPiC DiSorDErS anD aDHD: a nEED oF BlaCK SPoT Program<br />
m. Afifi, mBChB, mmed, DrPH<br />
Primary Health Care, Ministry of Health (HQ), <strong>Dubai</strong>, United Arab Emirates.<br />
1204<br />
THE QUaliTY oF liFE in aSTHmaTiC PaTiEnTS TrEaTED WiTH omaliZUmaB<br />
F. della torre 1 , A. limonta 1 , V. gaffuri riva 1 and E. Della torre 2<br />
1 General Pneumology, INRCA-IRCCS, Milan, Italy. 2 Internal Medicine, San Raffaele Hospital, Milan, Italy.<br />
1205<br />
aToPiC aSTHma anD BronCHiECTaSiS<br />
A. Khoury 1 and F. Ahmed 2<br />
1 Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria. 2 Pulmonology Department, Faculty of Medicine of Aleppo, Aleppo, Syria.<br />
1206<br />
EFFECT oF omaliZUmaB in JaPanESE PaTiEnTS WiTH SEVErE allErgiC aSTHma anD rHiniTiS<br />
F. nishihara, Y. takaku, K. nakagome, A. masumoto, t. Yamaguchi and m. nagata<br />
<strong>Allergy</strong> Center , Department of Respiratory Medicine, Saitama Medical University, Moroyama-Machi, Japan.<br />
1207<br />
managEmEnT oF mUCUS rElaTED rESPiraTorY HEalTH ProBlEmS THroUgH SinUSES anD airWaYS ClEaning<br />
EXErCiSES<br />
m. Prakash rao, B.Com., ll.m.<br />
Advocate, Hyderabad, India.<br />
1208<br />
THE rolE oF inTErlEUKin-13 in aSTHma<br />
A. Vafa<br />
Azerbaijan Medical University, Baku, Azerbaijan.<br />
1209<br />
imProVED HEalTH oUTComES For aDolESCEnTS WiTH aSTHma in JorDan: a ClUSTEr ranDomiZED ConTrollED<br />
Trial<br />
n. A. Al-sheyab 1 , r. gallagher 2 , J. Crisp 2 and s. shah, Dr 3<br />
1 Maternal and Child Health, Jordan University of Science and Technology, Irbid, Jordan. 2 University of Technology, Sydney, Sydney,<br />
Australia. 3 University of Sydney, Westmead, Australia.<br />
1210<br />
imPlEmEnTaTion oF gUiDElinES in rEal-WorlD UK aSTHma managEmEnT<br />
D. ryan, mD 1 , J. Haughney, mD 2 , m. thomas, mD 2 , H. Pinnock, mD 3 , D. Price, Prof, mD 2 , s. Ellis 4 and A. Chisholm 4<br />
1 Woodbrook Medical Centre, Loughborough, United Kingdom. 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen,<br />
United Kingdom. 3 <strong>Allergy</strong> and Respiratory Research Group, Centre for Population Health Sciences: GP Section, The University of<br />
Edinburgh, Edinburgh, United Kingdom. 4 Research in Real Life, Cawston, United Kingdom.<br />
1211<br />
iS THErE SUFFiCiEnT nEED For an aDUlT SEVErE aSTHma SErViCE in THE UK? a rEViEW oF 11 UK FamilY<br />
PraCTiTionErS<br />
D. Price, Professor, medical, Doctor 1 , m. Britton, Consultant, Physician 2 , l. mascarenhas 3 , V. Knowles 4 , E. J. sims 5 and s. Blagbrough 5<br />
1 Centre of Academic Primary Care,, University of Aberdeen, Aberdeen, United Kingdom. 2 Postgraduate Medical School, Faculty<br />
Health & Medical Sciences, University of Surrey, Guildford, United Kingdom. 3 NHS Surrey, Leatherhead. 4 SW Locality, Surrey<br />
Community Health, Farnham, United Kingdom. 5 Optimum Patient Care, Norwich, United Kingdom.<br />
www.worldallergy.org 57<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1212<br />
CHooSing ComBinaTion THEraPY For aSTHma: rESUlTS oF a Pan-EUroPEan aTTiTUDinal SUrVEY<br />
D. Price, Professor, mD<br />
Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom.<br />
1213<br />
ComBinaTion THEraPY For aSTHma: rESUlTS oF a DElPHi ProCESS<br />
D. Price, Professor, mD 1 and J. Bousquet, Professor 2<br />
1 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. 2 University of Montpellier, Montpellier, France.<br />
1214<br />
CorrElaTion BETWEEn aSTHma-rElaTED QUaliTY oF liFE anD aSTHma ConTrolS in aDUlT aSTHmaTiCS<br />
B. Anıl, P. Yıldız, E. Aynacı, E. Yıldırım, F. Şahin and F. seçik<br />
Pulmonology, Yedikule Chest Disease and Surgery Training and Research Hospital, İstanbul, İstanbul, Turkey<br />
1215<br />
aSTHma ComPliCaTion in PrEgnanCY<br />
n. H. Al shammari, O. randa, K. muna<br />
AL Qassimi Hospital, Sharjah, United Arab Emirates.<br />
1216<br />
THE ValUE oF aSPirin DESEnSiTiSaTion in THE managEmEnT oF aSTHma anD rHinoSinUSiTiS: EViDEnCE–BaSED<br />
E. Arafa, mBChB, Dip, allergy, msc, allergy, fellow, southampton, UK 1 and D. P. Howarth, Bsc, mBBs, Dm, FrCP 2<br />
1 <strong>Allergy</strong> Department, N M C Specialty Hospital, <strong>Dubai</strong>, United Arab Emirates. 2 Infection,Inflammation and Immunity research<br />
division,School of medicine, Southampton General Hospital, Southampton, United Kingdom.<br />
1217<br />
ESoPHagEal CanDiDiaSiS SUCCESSFUllY TrEaTED WiTH rEPlaCEmEnT oF inHalED CorTiCoSTEroiD<br />
A. P. Castro-Coelho, m. V. Aun, F. g. montenegro, D. B. Borges, r. C. Agondi, J. Kalil and P. giavina-Bianchi<br />
Clinical Immunolgy and <strong>Allergy</strong>, Sao Paulo University, Sao Paulo, Brazil.<br />
1218<br />
DEmograPHiC anD CliniCal CHaraCTEriSTiCS aSSoCiaTED WiTH THE aTTriTion in a CoHorT oF aDUlT aSTHma<br />
s. H. Kim 1 , t. B. Kim 2 , Y. s. Chang 3 , s. H. Kim 3 , H. W. Park 4 , s. W. Park 5 , Y. s. Cho 2 , J. W. Park 6 , D. H. nahm 7 , Y. J. Cho 8 , s. H. Cho 4 , B. W.<br />
Choi 9 , H. B. moon 2 and H. J. Yoon 1<br />
1 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South Korea. 2 Department of <strong>Allergy</strong> and Clinical<br />
Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Department of Internal Medicine,<br />
Seoul National University Bundang Hospital, Seongnam, South Korea. 4 Department of Internal Medicine, Seoul National University<br />
College of Medicine, Seoul, South Korea. 5 Division of Respiratory and <strong>Allergy</strong> Medicine, Soonchunhyang University Hospital, College<br />
of Medicine, Bucheon, South Korea. 6 Division of <strong>Allergy</strong> & Immunology Department of Internal Medicine, Yonsei University College of<br />
Medicine, Seoul, South Korea. 7 <strong>Allergy</strong> & Rheumatology, Ajou University School of Medicine, Seoul, South Korea. 8 <strong>Allergy</strong> and Clinical<br />
Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea. 9 Department of Internal Medicine,<br />
Chung-Ang University College of Medicine, Seoul, South Korea.<br />
1219<br />
EFFECT oF anTirEFlUX TrEaTmEnT on CoUgH FrEQUEnCY in STaBlE aDUlT aSTHmaTiCS<br />
m. n. Hamed, mD 1 , H. sliem, mD 2 and m. F. Hassan, mD 3<br />
1 Chest Diseases, Suez Canal University, Faculty of Medicine, Isamilia, Egypt. 2 Internal medicine, Suez Canal University, Faculty of<br />
Medicine, Ismailia, Egypt. 3 Infectious and tropical diseases, Suez Canal University, Faculty of Medicine, Ismailia, Egypt.<br />
1220<br />
PoTEnTial maSKing oF airWaY inFlammaTion BY ComBinaTion THEraPY in aSTHma<br />
B. J. lee, m.D., PhD., J. Y. lee and D. C. Choi<br />
<strong>Allergy</strong> and Clinical Immunology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,<br />
Seoul, South Korea.<br />
www.worldallergy.org 58<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1221<br />
THE USEFUlnESS oF Pram SCorE in aSSESSing THE SEVEriTY anD oUTComE oF an aCUTE EXaCErBaTion oF WHEEZE<br />
in CHilDrEn<br />
m. K. nagaraju, D. r, s. n and g. r<br />
Pediatric allergy and immunology, Kanchi Kamakoti CHILDS Trust Hospital, Chennai, India.<br />
17:00 - 18:30 PO 1-3: Asthma epidemiology and mechanishms sheikh rashid F<br />
To view full abstracts from this session, please reference pages 98-112 of the ‘Abstracts’ section in this program.<br />
Chairpersons: Paul greenberger<br />
Carla irani<br />
1300<br />
rElaTion oF PErimEnSTrUal aSTHma WiTH DiSEaSE SEVEriTY anD oTHEr allErgiC Co-morBiDiTiES-THE FirST<br />
rEPorT oF PErimEnSTrUal aSTHma PrEValEnCE in SaUDi araBia<br />
E. Y. sabry<br />
Chest OPD- Internal Medicine, Saudi German Hospital, Riyadh, Saudi Arabia.<br />
1301<br />
non-EoSinoPHiliC aSTHma: imPorTanCE anD PoSSiBlE mECHaniSmS<br />
s. raj and r. shah<br />
Bioinformatics, Sathyabama University, Chennai 73, India.<br />
1302<br />
aSTHma inCiDEnCE aFTEr agE 6 YEarS BY gEnDEr anD aToPiC STaTUS in THE CHilDHooD allErgY STUDY<br />
s. Ahmed, m.D. 1 , g. Wegienka, Ph.D. 1 , s. Havstad, mA 1 , C. Johnson, Ph.D., mPH 1 , D. Ownby, m.D. 2 , C. nageotte, m.D. 1 and E. Zoratti,<br />
m.D. 1<br />
1 <strong>Allergy</strong> and Immunology, Henry Ford Health System, Detroit, MI. 2 <strong>Allergy</strong> and Immunology, Medical College of Georgia, Augusta, GA.<br />
1303<br />
PrEVElanCE, TrEaTmEnT PaTTErnS anD riSK FaCTorS oF aSTHma anD rHiniTS among aDUlTS in THE UaE<br />
B. mahboub, Head, of, Pulmonary, medicine 1 , r. Pawankar, mD, Ph.D 2 , m. rafique 3 , n. sulaiman 4 , s. Al Hammadi, mBBs 5 and A.<br />
ibrahim 6<br />
1 Department of Pulmonary Medicine, Rashid Hospital, <strong>Dubai</strong>, United Arab Emirates. 2 <strong>Allergy</strong> and Rhinology, NIPPON MEDICAL<br />
SCHOOL, Tokyo, Japan. 3 Pulmonologist ,Dept of Pulmonary Medicine, Rashid Hospital, <strong>Dubai</strong>, United Arab Emirates. 4 Dept of family<br />
& community medicine& Behavioural sciences, Sharjah University, Sharjah, United Arab Emirates. 5 UAE University, United Arab<br />
Emirates. 6 Otorhinolaryngology, Al barha Hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
1304<br />
PollEn rElaTED aSTHma: THE moST FrEQUEnT aSTHma PHEnoTYPE in KUWaiTi SCHoolCHilDrEn<br />
m. s. Al-Ahmad, mBBCh, FrCPC 1 , n. Arifhodzic, Phd 2 , n. Al-Ahmed 1 , A. Al-Onizi 1 , r. Panicker 1 and n. Fakim 1<br />
1 <strong>Allergy</strong> Department, Kuwait <strong>Allergy</strong> Center, Kuwait, Kuwait. 2 <strong>Allergy</strong>, AL-Rashed allergy Centre, Kuwait, Kuwait.<br />
1305<br />
CYSTEinYl-lEUKoTriEnS oVErProDUCTion anD THE aSTHma SEVEriTY in PaTiEnTS WiTH aSPirin-inDUCED aSTHma<br />
C. mitsui, mD, m. taniguchi, n. Higashi, E. Ono, K. Kajiwara, Y. Hukutomi, t. tsuburai, K. sekiya, H. tanimoto, t. ishii, A. mori, H. mita,<br />
m. Hasegawa and K. Akiyama<br />
Clinical Research Center for <strong>Allergy</strong> and Rheumatology, National Hospital <strong>Organization</strong> Sagamihara National Hospital,<br />
Sagamihara,Kanagawa, Japan.<br />
1306<br />
CorrElaTion BETWEEn SPiromETrY rESUlTS anD BoDY maSS inDEX in PaTiEnTS WiTH aSTHma<br />
r. C. Agondi, C. Bisaccioni, m. ribeiro, J. Kalil and P. giavina-Bianchi<br />
Clinical Immunolgy and <strong>Allergy</strong>, Sao Paulo University, Sao Paulo, Brazil.<br />
www.worldallergy.org 59<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1307<br />
PrEValEnCE oF BronCHial aSTHma anD iTS aSSoCiaTion WiTH SmoKing HaBiTS among aDUlT PoPUlaTion in rUral<br />
arEa<br />
B. g. Parasuramalu, m.B.B.s., m.D. 1 , n. Huliraj 2 , r. B m 1 , P. K. s P 1 , g. Dr 1 and r. m. n r 1<br />
1 Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India. 2 Department of Thoracic<br />
Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India.<br />
1308<br />
analYSiS oF PUBmED- inDEXED aSTHma rESEarCH From THE araB WorlD in THE laST TEn YEarS<br />
m. Afifi, mBChB, mmed, DrPH1 and W. A. Hameed, mBChB2 1 2 Primary Health Care, Ministry of Health (HQ), <strong>Dubai</strong>, United Arab Emirates. Primary Health Care, Ministry of Health, Ajman, United<br />
Arab Emirates.<br />
1309<br />
THE imPaCT oF ConComiTanT allErgiC rHiniTiS anD aSTHma on QUaliTY oF liFE in iTalian PaTiEnTS oF gEnEral<br />
PraCTiTionErS: arga STUDY<br />
s. maio1 , s. Baldacci1 , m. Borbotti1 , A. Angino1 , F. martini1 , B. Piegaia1 , P. silvi1 , g. sarno1 , s. Cerrai1 , m. simoni1 , F. Di Pede1 and g.<br />
Viegi, mD2 1 2 Institute of Clinical Physiology, National Research Council, Pisa, Italy. CNR Institute of Biomedicine and Molecular Immunology,<br />
Palermo, Italy.<br />
1310<br />
19 YEarS raTE oF HoSPiTaliZaTion oF CHroniC BronCHial aSTHma in BaHrain; QUaliTY oF HEalTH CarE in mEDiCal<br />
DEParTmEnT oF SmC<br />
m. m. Jahromi<br />
Quality Assurance, Salmaniya Medical Complex,, Manama, Bahrain.<br />
1311<br />
PrEValEnCE oF allErgiC DiSEaSES in THE CiS CoUnTriES<br />
t. A. slavyanskaya and r. i. sepiashvili<br />
Department of Allergology and Clinical Immunology, Institute of Immunophysiology, Moscow, Russia.<br />
1312<br />
gUiDElinES aPPliCaTion For aSTHma anD rHiniTiS managEmEnT: arga (rESPiraTorY allErgiC DiSEaSES:<br />
moniToring STUDY oF gina anD aria gUiDElinES) ProJECT<br />
s. Baldacci1 , s. maio1 , s. Cerrai1 , g. sarno1 , m. Borbotti1 , A. Angino1 , F. martini1 , l. Carrozzi1 , F. Di Pede1 and g. Viegi, mD2 1 2 Institute of Clinical Physiology, National Research Council, Pisa, Italy. CNR Institute of Biomedicine and Molecular Immunology,<br />
Palermo, Italy.<br />
1313<br />
inHalED SoDiUm CromoglYCaTE rEDUCES THE EXPrESSion oF aSTHma-rElEVanT CYToKinES BY PEriPHEral BlooD T<br />
CEll in CHilD aSTHma. THiS SUPPorTS iTS PoSSiBlE USE aS PrEVEnTaTiVE THEraPY in CHilD aSTHma<br />
V. gemou-Engesaeth, mD., PhD1, 5, 6 1 , Q. Hamid, mD, PhD 2 , E. A. roedland, Dsc3 3 , H. E. Heier, mD., PhD4 4 , P. i. gaarder 4 , J. B.<br />
grogaard 1 , s. Halvorsen 1 and C. J. Corrigan, mD., PhD.5 5<br />
1 1Dept. of Pediatrics, Oslo Univers. Hospital5King’s College London School of Medicine and 6Athens University, A Pediatric Clinic,<br />
Oslo, Norway. 2 McGill University, Meakins-Christie Laboratories, Montreal, QC, Canada. 3 3Institute of Medical Microbiology,<br />
Rikshospitalet, Molecular Biology, Oslo, Norway. 4 Dept. of Immunology and Transfussion Medicine, Oslo University Hospital, Oslo,<br />
Norway. 5 Centre for Allergic Mechanisms of Asthma, King’s College London School of Medicine and MRC and Asthma, Centre for<br />
Allergic Mechanisms of Asthma, London, United Kingdom.<br />
www.worldallergy.org 60<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1314<br />
EConomiC CoST oF aDUlT aSTHmaTiCS in THE TErTiarY HoSPiTal oF KorEa<br />
s. H. lee 1 , t. W. Kim 1 , H. r. Kang 1 , s. H. Kim 2 , s. s. Kim 1 , Y. W. lee 3 , t. B. Kim 4 , s. H. Kim 5 , H. W. Park 1 , s. W. Park 6 , Y. s. Chang 2 , Y. s.<br />
Cho 4 , J. W. Park, mD., PhD. 7 , Y. J. Cho 8 , H. J. Yoon 5 , s. H. Cho 1 , B. W. Choi 9 , H. B. moon 4 and K. U. min 1<br />
1 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. 2 Department of Internal<br />
Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 3 Department of Internal Medicine, Yonsei University<br />
College of Medicine, Seoul, South Korea. 4 Department of <strong>Allergy</strong> and Clinical Immunology, Asan Medical Center, University of Ulsan<br />
College of Medicine, Seoul, South Korea. 5 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, South<br />
Korea. 6 Division of Respiratory and <strong>Allergy</strong> Medicine, Soonchunhyang University Hospital, College of Medicine, Bucheon, South<br />
Korea. 7 Division of <strong>Allergy</strong> & Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South<br />
Korea. 8 <strong>Allergy</strong> and Clinical Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea.<br />
9 Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.<br />
1315<br />
aSSoCiaTion BETWEEn SUBCUTanEoUS aBDominal FaT anD airWaY HYPErrESPonSiVEnESS<br />
K. m. Kim<br />
Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea.<br />
1316<br />
CHLAMYDOPHILA PNEUMONIAE-inFECTED HUman PEriPHEral mononUClEar CEllS rESiST CorTiCoSTEroiD- inDUCED<br />
SUPPrESSion oF mETalloProTEinaSE-9 anD TiSSUE inHiBiTor mETalloProTEinaSE-1 SECrETion<br />
C. s. Park 1 , t. B. Kim 2 , K. A. moon 3 , Y. J. Bae 2 , Y. s. lee 2 , m. K. Jang 3 , H. B. moon 2 and Y. s. Cho 2<br />
1 Department of Internal Medicine, Inje university Heaundae Paik Hospital, Busan, South Korea. 2 Department of <strong>Allergy</strong> and Clinical<br />
Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Asan Institute for Life Science,<br />
Seoul, South Korea.<br />
1317<br />
EFFECTS oF TraFFiC air PollUTion on rESPiraTorY HEalTH anD allErgiES in EgYPTian SCHoolCHilDrEn<br />
m. shamssain, Ph.D 1 , W. Al Qerem, B.sc 2 , K. mcgarry, Ph.D 1 and l. neshat, m.sc 1<br />
1 Pharmacy, Health and Wellbeing, University of Sunderland, U.K, Sunderland, United Kingdom. 2 Pharmacy, Health and Wellbeing,<br />
University of Sunderland, Sunderland, United Kingdom.<br />
1318<br />
aSSoCiaTion BETWEEn aToPiC ECZEma anD CHilDHooD aSTHma in SCHoolCHilDrEn From THE norTH EaST oF<br />
EnglanD<br />
m. shamssain, Ph.D<br />
Pharmacy, Health and Wellbeing, University of Sunderland, U.K, Sunderland, United Kingdom.<br />
1319<br />
TrEnDS in PrESCriBing inHalED CorTiCoSTEroiDS alonE anD in ComBinaTion WiTH long-aCTing β2-agoniSTS in<br />
EUroPE in 2004–2009<br />
D. Price, Professor, mD1 and C. Virchow, Professor2 1 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. Zentrum für Innere Medizin, Universität<br />
Rostock, Rostock, Germany.<br />
1320<br />
il-17 DriVES THE rECrUiTmEnT oF B CEllS To THE BronCHial TiSSUE oF SEVErE aSTHmaTiC PaTiEnTS<br />
r. Halwani, msc;, Ph.D 1 , s. Al-muhsen, mD, FrCPC, FAAP 2 and Q. Hamid, mD, PhD 3<br />
1 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University., Riyadh,<br />
Saudi Arabia. 2 Department of Pediatrics, College of Medicine, King Saud University. 3 McGill University, Meakins-Christie Laboratories,<br />
Montreal, Canada.<br />
1321<br />
EoSinoPHilS EnHanCE airWaY SmooTH mUSClE CEll ProliFEraTion<br />
r. Halwani, msc;, Ph.D 1 , s. Al-muhsen, mD, FrCPC, FAAP 2 and Q. Hamid, mD, PhD 3<br />
1 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University.,<br />
Riyadh, Saudi Arabia. 2 Department of Pediatrics, College of Medicine, King Saud University. 3 McGill University, 2 Meakins-Christie<br />
Laboratories, Montreal, Canada.<br />
www.worldallergy.org 61<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1322<br />
EPiTHElial CEll DEriVED CHEmoKinES EnHanCE THE ProliFEraTion anD SUrViVal oF airWaY SmooTH mUSClE CEllS<br />
Via THE aCTiVaTion oF ErK1/2 Signaling PaTHWaY<br />
s. Al-muhsen, mD, FrCPC, FAAP 1 , r. Halwani, msc;, Ph.D 2 , H. Al-Jahdali, mD, FrCPC, FCCP 3 and Q. Hamid, mD, PhD 4<br />
1 Department of Pediatrics, College of Medicine, King Saud University. 2 Asthma Research Chair and Prince Naif Center for<br />
Immunological Research, College of Medicine, King Saud University., Riyadh, Saudi Arabia. 3 King Saud University for health sciences,<br />
Riyadh, Saudi Arabia. 4 McGill University, Meakins-Christie Laboratories, Montreal, Canada.<br />
1323<br />
TH-17 CYToKinE moDUlaTion oF STEroiD inSEnSiTiViTY in PEriPHEral BlooD mononUClEar CEllS<br />
A. Vazquez tello, Ph.D. 1 , r. Halwani, msc;, Ph.D 2 , s. Al-muhsen, mD, FrCPC, FAAP 3 and Q. Hamid, mD, PhD 4<br />
1 Asthma Research Chair and Prince Naif center for Immunology Research, College of Medicine, King Saud University, Riyadh, Saudi<br />
Arabia. 2 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University.,<br />
Riyadh, Saudi Arabia. 3 Department of Pediatrics, College of Medicine, King Saud University. 4 McGill University, Meakins-Christie<br />
Laboratories, Montreal, QC, Canada.<br />
1324<br />
molD allErgEnS SEnSiTiZaTion in aSTHma PaTiEnTS iS aSSoCiaTED WiTH SEVEriTY oF DiSEaSE<br />
C. Bisaccioni, m. V. Aun, A. P. Castro-Coelho, F. g. montenegro, r. C. Agondi, J. Kalil and P. giavina-Bianchi<br />
Clinical Immunolgy and <strong>Allergy</strong>, Sao Paulo University, Sao Paulo, Brazil.<br />
1325<br />
imPaCT oF allErgiC rHiniTiS on PaTiEnTS WiTH BronCHial aSTHma in aBU DHaBi<br />
s. g. Bodi, mD, FCCP 1 , m. Ohri 2 , J. mn 2 , B. tn 2 and m. Khare 2<br />
1 Pulmonology, AHALIA HOSPITAL, ABU DHABI, United Arab Emirates. 2 Ent, AHALIA HOSPITAL, ABU DHABI, United Arab Emirates.<br />
1326<br />
analYSiS oF gEnE EXPrESSion ProFilES oF PEriPHEral BlooD B lYmPHoCYTES in VarioUS CliniCal PHEnoTYPES oF<br />
aSTHma<br />
n. E. Q. Ahmad 1 , r. Harun 2 and r. Othman 2<br />
1 Institute of Medical Science Technology (MESTECH), Universiti Kuala Lumpur (UniKL), Kajang, Malaysia. 2 UKM Medical Molecular<br />
Biology Institute (UMBI), Universiti Kebangsaan Malaysia (UKM), Cheras, Malaysia.<br />
1327<br />
aSTHma anD aToPY in CHilDrEn 7 To 9 YEarS aFTEr Viral rESPiraTorY inFECTionS<br />
C. B. Kartasasmita, Prof/PhD, B. setiabudiawan, g. sapartini, r. ghrahani, W. saptaputra, n. irwan, K. mutyara and E. A. simoes<br />
Department of Child Health, Hasan Sadikin/School of Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia.<br />
1328<br />
aETiologY oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE (CoPD) in non SmoKing WomEn oF KanDY DiSTriCT , Sri<br />
lanKa<br />
A. siribaddana, mBBs mD mrCP, P. C. Wanigasekara and K. senevirathne<br />
Respiratory Medicine Unit, Teaching Hospital, Kandy, Sri Lanka.<br />
17:00 - 18:30 PO1-4: rhinitis, rhinosinusitis and conjunctivitis sheikh rashid F<br />
To view full abstracts from this session, please reference pages 112-118 of the ‘Abstracts’ section in this program.<br />
Chairpersons: michael A. Kaliner<br />
Philip rouadi<br />
1400<br />
SElECT ParamETErS rElaTing To THE maXimal inSPiraTorY anD EXPiaTorY FloW raTE among THE rUral<br />
PoPUlaTionS inHaBiTing THE arEaS aroUnD ZamoSC, PolanD – a FolloW-UP To THE mUlTi-CEnTEr STUDY ECaP<br />
(EPiDEmiologY oF allErgiC DiSEaSES in PolanD)<br />
E. Krzych-Falta Jr. 1 , B. samoliñski2 , A. lusawa1 , B. rojek1 and W. Kapalczynski3 1Department of Prevention of Environmental Hazards and Allergology, Warsaw Medical University, Department of Clinical Allergol,<br />
Medical Uniwersity of Warsaw, Warsaw, Poland. 2Department of Prevention of Environmental Hazards and Allergology, Warsaw<br />
Medical University, Department of Clinical Allergol, M, Medical Uniwesity of Warsaw, Warsaw, Poland. 3University of Louisville School<br />
of Medicine, Louisville, United States, University of Louisville School of Medicine,, United States.<br />
www.worldallergy.org 62<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1401<br />
THE aSSoCiaTion BETWEEn DEgrEE oF SEnSiTiZaTion To allErgEn anD SEVEriTY oF allErgiC rHiniTiS<br />
n. s. mohd Ashari, W. m. Wm, n. K. Y, s. sah and C. m. CH<br />
Immunology, Universiti Sains Malaysia, Kota Bharu, Malaysia.<br />
1402<br />
Co-aDminiSTraTion oF CHEnoPoDiUm alBUm allErgEnS anD CPg oligoDEoXYnUClEoTiDES EFFECTS on PEriPHEral<br />
BlooD mononUClEar CEllS oF PaTiEnTS WiTH allErgiC rHiniTiS TrEaTED WiTH inTranaSal CorTiCoSTEroiDS anD<br />
anTiHiSTaminES<br />
s. Farrokhi sr., mD 1 , t. mousavi 1 , s. Arshi 1 , A. salekmoghadam 1 , A. Varasteh, PhD 2 and n. rezaei, mD, PhD 3<br />
1 Department of Immunology, Iran University of Medical Sciences, Tehran, Iran. 2 6. Immunobiochemistry Lab, Immunology Research<br />
Center, Avicenna Research Institute, 6. Immunobiochemistry Lab, Immunology Research Center, Avicenna Research Institute,<br />
Mashhad, ID, Iran. 3 Growth and Development Research Center, Children’s Medical Center, Tehran, Iran.<br />
1403<br />
TrEaTmET oF CHroniC allErgiC rHiniTiS:inTranaSal VS. oral THEraPY?<br />
A. Eatemadi<br />
Immunology & Infectious disease, Ahvaz university of medical sciences, Ahvaz, Iran.<br />
1404<br />
EFFiCaCY oF FEXoFEnaDinE in DiFFErEnT DoSagES For TrEaTmnET oF SEaSonal allErgiC rHiniTiS<br />
A. Eatemadi<br />
Immunology & Infectious disease, Ahvaz university of medical sciences, Ahvaz, Iran.<br />
1405<br />
THE moDiFiED SnoT-20 QUESTionnairE: rEPEaTaBiliTY anD aPPliCaBiliTY To rHiniTiS<br />
A. s. sami, mBBs, Bsc, ODtC, mCPs, mA, msc<br />
Ent, Royal National Throat, Nose and Ear Hospital, London, United Kingdom.<br />
1406<br />
a CommUniTY BaSED SUrVEY on THE PrEValEnCE oF rHiniTiS<br />
A. s. sami, mBBs, Bsc, ODtC, mCPs, mA, msc<br />
Ent, Royal National Throat, Nose and Ear Hospital, London, United Kingdom.<br />
1407<br />
EFFiCaCY oF mUlTiFaCETED aVoiDanCE mEaSUrES in THE managEmEnT oF PaTiEnTS WiTH PErSiSTEnT allErgiC<br />
rHiniTiS anD HoUSE DUST miTE allErgY<br />
s. s. Chao, FrCs and D. Y. Wang<br />
Department of Otolaryngology Head and Neck Surgery, National Univeristy of Singapore, Singapore, Singapore.<br />
1408<br />
EliminaTion oF oCUlar iTCHing BY oloPaTaDinE HCl oPHTHalmiC SolUTion, 0.2%<br />
m. s. Blaiss, mD1 , D. Amin, ms2 and m. tort, PhD3 1 2 3 University of Tennessee Health Science Center`, Memphis, TN. Global Medical Affairs, Alcon Research, Fort Worth, TX. Alcon<br />
Research ,Ltd, Fort Worth, TX.<br />
1409<br />
momETaSonE FUroaTE naSal SPraY inCrEaSES THE nUmBEr oF DaYS WiTH minimal SYmPTomS in PaTiEnTS WiTH<br />
aCUTE rHinoSinUSiTiS<br />
m. Danzig 1 , E. O. meltzer, mD 2 , D. gates 1 and g. gopalan, mD 3<br />
1 Schering-Plough Research Institute (now Merck Research Laboratories), Kenilworth, NJ. 2 <strong>Allergy</strong> and Asthma Medical Group &<br />
Research Center, San Diego, CA. 3 Merck & Co., Kenilworth, NJ.<br />
1410<br />
THE rECalCiTranT PoSTnaSal-DriP SYnDromE: THE grEaT CHallEngE For THE allErgiST-immUnologiST<br />
s. nsouli, mD, AnD, sEniOr, CliniCAl, rEsEArCH, AssOCiAtE<br />
Asthma and <strong>Allergy</strong>, DANVILLE ASTHMA AND ALLERGY CLINIC, CALIFORNIA, USA, Danville, CA.<br />
www.worldallergy.org 63<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
1411<br />
USEFUlnESS oF PEaK EXPiraTorY FloW raTE aSSESSmEnT in THE SCrEEning For BronCHial HYPEr rESPonSiVEnESS<br />
in CHilDrEn WiTH allErgiC rHiniTiS<br />
m. K. nagaraju, m. r iii, s. n and g. r<br />
Pediatric allergy and immunology, Kanchi Kamakoti CHILDS trust Hospital, Chennai, India.<br />
1412<br />
FoXP-3, a rEgUlaTorY T CEll SPECiFiC marKEr, anD iTS EXPrESSion in naSal PolYPS<br />
K. roongrotwattanasiri 1 , r. Pawankar, mD, Ph.D 2 , s. Kimura 3 , s. mori 3 and t. Yagi 3<br />
1 Otolaryngology, Chiang Mai University and Nippon Medical School, Chiang Mai, Thailand. 2 <strong>Allergy</strong> and Rhinology, NIPPON MEDICAL<br />
SCHOOL, Tokyo, Japan. 3 Rhinology and <strong>Allergy</strong>, Otorhinolaryngology, Nippon Medical School, Tokyo, Japan.<br />
1413<br />
DoES THE SinUS mUCoSa rESPonD To allErgEn ProVoCaTion?<br />
E. El Hassan, mBBs 1 , r. mösges, m.D., Ph.D., FAAAAi 2 and m. Kleiner, msc 1<br />
1 Faculty of Medicine, University of Cologne, Institute of Medical Statistics, Informatics und Epidemiology, University Hospital of<br />
Cologne, Cologne, Germany. 2 IMSIE, Cologne, Germany.<br />
www.worldallergy.org 64<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
Tuesday, 7 December 2010 – Poster Session 2<br />
outstanding Poster awards<br />
Abstracts that scored highly in the review process and have exceptional posters will be given WAO Outstanding Poster Awards.<br />
Awards will be announced at the beginning of this Poster session.<br />
Posters that receive this award will have a ribbon displayed on the poster board.<br />
13:00 - 14:15 PO2-1: Clinical immunology sheikh rashid F<br />
To view full abstracts from this session, please reference pages 118-123 of the ‘Abstracts’ section in this program.<br />
Chairpersons: Hani Ababneh<br />
lanny rosenwasser<br />
2100<br />
a rarE CaSE oF aTaXia TElangiECTaSia in malaYSia<br />
n. s. mohd Ashari, K. s. Ar and W. Z. Wah<br />
Immunology, Universiti Sains Malaysia, Kota Bharu, Malaysia.<br />
2101<br />
CHroniC EoSinoPHiliC PnEUmonia in PaTiEnT WiTH DiFFiCUlT-To-TrEaT aSTHma<br />
n. Pauk<br />
3rd Faculty of Charles University, Dept of Pneumology, Faculty Hospital Na Bulovce, Prague, Czech Republic.<br />
2102<br />
CliniCal CHaraCTEriSTiCS oF EoSinoPHiliC organ inVolVEmEnT DiSTingUiSHing From mETaSTaSiS in CanCEr<br />
PaTiEnTS WiTH EoSinoPHilia<br />
t. B. Kim, t. lee, Y. s. lee, Y. J. Bae, Y. s. Cho and H. B. moon<br />
Department of <strong>Allergy</strong> and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br />
2103<br />
oPPoSiTE EFFECT oF ETanErCEPT anD inFliXimaB on THE DEVEloPmEnT oF CUTanEoUS VaSCUliTiS<br />
J. g. Kim<br />
Pediatrics, Seoul National University College of Medicine and Rheumatology Research Institute, SNU Hospital, Seoul, South Korea.<br />
2104<br />
BronCHoalVEolar laVagE anD SErUm EoSinoPHil CaTioniC ProTEin lEVElS in CHroniC aSTHma anD BronCHial<br />
CarSinoma<br />
s. Kose 1 , m. Arici 2 , g. Cavdar 1 , s. Yavas 1 and g. Camci 1<br />
1 Infectious Diseases and Clinical Microbiology, Clinical <strong>Allergy</strong> and Immunology, Tepecik Educational and Research Hospital, Izmir,<br />
Turkey. 2 Pulmonery Diseases, Tepecik Educational and Research Hospital, Izmir, Turkey.<br />
2105<br />
SUlFaTED moDiFiCaTion oF lYCiUm BarBarUm PolYSaCCHariDE UnDEr miCroWaVE irraDiaTion anD THEir anTi-HiV<br />
aCTiViTiES<br />
X. Zhu and H. Zhang<br />
Beijing University of Technology, Beijing, China.<br />
2106<br />
THE lEVEl oF THE TUmor nECroSiS FaCTor in PaTiEnTS WiTH FEmoral nECK FraCTUrES<br />
O. Popova 1 , t. nurpeisov 2 and n. Batpenov 3<br />
1 Laboratory, Research Institute of Traumatology and orthopedy, Astana, Kazakhstan. 2 Research Institute of Cardiology, Almaty,<br />
Kazakhstan. 3 Research Institute of Traumotology and orthopedy, Astana, Kazakhstan.<br />
2107<br />
STUDY oF il-8 inDiCES in ElDErlY PEoPlE WiTH FEmoral nECK FraCTUrES<br />
O. Popova1 and t. nurpeisov 2<br />
1 2 Laboratory, Research Institute of Traumatology and Orthopedy, Astana, Kazakhstan, Astana, Kazakhstan. Research Institute of<br />
Cardiology, Almary, Kazakhstan.<br />
www.worldallergy.org 65<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2108<br />
EXPrESSion oF il-17a anD il-17F CYToKinES in B lYmPHoCYTES<br />
A. Vazquez tello, Ph.D. 1 , r. Halwani, msc;, Ph.D 2 , r. li, Ph.D. 3 , A. Bar-Or, mD 4 , B. mazer, mD 5 , s. Al-muhsen, mD, FrCPC, FAAP 6 and<br />
Q. Hamid, mD, PhD 7<br />
1 College of Medicine, Asthma Research Chair and Prince Naif center for Immunology Research, King Saud University, Riyadh, Saudi<br />
Arabia. 2 Asthma Research Chair and Prince Naif Center for Immunological Research, College of Medicine, King Saud University.,<br />
Riyadh, Saudi Arabia. 3 Montreal Neurological Institute and McGill University, Montreal, QC, Canada. 4 5 Montreal Neurological Institute<br />
and McGill University, Montreal, QC, Canada. 5 Meakins-Christie Laboratories and Respiratory Division, Department of Medicine,<br />
McGill University, Montreal, QC, Canada. 6 Department of Pediatrics, College of Medicine, King Saud University. 7 McGill University,<br />
Meakins-Christie Laboratories, Montreal, QC, Canada.<br />
2109<br />
CaSE rEPorT oF rElaPSing PolYCHonDriTiS in CHilDrEn<br />
B. setiabudiawan1 , s. F. Boesoerie2 , r. g. D. majangsari1 , g. sapartini1 and D. rosifah1 1 2 Child Health, Padjadjaran University, Bandung, Indonesia. Otorhinolaryngology Head & Neck, Padjadjaran University, Bandung,<br />
Indonesia.<br />
2110<br />
PEriPHEral EoSinoPHilia<br />
m. restrepo 1 , s. Diez 1 , J. sanchez 1 , C. Chinchilla 2 and r. Cardona 3<br />
1 Allergology, Universidad de Antioquia, Medellín, Colombia. 2 University of Antioquia - Grupo de Alergología Clínica y Experimental<br />
(GACE), Medellin, Colombia. 3 University of Antioquia, Medellin, Colombia.<br />
13:00 - 14:15 PO2-2: Drug and food allergy sheikh rashid F<br />
To view full abstracts from this session, please reference pages 123-132 of the ‘Abstracts’ section in this program.<br />
Chairpersons: suleiman Al Hamadi<br />
sandra gonzález-Díaz<br />
2200<br />
PoTEnTial aDVErSE rEaCTionS From ComPlEmEnTarY anD alTErnaTiVE mEDiCinE (Cam) anD DiETarY SUPPlEmEnT<br />
(DS) in norTH amEriCa<br />
H. C. g. Wong, mD, FrCPC, FACP, FAAAAi, FCCP<br />
Department of Medicine, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.<br />
2201<br />
inTErim FinDingS From ESTaBliSHing THE EFFECTiVEnESS, CoST-EFFECTiVEnESS anD SaFETY oF oral anD<br />
SUBlingUal immUnoTHEraPY For FooD allErgY: a SYSTEmaTiC rEViEW<br />
U. nurmatov 1 , g. Devereux 2 and A. sheikh 1<br />
1 <strong>Allergy</strong> & Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United<br />
Kingdom. 2 Department of Child Health, Royal Aberdeen Children’s Hospital, The University of Aberdeen, Aberdeen, United Kingdom.<br />
2202<br />
CiSPlaTin aDminiSTraTion FolloWing aCUTE HYPErSEnSiTiViTY To oTHEr PlaTinUm ComPoUnDS: a PHaSE ii STUDY<br />
E. syrigou, n. makrilia, K. Politi, g. Kaklamanos, l. manolopoulos and K. n. syrigos<br />
Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, Greece, Athens, Greece.<br />
2203<br />
FooD allErgY anD aToPiC DErmaTiTiS<br />
A. Hekmatdoost Jr.<br />
Dep Clinical Nutrition and Dietetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.<br />
2204<br />
CliniCal CHaraCTEriSTiCS oF raniTiDinE inDUCED HYPErSEnSiTiViTY<br />
Y. J. Cho<br />
<strong>Allergy</strong> and Clinical Immunology, Internal Medicine, Ewha Womans University Mockdong Hospital, Seoul, South Korea.<br />
www.worldallergy.org 66<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2205<br />
PangaSiUS HYPoPHTHalmUS HYPErSEnSiTiViTY<br />
m. t. Palomeque sr. 1 , m. torrecillas 1 , B. Bartolome 2 , n. martínez Borque 1 , m. r. gonzález mendiola 1 , E. martín Casáñez 1 , P. lara de la<br />
rosa 1 , g. soto Vargas 1 and D. martínez Bohigas 1<br />
1 Alergología, Complejo Hospitalario Universitario Albacete, Albacete, Spain. 2 Departamento I+D, Bial-Arístegui, Bilbao, Spain.<br />
2206<br />
FiXED DrUg ErUPTion inDUCED BY iBUProFEn anD aCETaminoPHEn<br />
m. torrecillas sr., m. t. Palomeque, E. martín, n. martínez, P. lara, g. soto, D. martínez and m. r. gonzález<br />
Alergología, Complejo Hospitalario Universitario Albacete, Albacete, Spain.<br />
2207<br />
FrEQUEnCY oF immEDiaTE, laTE anD DElaYED TYPE FooD HYPErSEnSiTiViTY in ProVoCaTion TEST For Egg allErgY<br />
anD iTS CorrElaTion WiTH Egg-WHiTE igE raST SCorE<br />
t. noma 1 , n. Ogawa 1 , n. Ogawa 2 , K. mikami 2 , t. saeki 1 , A. isozaki 3 , Y. Kawano 3 and H. Oshiba 4<br />
1 Pediatrics, Kitasato Univ, Sagamihara, Japan. 2 Pediatrics, Chiba Aiyukai Memorial Hospital, Japan. 3 Pediatrics, Yokohama City<br />
Minato Red Cross Hospital, Japan. 4 Pediatrics, Tokyo Kousei-Nenkin Hospital, Japan.<br />
2208<br />
anTi-igE anTiBoDY anD FooD igE-mEDiaTED DiSEaSES in SEVErE aSTHmaTiC PaTiEnTS<br />
g. Florio 1 , C. Oricchio 2 , m. Palmieri 1 , g. marone 3 and V. Patella 1<br />
1 Division of <strong>Allergy</strong> and Clinical Immunology, Agropoli General Hospital, Department of Medicine ASL Salerno, Salerno, Italy. 2 Unit of<br />
Transfusion Medicine, Agropoli General Hospital, ASL Salerno, Salerno, Italy. 3 Division of <strong>Allergy</strong> and Clinical Immunology and Center<br />
for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy.<br />
2209<br />
EFFECTS oF DiETarY CoUnSElling on ProTEin inTaKE anD PlaSmaTiC ProTEin ProFilE in CHilDrEn WiTH FooD allErgY<br />
E. D’Auria, m. mandelli, g. Cagnoli, A. m. lammardo, J. Zuvadelli, E. salvatici and m. giovannini<br />
Department of Pediatrics, San Paolo Hospital-University of Milan, Italy, Milan, Italy.<br />
2210<br />
THE rolE oF SKin PriCK TEST in DiagnoSiS oF CroSS –allErgY<br />
Z. Bartuzi 1 and K. napiórkowska 2<br />
1 Department Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University,<br />
Bydgoszcz, Poland. 2 Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University,<br />
Bydgoszcz, Poland.<br />
2211<br />
THE EFFECTiVEnESS oF THE mEaSUrEmEnT oF ToTal anD SPECiFiC igE in DiagnoSiS oF CroSS allErgY<br />
Z. Bartuzi 1 and K. napiórkowska 2<br />
1 Department Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University,<br />
Bydgoszcz, Poland. 2 Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Nicolaus Copernicus University,<br />
Bydgoszcz, Poland.<br />
2212<br />
aSSESSing PoTEnTial DETErminanTS oF PoSiTiVE ProVoCaTion TESTS in SUBJECTS WiTH nSaiD HYPErSEnSiTiViTY<br />
m. Viola, g. rumi, r. l. Valluzzi, F. gaeta, C. Caruso and A. romano<br />
<strong>Allergy</strong> Unit, Complesso Integrato Columbus, Rome, Italy.<br />
2213<br />
CoW milK SEnSiTiZaTion in a groUP oF EgYPTian allErgiC inFanTS anD CHilDrEn<br />
E. Hossny, mD, PhD, FAAAAi 1 , A. shehab, mD, PhD 2 , s. saad, mD, PhD 3 and m. Borick 3<br />
1 Pediatric <strong>Allergy</strong> and Immunology Unit, Children’s Hospital,, Ain Shams University, Cairo, Egypt. 2 Clinical Pathology Department, Ain<br />
Shams University, Cairo, Egypt. 3 Pediatric <strong>Allergy</strong> and Immunology Unit, Ain Shams University, Cairo, Egypt.<br />
2214<br />
EPiDEmiologiCal STUDY oF FooD allErgY in THE ToWn oF ConSTanTinE (algEria)<br />
H. Boughellout and m. n. Zidoune<br />
Nutrition and Food TECHNOLOGY Institute, UNIVERSITY MENTOURI CONSTANTINE, Constantine, Algeria.<br />
www.worldallergy.org 67<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2215<br />
anaPHYlaCTiC rEaCTion inDUCED BY HomEoToXiC DrUg<br />
m. naime, Estudiante, m. sofia and P. Elizabeth<br />
Escuela De Ciencias De La Salud, Universidad de oriente, Puerto La Cruz, Venezuela.<br />
2216<br />
anaPHYlaXiS aFTEr naSal ProVoCaTion TEST WiTH alTErnaria alTErnaTa EXTraCT<br />
C. gomez-garcia1 , s. sus-Carrizosa1 , m. Olivares1 , C. Chinchilla1 , r. ramirez1 , r. Cardona-Villa1 and m. restrepo2 1 2 University of Antioquia - Grupo de Alergología Clínica y Experimental (GACE), Medellin, Colombia. Allergology, Universidad de<br />
Antioquia, Medellín, Colombia.<br />
2217<br />
PaTiEnT WiTH PEanUT allErgY WiTH nEgaTiVE CUTanEoUS anD in ViTro TESTS, ConFirmED BY oral ConTrollED<br />
FooD CHallEngE<br />
s. Diez 1 , m. restrepo 1 , J. sanchez 1 and r. Cardona 2<br />
1 Allergology, Universidad de Antioquia, Medellín, Colombia. 2 University of Antioquia, Medellin, Colombia.<br />
2218<br />
ECZEma inDUCED BY FooD allErgY: CoUlD iT mimiC an immUnE DEFiCiEnCY?<br />
s. Arshi, m. nabavi, D. Babaie and B. ghalehbaghi<br />
<strong>Allergy</strong> and Clinical Immunology, hazrat-e rasool Hospital, Iran University of Medical Sciences, Tehran, Iran.<br />
13:00 - 14:15 PO2-3: skin and other diseases sheikh rashid F<br />
To view full abstracts from this session, please reference pages 132-138 of the ‘Abstracts’ section in this program.<br />
Chairpersons: salem H. Al-tamami<br />
Barbara rogala<br />
2300<br />
ComParaTiVE EValUaTion oF EPiDEmiologiCal FaCTorS anD ComPliCaTionS oF CaTaraCT SUrgErY in DiaBETiC<br />
PaTiEnTS VErSUS non DiaBETiC PaTiEnTS<br />
F. fayyaz Jahani sr. and A. sA.madani<br />
Medical, Tonekabon Azad University of Medical Sciences, Tonekabon, Iran.<br />
2301<br />
EFFECT oF a SYnBioTiC miXTUrE on aToPiC DErmaTiTiS in CHilDrEn: a ranDomiZED-ConTrollED Trial<br />
H. Ahanchian ii1 , r. Farid2 , F. Jabbari2 and t. moghiman2 1 2 Pediatric <strong>Allergy</strong> and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran. Mashhad University of Medical<br />
Sciences, Mashhad, Iran.<br />
2302<br />
EFFiCaCY oF omaliZUmaB monoTHEraPY in THE managEmEnT oF aToPiC DErmaTiTiS<br />
E. syrigou 1 , A. sinaniotis 1 , J. Paraskevopoulos 2 and P. Psarros 3<br />
1 Department of <strong>Allergy</strong>, “Sotiria” General Hospital, Athens, Greece. 2 Department of <strong>Allergy</strong>, 401 Army Hospital, Athens, Greece.<br />
3 Department of <strong>Allergy</strong>, Naval Hospital, Athens, Greece.<br />
2303<br />
EFFECTiVEnESS oF omaliZUmaB in THE TrEaTmEnT oF ColD UrTiCaria<br />
A. sinaniotis 1 , P. Psarros 2 , g. Paraskevopoulos 3 and E. syrigou 1<br />
1 Department of <strong>Allergy</strong>, “Sotiria” General Hospital, Athens, Greece. 2 Department of <strong>Allergy</strong>, Athens Naval Hospital, Athens, Greece.<br />
3 Department of <strong>Allergy</strong>, 401 Army Hospital, Athens, Greece.<br />
2304<br />
THE aCTiVE Form oF D ViTamin, CalCiTriol 1,25(oH)2D3 anD naTUral PPrgamma agoniST, -3 PolYUnSaTUraTED<br />
FaTTY aCiDS (PUFaS) migHT SErVE aS a nEgaTiVE FEEDBaCK looP To PrEVEnT EXCESSiVE inFlammaTion in PaTiEnTS<br />
WiTH SEVErE aToPiC DErmaTiTiS<br />
t. Zaharov 1 , A. Chaynava 2 , B. A. Kamenov 3 and s. Kamenov 4<br />
1 Pediatrics, Regional Hospital Næstved, Naestvad, Denmark. 2 Pediatrics, Regional Hospital Næstved, Naestved, Denmark. 3 Pediatric<br />
Clinic, Clinical Centre of Nis, Nis, Serbia and Montenegro. 4 Pediatric, Helth Centre of Nis, Nis, Serbia and Montenegro.<br />
www.worldallergy.org 68<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2305<br />
mETHoTrEXaTE For UrTiCarial VaSCUliTiS anD angioEDEma WiTH CrYogloBUlinEmia<br />
A. Butt, m.D., m. Alkhalil, m.D., D. ledford, m.D. and r. F. lockey, m.D.<br />
Division of <strong>Allergy</strong> & Immunology, University of South Florida and James A. Haley Veterans’ Hospital, Tampa, FL.<br />
2306<br />
anTi-igE (omaliZUmaB) EFFECTiVE aS SinglE-DrUg THEraPY For CHroniC iDioPaTHiC UrTiCaria<br />
J. gonzález-Cervera 1 , B. rodríguez-Domínguez sr. 1 , D. Antolín-Amérigo 2 , A. Henríquez-santana 2 , F. J. ruiz Hornillos 2 and D. manzano 1<br />
1 <strong>Allergy</strong>, Hospital General de Tomelloso, Tomelloso, Spain. 2 <strong>Allergy</strong>, Hospital de Valdemoro (Madrid), Madrid, Spain.<br />
2307<br />
PaTiEnT WiTH VaSCUliTiC aUToimmUnE anD PrESSUrE UrTiCaria SUCCESSFUllY TrEaTED WiTH omaliZUamB<br />
s. Diez, J. sanchez, l. tamayo, m. restrepo and r. Cardona<br />
Allergology, Universidad de Antioquia, Medellín, Colombia.<br />
2308<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE TrEaTmEnT oF HErEDiTarY angioEDEma<br />
(HaE) aTTaCKS<br />
t. J. Craig, DO 1 , B. Zuraw 2 , W. lumry 3 , J. Baker 4 , r. levy 5 , D. Hurewitz 6 , m. White 7 , m. riedl 8 , P. Busse 9 , l. Bielory 10 , J. A. grant 11 , i.<br />
Kalfus 12 , C. Broom 13 , s. Villano 13 , m. Uknis 13 , g. tillotson 13 and t. Cinryze study group 14<br />
1 Penn State University, Hershey, PA. 2 The Scripps Research Institute, La Jolla, CA. 3 <strong>Allergy</strong> and Asthma Specialists, Dallas, TX.<br />
4 University of Michigan, Ann Arbor, MI. 5 Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, GA. 6 <strong>Allergy</strong> Clinic of Tulsa, Inc., Tulsa, OK.<br />
7 Institute for Asthma and <strong>Allergy</strong>, Wheaton, MD. 8 UCLA Medical Center, Los Angeles, CA. 9 Mount Sinai School of Medicine, New York,<br />
NY. 10 UMDNJ - New Jersey Medical School, Newark, NJ. 11 University Texas Medical Branch, Galveston, TX. 12 Lev Pharmaceuticals,<br />
Plymouth Meeting, PA. 13 ViroPharma Incorporated, Exton, PA.<br />
2309<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE ProPHYlaXiS oF HErEDiTarY<br />
angioEDEma (HaE) aTTaCKS<br />
B. Zuraw 1 , J. Baker 2 , D. Hurewitz 3 , m. White 4 , A. Vegh 5 , l. Bielory 6 , W. lumry 7 , m. riedl 8 , m. Davis-lorton 9 , r. levy 10 , J. A. grant 11 , P.<br />
Busse 12 , A. Banerji 13 , H. H. li 14 , i. Kalfus 15 , C. Broom 16 , s. Villano 16 , m. Uknis 16 , g. tillotson 16 and t. Cinryze study group 17<br />
1 The Scripps Research Institute, La Jolla, CA. 2 University of Michigan, Ann Arbor, MI. 3 <strong>Allergy</strong> Clinic of Tulsa, Inc., Tulsa, OK. 4 Institute<br />
for Asthma and <strong>Allergy</strong>, Wheaton, MD. 5 Puget Sound <strong>Allergy</strong> Asthma and Imm., Tacoma, WA. 6 UMDNJ - New Jersey Medical School,<br />
Newark, NJ. 7 <strong>Allergy</strong> and Asthma Specialists, Dallas, TX. 8 UCLA Medical Center, Los Angeles, CA. 9 Winthrop - University Hospital,<br />
Mineola, NY. 10 Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, GA. 11 University Texas Medical Branch, Galveston, TX. 12 Mount Sinai<br />
School of Medicine, New York, NY. 13 Massachusetts General Hospital, Boston, MA. 14 Institute for Asthma & <strong>Allergy</strong>, Chevy Chase, MD.<br />
15 Lev Pharmaceuticals, Plymouth Meeting, PA. 16 ViroPharma Incorporated, Exton, PA.<br />
2310<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1inH) For TrEaTmEnT oF aCUTE aTTaCKS oF<br />
HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS<br />
t. J. Craig, DO 1 , W. lumry 2 , J. Baker 3 , m. Davis-lorton 4 , m. manning 5 , i. Kalfus 6 , C. Broom 7 , s. Villano 7 , m. Uknis 7 , g. tillotson 7 and t.<br />
Cinryze study group 8<br />
1 Penn State University, Hershey, PA. 2 <strong>Allergy</strong> and Asthma Specialists, Dallas, TX. 3 University of Michigan, Ann Arbor, MI. 4 Winthrop -<br />
University Hospital, Mineola, NY. 5 <strong>Allergy</strong> and Immunology Associates, Scottsdale, AZ. 6 Lev Pharmaceuticals, Plymouth Meeting, PA.<br />
7 ViroPharma Incorporated, Exton, PA.<br />
2311<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1 inH) For THE ProPHYlaXiS oF aTTaCKS oF<br />
HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS<br />
D. Hurewitz 1 , J. A. grant 2 , P. Busse 3 , m. Davis-lorton 4 , J. Baker 5 , m. riedl 6 , A. Banerji 7 , r. levy 8 , t. J. Craig, DO 9 , i. Kalfus 10 , C.<br />
Broom 11 , s. Villano 11 , m. Uknis 11 , g. tillotson 11 and t. Cinryze study group 12<br />
1 <strong>Allergy</strong> Clinic of Tulsa, Inc., Tulsa, OK. 2 University Texas Medical Branch, Galveston, TX. 3 Mount Sinai School of Medicine, New York,<br />
NY. 4 Winthrop - University Hospital, Mineola, NY. 5 University of Michigan, Ann Arbor, MI. 6 UCLA Medical Center, Los Angeles, CA.<br />
7 Massachusetts General Hospital, Boston, MA. 8 Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, GA. 9 Penn State University, Hershey,<br />
PA. 10 Lev Pharmaceuticals, Plymouth Meeting, PA. 11 ViroPharma Incorporated, Exton, PA.<br />
www.worldallergy.org 69<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
2312<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For TrEaTmEnT or ProPHYlaXiS oF aCUTE<br />
aTTaCKS oF HErEDiTarY angioEDEma (HaE) in PrEgnanT SUBJECTS<br />
J. Baker 1 , m. riedl 2 , A. Banerji 3 , D. Hurewitz 4 , r. levy 5 , t. J. Craig, DO 6 , i. Kalfus 7 , C. Broom 8 , s. Villano 8 , m. Uknis 8 , g. tillotson 8 and t.<br />
Cinryze study group 9<br />
1 University of Michigan, Ann Arbor, MI. 2 UCLA Medical Center, Los Angeles, CA. 3 Massachusetts General Hospital, Boston, MA.<br />
4 <strong>Allergy</strong> Clinic of Tulsa, Inc., Tulsa, OK. 5 Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, GA. 6 Penn State University, Hershey, PA. 7 Lev<br />
Pharmaceuticals, Plymouth Meeting, PA. 8 ViroPharma Incorporated, Exton, PA.<br />
www.worldallergy.org 70<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
Wednesday, 8 December 2010 – Poster Session 3<br />
9:30 – 10:30 PO3-1: immune mechanisms of allergy sheikh rashid F<br />
To view full abstracts from this session, please reference pages 139-145 of the ‘Abstracts’ section in this program.<br />
Chairpersons: robert lemanske<br />
Jung Wong Park<br />
3100<br />
an UnUSUal PrESEnTaTion oF PUlmonarY maSS liKE lESionS SEConDarY To an allErgiC CaUSE<br />
m. rafique, Pulmonologist and B. mahboub, Head, of, Pulmonary, medicine<br />
Department of Pulmonary Medicine, Rashid Hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
3101<br />
ForgoTTEn ParaSiTES in allErgY PraCTiCE<br />
P. Kumar, mD<br />
Medicine, Louisiana State University Health Sciences Center, New Orleans, LA.<br />
3102<br />
CHaraCTEriSTiCS oF rHinoVirUS-inDUCED PBmC immUnE rESPonSES in aSTHmaTiCS, From inFanCY To aDUlTHooD<br />
i. Katsuhito 1 , t. Katsunuma 1 , H. saito, mD, PhD, Director 2 and K. matsumoto, mD, PhD, laboratory, Head 2<br />
1 Pediatrics, Jikei University, school of medicine, Tokyo, Japan. 2 Laboratory for allergy, Department of <strong>Allergy</strong> and Immunology,<br />
National Research Institute for Child Health and Development, Tokyo, Japan, Tokyo, Japan.<br />
3103<br />
CUrCUmin maY inHiBiTS T CEll aCTiVaTion THroUgH STorE-oPEraTED Ca2+ EnTrY CHannElS anD K+ CHannElS<br />
W. K. Kim, Doctor1 and J. H. nam2 1 2 Asthma & <strong>Allergy</strong>, Dongguk University Ilsan Hospital, Goyang, South Korea. Physiology, Dongguk University collage of medicine,<br />
Kyung Ju, South Korea.<br />
3104<br />
nano-SiZED WElDing FUmE inCrEaSES inFlammaTorY CYToKinES, aPoPToSiS anD g2 arrEST in HUman T CEll linE<br />
Y. m. Chiung 1 , P. s. liu 2 , Y. Y. Chen 2 , J. B. lin 1 and C. J. tsai 3<br />
1 Division of Medicine, Institute of Occupational Safety & Health, Taipei County, Taiwan. 2 Department of Microbiology, Soochow<br />
University, Taipei, Taiwan. 3 Institute of Environmental Engineering, National Chiao Tung University, Hsinchu.<br />
3105<br />
THE EFFiCaCY oF a naSal anTiHiSTaminE oloPaTaDinE For THE TrEaTmEnT oF SEroUS oTiTiS mEDia in CHilDrEn<br />
s. nsouli, m, D.<br />
Asthma and <strong>Allergy</strong>, DANVILLE ASTHMA AND ALLERGY CLINIC, DANVILLE, CALIFORNIA, USA, Danville, CA.<br />
3106<br />
ComBinaTion oF a naSal anTiHiSTaminE oloPaTaDinE anD a naSal CorTiCoSTEroiD, momETaSonE For THE<br />
TrEaTmEnT oF SEaSonal allErgiC rHiniTiS PaTiEnTS noT CUrrEnTlY ConTrollED on monoTHEraPY inTranaSal<br />
anTiHiSTaminE or inTranaSal CorTiCoSTEroiD<br />
s. nsouli, mD, AnD, sEniOr, CliniCAl, rEsEArCH, AssOCiAtE<br />
Asthma and <strong>Allergy</strong>, DANVILLE ASTHMA AND ALLERGY CLINIC, CALIFORNIA, USA, Danville, CA.<br />
3107<br />
EXPErimEnTallY UnraVEling THE aToPiC marCH<br />
m. s. Wilson, PhD<br />
Molecular Immunology, NIMR, MRC, London, United Kingdom.<br />
3108<br />
a noVEl rolE For THE ComPlEmEnT rEgUlaTor CD46 in EPiTHElial TigHT JUnCTion FormaTion/rEgUlaTion<br />
s. t. Al-shouli1 and C. Kemper2 1 2 Clinical Immunology and <strong>Allergy</strong>., King’s College London Guy’s and S’t Thomas’ Hospital, London, United Kingdom. MRC Centre for<br />
Transplantation, London, United Kingdom.<br />
www.worldallergy.org 71<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
3109<br />
THE rolE oF EXTErnal PHYSiCal ForCES in TriggEring THE allErgiC rEaCTionS<br />
r. r. Athota, Dr1 , r. r. K. reddy, Dr2 , K. B. neerupudi, mr1 and r. A. sam, Dr3 1 2 3 Biochemsitry, Andhra University, Visakhapatnam, India. Department of Physics, S K University, Anantapur, India. Internal Medicine,<br />
Christian Medical College, Vellore, India.<br />
3110<br />
THE STaTiSTiCS TaKE iT all: ComParaTiVE analYSiS oF THE gEnomiC BaCKgroUnD oF CHilDHooD aSTHma in<br />
CaUCaSian PoPUlaTion<br />
E. Hadadi 1 , i. Ungvari 1 , V. Virag 1 , Z. nemeth 2 , g. Hullam 3 , P. Antal 3 , A. Falus 1 and C. szalai 1<br />
1 Genetics, Cell and Immunbiology, Semmelweis University, Budapest, Hungary. 2 Csertex Kft, Budapest, Hungary. 3 Department of<br />
Measurement and Information Systems, Budapest University of Technology and Economics, Budapest, Hungary.<br />
3111<br />
PrEValanCE oF HUman-mETaPnUEmoVirUS inFECTion in WHEEZY aDmiTTED CHilDrEn<br />
s. Alyasin Jr. 1 and A. moatari2 1 2 Pediatric, Shiraz University of Medical Science, Shiraz, Iran. Influenza Research Center, Shiraz University of Medical Science,<br />
Shiraz, Iran.<br />
3112<br />
SEroPrEValEnCE oF aniSaKiaSiS analiSYS rESiDEnTS From “alDEa DE PESCaDorES” ToWn, PUErTo la CrUZ,<br />
anZoaTEgUi 2010<br />
m. naime, Estudiante, m. sofia and P. Elizabeth<br />
Escuela De Ciencias De La Salud, Universidad de oriente, Puerto La Cruz, Venezuela.<br />
3113<br />
EFFECTS oF VarioUS rESPiraTorY VirUSES on DEr F-SEnSiTiZED moUSE moDEl oF aSTHma<br />
H. H. Kim, Y. H. Chun, J. s. Yoon, J. t. Kim and J. s. lee<br />
Pediatrics, The Catholic University of Korea, Pucheon-si, South Korea.<br />
3114<br />
igg4 aS THE PrEDominanT aUToanTiBoDY in SEra From PaTiEnTS WiTH aCTiVE STaTE oF PEmPHigUS VUlgariS<br />
m. Entezam1 and m. Ayatollahi2 1 2 Genetic Department, Shiraz University of Medical Sciences, Shiraz , Iran. Transplant Research Center, Shiraz University of Medical<br />
Sciences, Shiraz, Iran.<br />
9:30 – 10:30 PO3-2: immunotherapy sheikh rashid F<br />
To view full abstracts from this session, please reference pages 145-151 of the ‘Abstracts’ section in this program.<br />
Chairpersons: nasser Al-Ahmed<br />
glenis scadding<br />
3200<br />
EFFiCaCY oF SUB-lingUal immUnoTHEraPY in PollEn allErgiC aSTHma<br />
A. Khoury, r. Al-Fadel and K. sawas<br />
Chest Diseases, Aleppo Faculty of Medicine, Aleppo, Syria.<br />
3201<br />
SaFETY anD EFFiCaCY oF CarBamYlaTED monomEriC DErmaToPHagoiDES allErgoiD DEPoT FormUlaTion giVEn BY<br />
SUBCUTanEoUS roUTE<br />
P. Fancello1 , i. Atzeni1 , m. Bruno2 and P. Falagiani3 1 2 Allergology Service, “San Gavino Monreale” Hospital - ASL 6, Sanluri (CR), Italy. Medical Service, Lofarma S.p.A., Milan, Italy.<br />
3Scientific Direction, Lofarma S.p.A., Milan, Italy.<br />
3202<br />
CliniCal EFFiCaCY oF SUBCUTanEoUS immUnoTHEraPY giVEn aS a SinglE anD miXTUrE oF TWo non-CroSS<br />
rEaCTiVE allErgEnS in PaTiEnT WiTH SEaSonal allErgiC rHiniTiS<br />
n. A. Arifhodzic, mD, PhD<br />
Department of <strong>Allergy</strong> Clinical Immunology, Kuwait <strong>Allergy</strong> Centre, Kuwait city, Kuwait.<br />
www.worldallergy.org 72<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
3203<br />
ComPariSon BETWEEn THE EFFECT oF BoTH SUBCUTanEoUS anD SUBlingUal immUnoTHEraPY on CUTanEoUS<br />
rEaCTiViTY<br />
n. Al-Ahmed, m.D., ABim, FrCPC1 , n. Arifhodzic, Phd2 , m. Al-Ahmad1 and A. Al-Enezi1 1 2 Department of <strong>Allergy</strong>, Al-Rashed <strong>Allergy</strong> Centre, Ministry of Health, State of Kuwait, Kuwait, Kuwait. <strong>Allergy</strong>, AL-Rashed allergy<br />
Centre, Kuwait, Kuwait.<br />
3204<br />
KinD oF SEnSiTiZaTion in SUBJECTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE STUDY<br />
(ParT i)<br />
P. simone1 and P. Amboni2 1 2 USC Pneumologia, Ospedali Riuniti di Bergamo, Bergamo, Italy. USC Patologia Clinica e Laboratorio Analisi, Ospedali Riuniti di<br />
Bergamo, Bergamo, Italy.<br />
3205<br />
CliniCal CHaraCTEriSTiCS oF PaTiEnTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE<br />
STUDY (ParT ii)<br />
P. simone1 and P. Amboni2 1 2 USC Pneumologia, Ospedali Riuniti di Bergamo, Bergamo, Italy. USC Patologia Clinica e Laboratorio Analisi, Ospedali Riuniti di<br />
Bergamo, Bergamo, Italy.<br />
3206<br />
a SUrVEY oF allErgEn SPECiFiC immUnoTHEraPY in KorEa<br />
g. Y. Hur 1 , t. B. Kim 2 , m. Y. Han 3 , D. H. nahm 4 and J. W. Park, mD., PhD. 5<br />
1 Internal Medicine, Korea University College of Medicine, Seoul, South Korea. 2 Department of <strong>Allergy</strong> and Clinical Immunology,<br />
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3 Pediatrics, Pochon CHA University College of<br />
Medicine, Seoul, South Korea. 4 <strong>Allergy</strong> & Rheumatology, Ajou University School of Medicine, Seoul, South Korea. 5 Division of <strong>Allergy</strong><br />
& Immunology Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.<br />
3207<br />
SUCCESSFUl gamma-inTErFEron THEraPY in a CaSE oF rEFraCTorY VaCCinE-aSSoCiaTED aBSCESS in a CgD PaTiEnT<br />
m. nabavi 1 , s. maherbanai 1 and m. H. Bemanian 2<br />
1 Semnan Medical University, Tehran, Iran. 2 Yazd medical university, Yazd, Iran.<br />
3208<br />
FloW CYTomETrY aS a Tool For DElaYED DrUg allErgY rEaCTionS DiagnoSiS: oUr EXPEriEnCE<br />
s. Ardito 1 , m. De Donno 2 , V. Aiello 2 , m. l. iaia 1 and g. maietta 2<br />
1 <strong>Allergy</strong> Department, Perrino Hospital, Brindisi, Italy. 2 Cellular Immunology, Pignatelli Institute, Lecce, Italy.<br />
3209<br />
CliniCal CHaraCTEriSTiCS oF oral TolEranCE inDUCTion oF non-igE mEDiaTED FooD allErgY USing iFn-gamma<br />
J. H. lee sr. and g. noh<br />
Department of Pediatrics, School of Medicine, Chungnam National University, Taejeon, South Korea.<br />
3210<br />
THE rolE oF immUnoTHEraPY in aSTHma anD rHiniTiS<br />
l. Hwejeh, mD<br />
Chest Department, ALASAD UNIVERSITY HOSPITAL IN DAMASCUD, Damascus, Syria.<br />
3211<br />
CHroniC aSTHma in aDUlTS<br />
D. Aguilar<br />
MEDICINE DIVISION, JUAREZ HOSPITAL, Mexico DF, Mexico.<br />
www.worldallergy.org 73<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
3212<br />
SUBCUTanEoUS immUnoTHEraPY For TrEE PollEn allErgY WiTH a PrEParaTion WiTH oPTimiSED allErgEn<br />
alUminiUm HYDroXiDE raTio: an oPEn laBEl oBSErVaTional STUDY inVESTigaTing TolEraBiliTY anD<br />
EFFECTiVEnESS in THE roUTinE USE in DailY PraCTiSE<br />
U. neumann 1 , H. Wolf 2 , J. schnitker 3 and E. g. Wuestenberg 4<br />
1 ENT-Physician, Wolmirstedt, Germany. 2 Clinical Development, ALK-Abelló, Wedel, Germany. 3 Institut für angewandte Statistik,<br />
Bielefeld, Germany. 4 Medical and Regulatory Affairs, ALK-Abelló, Wedel, Germany.<br />
3213<br />
immUnomoDUlaTorY PoTEnTial oF mESEnCHYmal STEm CEll ProViDE a PromiSing alTErnaTiVE For TrEaTmEnT oF<br />
liVEr TranSPlanTaTion<br />
m. Ayatollahi 1 , m. Entezam 2 and B. geramizadeh 3<br />
1 Transplant Research Center, Stem Cells & Transgenic Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2 Genetic<br />
Department, Shiraz University of Medical Sciences. 3 Transplant Research Center, Shiraz University of Medical Sciences.<br />
9:30 – 10:30 PO3-3: Pediatric allergies sheikh rashid F<br />
To view full abstracts from this session, please reference pages 151-162 of the ‘Abstracts’ section in this program.<br />
Chairpersons: Alessandro Fiocchi<br />
nizar Kherallah<br />
3300<br />
STUDY oF THE rElaTionSHiP BETWEEn ToTal anD SPECiFiC igE in SCHool agE aSTHmaTiC CHilDrEn<br />
O. A. Al Janabi<br />
<strong>Allergy</strong>, <strong>Allergy</strong> And Asthma Center Baghdad, Baghdad, Iraq.<br />
3301<br />
a STaTiSTiCal STUDY oF THE moST Common allErgEnS in CHilDrEn, WHo SUFFEr From DiSEaSES or allErgiC<br />
rEaCTionS in THE CiTY oF laTaKia (SYrian CoaST)<br />
g. s. Did<br />
department of pediatric – faculty of medicine – Tishreen University – Lattakia - Syria, Lattakia, Syria<br />
3302<br />
ConnECTionS oF aSTHma anD rESPiraTorY inFECTionS in BoSnian CHilDrEn<br />
A. Bajraktarevic, Prim, Dr, med1 , A. Hadzimurtezic1 , V. Pavlovic1 , m. miokovic1 , A. mahinic1 , A. selimovic2 , i. suljevic3 , Z.<br />
Hadzimurtezic4 and l. sporisevic5 1 2 Pediatrics Department, Public Health Insitution of Canton Sarajevo, Sarajevo, Bosnia. Pulmonology Pediatrics Department,<br />
Pediatrics Clinic Sarajevo, Sarajevo, Bosnia. 3Department for Biochemistry, Clinical Medical Center Sarajevo, Sarajevo, Bosnia.<br />
4 5 Asthma Department, UMC Sarajevo- Clinic for Pulmology, Sarajevo, Bosnia. Pediatrics Department, First Medical Aid Sarajevo,<br />
Sarajevo, Bosnia.<br />
3303<br />
CHilDHooD aSTHma anD oPPorTUniSTiC inFECTionS oF HiV PoSiTiVE CHilDrEn in BoSnia anD HErZEgoVina<br />
A. Bajraktarevic, Prim, Dr, med1 , A. Hadzimurtezic1 , m. Omerovic1 , A. mahinic1 , Z. Hadzimurtezic2 , A. Djurdjevic Djulepa3 , l.<br />
sporisevic4 , A. selimovic5 , B. Vranic6 and i. suljevic7 1 2 Pediatrics Department, Public Health Insitution of Canton Sarajevo, Sarajevo, Bosnia. Asthma Department, UMC Sarajevo- Clinic<br />
for Pulmology, Sarajevo, Bosnia. 3Perinatology Department, General Hospital Sarajevo, Sarajevo, Bosnia. 4Pediatrics Department,<br />
First Medical Aid Sarajevo, Sarajevo, Bosnia. 5Pulmonology Pediatrics Department, Pediatrics Clinic Sarajevo, Sarajevo, Bosnia.<br />
6 7 Pulmonology Pediatrics Department, Infectious Clinic Sarajevo, Sarajevo, Bosnia. Department for Biochemistry, Clinical Medical<br />
Center Sarajevo, Sarajevo, Bosnia.<br />
3304<br />
THE EFFECT oF CEllUloSE PoWDEr (naSalEZE) on THE CoUrSE oF SEaSonal allErgiC rHiniTiS<br />
m. Kherkheulidze, n. Kavlashvili, E. Kandelaki and n. Adamia<br />
Pediatrics, State Medical University, Tbilisi, Georgia.<br />
www.worldallergy.org 74<br />
FinAl PrOgrAm
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
3305<br />
EPiDEmiologY oF rHiniTiS in SEConDarY SCHool CHilDrEn USing mSYPQ (moDiFiED Sino-naSal oUTComE TEST-20<br />
YoUng PErSon QUESTionnairE) anD ComPariSon WiTH moDiFiED SnoT-20 USED in aDUlT CommUniTY BaSED SUrVEY<br />
A. s. sami, mBBs, Bsc, ODtC, mCPs, mA, msc<br />
Ent, Royal National Throat, Nose and Ear Hospital, London, United Kingdom.<br />
3306<br />
SEVErE aToPiC DErmaTiTiS ComPliCaTED WiTH FooD ProTEin-inDUCED gaSTroinTESTinal SYnDromE, CaSE rEPorT<br />
oF 5 inFanTS<br />
K. Yamamoto, i. nomura, t. shoda, Y. tsumura, K. Yoshida, K. Horimukai, t. Fukuie, m. Futamura, m. narita and Y. Ohya<br />
Division of <strong>Allergy</strong>, National Center for Child Health and Development, Tokyo, Japan.<br />
3307<br />
THE PrEValEnCE oF CHilDHooD aSTHma, allErgiC rHiniTiS anD aToPiC DErmaTiTiS in YErEVan<br />
s. s. gambarov, l. V. Kostanyan and A. s. Zakharyan<br />
Clinical Immunology and <strong>Allergy</strong>, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia.<br />
3308<br />
PrEVEnTaBlE imPaCT oF SUPlaTaST ToSilaTE DoSagE on aSTHma onSET in inFanTS<br />
O. norifumi 1 , O. norifumi 2 , m. Kentaro 3 , O. Hiroaki 4 , i. Atsushi 5 , K. Yutaka 5 , s. toshiaki 2 and n. takeshi 2<br />
1 Pediatrics, Chiba Aiyukai Memorial Hospital, Chiba, Japan. 2 Pediatrics, Kitasato University School of Medicine, Japan.. 3 Department<br />
of Pediatrics, Chiba Aiyukai Memorial Hospital, Chiba, Japan. 4 Department of Pediatrics, Tokyo Kousei-Nenkin Hospital, Japan.<br />
5 Department of Pediatrics, Yokohama City Minato Red Cross Hospital, Japan.<br />
3309<br />
EValUaTion oF Small airWaYS oF JaPanESE CHilDHooD aSTHma BY HrCT anD iTS aSSoCiaTion WiTH SnPS<br />
m. tomikawa, m.D. 1 , t. Oguma, m.D. 2 , A. niimi, m.D., Ph.D. 2 , E. matsui, m.D., Ph.D. 3 , n. Kondo, m.D., Ph.D. 3 and m. Ebisawa, m.D.,<br />
Ph.D. 1<br />
1 Pediatrics, Sagamihara National Hospital, Sagamihara, Japan. 2 Respiratory Medicine, Graduate School of Medicine, Kyoto<br />
University, Kyoto, Japan. 3 Pediatrics, Graduate School of Medicine Gifu University, Gifu, Japan.<br />
3310<br />
riSK FaCTorS For CHilDHooD aSTHma<br />
n. Kavlashvili, m. Kherkheulidze, E. Kandelaki, n. Adamia and i. Chkhaidze<br />
Pediatrics, State Medical University, Tbilisi, Georgia.<br />
3311<br />
allErgiC ProFilE oF aSTHmaTiC CHilDrEn in a CoaSTal CiTY in THE WEST oF algEria<br />
A. Benyounes sr.<br />
ANAP, Algiers, Algeria.<br />
3312<br />
THE rolE oF CHiTinaSE-liKE ProTEinS in allErgiC inFlammaTion on PEDiaTriC aDEnoiD TiSSUE<br />
s. Y. shin 1 , Y. m. Ye 2 , K. H. lee 1 , s. W. Kim 1 , J. s. Cho 1 and H. s. Park 2<br />
1 Otorhinolaryngology-Head and Neck Surgery, Kyung Hee University, Seoul, South Korea. 2 Department of <strong>Allergy</strong> & Rheumatology,<br />
Ajou University School of Medicine, Suwon, South Korea.<br />
3313<br />
PaSSiVE SmoKing iS a maJor DETErminanT oF EXHalED niTriC oXiDE lEVElS in allErgiC aSTHmaTiC CHilDrEn<br />
Y. laoudi 1 , l. nikasinovic 2 , F. sahraoui 1 , A. grimfeld 1 , i. momas 2 and J. Just 1<br />
1 Department of Asthma and Allergic Diseases, Armand Trouseau Children University Hospital, Paris, France. 2 Laboratory of Public<br />
health and Environment, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris-Descartes, EA 4064, Paris, France.<br />
3314<br />
PrEValEnCE oF allErgiC rHiniTiS in SCHool CHilDrEn PoPUlaTion oF TBiliSi anD WESTErn gEorgia<br />
m. Kherkheulidze, n. Adamia, E. Kandelaki and n. Kavlashvili<br />
Pediatrics, State Medical University, Tbilisi, Georgia.<br />
www.worldallergy.org 75<br />
FinAl PrOgrAm<br />
POstErs
POstErs<br />
POstErs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
3315<br />
aDiPonECTin lEVElS in oBESE anD nonoBESE CHilDrEn WiTH aSTHma<br />
s. s. Zivanovic, l. m. saranac, D. r. Djordjevic, s. P. Kovacevic and B. A. Kamenov<br />
Pediatric Clinic, Clinical Centre of Nis, Nis, Serbia and Montenegro.<br />
3316<br />
rElaTionSHiP oF EoSinoPHil CoUnT anD igE WiTH THE SEVEriTY oF PErEnnial allErgiC rHiniTiS in CHilDrEn<br />
Y. H. rha1 and m. s. Kim2 1 2 Department of Pediatrics, Kyung Hee University Hospital, Seoul, South Korea. Department of Pediatrics, Aigumteo Children’s<br />
Hospital, Daegu, South Korea.<br />
3317<br />
rolE anTEnaTal anD PoSTnaTal FaCTorS in oCCUrrEnCE oF an allErgiC DiaTHESiS aT CHilDrEn WHo HaVE BEEn<br />
Born in CiTY loCaTED nEar To nUClEar EnTErPriSE<br />
n. Petrushkina<br />
Departament of physiology, Ural State Univercity Physical Culture, Chelyabinsk, Russia.<br />
3318<br />
an ESTimaTion oF THE rESPTaTorY’S FUnCTion CHilDrEn WHo liVE nEar aTomiC PlanT<br />
n. Petrushkina ii<br />
Departament of Physiology, Ural State Physical Culture, Chelyabinsk, Russia.<br />
3319<br />
PUlmonarY FUnCTion TEST in HEalTHY CHilDrEn 7 To 9 YEarS aFTEr rESPiraTorY Viral inFECTionS<br />
C. B. Kartasasmita iV, Prof/PhD, s. sudarwati, D. A. Wulandari, A. U. suwardi, W. saptaputra, i. nuradi, m. Kuswandewi and E. A.<br />
simoes<br />
Department of Child Health, Hasan Sadikin/School of Medicine Padjadjaran University, Bandung, Indonesia, Bandung, Indonesia.<br />
3320<br />
CliniCal ProFilE anD riSK FaCTorS in HoSPiTaliZED CHilDrEn WiTH BronCHioliTiS<br />
i. Kirovski, l. nikolovski, A. sazdovski, V. micevska and l. seckova<br />
Department of Pulmonology and Allergology, University Children’s Hospital, Skopje, Macedonia.<br />
3321<br />
aSSoCiaTion BETWEEn THE oVErWEigHT anD allErgiC DiSEaSES in SCHool agE CHilD PoPUlaTion oF TBiliSi<br />
m. Kherkheulidze, n. Kavlashvili, E. Kandelaki and n. Adamia<br />
Pediatrics, State Medical University, Tbilisi, Georgia.<br />
3322<br />
aSTHma anD iTS CorrElaTES in CHilDrEn<br />
n. takzaree 1 , n. Daneshvar 2 and A. takzaree 3<br />
1 Dept of Anatomy, Tehran university of Medical Sciences, Faculty of Medicine., Tehran, Iran. 2 Dapt of Histology, Amam khomnei<br />
Hospital, Tehran, Iran. 3 General Medicine, Amam khomnei Hospital, Tehran.<br />
3323<br />
CrEaTiVE agEnTS oF aSTHma in CHilDHooD<br />
n. takzare 1 , n. Daneshvar 1 , A. takzare 1 and H. Forutan 2<br />
1 Tehran university of Medical Sciences, Faculty of Medicine., Tehran, Iran. 2 Amam khomeine Hospital, Tehran, Iran.<br />
3324<br />
EValUaTion oF USing VBg inSTEaD oF aBg in aSTHma EXaCErBaTion<br />
m. Fatemi Khorasgani1 , E. niazi1 and s. Farzaneh2 1 2 Pediatrics, Islamic Azad University-Najafabad branch, Isfahan, Iran. Anesthesiology, Islamic Azad University-Najafabad branch,<br />
Isfahan, Iran.<br />
www.worldallergy.org 76<br />
FinAl PrOgrAm
ABstrACts<br />
ABstrACts<br />
PoSTEr SESSion 1-1: allergens and risk factors<br />
1100<br />
allErgiC aSTHma in SYrian aDUlTS<br />
Khoury, A., merrawi, m. and Joukaji, A.<br />
Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria.<br />
objective the interest of our study was to investigate the most important Allergens responsible for Atopic Bronchial Asthma in<br />
syrian Adults.<br />
methods :76 Adults asthmatics aging (16-45 y.) consulting our Department between January 2008- January 2009, with 37 male<br />
patients (48.6%), and 39 Female patients (51.3%), all patients had a skin Prick tests (sPts-stAllErgEnEs lab.)and specific and<br />
total igE measurements using the ClA-sYstEm method(multiple Allergens sensibility test).<br />
results the Prevalence of Allergic Asthma is more common in the town (70.3%) than in the Country (29.7%).there was a history<br />
of positive smoking in 18.5%of our group, with a 70.8%of patients had positive familial history of Asthma. there was an Allergic<br />
rhinitis(30.4%) , Allergic Conjunctivitis(15.3%) ,and Urticaria(10.7%) in our patients.<br />
the most common Allergens in the sPts were:Dpt+Df(59%),grass Pollens(50.66), Cats&Dogs(19.2%),Fungi(8.2%)and tree<br />
Pollens(4.6%).<br />
the most common Allergens in the mAst were: Dpt+Df(57.7%0,grassPollens(49.3%),Cats&Dogs(23.5%),Fungi(11.2%),and tree<br />
Pollens(3.9%).<br />
Conclusions Bronchial Asthma is a common disease in our Country. <strong>Allergy</strong> to House Dust mite and to grass Pollens were<br />
comparable to western European Countries, but <strong>Allergy</strong> to pets and tree pollens were lower<br />
1101<br />
oCCUPaTional aSTHma in PETroCHEmiSTrY WorKErS WiTH PErSiSTanT EXPoSUrE<br />
Eatemadi, A.<br />
immunology & infectious disease, Ahvaz univrsity of medical siences, Ahvaz, iran.<br />
Background: to evaluate the effect of treatment with Fluticasone / salmeterol combination on respiratory symptoms and<br />
pulmonary function tests ( PFt ) in petrochemistry workers with occupational asthma (OA) and persistant exposure in work place.<br />
method: 40 workers with known history of OA enrolled in this study.twice daily inhalation therapy with Fluticasone propionate (500<br />
mcg ) and salmeterol ( 50 mcg ) was initiated. At the enrollment and every 3 months, PFt and respiratory symptom score (rss)<br />
were checked for one year period. need for emergency use of salbutamol also was recorded .<br />
results: mean baseline FEV1 was 80% of predicted values, but no statistically significant differences in FEV1 and rss were seen<br />
compare to baseline values after one year treatment.<br />
Conclusion : regular use ofcombination therapy with inhaled corticosteroids and long-acting bronchodilators can prevent<br />
respiratory symptoms deterioration over one year period in petrochemistry workers with occupational asthma and persistant<br />
exposure in work place.<br />
1102<br />
SPECiFiC igE SEnSiTiZaTion To CEPHaloSPorinS in HoSPiTal PErSonnEl<br />
Kim, J. , Kim, s. , Jin, H. , Kim, J. , Ye, Y. and Park, H.<br />
Department of <strong>Allergy</strong> & rheumatology, Ajou University school of medicine, suwon, south Korea.<br />
Background: Cephalosporins can induce occupational allergies including asthma, urticaria, and anaphylaxis. this study evaluates<br />
the sensitization rate and the risk factors for sensitization to cephalosporins in hospital personnel.<br />
method: A total of 167 hospital personnel, including 128 nurses working at wards (currently being exposed group), 14 nurses<br />
working at outpatient clinics or at offices (not currently but previously exposed group), and 25 pharmacists (unexposed group) were<br />
enrolled. We also enrolled 86 unexposed non-atopic healthy controls. the questionnaire contained items including the work place,<br />
intensity of exposure, duration of employment, cephalosporin associated work related symptoms (Wrs), and past history of allergic<br />
diseases including bronchial asthma, allergic rhinitis, atopic dermatitis, chronic urticaria, and experiences of internal or parenteral<br />
antibiotic use and antibiotic allergy after those. skin prick tests (sPts) to commonly used intravenous cephalosporins including<br />
cefotiam, ceftriaxone, and ceftizoxime and sPt to common inhalant allergens were performed. serum specific igE antibodies to<br />
each cephalosporin-HsA conjugate were measured by ElisA. total igE level was measured by immunoCAP system. the binding<br />
specificities were confirmed by ElisA inhibition tests.<br />
www.worldallergy.org 78<br />
FinAl PrOgrAm
ABstrACts<br />
results: the prevalence of cephalosporin associated Wrs was 17.0%. Ceftriaxone was the only cephalosporin which responded<br />
to sPt and the sensitization rate using sPt to ceftriaxone was 3.1%. the sensitization rate using serum specific igE antibody to any<br />
cephalosporin-HsA conjugate was 17.0%, where the sensitization rate was the highest to cefotiam (9.1%) followed by ceftriaxone<br />
(6.7%) and ceftizoxime (3.6%). the past history of antibiotic allergy was a risk factor for cephalosporin associated Wrs (Or, 24.9;<br />
95% Ci, 2.6-238). On the other hand, the past history of atopic dermatitis was a risk factor for high serum specific igE antibody (Or,<br />
6.5; 95% Ci, 1.2-34.6) to cefotiam-HsA conjugate.<br />
Conclusion: Cephalosporins can be sensitized through the skin contact as well as inhalation in hospital personnel. Atopic dermatitis<br />
would be a risk factor for sensitization to cefotiam. monitoring of serum specific igE to cephalosporin-HsA conjugate would be more<br />
useful to detect the sensitized subjects than sPt.<br />
1103<br />
HoUSE DUST miTE allErgY – inDian PErSPECTiVE<br />
saha, g. K.<br />
Zoology, Department of Zoology, University of Calcutta, Kolkata, india.<br />
Background : An increasing trend in the prevalence of allergic diseases has been noticed from the developing countries due to<br />
many factors like metamorphic change in ambient air quality due to rapid urbanization and industrialization, subsequent increase<br />
in air pollution, change in living and dietary habits etc. mites being in house dust represent a major source of allergens resulting<br />
various allergic manifestations and information regarding the house dust mites (HDms) is of great importance to provide the<br />
patients with best possible diagnosis and management. As expected, information in this regard is mostly available from western<br />
and developed countries.<br />
methodology : the present study represents a comprehensive information on their diversity, habitat preference, seasonal<br />
occurrence in Kolkata metropolis and their probable role in nasobronchial allergic manifestations through allergy skin test,<br />
quantification of total igE antibody and detection of allergen specific igE antibodies.<br />
results & Discussion : During last ten years study period, a total of 54 species of mites belonging to 34 genera and 13 families<br />
under 3 orders have been identified, of which 5 species are new to science. Dermatophagoides pteronyssinus is the most<br />
predominant mite species, comprising 47% of total acarine fauna. species diversity index indicates that the maximum number and<br />
variety of mites are found in Pre-monsoon period and minimum in Winter. Patients’ bed contains higher mite population than the<br />
corresponding bed-room floor dust. results of skin Prick test (sPt) revealed that sensitivity towards house dust and house dust<br />
mites are 96% and among them more than 75% patients are sensitive to Dermatophagoides pteronyssinus, 63% to D. farinae and<br />
72% to Blomia tropicalis mite allergens. information regarding sensitivity to Blomia tropicalis mite is new to indian population. the<br />
difference between patients and control mean serum igE level is statistically significant (p< 0.05) and 93.5% patients are with<br />
elevated (300 iU/ml) serum igE level. identification of allergen specific igE antibodies by immuno CAP syatem shows that 79.77%<br />
patients respond to HD allergen, 71.91 % to DP and 88.76% to DF allergens while 90% patients respond to Bt allergen which<br />
further confirms the result of sPt.<br />
1104<br />
SEnSiTiZaTion raTE anD riSK FaCTorS For SEnSiTiZaTion To DigESTiVE EnZYmES in HoSPiTal PErSonnEl<br />
Kim, J. , Jin, H. , Kim, J. , Ye, Y. and Park, H.<br />
Department of <strong>Allergy</strong> & rheumatology, Ajou University school of medicine, suwon, south Korea.<br />
Background: Hospital personnel can be sensitized by the inhalation of digestive enzymes and develop occupational asthma and<br />
rhinitis. Our previous reports demonstrated a high prevalence of serum specific igE antibodies to digestive enzymes in exposed<br />
subjects with work related symptoms. this is a follow up study 3 years after the first intervention to evaluate the change of the<br />
sensitization rate and risk factors in hospital personnel. method: A total of 167 hospital personnel, including 25 pharmacists (higher<br />
exposure group) and 142 nurses (lower exposure group), in a tertiary hospital were enrolled. We also recruited 86 unexposed nonatopic<br />
healthy controls. the questionnaire contained items including the workplace, intensity of exposure, duration of employment,<br />
digestive enzyme-associated work related symptoms (Wrs), and past history of allergic diseases such as bronchial asthma, allergic<br />
rhinitis, atopic dermatitis, chronic urticaria, and drug allergies. skin prick tests (sPts) using biodiastase, the most commonly<br />
prescribed digestive enzyme, and common inhalant allergens were performed. serum specific igE antibodies to biodiastase and<br />
porcine α-amylase were measured by ElisA. the total igE level was measured by the immunoCAP system. results: the prevalence<br />
of digestive enzyme-associated Wrs was 36.0% in pharmacists and 4.2% in nurses. the sensitization rates in pharmacists using<br />
the sPt to biodiastase (37.5%) and serum specific igE antibodies to biodiastase and/or porcine α-amylase (25.0%) increased over<br />
the previous report (both 16.7%). the sensitization rate in nurses using the sPt to biodiastase (9.6%) was similar to that of the<br />
previous report (9.6%), while the sensitization rate using serum specific igE antibodies to biodiastase and/or porcine α-amylase<br />
(3.5%) decreased from that of the previous report (8.9%). Past history of atopic dermatitis (Or, 28.6; 95% Ci, 4.1-200.4) and drug<br />
www.worldallergy.org 79<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
allergies (Or, 6.9; 95% Ci 1.2-39.6) were found to be risk factors for the sensitization to digestive enzymes. Conclusion: the<br />
sensitization rate to digestive enzymes in pharmacists increased after the first intervention performed 3 years ago. the sPt to<br />
digestive enzymes would be more useful in the detection of sensitized subjects than the monitoring of serum specific igE antibodies<br />
to digestive enzymes. skin contact as well as inhalation could be a route for sensitization to digestive enzymes in hospital<br />
personnel.<br />
1105<br />
SKin TEST rEaCTiViTY in THE EaSTErn ProVinCE oF SaUDi araBia<br />
KHOUQEEr, r.<br />
<strong>Allergy</strong> and immunology, saad specialist Hospital, Alkhobar, saudi Arabia.<br />
Background: Allergic disease prevalence and incidence are increasing worldwide for unknown reasons, with the steepest rise<br />
occurring in industrialized societies. Allergic diseases affect more than 20% of the U.s. population and are the sixth leading cause<br />
of chronic disease in the United states. However in saudi Arabia still there are (scanty) data on the incidence and the prevalence<br />
of the allergic diseases. saudi Arabia has a fast growing population with an estimated population around 30 millions people, the<br />
majority of them in the young-middle age group<br />
there were conflicting data published earlier on the most common allergen in saudi Arabia with small size studies<br />
objective: to investigate the pattern of skin reactions among the Eastern Province population of the Kingdom of saudi Arabia<br />
methods: this is a cross sectional data analysis of standard prick and intradermal tests, which were performed to our patients,<br />
visited saad specialist Hospital in Al-Khobar city in saudi Arabia between<br />
results: A total of 217 subjects 192 saudi and 19 non-saudis age between July2006 -July2009 were tested, 181 of them had only<br />
Pst and 36 an iD skin test was done after the initial Pst, 27 of them tested to foods and 192 patients to aeroallergens, thee most<br />
common food allergen found was to Eggs 29.6% followed by milk 22.2% then Peanut 14.8%, the most frequent aeroallergens<br />
found were HDm (23.7%), cat (12%), russian thistle (11%), Kochia (8.6%), lambs Quarter (8%), followed by cockroach (6.6%) then<br />
mesquite (6%)<br />
Conclusion: Our food skin reactivity was consistent with that of the literature; on the aeroallergen we noticed a change in the<br />
pattern of the previously published data, which could be multifactorial in origin including environmental changes, a long with<br />
changes in the living habits of individuals.<br />
1106<br />
QUanTiFiCaTion oF a 24 KD maJor allErgEn oF CULEX QUINQUEFASCIATUS WHolE BoDY EXTraCT BY immUnologiCal<br />
TECHniQUES<br />
Kausar, m. A. 1 , Vijayan, V. 2 , Bansal, s. 3 , Vermani, m. 4 , siddiqui, W. 5 and Agarwal, m. 6<br />
1 2 Departments of respiratory <strong>Allergy</strong> and Applied immunology, VP Chest institute, University of Delhi, new Delhi, india. Department<br />
of respiratory medicine, V.P. Chest institute, Delhi, india. 3Department of Biochemistry, V.P. Chest institute, Delhi, india. 4Department of respiratory <strong>Allergy</strong> and Applied immunology, V.P. Chest institute, Delhi, india. 5Department of Biochemistry, Jamia Hamdard,, new<br />
Delhi, india. 6Department of respiratory <strong>Allergy</strong> and Applied immunology, Formerly at V.P. Chest institute, Delhi, india.<br />
introduction:<br />
in an earlier study, we have reported the identification, isolation and purification of a 24 kd major allergenic protein of crude<br />
mosquito (Culex quinquefasciatus; Cq) extract1 . We further quantified this 24 kd purified protein in crude Cq extract which may<br />
serve as a reference reagent for the quality control of commercially available Cq extract.<br />
methods:<br />
ElisA and ElisA inhibition assays were developed for quantification of 24 kd purified protein in crude Cq extract.<br />
results:<br />
Dose-related inhibition was obtained in Cq-Frib ElisA with the purified protein (24 kd) as well as crude Cq WBE. Dose of purified<br />
protein and crude Cq WBE required for 50% inhibition (calculated from inhibition curves) was 144 ng and 1145 ng, respectively;<br />
i.e. 125.8 μg/mg of crude lyophilized Cq WBE. since, 1 ml of 1:20 w/v Cq WBE solution contains 3.7 mg of crude Cq WBE, it is<br />
recommended that the amount of purified protein in this solution should be 465.5 μg/ml of 1:20 w/v mosquito extract. Further,<br />
for performing iD tests (1:500 w/v), the Cq extract solution should contain 18.6 μg/ml of the purified protein. Accordingly, the<br />
concentration of purified protein in the Cq WBE for various dilutions of immunotherapy vaccine may be also calculated for quality<br />
control purposes.<br />
Conclusion:<br />
the 24 kd purified major allergenic proteins of Cq may be used as a reference reagent for the standardization of Cq extract used for<br />
www.worldallergy.org 80<br />
FinAl PrOgrAm
ABstrACts<br />
effective diagnosis and efficacious immunotherapy of millions of patients of respiratory allergy in our country. it is recommended<br />
that this purified protein may be used as a reference reagent for quality control of commercially available mosquito WBE.<br />
reference:<br />
1. Kausar mA, Vijayan VK, Bansal sK, Vermani m and Agarwal mK. isolation and purification of a 24 kd major allergen of Culex<br />
quinquefasciatus whole body extract. Annals of <strong>Allergy</strong>, Asthma and immunology 2009;102:23.<br />
1107<br />
PrEValEnCE oF aSTHma in ElEmEnTarY SCHool STUDEnTS aFTEr an oil lEaK in THE WESTErn CoaST oF KorEa<br />
Jee, Y. 1 , Kim, K. 1 , Kim, D. 1 , Kim, Y. 1 , Park, J. 1 , Jeong, W. 2 , Hur, J. 2 , Jung, s. 3 and roh, s. 3<br />
1 2 internal medicine, Dankook University College of medicine, Cheonan, south Korea. taean institute of Environmental Health, taean,<br />
south Korea. 3Occupational and Environmental medicine, Dankook University College of medicine, Cheonan, south Korea.<br />
objective<br />
the aim of this study was to investigate the impact of the exposure to oil leak on pulmonary function and prevalence of asthma in<br />
the elementary school students in taean, where were located in the western coast of republic of Korea and exposed to offshore oil<br />
leak on December 7th , 2007<br />
Subjects and methods<br />
Of 662 eligible students, 477 (72.1%) subjects who agreed to and completed the health assessment were enrolled on June 2009.<br />
A Questionnaire developed by the international study of Asthma and Allergic diseases in Children (issAC) was modified and used.<br />
methacholine bronchial provocation tests (mBPt) were performed in 109 (22.9%) subjects who reported asthmatic symptoms in<br />
the questionnaire. Participants were stratified into two exposure groups (high vs. low). general characteristics and asthma-related<br />
symptoms, and prevalence of asthma were compared.<br />
results<br />
there were no statistically significant differences in sex, age, Bmi, and family history of asthma between the two groups. the<br />
number of children who was previously diagnosed asthma, began wheezing after oil leak or had current asthma symptoms was<br />
significantly higher in the high-exposure group than that in the low-exposure group (previously diagnosed asthma; 20.6% vs<br />
11.6%, P=0.008, wheezing after the oil leak; 6.7% vs 1.0%, P=0.01, current asthma symptoms; 30.6% vs 18.6%, P=0.00). FEV1 was significantly lower in the high-exposure group than that in the low-exposure group (82.6±10.8% vs 85.2±10.3%, P=0.01).<br />
those who showed positive (PC20°Â16mg/ml) response in the bronchial provocation test was significantly higher in the highexposure<br />
group than that in the low-exposure group (18.2% vs 7.6%, P=0.00). logistic regression on asthma indicated increased<br />
odds for male (Or: 1.88, 95%Ci: 1.04-3.41), children with family history of asthma (Or: 4.02, 95%Ci: 1.38-11.71), and highexposure<br />
group (Or: 3.26, 95%Ci: 1.79-5.92) adjusting for age, sex, and Bmi.<br />
Conclusion<br />
the study suggest that exposure to oil leak can be a risk factor in the development of asthma in elementary school students<br />
although the causality is not certain. Follow-up studies and further analyses with biologic exposure index will elucidate the<br />
relationship between oil leak and asthma.<br />
1108<br />
PrEValEnCE oF CHroniC oBSTrUCTiVE PUlmonarY DiSEaSE anD iTS aSSoCiaTion WiTH ToBaCCo SmoKing anD<br />
EnVironmEnTal ToBaCCo SmoKE EXPoSUrE among rUral PoPUlaTion<br />
B g, P. 1 , Huliraj, n. 2 , s P, P. K. 1 , B m, r. 1 , Dr, g. 1 , n r, r. m. 1 and C r, s. B. 3<br />
1 2 Department of Community medicine, Kempegowda institute of medical sciences, Bangalore, india. Department of thoracic<br />
medicine, Kempegowda institute of medical sciences, Bangalore, india. 3Department of radiology, Kempegowda institute of medical<br />
sciences, Bangalore, india.<br />
Background: the prevalence of COPD is increasing in india. Only few studies have been conducted in rural areas of india to find<br />
out the prevalence of COPD and its relationship with tobacco smoking, environmental tobacco smoke (Ets) exposure and type of<br />
cooking fuel used. Hence the present study was undertaken with the following objectives:i)<br />
to find out the prevalence of COPD in adult subjects of 35 years and above.<br />
ii) to determine the tobacco smoking, Ets exposure and type of cooking fuel used as an associated risk factor with COPD.<br />
material and methods: Field survey was conducted for COPD epidemiology in the rural field practice area of Kempegowda institute<br />
of medical sciences, Bangalore, india which covers a population of 44,387 residing in 71 villages using cluster sampling technique<br />
with the help of previously validated and standardized translated kannada (local language) version questionnaire for diagnosis of<br />
COPD among subjects of age 35 years and above. spirometry was performed to all those who gave positive response to COPD and<br />
www.worldallergy.org 81<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
they were graded according to gOlD criteria. results: Among 1400 subjects aged above 35 years, 693 (49.5%) were males and<br />
707 (51.5%) were females. the overall prevalence of COPD was 4.36%. the prevalence among males and females were 5.32%<br />
and 3.41% respectively. the prevalence was found to be increasing with increase in age [p
ABstrACts<br />
mWCnts on OVA-asthma model were analyzed by airway hyperreactivity (AHr) measurement, bronchoalveolar lavage fluid (BAlF)<br />
analysis, intracellular rOs production and histological analysis in lung tissue.<br />
Results: intranasally administrated-mWCnts easily loaded in alveolar macrophage, but did not result in significant lung<br />
inflammation and intracellular rOs production of the OVA-induced asthma model. in histological analysis, mWCnts exacerbated<br />
collagen deposition within the lung parenchyma of naïve mice and pre-existing allergic mice.<br />
Conclusion: these results suggest that combined OVA sensitization and mWCnts administration did not affected pre-existing<br />
allergic, but increased collagen deposition in lung parenchyma.<br />
1111<br />
PollEn CoUnTS ProFilE in gEorgia EValUaTED BY THE BUrKHarD PollEn TraP<br />
Chikhladze, m. V. 1 and sepiashvili, r. i. 2<br />
1 2 national institute of Allergology, Asthma & Clinical immunology, georgian Academy of sciences, tskhaltubo, georgia. Department<br />
of Allergology and Clinical immunology, institute of immunophysiology, moscow, russia.<br />
Aim and Methodology: the pollen counts in georgia were studied in 2006-2009 using the vacuum Burkhard Pollen trap (great<br />
Britain) donated by the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> (WAO) to the national institute of Allergology, Asthma and Clinical immunology<br />
in tskhaltubo (georgia). the dependence of allergic diseases prevalence on the geographic location and some other factors (air<br />
temperature, humidity, height above the sea level, spectrum of regional plants) were also studied.<br />
Results: it was stated that allergy to mold fungi and other bacteria more often occurred in the areas with high humidity and the<br />
morbidity level with hay fever and bronchial asthma was much higher than in dry areas. in cities situated on the Black sea (Batumi,<br />
Kobuleti, Poti), ragweed is widely distributed, which in the period of blossom caused numerous allergic diseases (allergic rhinitis,<br />
conjunctivitis, urticaria etc.). When ragweed blossom, the quantity of pollen in the air is extremely high and as it is a strong allergen<br />
it causes exacerbation and allergic disease in people sensitized to ragweed pollen. the highest percentage of allergy morbidity<br />
fall at plants allergens caused by pollen of numerous weeds and plants (pollen of ragweed, alder, birch, maple, walnut, mallow,<br />
cotton-plant etc.). in different areas of georgia people are more sensitive to various plants. in imeretia region, it is ragweed pollen,<br />
in Kakhetia and Kartli – platan and wheat. graphic chart of hay fever and bronchial asthma morbidity as a rule have two peaks –<br />
spring–summer and autumn–winter. it is the season of plants blossom and the quantity of pollen in the air is most high.<br />
Conclusion: the pollen counts obtained using the Burkhard Pollen trap allowed us to make a pollen calendar for different regions<br />
of georgia thus enabling to perform treatment and prophylactic measures in advance.<br />
1112<br />
air PUriFiEr THaT USES PHoTo CaTalYTiC oXiDaTion rEDUCED THE PoPUlaTion oF mrSa<br />
ghosh, n. 1 , Pratt, C. 1 , Bennert, J. 2 , Chudasama, J. 2 and Das, A. B. 3<br />
1 2 3 life, Earth and Environmental sciences, West texas A&m University, Canyon, tX. Air Oasis, Amarillo. Dept. of Agricultural<br />
Biotechnology, College of Agriculture, Orissa University of Agriculture & technology, india.<br />
the air surrounding us plays an extremely important role in our well being and efficiency. Breathing pure and clean air allows us to<br />
think more clearly, sleep more soundly, and stay healthier. studies show that we receive 56% of our energy from the air we breathe,<br />
more than from water and food combined. On average we breathe 37 pounds of air a day. the quality of the environment within<br />
buildings is a topic of major importance for public health and indoor Air Quality (iAQ) is a major concern at work places. the objective<br />
of the present study was to assess two negative ion purifiers - Xtreme 3000 and luna induct air purifiers on the net reduction of<br />
bacteria in the microbiology and mycology laboratories of Baptist saint Anthony’s Hospital (BsA) in Amarillo, texas and the specific<br />
effect on methicillin resistant Staphylococcus aureus, mrsA. mrsA has become a serious public health issue. luna induct air units use<br />
an advanced hydrated Photo-Catalytic Oxidation (PCO) filtration system. it produces a broad spectrum high intensity UV light targeted<br />
on a quad metallic catalyst in a low-level ozone and moist atmosphere. Bacteria isolated from petri plates exposed to the room air<br />
were gram positive bacilli such as Bacillus, Coryneform (diptheroids), coagulase negative Staphylococcus and Micrococcus spp., and<br />
encapsulated gram negative bacilli. in every case there was reduction in airborne pathogen with variable room sizes when the air<br />
purifiers were used. tsA plates with 5% sheep blood were placed for exposure rooms at different distances and intervals. Plates were<br />
evaluated for the total number of bacterial and fungal colonies at intervals of 24, 48, 72 and 120 hours. We plated the mrsA strains<br />
from the stock culture after dilution 10-4 to investigate the effect of air-purifiers on the production of number of colonies of mrsA. tsA<br />
plates were inoculated with the strain after serial dilutions as follows. 5 ml of stock culture was diluted to 10-4 after incubation at 37o C for 24 hours and were plated onto tsA petri plates. ‘t-test’ results show that there was a significant difference in the air purifier<br />
treated sets and a gradual reduction in the number of colonies. the reduction of latent bacteria in the air could possibly reduce the<br />
transmission of airborne disease.<br />
www.worldallergy.org 83<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1113<br />
inCrEaSing oF allErgY PoTEnCY oF PollEn grainS in HElianTHUS annUUS l. UnDEr BEnZo(Á) PYrEnE (BaP)<br />
EXPoSUrE<br />
Baghali, Z. 1 , majd, A. 2 , Chehregani, A. 3 , Pourpak, Z. 4 and Vatanchian, m. 3<br />
1 2 3 Dept. of Biology, tarbiat moallem University, Hamedan, iran. Dept. of Biology, tarbiat moallem University, tehran, iran. Dept. of Biology,<br />
Bu-Ali sina University, Hamedan, iran. 4immunology, Asthma and <strong>Allergy</strong> research institute, tehran University, tehran, iran.<br />
Background: <strong>Allergy</strong> prevalence was increased in recent years dramatically. the reason of this phenomenon was not clear but there is<br />
a scientific attention to air pollution. Diesel exhaust particles (DEP) are a major part of air pollutants that express both adjuvant activity<br />
for sensitization against common allergens and enhancing sensitized individuals. Benzo(α) Pyrene (BAP) is considered as the most<br />
important part of DEP. the aim of this research was study of the effect of BAP on allergenecity of pollen grains in Helianthus annuus l.<br />
method: in this research, H. annuus l. Var. record plants were grown from seed in green house controlled condition and shoots treated<br />
by different concentration of BAP solutions in phosphate buffer saline (PBs) (0.002, 0.02, 0.04 g/l) daily. Controls were sprayed by<br />
PBs. Pollen grains were collected and allergy potency of pollen grains was compared in different experimental groups and controls.<br />
Allergenecity of pollens was studied by means of skin prink test, determination of blood cells and evaluation of total igE in studied<br />
groups using sensitized guinea pigs as an experimental model. Pollen proteins were also studied by sDs-PAgE and immuno-blotting<br />
method for BAP-induced changes in protein profile and detection of allergen bands.<br />
result: Comparing of allergy potency of different pollen extracts showed that allergic skin reactions in animals that treated by polluted<br />
pollen grains was 2-3 times more than the groups treated by normal pollen extract and 5-6 times more than BAP treated group.<br />
Eosinophil number and igE level, as allergy indicators, were also increased considerably in the blood of the groups treated by BAP<br />
exposed pollen grains than control ones. results of sDs-PAgE showed that there are two additional bands in the BAP treated pollen<br />
grains. immuno-blotting study of pollen proteins showed that new bands act as allergens that are reacted with igE strongly.<br />
Conclusion: results of this research work concluded that BAP could increase the allergy potency of H. annuus pollen grains and<br />
also cause to formation of new protein bands that act as new allergens.<br />
1114<br />
rElaTionSHiP BETWEEn ToTal SErUm igE anD BoDY maSS inDEX in PaTiEnTS WiTH nonaToPiC rESPiraTorY allErgY<br />
Kim, s. , lee, W. Y. , Yong, s. J. , shin, K. C. , lee, s. n. , lee, s. J. and lee, m. K.<br />
Department of internal medicine, Yonsei University Wonju College of medicine, Wonju, south Korea.<br />
Background : <strong>Allergy</strong> skin test is a major tool in the diagnosis of atopy. some of the patients with respiratory allergy such as rhinitis<br />
and asthma show often no sensitization for common inhalant allergens when skin prick test is performed. Previous literature on<br />
the relationship between serum total igE and body mass index (Bmi) has been inconsistent. it is not known how this relationship is<br />
in patients with nonatopy. objective : We sought to examine the relationship of serum total igE and body mass index in respiratory<br />
allergy patients with nonatopy. methods : skin prick tests were performed with 33 common inhalant allergens on 934 respiratory<br />
allergy patients from January 2007 through December 2007 at a University hospital and total serum igE was measured. Atopy<br />
was determined by a positive skin prick test response to at least one common inhalant allergen. Among the studied subjects, 526<br />
patients were nonatopy. We excluded the cases with more than 500 iU/ml of total serum igE because which levels of igE were<br />
more associated with other causes, such as parasite infections. results : the subjects with nonatopy and less than 500 iU/ml of<br />
total igE level were 468 patients consisted of 169 male and 299 female. When the cutoffs were used for underweight, overweight,<br />
and obesity corresponding to Bmi of 18.5, 23.0, and 25.0 kg/m2 , the levels of mean total igE in female patients were 41.1±41.0<br />
in underweight (n=14), 64.6±87.3 in normal weight (n=104), 78.9±99.9 in overweight (n=57), and 85.5±87.6 iU/ml in obese<br />
patients (n=124), respectively. mean total igE levels were significant higher among obese and overweight patients than among the<br />
others (83.4 vs. 61.8 iU/ml, p=0.036). no statistical significance was observed in male patients. Conclusion : Obesity may be a<br />
contributor to the increased level of total serum igE in female patients with nonatopic respiratory allergy diseases.<br />
1115<br />
PollEn STUDY in inDonESia<br />
rengganis, i.<br />
Department of internal medicine, Faculty of medicine, University of indonesia, Jakarta, indonesia.<br />
<strong>Allergy</strong> is a human immediate hypersensitive reaction to allergens. it occurs when the body produces an excess of igE antibody<br />
as response to allergen. Pollens are important environmental allergens in subtropical countries which contribute to significant<br />
morbidity especially during the pollination period. Despite the all year long of plants flowering in indonesia, pollen allergy has not<br />
been well studied. the objectives of this study were to identify pollen from plants in a given area in indonesia which may cause<br />
www.worldallergy.org 84<br />
FinAl PrOgrAm
ABstrACts<br />
allergy in human. A Burkard spore trap was set for seven days sampling in lebak Bulus, district in south Jakarta, while a passive<br />
collectors with adhesive object glass were placed in Darmaga Bogor, Pasar minggu and Jagakarsa in south Jakarta. Using light<br />
and scanning electron microscopes (sEm), pollens that were trapped and identified were acacia (Acacia auriculiformis), cogon<br />
grass (Imperata cylindrica), coconut (Cocos nucifera), palm trees (Elaeis guineensis), maize (Zea mays), rice (Oryza sativa), and<br />
pine (Pinus merkusii). molecular weight of protein profiles from those pollen extract using sodium dodecyl sulfate-polyacrylamide<br />
gel electrophoresis analysis (sDs-PAgE) were dominated by 10-70 kD bands. Allergenicity in human to those pollen commercial<br />
grasses mix extract was also included in the test to people with and without history of allergy, 69 people each, using the skin prick<br />
test method. the seven pollen of plants trapped in indonesia are allergenic. Human sensitivity to Cogon grass and acacia pollen<br />
are more severe than to the rest of other pollen, however, the sensitivity was most found to commercial allergens of grasses mix.<br />
People with respiratory allergy was more sensitive than people without history of allergy. meanwhile, human sensitivity to acacia<br />
was the same in those two groups of people. Pollen of Cogon grass and acacia are potential allergens to be used for skin prick test<br />
in indonesia. Acacia trees are not recommended to be utilized as a shading tree since their pollen showed sensitivity reaction in<br />
human.<br />
Keywords: pollen, allergen, sensitivity, skin prick test.<br />
1116<br />
inHalanT allErgEnS SEnSiTiZaTion in PaTiEnTS WiTH aSTHma anD allErgiC rHiniTiS; rEViEW oF SKin TEST rESUlTS<br />
oVEr TWo YEarS PErioD aT SUlTan QaBooS UniVErSiTY HoSPiTal, mUSCaT – oman<br />
sharef, s. W. and Al-tamemi, s. H.<br />
Department of Child Health, sultan Qaboos University Hospital, muscat, Oman.<br />
Background: there are geographical variations with respect to allergens presence, and therefore identification of relevant allergens<br />
in each environment is important that may have diagnostic and therapeutic implications.<br />
method: A review of allergy skin prick tests during (April 2008 – march 2010) is performed at sultan Qaboos University Hospital,<br />
muscat - Oman. A new panel of inhalant allergen extracts was introduced in April 2008. Pediatric and adult patients with a<br />
diagnosis of Asthma or Allergic rhinitis (Ar) are referred by physicians for allergy skin tests. the skin prick tests were performed<br />
according to standard method. the data were collected and analyzed using sPss. the frequencies of positive allergens sensitization<br />
were calculated.<br />
results: there were a total of 561 patients with asthma and allergic rhinitis. the number of patients with asthma was 103<br />
(44.7% males and 55.3 % females). in these patients, the most common allergen sensitization is Dermatophagoides pteronyssinus<br />
(44.7%), followed by Dermatophagoides farinae (40.8%), Cat fur (21.4%), Dog Hair (18.4%), russian thistle (14.6%), Bermuda<br />
grass (13.6%), mosquite (11.7%), Feather mix (7.8%), 5 grasses mix (5.8%), Aspergillus mix (5.8%), Chenopodiaceous (5.8%),<br />
Penicillium mix (4.9%), Compositae (4.9%), Date Palm (4.3%), Wheat pollen (3.9%), Cladosprium mix (3.9%), Cattle Hair & Epithelia<br />
(1.7%). the number of patients with allergic rhinitis was 458 patients (53.9% males and 46.1 % females). in these patients, the<br />
most common allergen sensitization is Dermatophagoides pteronyssinus (33.8%), followed by Dermatophagoides farinae (30.1%),<br />
russian thistle (24.7%), Chenopodiaceous (16.6%), Dog Hair (14.6%), Cat fur (12.9%), mosquite (12.9%), Bermuda grass (12.4%),<br />
Date Palm (9.8%), Compositae (7.6%), 5 grasses mix (5.5%), Feather mix (5%), Wheat pollen (4.4%), Cattle Hair & Epithelia (4.3%),<br />
Aspergillus mix (3.3%), Cladosprium mix (2.6%), Penicillium mix (2.4%).<br />
Conclusion: the above data identified House dust mite as the commonest allergen sensitization (which is consistent with published<br />
data from other countries), other significant allergens are identified including date palm pollens. this will help physicians to manage<br />
allergic asthma and Ar patients. Ultimately pollen count may be necessary to identify other significant environmental allergens in<br />
Oman.<br />
1117<br />
SKin PriCK TEST in CHilDrEn rESiDing in a rUral CommUniTY in BanDUng, WEST JaVa, inDonESia<br />
sapartini, g. 1 , B.Kartasasmita, C. 1 , setiabudiawan, B. 1 , majangsari, r. g. D. 1 , saptaputra, W. 2 and irwan, n. 2<br />
1 2 Department of Child Health, school of medicine Padjadjaran University, Bandung, indonesia. Health research Unit, school of<br />
medicine Padjadjaran University, Bandung, indonesia, Bandung, indonesia.<br />
Background skin prick test (sPt) is a fast, safe, and efficient method to diagnose igE-mediated allergy that provides optimal<br />
information as long as it performed and interpreted correctly. it is important that the allergens tested for should be adjusted to<br />
the patient’s clinical condition and residential. the aim of this study is to report the result of sPt in children residing in a rural<br />
community in Bandung, West Java, indonesia.<br />
methods this study was a part of a nested case control study entitled, “rsV and recurrent wheezing in indonesia: 7-9 years<br />
follow-up study with lung function studies.” this study was conducted in Department of Child Health, Hasan sadikin Hospital from<br />
www.worldallergy.org 85<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
December 2009 to July 2010. Demographic data and history taking on the basis of standardized questionnaires were collected<br />
from all participants. the skin prick test was performed with 12 common allergens.<br />
results there were 218 subjects, 111 (50.9%) boys and 107 (49.1%) girls, age 8.4 to 13.4 years old, mean of age 10.4 ± 1.05<br />
years old, enrolled in the study. Positive sPt were found in 175 subjects (80.3%), negative sPt in 31 subjects (13.8%) and severe<br />
dermatographism in 13 subjects (6%). the positive rates of inhaled and food allergens were 33.1% and 6.3% respectively whereas<br />
positive rate to both allergens was 60.6%. the most common inhaled allergens were house dust mites i.e. Blomia tropicalis (58%),<br />
Dermatophagoides farinae (55%), and Dermatophagoides pteronyssinus (49.5%), followed by cockroach (32.6%), cat dander<br />
(26.6%), Alternaria alternata (24.3%), and Aspergillus mix (18.3%). Yolc egg was the most common food allergen (31.7%), followed<br />
by chocolate (30.7%), shrimp (22.5%), and soya (11.5%).<br />
Conclusion the percentage of positive sPt is high. the most common allergen is house dust mite (Blomia tropicalis).<br />
Keywords: Allergen, house dust mites, igE-mediated allergy, skin prick test<br />
1118<br />
ProTEin EXPrESSion ProFilE oF inDigEnoUS anD CommErCial EXTraCTS oF amaranTHUS PollEn in allErgY<br />
PaTiEnTS<br />
Hasnain, s. m. 1 , Al sini, H. 1 , Al-Qassim, A. 1 , Al Frayh, A. 2 , gad-El-rab, m. O. 3 and Alaiya, A. 1<br />
1 2 Biological and medical research, King Faisal specialist Hospital and research Centre, riyadh, saudi Arabia. king saud University<br />
&King Khalid Hospital riadh K s Ariyadh, riyadh. 3College of medicine, King saud University.<br />
Background: Amaranthus viridis and Amaranthus lividus, pollen are the most prevalent in various parts of saudi Arabia.<br />
Amaranthus species are allergenic and potential cause of respiratory allergy. However, neither are commercially available for<br />
diagnostic or therapeutic purposes.<br />
method: sPt was applied in this study. Five allergy patients were skin tested with locally prepared (indigenous and commercial<br />
pollen) as well as commercial extracts. Amaranthus pollen was collected from various indigenous sources. A. palmeri, A. retroflexus,<br />
A. hybridus, A. tuberculatus were acquired from greer and A. retroflexus, A. tamariscinus were acquired from Allergon. the raw<br />
pollen from these species was extracted in buffered saline PH 8.1. Protein patterns of eight different types of Amaranthus samples<br />
as well as serum samples from patients were analyzed using two-dimensional polyacrylamide gel electrophoresis (2-DE)/sDs PAgE<br />
and computer-assisted image analysis (PDQUEst).<br />
results: We have generated and characterized the expression of multiple proteins in human serum samples of patients exposed<br />
to 7 different types of Amaranthus allergens. two patients demonstrated similar high expression changes to 2 types of Amaranthus<br />
allergens and were classified as group 1 while three samples showed low expression to Amaranthus and were referred to as group<br />
2 of the Amaranthus allergens. Changes in the expression of 12 proteins were observed between groups 1 and group 2 samples.<br />
Conclusion: there appear to be proteins diversity in six major Amaranthus species and similarities in the two indigenous species.<br />
While the reactive and cross-reactive proteins between the indigenous and commercial species are being investigated, the available<br />
commercial extracts appear to have different protein profile and may not be fully relevant to this region for the diagnosis of inhalant<br />
pollen allergy and subsequent specific immunotherapy. Further validation of observed protein spots is warranted in order to support<br />
their usefulness as potential Amaranthus biomarkers for the diagnosis and therapy monitoring of allergy patients.<br />
1119<br />
naTUral rUBBEr laTEX-rElaTED oCCUPaTional aSTHma: SUCCESSFUl SUBlingUal DESEnSiTiZaTion<br />
D. schiavino, A Buonomo, t De Pasquale, V Pecora, V sabato, A Colagiovanni, A rizzi, A Aruanno, l Pascolini, E nucera.<br />
<strong>Allergy</strong> Department, Catholic University, rome, italy.<br />
Background: Occupational Asthma (OA) has become the most common work-related lung disease in industrialized countries. the<br />
most common triggers are wood dust, grain dust, latex (especially among health care workers associated with use of gloves) or<br />
other chemicals (especially diisocyanates). specific desensitization represents an important therapeutic tool in the management of<br />
patients with latex allergy. the aim of the study is to evaluate the safety and effectiveness of sublingual desensitization in patients<br />
with latex-induced asthma and its impact on patient capability to reintegrate at the previous work.<br />
method: We selected 13 patients affected by occupational latex-induced asthma. the diagnosis of nrl allergy was based on<br />
a positive allergological work-up, included execution of allergological tests (skin prick test and in vitro laboratory tests) and<br />
provocation challenges (glove-wearing, conjunctival, bronchial and sublingual provocation test) to confirm clinical latex allergy.<br />
Based on clinical history and positive allergological work-up, we decided to carry on a rush sublingual desensitization with latex,<br />
performed in 4 days with increasing doses of latex extract under patient’s tongue until the highest dose of 500 μg of undiluted latex<br />
solution. A maintenance therapy (10 drops of undiluted solution three times a week) was recommended. After 1-year treatment<br />
challenges were repeated and those with negative bronchial test underwent a 8-hour work place challenge in an operating room.<br />
www.worldallergy.org 86<br />
FinAl PrOgrAm
ABstrACts<br />
Patients with all negative challenges were reintegrated at the previous work and followed up for 1 year for the occurrence of<br />
modification of respiratory parameters.<br />
results: the treatment was tolerated by all patients and in 12 out of 13 bronchial challenge turned negative. they did not<br />
experience symptoms or modification of respiratory parameters during the workplace challenge and 10 were reintegrated at the<br />
previous work, being followed up for 1 year.<br />
Conclusion: sublingual immunotherapy with nrl has proven to be safe and efficacious for the management of patients affected by<br />
nrl-related occupational asthma. Our results are really encouraging even though they should be confirmed by further large casecontrolled<br />
1120<br />
ToTal igE SEnSiTiViTY ComParED WiTH SPECiFiC igE rESUlTS againST miTES anD molDS For THE SCrEEning oF TYPE<br />
1 allErgY in WorKErS oF a PoliCE inSTiTUTE in CaraCaS, VEnEZUEla<br />
silva, n. A. , monterrey, C. , Camacho, n. and nirsen, g.<br />
laboratory of Production and Quality Control, Corpodiagnostica, Caracas, Venezuela.<br />
igE mediated Allergies (type i) are chronic diseases that affect more than 20% of the population in some countries. We analyzed<br />
55 blood samples from workers of Universitary institute of scientific Police, iUPOlC Caracas, Venezuela, that presented Allergies<br />
related symptoms at the moment of the study. We used a specially designed survey to register that information. We tested serum<br />
total igE by ElisA method and a specific igE using an immunoblott nitrocellulose panel composed with mites and molds allergens<br />
of well know local prevalence, in order to calculate the diagnostic sensitivity of serum total igE as a marker for screening type<br />
i Allergies compared with allergen sensitivities detected on the individuals. We selected the most common reference values for<br />
serum total igE used in Venezuela. the sensitivity obtained for serum total igE was 66,67%,, specificity 100%, Positive Predictive<br />
Value 100%, and negative Predictive Value 61,29% . We discussed the possibility that the sensitivity obtained for total igE could<br />
be even lower if more number of allergens and skin tests were included on the study. We conclude that the use of total igE as<br />
screening diagnostic tool for Allergies must be used together with clinical history of the patient and other assays like i.e. specific<br />
igE. local Clinical laboratories should promote of better interpretation schemes (reference values) for total igE that actually helps<br />
to a better diagnosis of this disease. (1, 2).<br />
1.Bousquet J., Khaltaev n., Cruz A. A., Denburg J., Fokkens W. J., togias A., Allergic rhinitis and its impact on Asthma (AriA) 2008<br />
Update, in collaboration with the <strong>World</strong> Health <strong>Organization</strong>, gA2lEn and Allergen, <strong>Allergy</strong> 2008: 63 (suppl. 86): 8–160.<br />
2.Comité nacional de Alergia, Comité nacional de neumonología y Comité de Otorrinolaringología de sAP Filial Córdoba, Consenso<br />
nacional de rinitis Alérgica en Pediatría, Arch Argent Pediatr 2009:107,1,67-81.<br />
PoSTEr SESSion 1-2: asthma education and management<br />
1200<br />
omaliZUmaB ProVing To BE EFFECTiVE in PaTiEnTS WiTH normal igE lEVElS & rEFraCTorY aSTHma,<br />
B. mahboub1 , mohamed, r. 2 and mohamed, n. 3<br />
1 2 ,rashid hospital, <strong>Dubai</strong>, United Arab Emirates. Department of Pulmonary medicine, rashid hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
3 ,Department of Pulmonary medicine ,rashid hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
Backgroundto assess the response of Omalizumab in patients with normal igE levels regards asthma control & quality of life<br />
methodsA 38yr old female physician with childhood asthma from 5yrs, later developing into adulthood as severe uncontrolled<br />
asthma on high dose salmeterol/fluticasone 500mcg BD,anti-cholinergics,aminophylline,on nasal steroids & antihistamines<br />
for rhinitis control,antireflux measures with frequent need for nebulizations & subcutaneous sympathomimetics during severe<br />
attacks with high doses of 80mg to 60 mg of oral steroids.there is H/o atopy, eczema, allergic rhinitis & asthma in family.<br />
Work up for ABPA, carcinoid & endocrinopathies was negative. H/o intubation thrice since2002& steroid reduction not possible.<br />
in 2006methotrexate 20-25mg weekly achieved a steroid reduction of up to 10mg/day after 6mths.in 2008 she developed<br />
methotrexate alveolitis by HrCt which was treated with iv methylprednisolone & high oral steroids with resolution in subsequent<br />
follow up Ct after stopping methotrexateresults inspite of normal igE levels & negative specific igE to common aeroallergens<br />
Omalizumab started at a moderate dose of 225mg sc every 2weeks for 6months, showed a significant improvement in asthma<br />
control & rhinitis, no nocturnal symptoms, only once needed prn salbutamol, modest improvement in lung function, asthma control<br />
test scores up from 5 to 22 with half dose of oral steroids, eczema disappeared. After 6 months, omalizumab stopped due to<br />
economic reasons during which her symptoms recurred, to resolve again after a month when it was restarted Conclusionthis<br />
beneficial effect of omalizumab may be attributed to either long-term steroid use suppressing igE or to the production of local<br />
igE complexes in the pulmonary system and local pulmonary steroid resistance .this expands the role of Omalizumab & modifies<br />
www.worldallergy.org 87<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
the indication from the use of the drug based on purely igE levels as a parameter to patients symptoms and clinical improvement<br />
as an important factor.references1.Omalizumab (Xolair) in patients with steroid-resistant asthma:lessons to be learnt ,Philip<br />
j.thompson,neil l.misso & john woods respirology (2007) 12 (suppl.3),s29–s34. ref no2.Benefits of omalizumab as add-on<br />
therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (ginA 2002step 4<br />
treatment)innOVAtE, m.Humbert,r.Beasley,J.Ayres, r.slavin,J.H bert,J.Bousquet,<strong>Allergy</strong> 2005:60:309–316<br />
1201<br />
From TEmPEramEnT To PErSonaliTY: DoES aSTHma aFFECT DEVEloPmEnT?<br />
grønnerød, C.<br />
Department of Psychology, University of Oslo, Oslo, norway.<br />
this paper examines the relationship between temperament, personality and asthma in a longitudinal sample. A previous study<br />
have pointed to possible links between temperamental mismatch between parents and children, and asthma. Other studies have<br />
found links between asthma and negative emotionality, while some have not found such relationships. in the longitudinal PrAD<br />
study (lilljeqvist, smørvik & Faleide, 2003), 100 children with and without asthma were followed from birth to adolescence. no<br />
link was found between asthma and temperamental traits at 7-9 years of age, nor of asthma and personality traits at 15-17 years.<br />
the data did reveal a link between asthma at 7-9 years of age and elevations in the personality trait of neuroticism at 15-17 years.<br />
Possible etiological links are discussed.<br />
1202<br />
THE TrEaTmEnT oF PaTiEnTS WiTH BronCHial aSTHma anD arTErial HYPErTEnSion<br />
latysheva, E. A. 1 , Kurbacheva, O. m. 1 and gendlin, g. E. 2<br />
1 2 Allergology and Clinical immunology, institute of immunology FmBA russia, moscow, russia. Cardiology, russian medical<br />
University.<br />
the course and the prognosis of the bronchial asthma (BA) depend not only on the correct antiasthmatic treatment, but on the<br />
comorbid conditions. Cardiovascular diseases have a great impact and may complicate the treatment of the patients with BA. the<br />
influence of the cardiovascular pathology on the course of BA can be caused both with the illness itself and applied medications.<br />
Antihypertensive treatment sometimes is associated with direct negative influence on the bronchial resistance, sputum production,<br />
bronchial hyperreactivity and the quality of life. the purpose: to estimate the effectiveness and safety of angiotensin-converting<br />
enzyme inhibitors (ACEi) and their combination with calcium antagonists (CA) in patients with BA. methods: 60 patients with<br />
a controlled BA and not controlled arterial hypertension (AH) were selected. All patients underwent a complex examination,<br />
including spirography and bodypletismography, arterial blood pressure (BP) monitoring, echocardiography and quality of life (Ql)<br />
questionnaires. Afterwards they were randomized into 2 groups of similar age and gender. 1st group was treated with ACEi (enalapril<br />
2.5-20mg) and the 2nd received the combination of ACEi and CA in a fixed combination (verapamil + trandolapril 180/2). After 6<br />
month of treatment the complex examination was repeated. results: 3 (5%) patients were excluded because of cough after the<br />
beginning of ACEi treatment. the normal levels of BP were achieved in 100%. the antihypertensive treatment did not lead to the<br />
BA exacerbations (the reasons of the exacerbations were viral and bacterial infections of the respiratory tract). the treatment with<br />
enalapril decreased the hypertrophy of the left ventricle (p
ABstrACts<br />
both gender, suggesting a marked co-morbidity between asthma and ADHD. the association between AE and ADHD is modified<br />
by sleeping problems which are, in itself, known risk factors to rtAs. given the significant morbidity and mortality of rtAs, atopic<br />
disorders, and adult ADHD, the co- morbidity between these disorders should gain more attention from us. methods:<br />
the aim of this presentation is to shed the light on the black spot in managing the aforementioned co- morbidity. the author<br />
reviewed all publications investigating this co-morbidity in several databases.<br />
results and conclusion:<br />
then he would display in his 15 minutes oral presentation a black spot program to manage it.<br />
1204<br />
THE QUaliTY oF liFE in aSTHmaTiC PaTiEnTS TrEaTED WiTH omaliZUmaB<br />
della torre, F. 1 , limonta, A. 1 , gaffuri riva, V. 1 and Della torre, E. 2<br />
1 2 general Pneumology, inrCA-irCCs, milan, italy. internal medicine, san raffaele Hospital, milan, italy.<br />
introduction<br />
it is well known that some patients with severe persistent asthma remain inadequately controller despite receiving best available<br />
treatment and optimal management efforts. such patients, who have exhausted the therapeutic options available to them , are at<br />
risk of experiencing serious exacerbations and asthma related mortality<br />
We present two cases treated with omalizumab<br />
Case 1<br />
35 years old female brasilian, ,work as housekeeper, with rhinitis and asthma since age 12. she experienced several hospital<br />
admissions, frequent use of nebulizer, asthma worsening with numerous courses of iv and oral corticosteroids. skin prick tests<br />
were positive to dermatophagoides, grass, birch, plantago. Fev1= 25% ( of predicted) reversing to 42%, total serum igE = 91 iU/ml.<br />
she started Xolair in 2007 and after few months she improved her symptoms, reduced drugs and stopped with oral corticosteroids.<br />
in 2009 she had no hospitalizations, can work normally. igE = 281 iU/ml, FEV1= 57% reversed to 71%. Her health has improved<br />
and they are not so worried any more when she is out and about work and free time.<br />
Case 2<br />
severe persistent allergic asthma, 67 years old , severe asthma symptoms and exacerbations since 1980, ex smoker, ex<br />
bricklayer, obesity, hypertension, diabetes mellitus. He had rhinitis and asthma due to allergy to mite and was treated with<br />
subcutaneous specific immunotheraphy for 10 years with symptoms’ disappeared. since 2005 started with frequent asthma<br />
exacerbations ( 5 times per year ) required emergency treatment or hospitalization. Exacerbations and symptoms limited his<br />
activities of daily living, nocturnal symptoms, poor control despite maintenance oral steroids, inhaled steroids, salmeterol,<br />
cromoglycate, theophylline trials and need long term oxygen theraphy.<br />
in July 2007 skin prick test were positive for dermathophagoides, igE= 435 U/ml, FEV1 =70%. He started with Xolair treatment<br />
and after two months stopped oral corticosteroids and after fourth months stopped oxygen therapy. in January 2010 FEV 1 =75%,<br />
total serum igE : 494 iU/ml. improved symptoms, reduced wheezing shortness of breath, nocturnal symptoms uncommon. sleeps<br />
through the night. Fewer exacerbations. no hospitalizations since starting xolair<br />
Xolair doses were determined by serum total igE levels measured before treatment initiation and patient’s body weight. Dosing<br />
tables were used to calculate the appropriate dose.<br />
no side effects were reported.<br />
1205<br />
aToPiC aSTHma anD BronCHiECTaSiS<br />
Khoury, A. 1 and Ahmed, F. 2<br />
1 2 Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria. Pulmonology Department, Faculty of medicine of Aleppo, Aleppo, syria.<br />
Background:investigations using high-resolution Ct scan show that bronchiectasis is found in many patients with Asthma.<br />
materials and methods: in our study we had investigated the presence of Bronchodilatation in 80 patients with stable atopic<br />
Asthma and 20 healthy control subjects.<br />
results: At least one dilated bronchus was present in 35 Patients(43,8%) and 1 control subject(5%).<br />
Conclusion: We suggest to do HrCt-scan in Difficult to treat atopic asthma.<br />
www.worldallergy.org 89<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1206<br />
EFFECT oF omaliZUmaB in JaPanESE PaTiEnTS WiTH SEVErE allErgiC aSTHma anD rHiniTiS<br />
nishihara, F. , takaku, Y. , nakagome, K. , masumoto, A. , Yamaguchi, t. and nagata, m.<br />
<strong>Allergy</strong> Center , Department of respiratory medicine, saitama medical University, moroyama-machi, Japan.<br />
Background :<br />
there is evidence that humanized monoclonal antibody against igE (Omalizumab) is effective in mainly north American and or<br />
European population of severe allergic asthma. in this study, we examined the effectiveness of omalizumab on clinical symptoms,<br />
pulmonary function, and airway inflammation in Japanese patients with severe allergic asthma.<br />
method :<br />
We conducted a prospective open-label study that enrolled patients with severe allergic asthma in adult who visited <strong>Allergy</strong><br />
Center, saitama medical University in Japan. All patients were uncontrolled despite medication including high-dose inhalational<br />
corticosteroids, long-acting beta agonist, leukotriene receptor antagonist, theophylline, and oral predonisolone. Omalizumab was<br />
added on their treatments and we evaluated symptoms using Asthma Contol test(ACt), peak expiratory flow rate(PEFr), exhaled<br />
nitric oxide (enO), sputum eosinophils, and nasal symptoms before and 12-16 weeks after administering omalizumab.<br />
results :<br />
seven patients were enrolled, and administered with omalizumab for 12-16 weeks. the mean age was 52 years and four patients<br />
(57%) were female. All patients had allergic comorbidities (7 had rhinitis, 3 had dermatitis, 2 had conjunctivitis). the five patients<br />
(71%) were taking the oral corticosteroid as controller. Omalizumab significantly improved ACt scores especially dose of rescue<br />
use of short-acting beta2-agonist (p
ABstrACts<br />
1208<br />
THE rolE oF inTErlEUKin-13 in aSTHma<br />
Vafa, A.<br />
Azerbaijan medical University, Baku, Azerbaijan.<br />
Background: interleukin-13 (il-13), the most recently identified cytokine to join the th2 cytokine family, is distantly related to il-4.<br />
the aim of this study was to identify the role of il-13 in asthmatic children.<br />
method: With purpose to study the parameters of cytokine profile, the clinical and laboratorial indicators of 62 patients with halfserious<br />
and serious atopic bronchial asthma were examined.<br />
the study included 3 groups. group A consisted of 10 children with serious atopic bronchial asthma (age 1-16 years), group B of<br />
52 children with half-serious atopic bronchial asthma and group C (Control group) of 15 healthy children without asthma or other<br />
atopic disease.<br />
results: the results of serum igE, il-13, il-17, il-4 and il-5 are shown in the table:<br />
table 1:<br />
igE and Cytokines group A group B group C<br />
igE 524,4 335,4 213,8<br />
il-13 6,53 4,28 1,74<br />
il-17 10,65 7,04 3,14<br />
il-4 7,08 5,25 1,37<br />
il-5 40,5 29,7 10,4<br />
Conclusions: the asthmatic phenotype in humans is accompanied by elevated expression of il-13. the latter is a key factor in the<br />
asthmatic phenotype but its role remains elusive. the anti-inflammatory cytokine il-17, as well as th-2 cytokines il-4 and il-5<br />
may be useful markers of chronic inflammation in childhood asthma without helping to determine the state of the disease. Further<br />
studies are required to elucidate the exact role of the above cytokines in children with asthma<br />
1209<br />
imProVED HEalTH oUTComES For aDolESCEnTS WiTH aSTHma in JorDan: a ClUSTEr ranDomiZED ConTrollED<br />
Trial<br />
Al-sheyab, n. A. 1 , gallagher, r. 2 , Crisp, J. 2 and shah, s. 3<br />
1 2 maternal and Child Health, Jordan University of science and technology, irbid, Jordan. University of technology, sydney, sydney,<br />
Australia. 3University of sydney, Westmead, Australia.<br />
oBJECTiVE. the objective of this study was to determine the effect of a peer related outcomes in students with asthma-program on<br />
health led asthma education attending high schools in Jordan.<br />
mETHoDS. in this cluster-randomized controlled trial, 4 high schools in irbid, Jordan, were randomly assigned to receive the<br />
Adolescent Asthma Action (triple A) program or standard practice. trained bilingual health workers facilitated the triple A, which<br />
uses a three-step cascade process to train peers from years 10 and 11 over a three week period. this peer training aims at<br />
delivering asthma education for the school community, with the aid of well-established resources including peer training manuals,<br />
videos and props. students with asthma (n = 261) in years 8, 9 and 10 were surveyed at baseline in December 2006 and three<br />
months post-intervention. the main outcomes were asthma-related quality of life, knowledge of asthma management, and selfefficacy<br />
to resist smoking.<br />
rESUlTS. statistically and clinically significant improvements at three months in the intervention group in comparison to the<br />
control group for quality of life (mean difference = 1.35, 95% Ci 1.04 – 1.76), asthma-related knowledge (mean difference = 1.62,<br />
95% Ci 1.15 – 2.19), and self-efficacy to resist smoking (mean difference = 4.63, 95% Ci 2.93 – 6.35).<br />
ConClUSionS. this randomized controlled trial demonstrated the success of a school-based, peer-led education program in<br />
improving important outcomes for adolescents with asthma. Furthermore, it is clear that triple A can be readily adapted to suit<br />
different cultures and contexts. Adolescents can teach their peers about managing asthma and avoiding smoking and also be<br />
capable allies and responsible partners in health promotion programs when they are given an opportunity. <strong>Final</strong>ly, school-based<br />
peer-led health education programs have strong potential to be used for other adolescent health issues such as smoking and<br />
obesity prevention.<br />
www.worldallergy.org 91<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1210<br />
imPlEmEnTaTion oF gUiDElinES in rEal-WorlD UK aSTHma managEmEnT<br />
ryan, D. 1 , Haughney, J. 2 , thomas, m. 2 , Pinnock, H. 3 , Price, D. 2 , Ellis, s. 4 and Chisholm, A. 4<br />
1 2 Woodbrook medical Centre, loughborough, United Kingdom. Centre of Academic Primary Care, University of Aberdeen, Aberdeen,<br />
United Kingdom. 3<strong>Allergy</strong> and respiratory research group, Centre for Population Health sciences: gP section, the University of<br />
Edinburgh, Edinburgh, United Kingdom. 4research in real life, Cawston, United Kingdom.<br />
Background: Current asthma guidelines suggest use of add-on therapy (i.e. leukotriene receptor antagonists (ltrAs), theophylline<br />
(theo), oral beta -agonists) in patients whose asthma control remains inadequate despite daily high-dose inhaled corticosteroid<br />
2<br />
(hdiCs) and long-acting beta -agonist (lABA) therapy.<br />
2<br />
objectives: to evaluate the proportion of patients on daily hdiCs/lABA therapy experiencing exacerbations (1, 2 and ≥3<br />
exacerbations annually), but who have not received a trial of additional add-on therapy.<br />
methods: retrospective study using the general Practice research Database (gPrD) to identify inadequately controlled hdiCs/lABA<br />
patients (average iCs daily dose of ≥800mcg beclometasone dipropionate equivalent in the prior year and ≥1 lABA prescription<br />
in the prior 2 years) and the proportion prescribed appropriate “additional add-on therapy” (namely ≥1 month of: ltrA, or theo, or<br />
oral beta -agonists ever). We used a history of exacerbations (1, 2, ≥3 exacerbations) as evidence of poor control. High risk patients<br />
2<br />
were those with ≥2 exacerbations in the prior year, detected using a composite measure based on the American thoracic society /<br />
European respiratory society exacerbation definition, namely records of: acute oral steroid prescriptions, hospital admissions and<br />
Accident & Emergency attendance for asthma.<br />
results: Of 96,964 asthma patients in the dataset, 21,994 (23%) were prescribed hdiCs+lABA. Of these, 17,971 (82%) had<br />
never received additional add-on therapy. Although patients experiencing exacerbations were more likely to have been prescribed<br />
additional add-on therapy (p
ABstrACts<br />
of oral steroids in last year) and asthma control (defined according to ginA guideline definitions: Controlled, Partly controlled and<br />
Uncontrolled).<br />
results: 11 gP practices from surrey Primary Care trust were reviewed. 5134 asthma patients, from a patient population of<br />
112,272, were identified (prevalence: 4.57%). 4451 were adults (aged ≥18 years), of which 720 (16%) were receiving high<br />
dose iCs and lABA, and 8 (0.2%) were also receiving long term oral steroids. 41 were considered high risk. results using the<br />
ginA guideline definitions of control are shown in table 1. Extrapolating to PCt level (1,154,068 patients), 1696 (226 High risk),<br />
uncontrolled patients would require referral to a severe asthma service.<br />
table 1: results for ginA definition of Control<br />
Patients High risk<br />
ginA definition of Control<br />
n (%) n (%)<br />
Controlled 25 (4.3%) 1 (2.63%)<br />
Partly Controlled 391 (67.3%) 15<br />
(39.5%)<br />
Uncontrolled 165 (28.4%) 22<br />
(57.9%)<br />
total with available data 581 (100%) 38 (100%)<br />
Data Unavailable 147 3<br />
Conclusion: in the practices reviewed, there is an unmet need for referral to a severe asthma clinic. Use of ginA criteria for asthma<br />
control are dependent upon data collection.<br />
1http://www.goldcopd.com/download.asp?intid=554 2http://www.britthoracic.org.uk/Portals/0/Clinical%20information/Asthma/guidelines/sign101%20revised%20June%2009.pdf 1212<br />
CHooSing ComBinaTion THEraPY For aSTHma: rESUlTS oF a Pan-EUroPEan aTTiTUDinal SUrVEY<br />
Price, D.<br />
Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom.<br />
Background. A recent Delphi consensus found that the factors considered to be most important in the selection of inhaled<br />
corticosteroids (iCss) and long-acting β -agonists (lABAs) as part of a stepped approach to asthma management are: flexibility<br />
2<br />
of dosing (88% agreement), long-term safety of the iCs and lABA (81%), clinical efficacy (81%), lABA speed of onset (69%) and<br />
iCs potency (69%). An attitudinal research survey was subsequently developed to evaluate whether physician attitudes in reallife<br />
practice are similar to the expert consensus. the aim of this study was to evaluate physician attitudes towards combination<br />
therapies for asthma and to identify important factors influencing treatment in the real-world setting.<br />
methods. Based on the responses of the Delphi consensus group, an attitudinal questionnaire was developed, translated and<br />
pilot-tested in face-to-face interviews. Computer-assisted web interviews were then conducted by Kantar Health in 13 European<br />
countries. Physicians who treated fewer than 15 asthma patients a month or who had responded to previous surveys on asthma in<br />
the past 3 months were excluded.<br />
results. Of 1861 respondents, 1007 (54%) were eligible for inclusion; 85% of eligible respondents were respiratory specialists<br />
and 15% were primary physicians with a specialist interest in asthma, treating a mean of 59 asthma patients per month. Half<br />
(50%) of the patients with asthma were being treated with iCs/lABA fixed combinations, 15% with iCs alone, 10% with iCs/lABA<br />
free combinations, 10% with short-acting β -agonists alone, other therapy (10%) and 5% with lABAs alone. When choosing an<br />
2<br />
iCs/lABA combination, the factors considered the most important (ranked 1 or 2 out of 5) were symptom improvement (71%),<br />
iCs potency (55%), improvement in fixed expiratory volume in 1 second (FEV ; 50%), safety and tolerability (43%), speed of onset<br />
1<br />
(42%), flexibility of dosing (40%) and duration of action (37%).<br />
Conclusion: in this pan-European survey, physician attitudes to iCs/lABA therapy differed from those observed in the Delphi<br />
consensus in terms of the importance given to specific treatment attributes. However, both initiatives indicated that clinical efficacy,<br />
safety and tolerability, speed of onset of the lABA, potency of the iCs, and flexibility of dosing influence the choice of treatment in<br />
real-life practice.<br />
www.worldallergy.org 93<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1213<br />
ComBinaTion THEraPY For aSTHma: rESUlTS oF a DElPHi ProCESS<br />
Price, D. 1 and Bousquet, J. 2<br />
1 2 Centre of Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom. University of montpellier, montpellier, France.<br />
Background. international guidelines recommend combination therapy with an inhaled corticosteroid (iCs) and a long-acting<br />
β -agonist (lABA) as part of a stepped approach to asthma management, but do not provide guidance on how to choose specific<br />
2<br />
combinations. We report here the findings of an initiative undertaken under the auspices of the global <strong>Allergy</strong> and Asthma<br />
European network (gA2lEn) to reach agreement on which factors are the most important to consider when choosing an iCs/lABA<br />
combination for asthma.<br />
methods. A Delphi process was used to elicit three rounds of structured feedback from a panel of European respiratory experts<br />
from primary and secondary care who had a specialist research interest in the management of asthma. in round 1, panel members<br />
recommended factors to consider using free text. responses were then coded and grouped for voting in round 2 using a 5-point<br />
anchored likert scale (from 0 [not important] to 4 [very important]). the factors rated most important were included in statements<br />
circulated to the panel, who then voted their level of agreement in round 3. Consensus was defined a priori as ≥ 66% agreement.<br />
results. thirty-two experts from 9 European countries (Austria, Finland, France, germany, italy, spain, sweden, switzerland and<br />
the UK) were invited to participate; response rates were 59.4% in round 1, 84.2% in round 2 and 84.2% in round 3. Fifteen factors<br />
were identified through the free-text responses in round 1. nine of these were rated as important or very important by ≥ 75% of<br />
the panel in round 2. in the final round, the panel reached consensus that the most important factors were: availability of a range of<br />
doses; clinical efficacy of the combination and long-term safety and tolerability of the components; speed of onset of the lABA and<br />
potency of the iCs.<br />
Conclusion. in the absence of clear recommendations from international guidelines regarding the criteria that should inform the<br />
selection of an iCs/lABA combination therapy for asthma, the results of this Delphi process may help to guide the evaluation and<br />
assessment of these treatments.<br />
1214<br />
CorrElaTion BETWEEn aSTHma-rElaTED QUaliTY oF liFE anD aSTHma ConTrolS in aDUlT aSTHmaTiCS<br />
Anıl, B. , Yıldız, P. , Aynacı, E. , Yıldırım, E. , Şahin, F. and seçik, F.<br />
Pulmonology, Yedikule Chest Disease and surgery training and research Hospital, İstanbul, İstanbul, turkey.<br />
Asthma has a multiface nature that results in a functional and emotional impairments.<br />
Aim: the purpose of the present study was to evaluate relationship between the Asthma Control test (ACt), Asthma Control<br />
Questionnaire (ACQ) and Asthma-related Quality of life Questionnaire (AQlQ) in adult asthmatics.<br />
PAtiEnts AnD mEtHODs: 91 patients (72 female, 19 male; mean age 35.91 yrs) included in this prospective study. Patients were<br />
followed-up for 3 months. they were completed the ACt and ACQ in order to assess disease control and AQlQ at 2 physician visits.<br />
Pulmonary function was measured in each visit and asthma specialist rated asthma control and decided for treatment according to<br />
the global initiative for Asthma (ginA) quideline.<br />
rEsUlts: Uncontrolled patient ratio was 79% (72/91) before treatment. significant decreases to the 26 % (24/91) has been<br />
shown with the 3 months asthma medication according to ginA guideline (p
ABstrACts<br />
1215<br />
aSTHma ComPliCaTion in PrEgnanCY<br />
Al shammari, n. H., O. randa, K. muna<br />
Al Qassimi Hospital, sharjah, United Arab Emirates.<br />
A case presentation:<br />
status asthmatic complicated by emphysema and pneumomediastinum during pregnancy A 25 y old 30 week pregnant, p3+2,<br />
known asthmatic on steroids, she stopped her medication during pregnancy thinking that its harmful to the baby,developed sever<br />
attack due to acute exacerbation after exposure to allergen , intubated .then, she developed emphysema &pneumomediastinum<br />
,she had emergency caserean section ,the baby Apgar scor was very poor and unfortunately died after few days due to fetal<br />
hypoxia.<br />
sever & poorly controlled asthma has been associated with numerous adverse perinatal outcome including preeclampsia ,<br />
pregnancy induce hypertension ,uterine haemorrhage, pretermlabour, congenital abnormalities, fetal growth restriction & low birth<br />
weight.<br />
review of pathophysiology of asthma & the effect of the physiological changes of pregnancy on asthma.<br />
the clinical assessment of asthma include both subjective evaluation & pulmonary function test & how to do that properly?<br />
goals of management:<br />
is to reduce hospitalization, emergency room admission, prevent work loss& chronic disability.<br />
the key of treatment is by frequent assessment of the patients, the severity of the attack and the patient response to treatment.<br />
Both number & dosage of medications can be increased as asthma severity increased.<br />
Hypoxia, acidosis, hypercapniea & pneumothorax is a warning sign of sever exacerbations<br />
the medication:<br />
B2 agonist is the mainstay of treatment; budesonide is the preferred inhaled steroid.<br />
Early systemic steroid,,theophylline, antihistamin oxygen supply, intravenous fluid, avoids tranquilizer& sedative.<br />
Discussing the criteria for hospital admission & iCU admission &ventilation setting.<br />
the prognosis; great risk in the last portion of pregnancy.<br />
Patient education:<br />
it is important because of most complication were due to under medication,<br />
Prevention & avoidance of triggers, allergens & irritant<br />
Home use of metered dose inhalers& pulmonary function test, using written diary to record PEFr<br />
Use a written guideline for management of exacerbation.<br />
1216<br />
THE ValUE oF aSPirin DESEnSiTiSaTion in THE managEmEnT oF aSTHma anD rHinoSinUSiTiS: EViDEnCE–BaSED<br />
Arafa, E. 1 and Howarth, D. P. 2<br />
1 2 <strong>Allergy</strong> Department, n m C specialty Hospital, <strong>Dubai</strong>, United Arab Emirates. infection,inflammation and immunity research<br />
division,school of medicine, southampton general Hospital, southampton, United Kingdom.<br />
Background: Aspirin is one of the gold standard medications used in a wide range of therapeutic and preventive indications.<br />
Aspirin hypersensitivity is a non-direct immunological mediated allergic reaction. it is responsible for aspirin exacerbated<br />
airway disease (AErD) and can cause asthma, rhinosinusituis, nasal polyps, urticaria and angioedema. the prevalence of aspirin<br />
hypersensitivity is 2.5 % (1) Aspirin Desensitisation (AD) has to be used for treating such cases. aim : in this review, we evaluated<br />
and rated the available evidence-based data for the value of AD on asthma and rhinosinusitis. methods: An electronic search<br />
of databases; Pubmed, Cochran’s database and American college of physicians. results: 393 publications were relevant to AD.<br />
Duplicated, non-human and non-English language references were excluded. Papers of unclear objectives and outcomes were<br />
excluded. the remaining 44 papers have evidence on the value of AD for management of asthma and rhinosinusitis. the evaluation<br />
was based on diagnosis, efficacy, failure, safety and cost-effectiveness. level of evidence (l) was rated according to a new scheme<br />
of oxford Centre of Evidence-based medicine (CEBm) (2) . According to EACCi/gA2lEn 2007 guidelines for diagnosis of aspirin<br />
hypersensitivity, aspirin provocation challenge tests are recommended for diagnosis of aspirin induced asthma, and rhinosinusitis.<br />
AD is an effective treatment option and may alter the course of the ArED in patients with ArED who require aspirin for other<br />
therapeutic indications. Evidence is from five randomised controlled trials (lii), one small retrospective, one prospective study, three<br />
www.worldallergy.org 95<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
systematic review of non-randomised trials and one cross over study (liii), 21 case reports, expert opinion and clinical experience<br />
(lV). AD is a safe treatment with low aspirin dosage (lV, liii) and high dose (lii). it is a cost effective option in cardiovascular<br />
diseases (liii). in spite of the confirmed efficacy of AD, there is some failures (lV).Conclusion: AD has a small evidence data base,<br />
however, based on current available evidence AD is effective, safe and an alternative option for AErD patients. AD might be a cost<br />
effective option for cardiovascular diseases. more randomised multicentre controlled trials are needed in AErD.<br />
1217<br />
ESoPHagEal CanDiDiaSiS SUCCESSFUllY TrEaTED WiTH rEPlaCEmEnT oF inHalED CorTiCoSTEroiD<br />
Castro-Coelho, A. P. , Aun, m. V. , montenegro, F. g. , Borges, D. B. , Agondi, r. C. , Kalil, J. and giavina-Bianchi, P.<br />
Clinical immunolgy and <strong>Allergy</strong>, sao Paulo University, sao Paulo, Brazil.<br />
Background: Over the last few decades, inhaled corticosteroids (iCs) became the cornerstone in the treatment of persistent<br />
asthma. Esophageal candidiasis is a rare complication resulting from iCs administration, but it is probably underdiagnosed. We have<br />
recently described a prevalence of 5.7% in severe asthma patients. it was also shown that the device and type of iCs used can<br />
influence the occurrence of this complication.<br />
methods: We describe two patients who recovered from esophageal candidiasis after replacing budesonide dry powder with<br />
ciclesonide pressurized metered-dose inhaler (HFA).<br />
results: We report two cases of female patients aged 65 and 46 years with difficult-to-control asthma who had to use budesonide<br />
aeroliser 2000mcg/day associated with formoterol 60mcg/day to maintain asthma partially controlled. the patients complained of<br />
abdominal pain and heartburn and therefore underwent EgD, which revealed esophageal candidiasis. the diagnosis was confirmed<br />
by esophagus biopsy. they were both treated with fluconazole, with no improvement of the symptoms and the endoscopic lesions.<br />
We repeated the antifungal treatment once more, but it was again ineffective. Budesonide was then replaced with ciclesonide<br />
1280mcg/day. the asthma continued stable and the infection was healed, without antifungal administration.<br />
Conclusion: Ciclesonide is delivered as an inactive prodrug, which is cleaved to the active molecule by intracellular esterases<br />
located in the lungs. this and other pharmacodynamic and pharmacokinetic properties may limit the amount of active molecule<br />
outside the lung and may reduce the incidence of side effects. this could explain why our patients recovered from esophageal<br />
candidiases. We showed that replacement of budesonide aeroliser with ciclesonide aerosol without antifungal treatment can be<br />
enough to eliminate Candida infection.<br />
1218<br />
DEmograPHiC anD CliniCal CHaraCTEriSTiCS aSSoCiaTED WiTH THE aTTriTion in a CoHorT oF aDUlT aSTHma<br />
Kim, s. 1 , Kim, t. 2 , Chang, Y. 3 , Kim, s. 3 , Park, H. 4 , Park, s. W. 5 , Cho, Y. s. 2 , Park, J. 6 , nahm, D. 7 , Cho, Y. J. 8 , Cho, s. 4 , Choi, B. 9 ,<br />
moon, H. 2 and Yoon, H. J. 1<br />
1 2 Department of internal medicine, Hanyang University College of medicine, seoul, south Korea. Department of <strong>Allergy</strong> and Clinical<br />
immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Department of internal medicine,<br />
seoul national University Bundang Hospital, seongnam, south Korea. 4Department of internal medicine, seoul national University<br />
College of medicine, seoul, south Korea. 5Division of respiratory and <strong>Allergy</strong> medicine, soonchunhyang University Hospital, College<br />
of medicine, Bucheon, south Korea. 6Division of <strong>Allergy</strong> & immunology Department of internal medicine, Yonsei University College of<br />
medicine, seoul, south Korea. 7<strong>Allergy</strong> & rheumatology, Ajou University school of medicine, seoul, south Korea. 8<strong>Allergy</strong> and Clinical<br />
immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea. 9Department of internal medicine,<br />
Chung-Ang University College of medicine, seoul, south Korea.<br />
Background in observational studies, unexpected attrition of patients can significantly reduce statistical power and comprise study<br />
objectives. in this study, we aimed to assess the factors predicting attrition in a cohort of adult asthma.<br />
methods in an adult asthma cohort (COrEA) from 11 university hospitals in Korea, we estimated the proportion of completers and<br />
dropouts among the patients who enrolled more than 18 months ago. Completers were defined as the patients who had one or<br />
more visit records in the next 12-18 months after registration. Demographic and clinical features were compared between dropouts<br />
and completers.<br />
results Of 1,499 patients, 670 (44.7%) patients dropped out in the study period. the dropouts showed lower mean age (43.1 ±<br />
15.8 vs. 51.1 ± 14.3, P
ABstrACts<br />
to allergens, lower severity of asthma, and less use of HCU for asthma. these findings suggest the factors predicting attrition in the<br />
management of asthma.<br />
Keywords: attrition, drop-outs, asthma, characteristics<br />
1219<br />
EFFECT oF anTirEFlUX TrEaTmEnT on CoUgH FrEQUEnCY in STaBlE aDUlT aSTHmaTiCS<br />
Hamed, m. n. 1 , sliem, H. 2 and Hassan, m. 3<br />
1 2 Chest Diseases, suez Canal University, Faculty of medicine, isamilia, Egypt. internal medicine, suez Canal University, Faculty of<br />
medicine, ismailia, Egypt. 3infectious and tropical diseases, suez Canal University, Faculty of medicine, ismailia, Egypt.<br />
Background: gastroesophageal reflux disease (gErD) is common in patients with asthma, but the target population for antireflux<br />
treatment, are not precisely defined.<br />
The purpose of the study: to assess the effect of the proton pump inhibitor omeprazole and prokinetic domperidone on cough<br />
frequency, in patients with stable asthma of different severity (persistent mild to severe asthma) with chronic cough.<br />
Methods: in this case – control study, 45 adult stable asthmatics, received omeprazole 40 mg twice daily, with domperidone 5<br />
mg half an hour before meal three times daily for 4 weeks, and followed for cough frequency (score of 5[no=0, rare =1, usual =2,<br />
common =3, frequent =4] ) according to patient daily records . According to gErD esophageal symptoms, subjects were divided<br />
into two matched groups: with gErD group (25 patients) and without gErD group (20 patients).<br />
Main Results: there were statistically highly significant (P < .0001) improvements in cough frequency, in the overall study<br />
population (35/45patients [77.8%], Z=-5.11), and in both groups (gErD19/25patients [76. %] Z= -3.72, without gErD 16/20<br />
patients [80%] Z= -3.64).<br />
But there was no statistically significant difference, as regard cough frequency improvement, between groups.<br />
According to cough frequency score ≥ 2, the probability (the positive predictive value) that a subject has gErD -assessed by cough<br />
improvement on antireflux treatment- was 85.7% in the 45 patients, 88.23% in gErD group, and 81.8% in without gErD group.<br />
Conclusions: omeprazole combined with domperidone improved cough frequency in 45 subjects with stable asthma either with or<br />
without gErD esophageal symptoms, which makes the possibility of hidden gErD (without esophageal symptoms) high in patients<br />
without gErD esophageal symptoms; the high positive predictive value of cough frequency<br />
(≥ 2) in predicting gErD in such patients, nominate it as a possible guide for prescribing antireflux treatment in such stable<br />
asthmatics, even in patients without esophageal gErD symptoms.<br />
1220<br />
PoTEnTial maSKing oF airWaY inFlammaTion BY ComBinaTion THEraPY in aSTHma<br />
lee, B. , lee, J. and Choi, D.<br />
<strong>Allergy</strong> and Clinical immunology, Department of medicine, samsung medical Center, sungkyunkwan University school of medicine,<br />
seoul, south Korea.<br />
Background: there is a concern about safety of long-acting beta2 agonists (lABA), because lABA might mask ongoing<br />
bronchial inflammation and thereby leave the asthmatic patient at risk for more severe exacerbations. We compared the effect of<br />
combination therapy including low dose of inhaled corticosteroids (iCs) and lABA with the effect of medium dose of iCs alone on<br />
airway inflammation in asthma. methods: twenty-four patients whose asthma is not controlled by low dose iCs (400 ug a day of<br />
budesonide) were enrolled in this prospective crossover study. Participating patients were randomized into two treatment phases:<br />
one receiving higher dose (800 ug a day) budesonide (iCs phase), and the other receiving a combination therapy of budesonide/<br />
formoterol (360 ug/9 mg a day) delivered by a single inhaler (lABA phase). Each treatment phase was lasted for 6 weeks then<br />
crossed over. Asthma symptoms, lung function, and airway inflammation were compared between the two phases. results: Among<br />
23 patients who completed the study, adequate sputum for the analysis was available in 17 patients. Asthma symptoms and lung<br />
function remained similar in the two phases. By contrary, the mean sputum eosinophil percentile was significantly higher in lABA<br />
phase than iCs phase (5.07 ± 3.82 % vs. 1.02 ± 1.70 %, p < 0.01). sputum eosinophilia (≥3 %) remained in six subjects during<br />
the lABA phase, but in two subjects during the iCs period. Conclusion: Combination therapy of low dose iCs and lABA may mask<br />
airway eosinophilic inflammation in asthmatic patients compared to medium dose iCs alone.<br />
www.worldallergy.org 97<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1221<br />
THE USEFUlnESS oF Pram SCorE in aSSESSing THE SEVEriTY anD oUTComE oF an aCUTE EXaCErBaTion oF WHEEZE<br />
in CHilDrEn<br />
nagaraju, m. K. , r, D. , n, s. and r, g.<br />
Pediatric allergy and immunology, Kanchi Kamakoti CHilDs trust Hospital, Chennai, india.<br />
Background:<br />
Clinical scores are valuable tools to assess asthma severity in children. Among the available scores the Pediatric respiratory<br />
Assessment measure (PrAm) score is very useful one .<br />
aims of study:<br />
to study the usefulness of PrAm score in assessing the severity and outcome of an acute exacerbation of wheeze in children aged<br />
1-17yrs.to identify the PrAm score predicting the need for hospitalization and iCU care. Period of study:<br />
August 2008 to Dec 2009<br />
Study design:<br />
this is a prospective cohort study<br />
Sample size:<br />
127 children was calculated based on the pilot study from the initial 20 children. Assuming an alpha error of 5% and 80% power.<br />
methodology :<br />
Children diagnosed to have asthma based on ginA guidelines 2008 came with acute exacerbation of wheeze were enrolled in the<br />
study ,had PrAm scores done at admission and following each treatment administered in the Er. All children were triaged and<br />
treated as mild, moderate, severe exacerbation and appropriate treatment was given in the emergency room and the outcome<br />
was recorded. statistical Analysis done using sPss – 15 version. relationship between admission scores and the outcome<br />
were evaluated using paired t tests and one way AnOVA f test. receiver operator curve analysis(rOC)was used to identify score<br />
predicting admission and need for iCU care.<br />
results :<br />
Of the 127 children 52% were aged 1 - 3 years, 27.6% between the ages of 3 – 6 years and 20.4% between the ages of 6 - 17<br />
years . the mean PrAm scores at admission and discharge in all the 3 age groups was 7.3 and 4.1 respectively ,this difference is<br />
statistically significant. rOC score of 5.5 and above had 89% sensitivity and 64% specificity for admission.<br />
Conclusion:<br />
PrAm scores is a useful score to assess asthma severity in children and a score of 6 predicted the need for hospitalization and<br />
score of 9 predicted the need for iCU care .<br />
PoSTEr SESSion 1-3: asthma epidemiology and mechanisms<br />
1300<br />
rElaTion oF PErimEnSTrUal aSTHma WiTH DiSEaSE SEVEriTY anD oTHEr allErgiC Co-morBiDiTiES-THE FirST<br />
rEPorT oF PErimEnSTrUal aSTHma PrEValEnCE in SaUDi araBia<br />
sabry, E. Y.<br />
Chest OPD- internal medicine, saudi german Hospital, riyadh, saudi Arabia.<br />
Background: Perimenstrual asthma (PmA) has been documented in 30% to 40% of asthmatic women; however, there have been<br />
few epidemiological investigations of PmA in practice.<br />
objectives: in this study, we analyzed PmA prevalence and relation to disease severity based on direct questions carried out in taif-<br />
KsA and compared the results with those of studies reported previously.<br />
results: the prevalence of PmA and its’ relation to asthma severity and to other allergic co-morbidities were studied. Prevalence<br />
was 8.2% and asthma severity was found to be significantly related to PmA (p
ABstrACts<br />
1301<br />
non-EoSinoPHiliC aSTHma: imPorTanCE anD PoSSiBlE mECHaniSmS<br />
raj, s. and shah, r.<br />
Bioinformatics, sathyabama University, Chennai 73, india.<br />
Aim: to study the aetiology of asthma including the underlying inflammatory profiles. introduction: Asthma is a common chronic<br />
inflammatory disease of the airways characterized by variable and recurring symptoms, airflow obstruction, and bronchospasm.<br />
symptoms include wheezing, cough, chest tightness, and shortness of breath. there is increasing evidence that inflammatory<br />
mechanisms other than eosinophilic inflammation may be involved in producing the final common pathway of enhanced bronchial<br />
reactivity and reversible airflow obstruction that characterises asthma. A review of the literature has shown that, at most, only 50%<br />
of asthma cases are attributable to eosinophilic airway inflammation. it is hypothesised that a major proportion of asthma is based<br />
on neutrophilic airway inflammation, possibly triggered by environmental exposure to bacterial endotoxin, particulate air pollution,<br />
and ozone, as well as viral infections. if there are indeed two (or more) subtypes of asthma, and if non-eosinophilic (neutrophil<br />
mediated) asthma is relatively common, this would have major consequences for the treatment and prevention of asthma since<br />
most treatment and prevention strategies are now almost entirely focused on allergic/eosinophilic asthma and allergen avoidance<br />
measures, respectively. it is therefore important to study the aetiology of asthma further, including the underlying inflammatory<br />
profiles.<br />
Conclusion: Asthma is thus an inflammatory disease caused by the inflammation of bronchioles. Also asthma cases are attributable<br />
to eosinophilic airway inflammation.<br />
Keywords: Asthma, eosinophilic inflammation, bronchioles.<br />
1302<br />
aSTHma inCiDEnCE aFTEr agE 6 YEarS BY gEnDEr anD aToPiC STaTUS in THE CHilDHooD allErgY STUDY<br />
Ahmed, s. 1 , Wegienka, g. 1 , Havstad, s. 1 , Johnson, C. 1 , Ownby, D. 2 , nageotte, C. 1 and Zoratti, E. 1<br />
1 2 <strong>Allergy</strong> and immunology, Henry Ford Health system, Detroit, mi. <strong>Allergy</strong> and immunology, medical College of georgia, Augusta, gA.<br />
Background: Asthma is more prevalent in males before adolescence, yet more common among adult women. later-onset asthma<br />
is often perceived to be less associated with atopy. We explored gender-specific asthma incidence in a birth cohort, stratifying by<br />
atopic status.<br />
method: We used data from the Detroit Childhood <strong>Allergy</strong> study to analyze the role of atopy during the period of apparent transition<br />
from male to female asthma predominance (i.e. between age 6 and 20). self or parental report of physician-diagnosed asthma was<br />
used to define incident asthma. Atopy was defined as a specific igE ≥ 0.35 for at least 1 of 7 common allergens. A log-rank test<br />
was performed to determine the association of time to asthma among atopic and non-atopic males and females. A Cox regression<br />
analysis was done with the male, non-atopic group as the reference group.<br />
results: Of the 565 subjects included, 53% were female and 47% male. Females overall developed asthma after age 6 at a rate<br />
1.73 times higher than males, hazard ratio (Hr)=1.73 (1.04, 2.85), p=0.033. the proportion of atopy among asthmatic females<br />
was 69% versus 70% among asthmatic males. Atopic females were more than twice as likely to develop asthma compared to nonatopic<br />
females, Hr=2.27 (1.21, 4.27); p=0.011.<br />
Conclusion: Between the ages of 6 and 20 years, females developed asthma at a higher rate than males and associated atopy<br />
was common among new onset asthma in females. in young adults atopic asthma was equally prevalent in males and females and<br />
more than twice as common as non-atopic asthma.<br />
1303<br />
PrEVElanCE, TrEaTmEnT PaTTErnS anD riSK FaCTorS oF aSTHma anD rHiniTS among aDUlTS in THE UaE<br />
mahboub, B. 1 , Pawankar, r. 2 , rafique, m. 3 , sulaiman, n. 4 , Al Hammadi, s. 5 and ibrahim, A. 6<br />
1 2 Department of Pulmonary medicine, rashid Hospital, <strong>Dubai</strong>, United Arab Emirates. <strong>Allergy</strong> and rhinology, niPPOn mEDiCAl<br />
sCHOOl, tokyo, Japan. 3Pulmonologist ,Dept of Pulmonary medicine, rashid Hospital, <strong>Dubai</strong>, United Arab Emirates. 4Dept of family<br />
& community medicine& Behavioural sciences, sharjah University, sharjah, United Arab Emirates. 5UAE University, United Arab<br />
Emirates. 6Otorhinolaryngology, Al barha Hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
objective to assess the prevalence of symptoms of Chronic respiratory diseases like asthma, and allergic rhinitis especially in<br />
adults in the UAE. due to lack of epidemiological data methods 1,225 direct interviews were conducted (in English and Arabic)<br />
on randomly selected people of all age groups, throughout the 7 emirates (males :66.5%, females: 33.5%). modified European<br />
Community respiratory Health survey (ECrHs)ii Questionnaire, both the short screening & main ones were used with changes to<br />
www.worldallergy.org 99<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
reflect environmental & cultural nuances of the UAE. results From the screening questionnaire the prevalence of wheezing in the<br />
past 1yr was 10.1%. Of those interviewed, 8.1% had asthma attacks in the last 1yr, 7.9%are were currently on asthma drugs, 6.9%<br />
had nasal allergies. the key findings in known 188 asthmatics were 58.5% claimed to have asthma. more asthma attacks were<br />
seen in Jan/Feb (26.1%) and (19.1%) in nov/Dec, Fewer attacks were reported in march/April. About, 36.2% had nasal allergies<br />
and 23.4% took treatment for it.. About 10.1% had eczema or skin rash and 47.9% took asthma medications. Of the asthmatics,<br />
19.1% woke up less than twice a month because of their asthma in past 3months and 10.5 workdays were lost due to asthma<br />
in past 1yr. Average age when they first experienced an asthma attack was 13.5 years. the average no of attacks experienced in<br />
the past 1yr was 9.5.short acting beta agonist inhalers (41.5%) was the most used followed by long acting beta agonist inhalers<br />
(6.9%.onl) Approximately, 3.7% were on inhaled steroids alone and 8.5% were using oral beta agonists followed by methyxanthines<br />
(2.1%) and antileukotrienes (1.6%). Only 9.6% had a spirometry or laboratory test done. Alternative remedies comprised of 9% on<br />
breathing exercises, 6.9% on diet control, 4.3% on swimming/other exercises & 3.7% homeopathy. About 18.1% of asthmatics<br />
were regularly exposed to tobacco smoke in the past 1yr Conclusion A high prevalence of asthma symptoms and nasal allergies in<br />
adults was found. Environmental factors had an important role. the level of annoyance by outdoor air pollution was 6.4. there was<br />
more use of short acting beta agonist as the main stay of asthma treatment with underutilisation of spirometry, peak flow meters,<br />
allergy tests, xrays in diagnosis and increasing dependence on alternative remedies (19.7%). reference Asthma insights and<br />
reality in the gulf and the near East. Khadadah m, mahboub B, Al-Busaidi nH, sliman n, soriano JB, BahousJ ,int J tuberc lung Dis.<br />
2009 Aug;13(8):1015-22<br />
1304<br />
PollEn rElaTED aSTHma: THE moST FrEQUEnT aSTHma PHEnoTYPE in KUWaiTi SCHoolCHilDrEn<br />
Al-Ahmad, m. s. 1 , Arifhodzic, n. 2 , Al-Ahmed, n. 1 , Al-Onizi, A. 1 , Panicker, r. 1 and Fakim, n. 1<br />
1 2 <strong>Allergy</strong> Department, Kuwait <strong>Allergy</strong> Center, Kuwait, Kuwait. <strong>Allergy</strong>, Al-rashed allergy Centre, Kuwait, Kuwait.<br />
introduction: indoor allergens (house dust mites) are the leading cause of allergic asthma in children worldwide. However, a desert<br />
climate does not provide optimal conditions for mite thriving.<br />
The aim of study: to evaluate the relationship between sensitization to indoor vs. outdoor inhalant allergens in asthma<br />
development in Kuwaiti schoolchildren.<br />
methods: in a cohort of 246 randomly selected asthmatic children, both gender, aged 8-15 years old. Patients were recruited from<br />
september 2006 - October 2007 from Kuwait allergy center. All patients completed disease history questionnaire, underwent PFt<br />
and skin prick test (sPt) with the battery of inhalant allergens (stellergenes, France), including those typical for desert climate. One<br />
hundred eleven healthy, age and gender matched children served as control<br />
results: majority of asthmatic children, 86.9 %,( mean age of 11.3 ± 2.9 years) had positive sPt to one or more inhalant allergens<br />
in comparison to 26.1% of healthy control. sensitization to outdoor allergens prevailed in all asthmatic children, (44, 3% vs. 15.6%<br />
to house dust mites; p 0.05) in asthma severity between children sensitized to either indoor or outdoor allergens was found.<br />
(indoor allergens: mild intermittent: 44.1%, mild - moderate persistent: 55.9%; Outdoor allergens: 42.6% and 57.3 % respectively).<br />
Co - morbid allergic rhinitis was found in more than 50% of our patients.<br />
Conclusion: Unlike other countries, where asthma is most frequently related to exposure to indoor allergens, it is not the case in<br />
our region. Pollen allergens a major cause of asthma of Kuwaiti asthmatic school children. Extremely long pollination season in<br />
Kuwait region characterized by two typical, almost constant peaks, (spring and autumn) has important impact on pollen related<br />
asthma development. Harsh desert climate with drastic environmental changes, have a major impact on asthma phenotype.<br />
Key words: indoor allergens, outdoor allergens, asthma development.<br />
1305<br />
CYSTEinYl-lEUKoTriEnS oVErProDUCTion anD THE aSTHma SEVEriTY in PaTiEnTS WiTH aSPirin-inDUCED aSTHma<br />
mitsui, C. , taniguchi, m. , Higashi, n. , Ono, E. , Kajiwara, K. , Hukutomi, Y. , tsuburai, t. , sekiya, K. , tanimoto, H. , ishii, t. , mori, A. ,<br />
mita, H. , Hasegawa, m. and Akiyama, K.<br />
Clinical research Center for <strong>Allergy</strong> and rheumatology, national Hospital <strong>Organization</strong> sagamihara national Hospital,<br />
sagamihara,Kanagawa, Japan.<br />
Background: the unique pathophysiology of aspirin-induced asthma (AiA) is cysteinyl-leukotriens (Cyslt) overproduction. Almost<br />
patients with AiA show severe asthma, but some of them have mild asthma. the mechanisms underlying asthma severity in AiA<br />
patients remain unclarified. We hypothesized that Cyslt overproduction is related to the asthma severity of AiA and tried to clarify<br />
the correlation between Cyslt production and asthma severity in AiA patients.<br />
methods: Forty AiA patients, whose aspirin sensitivity was determined by the aspirin challenge test, and twenty healthy subjects<br />
www.worldallergy.org 100<br />
FinAl PrOgrAm
ABstrACts<br />
participated in this study. We measured urinary leukotrien E4 (U-ltE4) level under stable asthma condition, using Cayman’s EiA<br />
kit after purification by HPlC, as we reported previously. AiA patients were classified into three groups, 1) patients with mild to<br />
moderate asthma which was controlled at less than ginA step 3 treatment,2) patients with stable but severe asthma which was<br />
well controlled at ginA step 4 treatment, and 3) patients with difficult-to-treat asthma which was not controlled at ginA step 4<br />
treatment.<br />
results: the AiA groups 1-3 showed median U-ltE4 concentrations 108, 259, and 582 pg/mg creatinine, respectively. there was no<br />
significant difference between patients with mild to moderate asthma and healthy controls. On the other hand, the concentrations of<br />
U-ltE4 in patients with severe but stable AiA patients and difficult-to-treat AiA patients significantly increased according to asthma<br />
severity as compared with AiA patients with mild to moderate asthma.<br />
Conclusion: Cyslt overproduction may be related to the asthma severity in AiA patients.<br />
1306<br />
CorrElaTion BETWEEn SPiromETrY rESUlTS anD BoDY maSS inDEX in PaTiEnTS WiTH aSTHma<br />
Agondi, r. C. , Bisaccioni, C. , ribeiro, m. , Kalil, J. and giavina-Bianchi, P.<br />
Clinical immunolgy and <strong>Allergy</strong>, sao Paulo University, sao Paulo, Brazil.<br />
Background: studies have suggested that asthma in obese individuals differs from the classic asthma phenotype, presenting as<br />
a disease that is more difficult to control and that does not respond as well to inhaled corticosteroids. the objective of the present<br />
study was to determine whether obesity, age or a combination of the two are associated with abnormal spirometry results in<br />
patients with asthma.<br />
method: this was an observational, cross-sectional, retrospective study involving patients over 18 years of age who had been<br />
diagnosed with asthma. We evaluated the results of spirometric tests conducted between February of 2009 and August of 2009.<br />
the patients were classified in accordance with two criteria: body mass index (Bmi) and age.<br />
results: We evaluated 453 patients and 453 corresponding sets of spirometry results. in the present study, the pulmonary function<br />
parameters were negatively correlated with Bmi. in the obese group, the mean FEV value was 17.4% lower than that observed in<br />
1<br />
the normal-weight group. Within that group, the number of abnormal spirometry results was significantly higher among the patients<br />
≥ 60 years of age than among those 18-59 years of age. the proportion of females was also higher in the obese group.<br />
Conclusion: Our results indicate that FEV and FVC decrease significantly in proportion to increases in Bmi and age. Because<br />
1<br />
obesity is yet another factor that makes asthma control difficult, the weight of asthma patients should be closely monitored.<br />
1307<br />
PrEValEnCE oF BronCHial aSTHma anD iTS aSSoCiaTion WiTH SmoKing HaBiTS among aDUlT PoPUlaTion in rUral<br />
arEa<br />
Parasuramalu, B. g. 1 , Huliraj, n. 2 , B m, r. 1 , s P, P. K. 1 , Dr, g. 1 and n r, r. m. 1<br />
1 2 Department of Community medicine, Kempegowda institute of medical sciences, Bangalore, india. Department of thoracic<br />
medicine, Kempegowda institute of medical sciences, Bangalore, india.<br />
Background: Only few studies have been conducted in rural areas in india to study the relationship of active tobacco smoking in<br />
bronchial asthma. Hence the present study was conducted with the objectives: 1. to find out the prevalence of bronchial asthma. 2.<br />
to find out the association between tobacco smoking and bronchial asthma. materials and methods: A cross sectional study was<br />
conducted in the rural field practice area of Kempegowda institute of medical sciences, Bangalore. totally 3194 adult individuals<br />
(18-70years) were selected from 30 villages (clusters) using cluster-sampling technique. On visiting each house, previously<br />
validated and standardized translated Kannada version questionnaire was administered. individuals with symptoms suggestive of<br />
asthma were subjected for clinical examination for the diagnosis of asthma. the data was compiled and analyzed. results: Among<br />
the 3194 respondents, 1518 (47.5%) were males & 1676 (52.5%) were females. the prevalence of bronchial asthma was 2.88%.<br />
the prevalence of asthma was higher among those reporting a history of current smoking. Among current smokers the number of<br />
cigarettes/ bidis/ hookah smoked daily did not differ (p>0.05) between individuals without asthma and with asthma, whereas the<br />
mean number of years of smoking did differ (p
ABstrACts<br />
ABstrACts<br />
1308<br />
analYSiS oF PUBmED- inDEXED aSTHma rESEarCH From THE araB WorlD in THE laST TEn YEarS<br />
Afifi, m. 1 and Hameed, W. A. 2<br />
1 2 Primary Health Care, ministry of Health (HQ), <strong>Dubai</strong>, United Arab Emirates. Primary Health Care, ministry of Health, Ajman, United<br />
Arab Emirates.<br />
oBJECTiVES: We aimed to identify the gaps in asthma research in the Arab world and suggest recommendations for untapped<br />
areas. Hence we analyzed ten- years Pubmed- indexed publications related to bronchial asthma, produced by authors affiliated to<br />
the Arab countries.<br />
mETHoDS: a medline search was performed on 1st July 2010 to have the total number of citation from the 22 Arab countries<br />
during the ten years prior to the search. Another search in the mesH database of the medline for citations under “asthma”<br />
Or “ bronchial asthma” category was followed. the two search strategies were then combined by “AnD” and inspected for<br />
validation. the search was then saved in medline format text file, which was converted into Excel file and captured as a new<br />
database query via sPss software. the methodology of capturing research of the Arab countries and converting a medline search to<br />
an sPss data file was discussed in more details in previously published research by the first author. 1,2<br />
rESUlTS: the number of asthma related publications affiliated to the Arab countries over the last 10 years totaled 275 articles.<br />
the number of research was doubled in 2010 relative to 2000. However, only three countries- namely KsA, Egypt and Kuwaitpublished<br />
63% of the total publications. the three major areas studied were the epidemiological issues of asthma, its management,<br />
and its immunological issue (32%, 18.55%, and 18.05% respectively of total publications). Health system research constituted<br />
only 11.27% of publications. Areas as asthma in primary care and gender differences in morbidity and response to treatment are<br />
relatively neglected. the majority of publications were journal articles (82.9%), whereas clinical trial articles and evaluation studies<br />
constituted only 1.1 % and 3.6 % respectively. the saudi med J followed by J Asthma and Ann thorac med came on top of the list<br />
of 131 journals that published asthma research (12 %, 5.09% and 4.37% respectively).<br />
ConClUSion: Despite the increase in asthma publications, the outcome of some Arab countries was not satisfactory. Areas as<br />
health system research, asthma in primary care, and gender differences should have more consideration from Arab researchers.<br />
references:<br />
1: Osman Ot, Afifi m. troubled minds in the gulf: mental health research in the<br />
United Arab Emirates (1989-2008). Asia Pac J Public Health. 2010 Jul;22(3<br />
suppl):48s-53s.<br />
2: Afifi mm. mental health publications from the Arab world cited in Pubmed,<br />
1987-2002. East mediterr Health J. 2005 may;11(3):319-28.<br />
1309<br />
THE imPaCT oF ConComiTanT allErgiC rHiniTiS anD aSTHma on QUaliTY oF liFE in iTalian PaTiEnTS oF gEnEral<br />
PraCTiTionErS: arga STUDY<br />
maio, s. 1 , Baldacci, s. 1 , Borbotti, m. 1 , Angino, A. 1 , martini, F. 1 , Piegaia, B. 1 , silvi, P. 1 , sarno, g. 1 , Cerrai, s. 1 , simoni, m. 1 , Di Pede,<br />
F. 1 and Viegi, g. 2<br />
1 2 institute of Clinical Physiology, national research Council, Pisa, italy. Cnr institute of Biomedicine and molecular immunology,<br />
Palermo, italy.<br />
Background: epidemiological studies show that allergic rhinitis is very common in patients with asthma, and that the co-presence<br />
of these two diseases can worsen the patients’ quality of life.<br />
aims: to evaluate the impact of the concomitance of asthma and rhinitis (Ar) on quality of life in italian patients of general<br />
practitioners (gP).<br />
methods: prospective observational study in different italian areas. 107 gP enrolled patients with asthma/rhinitis diagnosis and<br />
with anti-asthmatic or anti-rhinitic therapy or symptoms in the last 12 months. Questionnaires were used to collect data on<br />
respiratory allergic diseases. the rhinasthma questionnaire was used to assess the patients’ quality of life.<br />
Univariate analyses were used to assess the relationship between presence of only asthma, Ar or Ar and any one among other<br />
allergic diseases (sinusitis, conjunctivitis, atopic dermatitis and nasal polyposis) (ArOAD) and quality of life, disease severity levels<br />
and asthma symptoms. linear regression analysis was used to assess the relationship between quality of life and presence of Ar or<br />
ArOAD adjusting for age, gender, smoking habits and asthma severity levels.<br />
results: 46.8% of 936 subjects had only asthma, 36.2% Ar and 17.0% ArOAD. Univariate analyses showed a significantly higher<br />
frequency of moderate-severe asthma (36.0% vs 33.8%) and asthma symptoms (95.4% vs 89.9% for wheeze, 93.5% vs 88.7%<br />
www.worldallergy.org 102<br />
FinAl PrOgrAm
ABstrACts<br />
for attacks of shortness of breath, 92.8% vs 85.4% for asthma symptoms in the last 12 month) in subjects with ArOAD with<br />
respect to those with only asthma; the presence of Ar or ArOAD, with respect to only asthma, was associated with a significantly<br />
worse quality of life (mean values of global score derived from rhinasthma questionnaire: 19.8±14.6, 20.2±14.3, 29.9±16.3,<br />
respectively). the multivariate linear regression analysis confirmed that the presence of Ar or ArOAD is an independent risk factor<br />
for a worse quality of life (beta coefficient: 0.253, p-value
ABstrACts<br />
ABstrACts<br />
uptake, dominated the disease with medium-severe course. Conclusion: Epidemiological studies can provide reliable information<br />
on the prevalence, structure and severity of AD. monitoring of the true prevalence of AD shows hypodiagnostics of all forms of AD in<br />
the Cis-C, related to the underestimation of mild forms of the disease. Accounting for the structure and expression of sensitization<br />
to allergens, taking into account climate and geographic features, allows to plan the work of allergic services and to organize<br />
preventive and curative interventions.<br />
1312<br />
gUiDElinES aPPliCaTion For aSTHma anD rHiniTiS managEmEnT: arga (rESPiraTorY allErgiC DiSEaSES:<br />
moniToring STUDY oF gina anD aria gUiDElinES) ProJECT<br />
Baldacci, s. 1 , maio, s. 1 , Cerrai, s. 1 , sarno, g. 1 , Borbotti, m. 1 , Angino, A. 1 , martini, F. 1 , Carrozzi, l. 1 , Di Pede, F. 1 and Viegi, g. 2<br />
1 2 institute of Clinical Physiology, national research Council, Pisa, italy. Cnr institute of Biomedicine and molecular immunology,<br />
Palermo, italy.<br />
Background: in italy, a big effort has been made to disseminate ginA and AriA guidelines (gl) for asthma and rhinitis management<br />
within the setting of specialist and general practice. Despite a general good knowledge of gl, their implementation within the<br />
clinical practice seems still poor.<br />
Objective: to assess the level of application of gl for asthma and rhinitis management within general practitioners (gP).<br />
methods: cross-sectional italian survey (2007-10); 107 gP (89% of the expected sample) enrolled patients with asthma/rhinitis<br />
diagnosis and pharmacologic treatment and/or rhinitis/asthma symptoms in the last 12 months.<br />
For each patient (n=1820), a questionnaire was filled in by gPs on: diagnosis of allergopathies, asthma and rhinitis severity<br />
according to gl, instrumental tests used for diagnosis/monitoring, educational activity, drug prescriptions for asthma/rhinitis.<br />
results: patients are: 47% rhinitic (7% moderate-severe persistent), 25% asthmatics (2% severe persistent) 28% with both asthma<br />
and rhinitis (Ar) (8% with moderate-severe persistent rhinitis, 6% with severe persistent asthma).<br />
the prevalence of prescribed instrumental tests for rhinitis diagnosis/monitoring ranges between 32% (objective nasal test) and<br />
62% (prick test) while for asthma is between 6% (exhaled nitric oxide) and 87% (spirometry). Ar increases the prevalence of<br />
prescribed instrumental tests for rhinitis and decreases that for asthma instrumental investigations.<br />
58% of rhinitic patients, 68% of asthmatics and 68% of Ar subjects receive a specific education (regular controls, written<br />
therapeutic plans, auto-monitoring education, support groups). 35% of rhinitic, 29% of asthmatics and 26% of Ar patients receive<br />
general information. 6% of rhinitic, 3% of asthmatics and 5% of Ar patients do not receive any educational intervention.<br />
Considering the prescribed pharmaco-therapeutic categories, 43% of rhinitic, 77% of asthmatic and 54% of Ar subjects do not<br />
receive an appropriate treatment in relation to the severity level.<br />
Conclusions: contrary to gl recommendations, use of instrumental tests for asthma and rhinitis diagnosis/monitoring appears still<br />
incomplete as well as use of specific educational support for the patients. Anyway, it is the pharmacologic treatment for rhinitis and<br />
even more for asthma that presents the lower level of implementation within the general practice.<br />
Work supported by the italian medicines Agency (AiFA), contract no. FArm5JYs5A.<br />
1313<br />
inHalED SoDiUm CromoglYCaTE rEDUCES THE EXPrESSion oF aSTHma-rElEVanT CYToKinES BY PEriPHEral BlooD T<br />
CEll in CHilD aSTHma. THiS SUPPorTS iTS PoSSiBlE USE aS PrEVEnTaTiVE THEraPY in CHilD aSTHma<br />
gemou-Engesaeth, V. 1 , Hamid, Q. 2 , roedland, E. A. 3 , Heier, H. E. 4 , gaarder, P. i. 4 , grogaard, J. B. 1 , Halvorsen, s. 1 and Corrigan, C. J. 5<br />
11Dept. of Pediatrics, Oslo Univers. Hospital5King’s College london school of medicine and 6Athens University, A Pediatric Clinic,<br />
Oslo, norway. 2mcgill University, meakins-Christie laboratories, montreal, QC, Canada. 33institute of medical microbiology,<br />
rikshospitalet, molecular Biology, Oslo, norway. 4Dept. of immunology and transfussion medicine, Oslo University Hospital, Oslo,<br />
norway. 5Centre for Allergic mechanisms of Asthma, King’s College london school of medicine and mrC and Asthma, Centre for<br />
Allergic mechanisms of Asthma, london, United Kingdom.<br />
We addressed the in vivo anti-inflammatory effects of inhaled sodium cromoglycate (sCg) in childhood asthma. Ethical approval<br />
was granted by the regional ethics committee. All patients and their parents received written information concerning the purpose of<br />
the study, and parents provided written consent.<br />
seven asthmatic children aged 7-13 years needing regular preventative therapy for the first time for asthma control were followed<br />
for 4-6 (mean 4.8) months after commencing sCg at a dosage of 10 mg 4 times daily by metered-dose inhaler. Just prior to<br />
commencing therapy and at the end of follow-up, CD4 and CD8 t cells were isolated from peripheral blood samples and the<br />
percentages of these cells expressing mrnA encoding interleukin-4 (il-4) and il-5 determined using in situ hybridisation with<br />
specific, anti-sense riboprobes. Clinical improvement was accompanied by significant reductions in the percentages of peripheral<br />
www.worldallergy.org 104<br />
FinAl PrOgrAm
ABstrACts<br />
blood CD4+ t cells expressing mrnA encoding il-5 and il-4, and CD8+ t cells expressing il-5 mrnA. the data are compatible<br />
with the hypothesis that clinical improvement associated with inhaled sCg therapy in childhood asthma results at least in part from<br />
inhibition of elevated th2 cytokine synthesis by t cells.<br />
1314<br />
EConomiC CoST oF aDUlT aSTHmaTiCS in THE TErTiarY HoSPiTal oF KorEa<br />
lee, s. 1 , Kim, t. 1 , Kang, H. 1 , Kim, s. 2 , Kim, s. 1 , lee, Y. 3 , Kim, t. 4 , Kim, s. 5 , Park, H. 1 , Park, s. W. 6 , Chang, Y. 2 , Cho, Y. s. 4 , Park, J. 7 ,<br />
Cho, Y. J. 8 , Yoon, H. J. 5 , Cho, s. 1 , Choi, B. 9 , moon, H. 4 and min, K. 1<br />
1 2 Department of internal medicine, seoul national University College of medicine, seoul, south Korea. Department of internal<br />
medicine, seoul national University Bundang Hospital, seongnam, south Korea. 3Department of internal medicine, Yonsei University<br />
College of medicine, seoul, south Korea. 4Department of <strong>Allergy</strong> and Clinical immunology, Asan medical Center, University of Ulsan<br />
College of medicine, seoul, south Korea. 5Department of internal medicine, Hanyang University College of medicine, seoul, south<br />
Korea. 6Division of respiratory and <strong>Allergy</strong> medicine, soonchunhyang University Hospital, College of medicine, Bucheon, south<br />
Korea. 7Division of <strong>Allergy</strong> & immunology Department of internal medicine, Yonsei University College of medicine, seoul, south<br />
Korea. 8<strong>Allergy</strong> and Clinical immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea.<br />
9Department of internal medicine, Chung-Ang University College of medicine, seoul, south Korea.<br />
Background: the prevalence of asthma is increasing and asthma cause a considerable socioeconomic burden worldwide.<br />
However, few studies were conducted to evaluate the risk factors associated with economic cost of asthma in Korea. this study<br />
was aimed to evaluate asthma cost according to severity and patients’ factors in the Korean tertiary hospital.<br />
methods: Direct and indirect cost was assessed in the 314 physician-diagnosed adult asthmatics randomly recruited in eight<br />
tertiary hospitals in Korea. Official direct medical cost was derived from the analysis of one-year(2009) expenditure related with<br />
asthma-related hospital care utilization and medication. non-official direct cost(oriental medicine, instrument, and alternative<br />
medicine) and indirect cost(productivity loss cost caused by hospital care utilization, work day loss and activity limitation) were<br />
analyzed using a questionnaire designed for the study.<br />
results: mean direct and indirect cost of the total subjects was estimated at 1,690 dollars and 1,503 dollars respectively.<br />
multivariate analysis revealed that the most important risk factor affecting economic cost was asthma severity. Direct and indirect<br />
cost were significantly higher in the severe persist asthma than in the mild to moderate persistent asthma (2,825 vs. 1,246<br />
dollars, p=0.001, 3,734 vs. 594 dollars, p
ABstrACts<br />
ABstrACts<br />
1316<br />
CHLAMYDOPHILA PNEUMONIAE-inFECTED HUman PEriPHEral mononUClEar CEllS rESiST CorTiCoSTEroiD- inDUCED<br />
SUPPrESSion oF mETalloProTEinaSE-9 anD TiSSUE inHiBiTor mETalloProTEinaSE-1 SECrETion<br />
Park, C. s. 1 , Kim, t. 2 , moon, K. 3 , Bae, Y. 2 , lee, Y. s. 2 , Jang, m. K. 3 , moon, H. 2 and Cho, Y. s. 2<br />
1 2 Department of internal medicine, inje university Heaundae Paik Hospital, Busan, south Korea. Department of <strong>Allergy</strong> and Clinical<br />
immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Asan institute for life science,<br />
seoul, south Korea.<br />
Background: it has been suggested that Chlamydophila pneumoniae infection contributes to the development of severe asthma.<br />
the major characteristics of severe asthma include a reduced response to corticosteroid treatment and progressive airway<br />
remodeling in which an imbalance of metalloproteinase-9 (mmP-9) and tissue inhibitor metalloproteinase-1 (timP-1) is believed<br />
to have an important role. We hypothesized that C. pneumoniae infection affects the secretion of mmP-9 and timP-1 and induces<br />
altered responsiveness to corticosteroids in inflammatory cells.<br />
methods: Human peripheral blood mononuclear cells (PBmCs) were cultured in vitro in the presence or absence of C. pneumonia<br />
infection. Dexamethasone was used in each experiment to assess the responsiveness to the corticosteroid. the values of secreted<br />
mmP-9 and timP-1 were measured by ElisA. to evaluate the underlying mechanism, the expression of human glucocorticoid<br />
receptor (gr)-β, known as an endogenous antidote for gr, was observed in PBmCs with or without C. pneumoniae infection using<br />
immunohistochemistry.<br />
results: the secretion of mmP-9 and timP-1 was remarkably suppressed by corticosteroid treatment in PBmCs without<br />
C. pneumoniae infection. in C. pneumoniea-infected PBmCs, the suppressed secretion of mmP-9 by the corticosteroid was<br />
significantly inhibited, while the level of timP-1 secretion did not change compared with those levels in untreated PBmCs.<br />
therefore, the molar ratio of secreted mmP-9/timP-1 was decreased by C. pneumonia infection and was more exaggerated under<br />
corticosteroid treatment. the expression of gr-β was significantly increased in C. pneumoniae-infected PBmCs.<br />
Conclusion: C. pneumoniae infection in inflammatory cells may induce altered secretion of tissue enzymes associated with airway<br />
remodeling through a decreased responsiveness to corticosteroids and may be linked to the pathogenesis of severe asthma.<br />
Key words: Asthma, Chlamydophila pneumoniae, Peripheral blood mononuclear cells, mmP-9, timP-1, glucocorticoid receptor (gr)<br />
- β<br />
1317<br />
EFFECTS oF TraFFiC air PollUTion on rESPiraTorY HEalTH anD allErgiES in EgYPTian SCHoolCHilDrEn<br />
shamssain, m. 1 , Al Qerem, W. 2 , mcgarry, K. 1 and neshat, l. 1<br />
1 2 Pharmacy, Health and Wellbeing, University of sunderland, U.K, sunderland, United Kingdom. Pharmacy, Health and Wellbeing,<br />
University of sunderland, sunderland, United Kingdom.<br />
Background<br />
studies suggest that traffic exposures can influence asthma and allergic symptoms among children; air pollution is associated with<br />
exacerbation of asthma symptoms in children with asthma. there has been few studies about the susceptibility of subgroups and<br />
on new onset asthma.the objective of the study is to investigate the effects of traffic air pollution on allergies with emphasis on<br />
gender differences in the respiratory effects of air pollution.<br />
methods<br />
We studied 1400 schoolchildren from two locations in Egypt: Cairo with high level of air pollution and shbeen Al Koom in the<br />
Delata with low level of air pollution. lung function testing was done by the Vitalograph spirometer. the Arabic version of isAAC<br />
questionnaire was used (the international study of Asthma and Allergies in Childhood). Air pollution measurements were collected<br />
from the government sites in both locations.<br />
results<br />
mean values of sO2, nO2, Ozone, CO, and Pm10 in Cairo were significantly lower than shbeen Al Koom (39.0 vs 17.0;62.8 vs<br />
55.8 ug/m3; 93.0 vs 28.8 ug/m3; 3.0 vs 1.3 mg/m3; and 263.5 vs 94.0 ug/m3, respectively. Forced vital capacity (FVC), forced<br />
expiratory volume in the first second (FEV1) and peak expiratory flow rate (PEFr) were lower in children in Cairo compared to shben<br />
Al Koom (1.99 vs 2.03 l; 1.70 vs 1.79 l; and 204.4 vs 207.4 l/min, respectively. the prevalence rates of current wheeze, asthma,<br />
rhinitis, hay fever and eczema in Cairo were higher than shbeen Al Koom (6.9 vs 5.6% ; 5.5 vs 3.3%; 24.2 vs 17.9; 9.5 vs 6.4%;<br />
and 9.1 vs 5.6% , respectively. the prevalence rates of ever rhinitis were 6.0% and 3.0% higher in boys and girls in Cairo compared<br />
to shbeen Al Koom, respectively. Children who developed rash less than 2 years of age were 2.0% and 5.0% higher in boys and<br />
girls in Cairo compared to shbeen Al Koom, respectively.<br />
www.worldallergy.org 106<br />
FinAl PrOgrAm
ABstrACts<br />
Conclusion<br />
Air pollution is associated with increased prevalence of asthma and allergies in these children. the present study illustrates that<br />
there is an adverse respiratory effects of exposure to traffic air pollution on children showing gender differences. the present study<br />
will help to implement strategic health intervention programmes to improve the respiratory health of these children.<br />
1318<br />
aSSoCiaTion BETWEEn aToPiC ECZEma anD CHilDHooD aSTHma in SCHoolCHilDrEn From THE norTH EaST oF<br />
EnglanD<br />
shamssain, m.<br />
Pharmacy, Health and Wellbeing, University of sunderland, U.K, sunderland, United Kingdom.<br />
Background respiratory epidemiologists have special international interest in the sequential progression of multiple allergic<br />
conditions (allergic march). individuals who develop an allergic disease are at increased risk of developing further allergic<br />
conditions.many large studies have estimated the prevalence of eczema, asthma and allergic rhinitis which are common and<br />
useful in reducing the co-morbidity associated with these disorders. However, the progression and the association between these<br />
conditions remain understudied. the aims of the study is to investigate the association between atopic eczema and childhood<br />
asthma. methods We studied 600 schoolchildren, aged 6-7 and 13-14 years, from the north east of England. We used the<br />
international study of Asthma and Allergies in Childhood (isAAC) questionnaire and illustrative manual of childhood eczema<br />
developed by isAAC group. results Atopic eczema was the most common allergic disease of girls, with a lifetime prevalence<br />
of 27%. there was a negative association between maternal smoking and eczema (p
ABstrACts<br />
ABstrACts<br />
1320<br />
il-17 DriVES THE rECrUiTmEnT oF B CEllS To THE BronCHial TiSSUE oF SEVErE aSTHmaTiC PaTiEnTS<br />
Halwani, r. 1 , Al-muhsen, s. 2 and Hamid, Q. 3<br />
1Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University., riyadh,<br />
saudi Arabia. 2Department of Pediatrics, College of medicine, King saud University. 3mcgill University, meakins-Christie laboratories,<br />
montreal, Canada.<br />
Background: B-cells play an important role in asthma development mostly via the production of igE. A number of reports have<br />
shown local production of igE in B cells present in lung tissues of mild allergic asthmatics. However, it is not clear whether there<br />
is an increase in the number of B cells in severe asthma and how do B cell migrates to the mucosal site. Our objective in this<br />
study was to determine the number and pattern of infiltrated B cells into lung tissues in severe compared to mild asthma and to<br />
investigate the mechanism behind this infiltration.<br />
methods: Bronchial biopsies from severe versus mild asthmatics were stained for B cells marker (CD20) using<br />
immunohistochemistry. moreover, migration towards il-17 gradient was determined using Boyden chamber.<br />
results: the number of CD20 positive cells in severe asthmatic biopsies was significantly higher than those in mild asthmatics.<br />
interestingly, we have also observed lymph follicles in 40% of severe compared to 15% of mild asthmatic airways. most of<br />
the cells in the lymph follicles were CD20 positive cells. these lymph follicles were very close to the epithelial surface. We<br />
have recently reported high expression of il-17 in severe asthma. We tested the hypothesis that il-17 is involved in migration<br />
of B cells to the mucosal surface of the airways. Although B cells were shown to migrate towards both il-17A and il-17F,<br />
much lower concentrations of il-17F, compared to il-17A, were sufficient to induce migration. moreover, B cells within airway<br />
mucosa of severe asthmatics were shown to express higher level of il-17r compared to those of mild asthmatic patients using<br />
immunohistochemistry as well as qPCr.<br />
Conclusion:il-17 might drive the migration of B cells in the lung tissues and could play a critical role in the formation of lymphoid<br />
follicles in severe asthmatic airways.<br />
1321<br />
EoSinoPHilS EnHanCE airWaY SmooTH mUSClE CEll ProliFEraTion<br />
Halwani, r. 1 , Al-muhsen, s. 2 and Hamid, Q. 3<br />
1Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University.,<br />
riyadh, saudi Arabia. 2Department of Pediatrics, College of medicine, King saud University. 3mcgill University, 2meakins-Christie laboratories, montreal, Canada.<br />
Background: Asthma is a chronic inflammatory disorder of the lung airways that is associated with airway remodeling and<br />
hyperresponsiveness. its is well documented that the smooth muscle mass in asthmatic airways is increased due to hypertrophy<br />
and hyperplasia of the Asm cells. moreover, eosinophils have been proposed in different studies to play a major role in airway<br />
remodeling. Here, we hypothesized that eosinophils modulate the airways through enhancing Asm cell proliferation. the aim of this<br />
study is to examine the effect of eosinophils on Asm cell proliferation using eosinophils isolated from asthmatic and normal control<br />
subjects.<br />
methods: Eosinophils were isolated from peripheral blood of 6 mild asthmatics and 6 normal control subjects. Asm cells were<br />
incubated with eosinophils or eosinophil membranes and Asm proliferation was estimated using thymidine incorporation. the<br />
mrnA expression of extracellular matrix (ECm) in Asm cells was measured using quantitative real-time PCr. the effect of<br />
eosinophil-derived proliferative cytokines on Asm cells was determined using neutralizing antibodies.<br />
results: Co-culture with eosinophils significantly increased Asm cell proliferation. However, there was no significant difference in<br />
Asm proliferation following incubation with eosinophils from asthmatic versus normal control subjects. Co-culture with eosinophil<br />
membranes had no effect on Asm proliferation. moreover, there was no significant change in the mrnA expression of ECm proteins<br />
in Asm cells following co-culture with eosinophils when compared with medium alone.<br />
Conclusion: Eosinophils induces Asm cell proliferation independent of direct cell to cell contact or ECm synthesis. Eosinophils may<br />
induce Asm proliferation via the secretion of proliferative cytokines.<br />
www.worldallergy.org 108<br />
FinAl PrOgrAm
ABstrACts<br />
1322<br />
EPiTHElial CEll DEriVED CHEmoKinES EnHanCE THE ProliFEraTion anD SUrViVal oF airWaY SmooTH mUSClE CEllS<br />
Via THE aCTiVaTion oF ErK1/2 Signaling PaTHWaY<br />
Al-muhsen, s. 1 , Halwani, r. 2 , Al-Jahdali, H. 3 and Hamid, Q. 4<br />
1 2 Department of Pediatrics, College of medicine, King saud University. Asthma research Chair and Prince naif Center for<br />
immunological research, College of medicine, King saud University., riyadh, saudi Arabia. 3King saud University for health sciences,<br />
riyadh, saudi Arabia. 4mcgill University, meakins-Christie laboratories, montreal, Canada.<br />
Background: the increase in AsmC mass is a major structural change described in asthma. this increase has been attributed to<br />
AsmC hyperplasia and hypertrophy. recent studies have suggested a role of chemokines in smC migration toward the epithelium.<br />
the objective of the current study is to test the hypothesis that chemokines (Eotaxin, rAntEs, il-8 and miP-1α) can increase the<br />
rate of proliferation and enhance the survival of Asm cells.<br />
methods: AsmCs were exposed to different concentrations of eotaxin, rAntEs, il-8 or miP-1α. to test for proliferation, stimulated<br />
AsmC were pulsed with 3H-thymidine or AsmCs were stained with BrdU and then analyzed with flow cytometry. Apoptosis was<br />
measured using Annexin-V and flow cytometry.<br />
results: in a concentration-dependent manner, chemokines such as Eotaxin, rAntEs, il-8 and miP-1α increased AsmCs<br />
3H-thymidine incorporation and DnA synthesis. this increase, however, was inhibited using ErK1/2 phosphorylation inhibitors. il-8,<br />
Eotaxin, and miP-1α decreased the number of apoptotic AsmCs compared to the matched controls.<br />
Conclusion: We conclude that chemokines might contribute to airway remodeling seen in asthma by increasing Asm mass through<br />
enhancing AsmCs proliferation and survival.<br />
1323<br />
TH-17 CYToKinE moDUlaTion oF STEroiD inSEnSiTiViTY in PEriPHEral BlooD mononUClEar CEllS<br />
Vazquez tello, A. 1 , Halwani, r. 2 , Al-muhsen, s. 3 and Hamid, Q. 4<br />
1Asthma research Chair and Prince naif center for immunology research, College of medicine, King saud University, riyadh, saudi<br />
Arabia. 2Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University.,<br />
riyadh, saudi Arabia. 3Department of Pediatrics, College of medicine, King saud University. 4mcgill University, meakins-Christie<br />
laboratories, montreal, QC, Canada.<br />
Background. inhaled corticosteroids represent the most common treatment for asthma. Although most asthmatic patients respond<br />
well, a significant proportion of severe asthmatic patients either require high doses or even fail to respond to oral or inhaled<br />
corticosteroids. We have previously reported that glucocorticoid receptor-beta is associated with corticosteroid resistance. We<br />
have also shown that in severe asthmatic patients, th-17 cytokines increase steroid insensitivity in airway epithelial cells via a<br />
mechanism involving gr-beta upregulation.<br />
objective. to investigate whether il-17A and F cytokines enhance steroid unresponsiveness in PBmCs isolated from normal and<br />
severe asthmatic subjects via the upregulation of gr-beta isoform.<br />
methods. PBmCs were isolated from the blood of healthy and severe asthmatics subjects and cultured for 48 hours in the presence<br />
or absence of il-17A, il-17F, il-17A+il-17F, or il-2+il-4 cytokines. inhibition of proliferation by Dexamethasone (iC50) was then<br />
assessed on PHA-treated cells using 3H-thymidine pulse labeling. Expression of gr-alpha, gr-beta, gilZ and il-6 was determined<br />
using real time rt-PCr and/or Western blotting.<br />
results. treatment of PBmCs with il-17A+F cytokines significantly decreased the level of expression of gr-alpha m-rnA while<br />
the of expression of gr-beta m-rnA was significantly upregulated. moreover, while treating PBmCs with il-2+il-4 had a more<br />
remarkable decrease in gr-alpha expression, this cytokine combination had no effect on gr-beta receptors. Both cytokine<br />
combinations significantly decreased the inhibitory effect of Dexamethasone on PBmC proliferation (il-17A+F, iC50=190 nm Dex;<br />
il-2+4, iC50=1060 nm Dex); no significant differences were observed between the PBmCs from normal subjects and severe<br />
asthmatics. treatment with il-2+4, but not il-17A+F, inhibited the dexamethasone-induced expression of the glucocorticoidinducible<br />
leucine zipper gene (gilZ) in PBmCs from both normal (60%) and asthmatics (45-50%).<br />
Conclusion. il-17A, il-17F, il-2 and il-4, which are known to be upregulated in the blood and lung tissue of asthmatics, contribute<br />
to steroid insensitivity of severe asthmatic patients by modulating the expression of gr-alpha and gr-beta receptors on peripheral<br />
blood PBmCs. Furthermore, the increased gr-beta/gr-alpha ratios by both il-17A+F and il-2+4 cytokines correlates with the<br />
decreased inhibitory effect of Dexamethasone on PHA-induced PBmC proliferation.<br />
www.worldallergy.org 109<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1324<br />
molD allErgEnS SEnSiTiZaTion in aSTHma PaTiEnTS iS aSSoCiaTED WiTH SEVEriTY oF DiSEaSE<br />
Bisaccioni, C. , Aun, m. V. , Castro-Coelho, A. P. , montenegro, F. g. , Agondi, r. C. , Kalil, J. and giavina-Bianchi, P.<br />
Clinical immunolgy and <strong>Allergy</strong>, sao Paulo University, sao Paulo, Brazil.<br />
Background: mold allergens can induce hypersensitivity reactions, including igE-mediated disease. Exposure to mold, which are<br />
considered indoor and outdoor allergens, is associated with asthma. Furthermore, proteases produced by fungi can act as adjuvants<br />
to promote tH2 responses, disrupt the airway epithelium and increase hyperresponsiveness. Environmental control to mold is<br />
limited and, despite the pharmacological treatment available for asthma control, patients with sensitivity to mold appear to have<br />
increased risk of potentially fatal asthma exacerbations. Our objective was to evaluate mold allergens sensitization in patients with<br />
allergic asthma and correlate this with severity of disease.<br />
method: this was a retrospective observational study. We evaluated patients with persistent allergic asthma who were at followup<br />
in our clinic. Data were extracted from our electronic medical record (PrOntmED), between 2005 and 2010. sensitization was<br />
determined by skin prick test or in vitro specific igE detection (immunoCAP). We studied the following allergens: dust mites, cat,<br />
dog, cockroaches, pollen and molds (Aspegillus fumigatus, Cladosporium herbarum, Alternaria alternata, Penicillium notatum and<br />
Candida albicans). the severity of asthma was classified using ginA criteria. We excluded patients who met diagnostic criteria for<br />
ABPA.<br />
results: We studied 352 patients: 58 classified as mild asthma, 79 as moderate asthma and 215 as severe asthma. mold<br />
sensitization was found in 18.96%, 18.98% and 35.34%, respectively. We did not find patients with mild or moderate asthma<br />
sensitized only to molds, but there were six patients monossensitized to mold (five to Aspergillus fumigatus).<br />
Conclusion: Our study corroborates data recently published in the literature showing association between mold sensitization and<br />
asthma severity. However, much remains to be studied about the sources and degrees of fungal exposure, the role of exposure in<br />
the clinical outcome of asthmatic patients and the most effective measures to prevent this contact.<br />
1325<br />
imPaCT oF allErgiC rHiniTiS on PaTiEnTS WiTH BronCHial aSTHma in aBU DHaBi<br />
Bodi, s. g. 1 , Ohri, m. 2 , mn, J. 2 , tn, B. 2 and Khare, m. 2<br />
1 2 Pulmonology, AHAliA HOsPitAl, ABU DHABi, United Arab Emirates. Ent, AHAliA HOsPitAl, ABU DHABi, United Arab Emirates.<br />
introduction:<br />
respiratory allergies are rapidly increasing , with more than 300 million people affected by Asthma worldwide.many studies<br />
have shown a strong link between Asthma and Allergic rhinitis . there are few studies in the gulf region on asthma and allergic<br />
rhinitis and hence we made an attempt to study the impact of allergic rhinitis on asthmatics in a respiratory department of a<br />
multispeciality hospital in Abu Dhabi .<br />
objective:<br />
to study the impact of Allergic rhinitis in patients of Bronchial asthma.<br />
methods:<br />
study design : retrospective study .<br />
setting : respiratory department of a 50 bedded multi speciality hospital in Abu Dhabi , (Ahalia Hospital).<br />
subjects : 94 out of 161 patients of Asthma fulfilled the study criteria for Allergic rhinitis (AriA guiidelines).<br />
results:<br />
94 out of 161 patients of Asthma( 58.4%)had associated Allergic rhinitis.the mean age of these patients was 34.56 among<br />
females and 35.28 among males.71.4% of female asthmatics as compared to 53.8 % males have associated Allergic rhinitis(.<br />
p
ABstrACts<br />
1326<br />
analYSiS oF gEnE EXPrESSion ProFilES oF PEriPHEral BlooD B lYmPHoCYTES in VarioUS CliniCal PHEnoTYPES oF<br />
aSTHma<br />
Ahmad, n. E. Q. 1 , Harun, r. 2 and Othman, r. 2<br />
1 2 institute of medical science technology (mEstECH), Universiti Kuala lumpur (UniKl), Kajang, malaysia. UKm medical molecular<br />
Biology institute (UmBi), Universiti Kebangsaan malaysia (UKm), Cheras, malaysia.<br />
Background B lymphocytes play important roles in the inflammatory response in asthma including igE production, antigen<br />
presentation and secretion of certain cytokines. However the exact molecular pathways are still largely unknown. the objectives of<br />
this study were to identify gene expression profiles of peripheral blood B lymphocytes and subsequently determine gene signatures<br />
that were associated with different clinical phenotypes of asthma. in addition we aimed to identify biological processes and<br />
pathways involved in the molecular mechanisms of asthma.<br />
method Peripheral blood B cells were isolated from subjects with different manifestations of asthma: mild (n=8), moderate<br />
controlled (n=8), moderate uncontrolled (n=10), severe steroid dependant (n=7), severe steroid resistant (n=7) and normal<br />
control (n=8). total rnA were extracted from the B lymphocytes, reverse transcribed and amplified linearly before being labelled<br />
and hybridized on illumina Humanref-8 Expression BeadChips that had 24,355 elements. microarray data was analysed using<br />
genespring gX 10.0.02 software and real-time PCr was performed to validate the microarray gene expression.<br />
results Data were analysed according to several conditions including asthma control status, steroid response, asthma severity and<br />
disease status. Differential gene analyses, corrected for multiple testing, revealed 7 (p
ABstrACts<br />
ABstrACts<br />
recognized cause of COPD, most of sri- lankan women are non smokers. therefore females having COPD become an important<br />
group to study aetiology of COPD other than smoking.the aim of this study is to identify causes of COPD in females of Kandy, sri<br />
lanka.<br />
method: the study consisted of 54 patients who were diagnosed of having COPD on the basis FEV1/ FEC ratio of below 70%<br />
and had bronchodilator reversibility of less than 12%. the cohort of patients was selected from patients investigated for cough<br />
and dyspnoea presented to the Chest Clinic, Kandy for a period of 9 months from 01 Jul 2008 to 31 mar 2009 the study group<br />
of patients was interviewed using a prepared questionnaire .their demographic data including social status was recorded . the<br />
aetiologies of smoking recurrent chest infections in early childhood and indoor air pollution were recorded<br />
results: the age range of the patients was 48y to 82y with a mean age of 69.8y. All the patients were life time nonsmokers. 26%<br />
reported to have inhaling secondhand smoke from one or more household smokers. Only 7% had recurrent chest infections<br />
in childhood. 82% of patients had exposure to indoor air pollution in the form of using firewood for cooking in under ventilated<br />
kitchens. 88% of the patients were form suburban and rural areas and 68% belonged to poorer social classes. in spite of the high<br />
literacy ratio of srilana 5.2% of the study population was illiterate.<br />
Conclusion: indoor air pollution is a significant cause of COPD in women of Kandy, sri lanka COPD .affects women of poorer social<br />
strata. since around 80% of sri lankan households use firewood for cooking, it is very important to improve standards of cooking<br />
and ventilation in kitchens,and to empower women with knowledge in causative factors and prevention of COPD.<br />
PoSTEr SESSion 1-4: rhinitis, rhinosinusitis and conjunctivitis<br />
1400<br />
SElECT ParamETErS rElaTing To THE maXimal inSPiraTorY anD EXPiaTorY FloW raTE among THE rUral<br />
PoPUlaTionS inHaBiTing THE arEaS aroUnD ZamoSC, PolanD – a FolloW-UP To THE mUlTi-CEnTEr STUDY ECaP<br />
(EPiDEmiologY oF allErgiC DiSEaSES in PolanD)<br />
Krzych-Falta, Jr., E. 1 , samoliñski, B. 2 , lusawa, A. 1 , rojek, B. 1 and Kapalczynski, W. 3<br />
1Department of Prevention of Environmental Hazards and Allergology, Warsaw medical University, Department of Clinical Allergol,<br />
medical Uniwersity of Warsaw, Warsaw, Poland. 2Department of Prevention of Environmental Hazards and Allergology, Warsaw<br />
medical University, Department of Clinical Allergol, m, medical Uniwesity of Warsaw, Warsaw, Poland. 3University of louisville school<br />
of medicine, louisville, United states, University of louisville school of medicine,, United states.<br />
the objective of this study is to determine the average value of various upper and lower respiratory tract parameters (PniF, FEV1,<br />
FEV1/VC) as they relate to a patient’s clinical diagnosis. All diagnoses were made during medical examination by a physician based<br />
on specific criteria. the study encompassed 288 ECAP participants (96 participants 9-10 years of age, 84 participants 16-17 years<br />
of age, and 108 participants 23-47 years of age) residing in the areas surrounding ZamoϾ. research methods employed included<br />
spirometry and the measurement of peak nasal inspiratory flow in l/min using a specially constructed mask. For analysis of the<br />
results, the participants were divided into three groups:<br />
- Patients diagnosed with seasonal rhinitis- mean values: PniF: 90.23 l/min, FEV1: 99.27%, FEV1/VC: 101.95%<br />
- Patients diagnosed with perennial rhinitis- mean values: PniF: 99.93 l/min, FEV1: 98.77%, FEV1/VC: 98.83%<br />
- Patients with diagnosed asthma including:<br />
- light asthma- mean values: PniF: 86.15 l/min, FEV1: 90.31%, FEV1/VC: 96.15%.<br />
- moderate asthma- mean values: PniF: 92.5 l/min, FEV1: 89%, FEV1/VC: 93.25%,<br />
- Severe asthma- mean values: PniF: 87.23 l/min, FEV1: 87.73%, FEV1/VC: 95.45%.<br />
in conclusion, the lowest values for the selected upper and lower respiratory tract parameters were obtained from the group of<br />
patients diagnosed with bronchial asthma, especially severe asthma.<br />
1401<br />
THE aSSoCiaTion BETWEEn DEgrEE oF SEnSiTiZaTion To allErgEn anD SEVEriTY oF allErgiC rHiniTiS<br />
mohd Ashari, n. s. , Wm, W. m. , Y, n. K. , sah, s. and CH, C. m.<br />
immunology, Universiti sains malaysia, Kota Bharu, malaysia.<br />
Allergic rhinitis is the most common allergic disease affecting an estimated four million people in malaysia. Although allergic<br />
rhinitis is not usually severe diseases, it significantly alters the social life of patients and affects school learning performance as<br />
well as work productivity. this study was done to determine the levels of allergen specific immunoglobulin E assay in allergic<br />
www.worldallergy.org 112<br />
FinAl PrOgrAm
ABstrACts<br />
rhinitis patients in Hospital Universiti sains malaysia (HUsm), malaysia before proceed with evaluation of possible association<br />
between this parameter with severity of allergic rhinitis.<br />
in this cross sectional study, total and specific igE to 28 types of allergens were measured in serum samples from 128 allergic<br />
rhinitis patients. the interviewer guided questionnaire was used to evaluate the severity of symptoms using AriA criteria.<br />
in this study, we found that among the aeroallergens, Dermatogoides farinae (97%) was the most common followed by<br />
Dermatogoides pteronyssinus (83%) and house dust mite (43%). Among the food allergen group, shrimp (28.9%) was the most<br />
common implicated food followed by soybean (26.6%), crab (23.4%), clam (22.7%), wheat (21.9%), peanut (20.3%), yolk egg<br />
(18.8%), cow’s milk (18.0%), citrus mix (18.0%), beef(14.1%), white egg (12.5%), tuna (11.7%) and chicken (11.7%). For fungal<br />
allergen, aspergillus spp (23.4%) was found to be the most common fungal followed by candida spp (20.3%), altenaria spp (16.4%),<br />
mucor spp (14.8%), penicillium spp (12.5%) and clasdosporium spp (10.9%). Cockroach (49.2%) was the most common animal<br />
allergen. Cat (44.5%), dog (43.0%), latex (42.2%), Bermuda (28.9%) and Johnson (21.9%) grass were also common. in this study,<br />
we also found a significant association between the specific igE levels and the severity of allergic rhinitis for Dermatogoides farinae<br />
(p=0.024), Dermatogoides pteronyssinus (p=.039), cockroach (p = 0.038), cat (p = 0.042) and latex (p = 0.044).<br />
in conclusion this study revealed a significant association between specific igE levels and the severity of allergic rhinitis symptoms<br />
for Dermatogoides farinae, Dermatogoides pteronyssinus, cockroach, cat and latex.<br />
1402<br />
Co-aDminiSTraTion oF CHEnoPoDiUm alBUm allErgEnS anD CPg oligoDEoXYnUClEoTiDES EFFECTS on PEriPHEral<br />
BlooD mononUClEar CEllS oF PaTiEnTS WiTH allErgiC rHiniTiS TrEaTED WiTH inTranaSal CorTiCoSTEroiDS anD<br />
anTiHiSTaminES<br />
Farrokhi, sr., s. 1 , mousavi, t. 1 , Arshi, s. 1 , salekmoghadam, A. 1 , Varasteh, A. 2 and rezaei, n. 3<br />
1 2 Department of immunology, iran University of medical sciences, tehran, iran. 6. immunobiochemistry lab, immunology research<br />
Center, Avicenna research institute, 6. immunobiochemistry lab, immunology research Center, Avicenna research institute,<br />
mashhad, iD, iran. 3growth and Development research Center, Children’s medical Center, tehran, iran.<br />
Objective. Allergic rhinitis (Ar) is one of the most common chronic diseases in the developed countries, associated with substantial<br />
economic burden and morbidity. this study was performed to investigate the effect of Cpg-ODn in alteration of t-helper (th)1/th2<br />
balance of patients with Ar treated with intranasal corticosteroids (inCs) and antihistamines.<br />
methods. Peripheral blood mononuclear cells (PBmCs) of 20 patients with Ar were isolated before and after 45 days treatment<br />
with inCs and antihistamines. Cytokine production (il-4, il-10, il-13, iFn-γ) and specific Ch.a igE in response to Cpg-ODn<br />
co-administration of natural chenopodium album (Cpg/Ch.a) or recombinant Ch.a (Cpg/rCh.a) allergen were investigated using<br />
ElisA method. intracellular il-10 was also assessed in CD4 + cells using flow cytometry. For statistical analysis sPss 16 software<br />
packagresults. significant increases in production of iFn-γ and il-10 and a significant decrease in production of il-4 were found<br />
in PBmCs stimulated with either Cpg/Ch.a or Cpg/rCh.a compared to stimulated cells with allergens alone, before and after therapy<br />
of patients. After therapy, only iFn-γ production with Cpg/Ch.a stimulant was significantly increased in comparison with before<br />
treatment (237 vs. 44 pg/ml, p=0.001). iFn-γ and il-10 production with Cpg/rCh.a stimulant was significantly increased after<br />
therapy compared to before (407.6 vs. 109 pg/ml, p=0.01 for iFn-γ; 171.7 vs. 52.6 pg/ml, p=0.008 for il-10), whilst production<br />
of il-4 was significantly decreased (2.1 vs. 5.8 pg/ml, p=0.02). intracellular il-10 expression was also significantly increased<br />
in response to either Cpg/Ch.a or Cpg/rCh.a. Altogether, the comparison of all results obtained from il-10 assay with either<br />
intracellular or secreted form showed that intracellular assay could be more sensitive than ElisA. specific igE was significantly<br />
decreased after therapy in response to either Cpg/Ch.a or Cpg/rCh.a stimulant.<br />
Conclusion. treatment of PBmCs from Ar patients with Cpg/Ch.a or Cpg/rCh.a inhibits th2 cytokine responses and induces th1biased<br />
immune responses. Also, treatment with intranasal corticosteroids and antihistamines could enhance this Cpg effect, in vitro.<br />
However, further clinical studies are recommended to confirm these findings.<br />
1403<br />
TrEaTmET oF CHroniC allErgiC rHiniTiS:inTranaSal VS. oral THEraPY?<br />
Eatemadi, A.<br />
immunology & infectious disease, Ahvaz univrsity of medical siences, Ahvaz, iran.<br />
Background:Allergic rhinitis is common among iranian people.the aim of this study was compare the efficacy of intranasal vs. oral<br />
therpy for chronic allergic rhinitis( CAr). method: A randomised controlled study was conducted in 51 patients with diagnosis of<br />
CAr who divided to received either intranasal budesonide 256 mg ( group 1) or combination therapy wih 10 mg cetirizine plus 10<br />
mg montelukast( group 2) daily for two months. results: At the end of treatment, group 1 had significantly better total nasal score<br />
and subjective symptoms than group 2, but did not have any diffrences in post nasal drip. Conclusion: intranasal budesonide is mor<br />
effective than cetirizine plus montelukst for treatment of chronic allergic rhinitis.<br />
www.worldallergy.org 113<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
1404<br />
EFFiCaCY oF FEXoFEnaDinE in DiFFErEnT DoSagES For TrEaTmnET oF SEaSonal allErgiC rHiniTiS<br />
Eatemadi, A.<br />
immunology & infectious disease, Ahvaz univrsity of medical siences, Ahvaz, iran.<br />
Background: the aim of this study was to determine the efficacy of fexofenadine in different dosages for treatment of seasonal<br />
allergic rhinitis ( sAr).method: A placebo-controlled, double blind study was conducted in 114 patients with diagnosis of sAr.<br />
they were randomly assigned to received either 60 mg, 120 mg , 180 mg once daily fexofenadine or placebo for one month.<br />
Patients were evaluated by using total symptom score ( tss ) and total nasal score ( tns ) during and at the end of treatment.<br />
results: Fexofenadine 120-180 mg was significantly more effective than placebo for improvement of sAr signs and symptoms.<br />
no statistically significant difference was seen between two dosages ( 120 mg vs. 180 mg ). Conclusion: Once dail 120 mg<br />
fexofenadine is an effective and safe treatment for seasonal allergic rhinitis.<br />
1405<br />
THE moDiFiED SnoT-20 QUESTionnairE: rEPEaTaBiliTY anD aPPliCaBiliTY To rHiniTiS<br />
sami, A. s.<br />
Ent, royal national throat, nose and Ear Hospital, london, United Kingdom.<br />
Background<br />
rhinitis is a clinically prevalent disease, symptomatically characterised by nasal itch, sneezing and difficulty breathing through the<br />
nose. Patients with rhinitis often suffer from associated symptoms related to posterior nasal, sinus and ear disease. Other effects on<br />
the psychological well being are also accountable to rhinitis.<br />
A number of these features are encompassed in disease specific quality of life (Qol) questionnaires. However, the modified snOt-<br />
20 (msnOt-20) questionnaire aims to correspond to the requirements for a complete and comprehensive assessment of rhinitis<br />
and its impact. it uses a six-point scale to identify clinical severity (0=no problem, 5=very severe problem). method<br />
the msnOt-20 questionnaire was evaluated in a pilot study of disease and non-disease and then used to assess the prevalence of<br />
rhinitis and associated features in a community based survey. Following a successful pilot project, 2000 postal questionnaires were<br />
sent to randomly selected adults from the electoral register in Farnborough. Differences in housing, social class and environment<br />
were balanced with repeat questionnaires sent for non-respondents. results<br />
in the pilot study, there were significant differences (p < 0.001) in symptom reporting between rhinitics and non-rhinitics, with<br />
92.67% of the healthy controls responding on all 20 questions either 0=no problem (85.67%) or 1=very mild problems (7%) in<br />
comparison to 42.07 % in the rhinitis group (28.7 % of responses no problem, 13 % very mild problems). A score of 0 or 1 was thus<br />
taken as normal and 2-5 taken as abnormal.<br />
in the community survey in Farnborough, 68% of 1580 evaluable respondents (79.8 % response rate) had a total snOt-20 score of<br />
0-20 (max 100) with 32% scoring 21 + (max 88). there were significant correlations between the rhinitis domain and the 4 other<br />
domains (paranasal [sinus and ear], sleep, social and emotional). the repeatability of these responses was evaluated in a follow-up<br />
evaluation in a subpopulation. Conclusion<br />
msnOt-20 questionnaire is a disease-related Qol rhinitis questionnaire, which is valid for the evaluation of rhinitis and the impact<br />
of disease on quality of life. it identified a high prevalence of nasal and paranasal problems within the community with significant<br />
co-morbidity caused by rhinitis.<br />
1406<br />
a CommUniTY BaSED SUrVEY on THE PrEValEnCE oF rHiniTiS<br />
sami, A. s.<br />
Ent, royal national throat, nose and Ear Hospital, london, United Kingdom.<br />
Background<br />
rhinitis is an increasingly common condition although there is limited information as to its true prevalence within the community.<br />
this study aimed to obtain a current prevalence of rhinitis within the community and to explore its impact on social and emotional<br />
functioning. A survey of 2000 adults in the Farnborough area was devised and carried out using the modified snOt-20 (msnOt-20)<br />
questionnaire for this study.<br />
method<br />
A postal survey of rhinitis was conducted in the Farnborough area with 2000 msnOt-20 questionnaires being sent to randomly<br />
www.worldallergy.org 114<br />
FinAl PrOgrAm
ABstrACts<br />
selected adults from the electoral register. there were 1595 returned (79.8%) of which 1580 were evaluable. 58% of respondents<br />
were female and 41.9% male.<br />
results<br />
the population age range was 16.9 to 92.4 years (mean 48.6 years). A score of 0-1 on a six-point rating scale was taken as normal<br />
for each question and a score of 2-5 taken as abnormal. 32.5% of the population had an abnormal score for “needing to blow their<br />
nose”, 31.4% for “sneezing”, 25.4% for “runny nose’ and 30.1 % for “blocked nose”. the combined nasal sub-score (sum of 4<br />
questions, max score 20) identified a score of 4 or less in 62.1 % (39.9 % abnormal rhinitis score).<br />
those with rhinitis were more likely to score abnormally on the other domains in comparison to those with normal scores;<br />
paranasal (55.5% vs. 28.8%), sleep (41.5% vs. 22.1%), social and emotional (38.9 vs. 19.6%).<br />
Conclusion<br />
this study identifies the common prevalence of rhinitis and the associated morbidity, with over 30% of the population experiencing<br />
nasal blockage, sneezing and need to blow their nose.<br />
A total msnOt-20 score does not provide information exclusively on Ent disease; due to the wide range of conditions affecting<br />
quality of life. subdivision into separate symptom clusters does, however, permit exploration of disease prevalence. Using symptom<br />
clusters, this study identified that there is also a high prevalence of Ent morbidity within the community.<br />
1407<br />
EFFiCaCY oF mUlTiFaCETED aVoiDanCE mEaSUrES in THE managEmEnT oF PaTiEnTS WiTH PErSiSTEnT allErgiC<br />
rHiniTiS anD HoUSE DUST miTE allErgY<br />
Chao, s. s. and Wang, D. Y.<br />
Department of Otolaryngology Head and neck surgery, national Univeristy of singapore, singapore, singapore.<br />
Background<br />
in patients with persistent allergic rhinitis (PAr) and allergy to house dust mites (HDm), the use of HDm avoidance measures is<br />
logical. there is however, uncertainty in the literature regarding its efficacy. single intervention methods were felt to be ineffective. it<br />
was proposed that multifaceted interventions may be necessary. We hence designed a study to evaluate the efficacy of multifaceted<br />
avoidance measures in patients with PAr and confirmed allergy to HDm.<br />
method<br />
newly diagnosed adults with PAr and skin prick test positive to HDm were randomized to receive multifaceted dust mite avoidance<br />
measures (group 1, n=51) or no intervention (group 2, n=48). the avoidance measures used were dust mite impermeable bedding<br />
covers, ascaricides, removal of dust collecting items and regular cleaning of beddings and bedrooms at stipulated intervals. the<br />
study was conducted over 6 weeks. the end points were changes in the total symptoms score (tss, average of scores for nasal<br />
congestion, rhinorrhoea, sneezing, itch and eye symptoms) and the rhinoconjunctivitis Quality of life Questionnaire (rQlQ) scores.<br />
results<br />
Of the 89 patients recruited, 27 were excluded from the analysis as they either did not comply with the multifaceted measures<br />
or used 15 days or more of rescue medication. the final number in group 1 was 47 and group 2 was 25. there was a significant<br />
reduction in dust mite load in group 1 (16.88 ng/ml ± 6.61 (P=0.02)), but not in group 2 (10.21ng/ml ± 7.88 (P=0.21)). statistically<br />
significant improvements were seen in both tss and rQlQ scores in patients receiving multifaceted avoidance measures. the<br />
improvements in tss were 2.86 + 0.48 and 1.15 ± 0.46 (p
ABstrACts<br />
ABstrACts<br />
ragweed, dust mites, grasses, and/or trees. subjects were asked to rate their ocular itching on a scale of 0 to 4 in increments of<br />
0.5, with 0 = none and 4 = severe. All subjects were required to have zero itching bilaterally (both scores = 0) at baseline. this<br />
analysis focused on a subset of 40 subjects who were dosed in one eye with olopatadine 0.2% and in the contralateral eye with<br />
placebo. Eligible subjects were challenged with antigen at 27 minutes after dosing with drug or placebo. this post hoc efficacy<br />
analysis evaluated the ability of the drug to reduce itching scores to zero.. the safety analysis was based on an evaluation of the<br />
exposure to study drug, adverse events, visual acuity, ocular signs, and fundus parameters.<br />
results: the 40 subjects had an average age of 39 ± 11 years; 65% were women and 35% were men. At 3 minutes after the<br />
antigen challenge, 63% of subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 3% of<br />
subjects (1 of 40) reported having zero itching in their placebo-treated eyes. At 5 minutes after the antigen challenge, 63% of<br />
subjects (25 of 40) reported having zero itching in their olopatadine-treated eyes, while only 5% of subjects (2 of 40) reported zero<br />
itch in their placebo-treated eyes. At 7 minutes after the antigen challenge, 65% of subjects (26 of 40) reported zero itch in their<br />
olopatadine-treated eyes, while only 10% of subjects (4 of 40) reported zero itch in their placebo-treated eyes. the percentages<br />
of eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every time point (p <<br />
0.05). no treatment-related adverse events were reported during the study.<br />
Conclusion: in this placebo-controlled, contralateral-designed, double-masked conjunctival antigen challenge study, olopatadine<br />
HCl ophthalmic solution 0.2% prevented any allergen-induced ocular itching response in a majority of eyes. the percentages of<br />
eyes with zero itch scores were significantly higher in the olopatadine group than in the placebo group at every analysis time point.<br />
1409<br />
momETaSonE FUroaTE naSal SPraY inCrEaSES THE nUmBEr oF DaYS WiTH minimal SYmPTomS in PaTiEnTS WiTH<br />
aCUTE rHinoSinUSiTiS<br />
Danzig, m. 1 , meltzer, E. O. 2 , gates, D. 1 and gopalan, g. 3<br />
1 2 schering-Plough research institute (now merck research laboratories), Kenilworth, nJ. <strong>Allergy</strong> and Asthma medical group &<br />
research Center, san Diego, CA. 3merck & Co., Kenilworth, nJ.<br />
Background: Acute rhinosinusitis is a potentially serious inflammatory disease triggered by viral or, rarely, bacterial infections,<br />
causing symptoms for up to 4 weeks. We studied therapeutic effects of mometasone furoate nasal spray (mFns) vs amoxicillin and<br />
placebo on increasing number of minimal symptom days.<br />
methods: Double-blind, parallel-group, placebo- and active-controlled 15-day study randomized subjects ≥12 old to mFns 200<br />
mcg QD, mFns 200 mcg BiD, amoxicillin 500 mg tiD, or placebo. subjects maintained daily symptom diaries. Qualified subjects<br />
had major rhinosinusitis symptom score (sum of rhinorrhea, postnasal drip, congestion, sinus headache, facial pain) ≥5 and ≤12<br />
(maximum score, 15) for ≥7 but
ABstrACts<br />
nasal Olopatadine led to more significant resolution of the postnasal-drip syndrome due to the possible synergistic effect of the<br />
combination drug regimen.<br />
1411<br />
USEFUlnESS oF PEaK EXPiraTorY FloW raTE aSSESSmEnT in THE SCrEEning For BronCHial HYPEr rESPonSiVEnESS<br />
in CHilDrEn WiTH allErgiC rHiniTiS<br />
nagaraju, m. K. , r, iii, m. , n, s. and r, g.<br />
Pediatric allergy and immunology, Kanchi Kamakoti CHilDs trust Hospital, Chennai, india.<br />
Background: the unified airway hypothesis explains the sequence in onset of atopic march from Allergic rhinitis(Ar) to bronchial<br />
hyper responsiveness (BHr) and subsequently to asthma in most of the children with Ar. BHr better identified with Peak expiratory<br />
flow rate (PEFr) assessment .<br />
aim identifying BHr in children with Ar with PEFr and to determine the effect of treatment of Ar on BHr.<br />
methodology :<br />
study design :Prospective observational study<br />
study Period : October 2007 – september 2008<br />
setting : <strong>Allergy</strong> clinic Kanchi Kamakoti CHilDs trust Hospital<br />
inclusion criteria : children > 5 yrs fulfilling Allergic rhinitis and its<br />
impact on Asthma (AriA) criteria were included in the study and classified as<br />
A.mild intermittent<br />
B.mild Persistant<br />
C.severe intermittent<br />
D.severe persistant.<br />
Exclusion Ceriteria :<br />
Children aged < 5 yrs and Unable to perform PEFr<br />
sample size : 82 was arrived with confidence interval of 95%<br />
Prevalence of 10% based on previous studies<br />
method: same Postgraduate will confirm the inclusion ,exclusion<br />
Criteria. Detailed history ,complete examination and investigations (ig E levels ,Absolute eosinophil count and PEFr will be done<br />
after obtaining informed consent. treatment (oral Antihistamines and or inhaled nasal steroids ) as per AriA CritEriA for various<br />
subgroups . Follow up done.<br />
results: total 85 children were included and 58.8% were males and majority were in 6-9 yrs age group. mild intermittent ,mild<br />
Persistant ,severe intermittent, severe persistant Allergic rhinitis were observed in 48,28,5,4 children respectively.As severity<br />
increases PEFr declined (P
ABstrACts<br />
ABstrACts<br />
for these cells. to evaluate the role of regulatory t cells (treg) in the pathogenesis of nasal polyposis, we analyzed the numbers of<br />
FOXP3+ cells in nasal polyps versus nasal mucosa from patients with allergic rhinitis (Ar).<br />
materials and method FOXP3 expression in the nasal mucosa of 15 patients with Ar and nasal polyp tissue from 17 patients<br />
with chronic rhinosinusitis with nP were analyzed by immunohistochemistry. results are expressed as the number of positively<br />
stained cells in the epithelial and subepithelium layer. statistical Data analysis was done using the student t-test at 95% interval<br />
and a P value of less than 0.05 was accepted as indicating a statistically significant differresults the number of FOXP3+ cells in<br />
the subepithelium of nasal polyps was significantly lower than that in the nasal mucosa of Ar patients (2.79 and 5.99 respectively,<br />
p=0.002). no difference was noted in the number of FOXP3+ cells in epithelium ( 3.60 and 2.35 respectively) of nasal polyps and<br />
nasal mucosa (p=0.130). therefore, the numbers of t reg cells were significantly lower in nasal polyps than in the nasal mucosa of<br />
patients with Ar.<br />
Conclusion nasal polyps have lower numbers of t reg cells (FOXP3 expression) as compared to the nasal mucosa of Ar patients.<br />
since the severity of eosinophilic, th2 type inflammation and levels of inflammatory mediators are much higher in nP than in the<br />
nasal mucosa of Ar patients, this may reflect an inverse co-relation with these factors and could explain at least in part the more<br />
pronounced structural alterations in nP. Further studies are needed to confirm this.<br />
1413<br />
DoES THE SinUS mUCoSa rESPonD To allErgEn ProVoCaTion?<br />
El Hassan, E. 1 , mösges, r. 2 and Kleiner, m. 1<br />
1Faculty of medicine, University of Cologne, institute of medical statistics, informatics und Epidemiology, University Hospital of<br />
Cologne, Cologne, germany. 2imsiE, Cologne, germany.<br />
Background: in the common cold infection, the nose and sinus mucosa react as one entity to the virus, both simultaneously<br />
demonstrating the typical inflammatory changes (gwaltney 1994). little is however known about whether a similar phenomenon<br />
exists in other pathological settings.<br />
Aim: Our study examines the behaviour of the mucosa of the paranasal sinuses in comparison to the nasal mucosa, when the<br />
subject is exposed to the accused allergen.<br />
methods: the allergen applied was birch pollen, to which the patient had a known allergy but however took no medications and<br />
was asymptomatic at the experiment baseline. An Ent specialist examined the nasal mucosa at two visits, one before, the other<br />
after an allergen provocation tests, for signs of a nasal mucosal reaction. to assess changes in the mucosal lining of the sinuses, its<br />
thickness was measured at different points on 3 sections taken from mri images taken at the same two visits. the area enclosed<br />
by the maxillary sinus mucosa was also measured, as well as the volume it contains, which was done by devising two different<br />
methods devising 3D reconstructions, in order to indirectly assess any possible mucosal thickness changes.<br />
results: there was no change detectable in the inner lining of the frontal, sphenoidal, ethmoidal and maxillary sinuses. the mean<br />
change in mucosal thickness at the different points taken was 0.45 ± 0.32 mm. All values before and after provocation lie within<br />
the physiological range for normal sinus mucosal thickness. the area enclosed by the maxillary mucosa changed by a mean value<br />
of only 1.82%. the volume measured inside each of the sinuses (right, left) changed on average by 1.035 ml, from initial volumes<br />
of 20.68 ± 1.61 ml. meanwhile the Ent examination reported the expected typical nasal mucosal reaction, the slight variations in<br />
sinus mucosal thickness measured were considered not significant.<br />
Conclusion: Our study reports for the first time that there is no relationship in the behaviour and response of the nose and sinus<br />
mucous membrane to test allergen exposure. When the former is provoked by an allergen, the thickness of the latter remains<br />
anatomically unchanged.<br />
PoSTEr SESSion 2-1: Clinical immunology<br />
2100<br />
a rarE CaSE oF aTaXia TElangiECTaSia in malaYSia<br />
mohd Ashari, n. s. , Ar, K. s. and Wah, W. Z.<br />
immunology, Universiti sains malaysia, Kota Bharu, malaysia.<br />
Ataxia-telangiectasia is a rare multisystem neurodegenerative genetic disorder due to mutation of Atm gene. the disease<br />
is characterized by progressive neurologic impairment, cerebellar ataxia, variable immunodeficiency with susceptibility to<br />
sinopulmonary infections, impaired organ maturation, ocular and cutaneous telangiectasia and a predisposition to malignancy. We<br />
report a rare case of ataxia telangieectasia who was diagnosed only at the age of 14. the patient presented to Hospital Universiti<br />
sains malaysia (HUsm), malaysia, 12 years ago with motor developmental delay at the age of 2 years. Diagnosis made at that<br />
time was dyskinetic cerebral palsy secondary to ? kernicterus. Patient was then referred for rehabilitation and occupational<br />
www.worldallergy.org 118<br />
FinAl PrOgrAm
ABstrACts<br />
therapy. However, patient defaulted followed up on and off after that. Eight years later during followed up at the paediateric clinic,<br />
a doctor noted that the patient not only having learning difficulty but also recurrent chest infection for the past 2 years. there was<br />
also presence of unsteady gait, telangiectasia at the conjunctivae, nystagmus, multiple healed infected skin lesion, generalized<br />
crepitations in both lungs and positive cerebellar sign. serum iggAm was 8.8/5.63/2.09 g/l. Based on the patient complaint and<br />
physical findings, the final the diagnosis of ataxia telangiectasia was made.<br />
2101<br />
CHroniC EoSinoPHiliC PnEUmonia in PaTiEnT WiTH DiFFiCUlT-To-TrEaT aSTHma<br />
Pauk, n.<br />
3rd Faculty of Charles University, Dept of Pneumology, Faculty Hospital na Bulovce, Prague, Czech republic.<br />
introduction<br />
idiopathic chronic eosinophilic pneumonia (iCEP) is a rare disorder of unknown cause characterised by subacute or chronic<br />
respiratory and general symptoms, alveolar and /or blood eosinophilia, and peripheral pulmonary infiltrates on chest imaging .<br />
interestingly, some but not all patients diagnosed with iCEP have a history of asthma, whilst others may develop asthma after a<br />
dignosis of iCEP has been made.<br />
Case presentation<br />
An 66-year-old woman with a history of asthma and chronic rhinitis with polyps , nonsmoker, history of allergies negative, formerly<br />
farming work..<br />
she received antiasthmatic treatment with salmeterol/fluticasone propionate (50/500) bid since 2005, no other drugs. she suffered<br />
from frequent exacerbations of asthma .On 1st .of september 2006 she had sudden fever, weight loss, malaise and impaired<br />
dyspnea with productive cough, mild chest pain on sternum and respiratory failure. A chest radiograph demonstrated bibasilar<br />
infiltrates.<br />
Peripheral blood smear showed a newly developed, marked eosinophilia (20%), and a chest X-rays and HrCt scan revealed a<br />
diffuse patchy nodular infiltrate in all lung fields.<br />
Discussion<br />
We present this case, because iCEP is a rare complication of asthma, although it is seldom mentioned in reviews ant textbooks on<br />
asthma. Asthma in patients with iCEP is relatively severe and get worse after diagnosis of iCEP .<br />
the presence of asthma at the time of diagnosis of iCEP, is associated with less relapses of iCEP, possibly because of a higher<br />
frequency of long-term inhaled corticosteroids use in asthmatics .<br />
in our case no clinical relevant relaps of iCEP has occurred during 4-year follow-up.<br />
Conclusion<br />
Clinicians should consider pulmonary eosinophilia in the differential diagnosis of patients treated for asthma who develop<br />
pulmonary infiltrates with dyspnea.<br />
2102<br />
CliniCal CHaraCTEriSTiCS oF EoSinoPHiliC organ inVolVEmEnT DiSTingUiSHing From mETaSTaSiS in CanCEr<br />
PaTiEnTS WiTH EoSinoPHilia<br />
Kim, t. , lee, t. , lee, Y. s. , Bae, Y. , Cho, Y. s. and moon, H.<br />
Department of <strong>Allergy</strong> and Clinical immunology, Asan medical Center, University of Ulsan College of medicine, seoul, south Korea.<br />
Background: Eosinophilic organ involvement should be differentiated from metastasis of primary cancer, when space occupying<br />
lesions were newly developed together with peripheral blood eosinophilia in a patient who has been diagnosed with cancer,<br />
because further chemotherapy may be needed.<br />
objective: to investigate clinical characteristics of eosinophilic organ involvement compared with distant metastasis in patients<br />
with primary cancer.<br />
methods: We retrospectively reviewed medical records of thirty cancer patients who newly developed hepatic or pulmonary<br />
nodules with peripheral blood eosinophilia from January, 2005 to February, 2010 in Asan medical Center in seoul. Eosinophilic<br />
infiltration or distant metastasis was defined by pathologic findings and radiologic features. mann-Whitney U test or Kruskal-Wallis<br />
test were used for statistical analysis.<br />
results: twenty patients (66%) were diagnosed with eosinophilic infiltration, 5 (17%) with cancer metastasis, and 5 (17%)<br />
with undetermined. History of raw food diet, high serum levels of total igE, normal liver function test, fewer and smaller nodules<br />
www.worldallergy.org 119<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
were significantly associated with eosinophilic infiltration rather than metastasis. Causes of eosinophilic infiltration were parasite<br />
infection (n=15), drug (n=1) and undetermined (n=14).<br />
Conclusion: Our results suggest that eosinophilic organ infiltration has distinguished clinical characteristics compared with<br />
cancer metastasis. moreover, physicians need to have more efforts to find the causes of organ involvement with peripheral blood<br />
eosinophilia, especially in cancer patients.<br />
2103<br />
oPPoSiTE EFFECT oF ETanErCEPT anD inFliXimaB on THE DEVEloPmEnT oF CUTanEoUS VaSCUliTiS<br />
Kim, J.<br />
Pediatrics, seoul national University College of medicine and rheumatology research institute, snU Hospital, seoul, south Korea.<br />
We report here a case that showed opposite effect of two tnF-α antagonists, etanercept and infliximab, on cutaneous vasculitis<br />
in a patient with JrA. three tnF-α antagonists, etanercept, infliximab, and adalimunmab are now available for the treatment of<br />
JrA in Korea. As JrA is a chronic condition, increase of adverse effects by long-term use is a major obstacle in tnF-α antagonists<br />
therapy. these include injection-site reaction, infusion-related reactions, infections, lymphoma, and lupus-like symptoms.<br />
recently, development of cutaneous vasculitis has been observed in patients receiving tnF-α antagonists. We experienced<br />
a JrA patient treated with etanercept(25~50mg/week) for 2 1/2 years developed cutaneous vasculitis on both of lower legs.<br />
Pathological examination of skin biopsy revealed leukocytoclastic vasculitis. thus, etanercept therapy was discontinued due to<br />
the extent and severity of vasculitis. After cessation of treatment for 4 months, the patient’s disease activity developed again and<br />
infliximab(100mg/8weeks) was administered with remission of disease activity. Unexpectedly, however, we found that cutaneous<br />
vasculitis was improved effectively by infliximab. this observation indicates that cutaneous vasculitis developed after introduction of<br />
one tnF-α antagonist(etanercept) can be improved with administration of another tnF-α antagonist(infliximab) and suggests that<br />
the opposite effect of these agents is probably associated with their ability to bind to tnF- α.<br />
2104<br />
BronCHoalVEolar laVagE anD SErUm EoSinoPHil CaTioniC ProTEin lEVElS in CHroniC aSTHma anD BronCHial<br />
CarSinoma<br />
Kose, s. 1 , Arici, m. 2 , Cavdar, g. 1 , Yavas, s. 1 and Camci, g. 1<br />
1infectious Diseases and Clinical microbiology, Clinical <strong>Allergy</strong> and immunology, tepecik Educational and research Hospital, izmir,<br />
turkey. 2Pulmonery Diseases, tepecik Educational and research Hospital, izmir, turkey.<br />
inTroDUCTion<br />
immunoglobuline E (igE) and eosinophil cationic protein (ECP) are important markers for atopy and allergic inflamation. Elevated<br />
ECP levels may be found in the serum as well as the bronchoalveolar and nasopharyngeal secretions in many diseases, including<br />
asthma, bronchiolitis and infections.<br />
mETHoDS<br />
the ECP in bronchoalveolar lavage fluid and in serum was measured in 15 patients with chronic pulmonary diseases such as<br />
bronchial carsinoma (7 of patients) and asthma (8 of patients).<br />
rESUlTS<br />
ECP levels in BAl fluids were higher in the patients with asthma (mean ECP level : 1,75 mcg/l) than in the bronchial carsinoma<br />
group (mean ECP level : 4 mcg/l). serum ECP levels ; were found 8,5 mcg/l in asthmatic group, and 3,4 mcg/l in patients with<br />
bronchial carcinoma.<br />
DiSCUSSion<br />
in conclusion we can say that serum and BAl ECP levels are useful markers for predicting eosinophilic airways inflamation, and<br />
serum ECP concentrations may be helpful noninvasive markers of atopic asthma.<br />
2105<br />
SUlFaTED moDiFiCaTion oF lYCiUm BarBarUm PolYSaCCHariDE UnDEr miCroWaVE irraDiaTion anD THEir anTi-HiV<br />
aCTiViTiES<br />
Zhu, X. and Zhang, H.<br />
Beijing University of technology, Beijing, China.<br />
the sulfated Lycium barbarum polysaccharide (lBP) were prepared by chlorosulfonic acid–pyridine (Py-sO ) method according to<br />
3<br />
orthogonal l (3) 9 4 test under microwave irradiation. Eight sulfated slBP, with various degrees of sulfate (Ds) and the number average<br />
molecular weight (M ), were obtained and their anti-HiV activities were compared by mtt and ElisA assay. the results indicated<br />
w<br />
www.worldallergy.org 120<br />
FinAl PrOgrAm
ABstrACts<br />
that when Ds within the scope of 0.2–0.5 and the M w in the range of 40–50 kDa, slBP exhibited significantly strong inhibition of<br />
HiV activity, and it was confirmed by real-time biomolecular interaction analysis (BiAcore). the optimum sulfation conditions were<br />
reaction temperature of 45°C, the molar ratio of Py-sO 3 to lBP of 2:1 and the reaction time of 6 min at the microwave power of<br />
45W in DmF.<br />
2106<br />
THE lEVEl oF THE TUmor nECroSiS FaCTor in PaTiEnTS WiTH FEmoral nECK FraCTUrES<br />
Popova, O. 1 , nurpeisov , t. 2 and Batpenov , n. 3<br />
1 2 laboratory, research institute of traumatology and orthopedy, Astana, Kazakhstan. research institute of Cardiology, Almaty,<br />
Kazakhstan. 3research institute of traumotology and orthopedy, Astana, Kazakhstan.<br />
Methods: We have investigated the dynamics of the tnF level in patients with femoral neck osteoporotic fractures. the main group<br />
of 132 patients aged 60–75 with fractures of the proximal section of the neck of femur and the controlling group of 78 patients of<br />
the same age without the fracture were the object of our investigation.<br />
Results: in assessing the tnF-a serum level in patients with femoral neck osteoporotic fractures we revealed its trustworthy<br />
growth. in the group of patients with femoral neck osteoporotic fractures we observed a sharp increase of tnF-a concentration<br />
(93,8 ± 5,9 pg/ml) which exceeded the indices of the controlling group of patients by 3,4 times (r < 0,5). the investigation of the<br />
tnF-a serum level before the operation in patients with femoral neck osteoporotic fractures according to the type of the fracture in<br />
comparison with the controlling group made it possible to state that the content of this cytokine in all the patients was heightened.<br />
the highest indices were recorded in patients with subcapital femoral neck fractures.<br />
Conclusions: We have revealed high rates of tnF-a in patients with femoral neck osteoporotic fractures which exceeded the<br />
indices of the controlling group of patients by 3,4 times (r < 0,5). moreover, during the first 24 hours after the operation a higher<br />
level was found in the group of patients with subcapital and pertrochanteric femoral neck fractures. later, on the 14-th day after the<br />
operation, we observed the tendency to reduction of the tnF-a rate by 1,4 and 2,1 times, accordingly. On the contrary, in patients<br />
with spit and transcervical fractures the tnF-a level reduced during the first 24 hours, but there was a tendency to augmentation<br />
on the 14-th day by 0,8 and 0,7 times, accordingly. the obtained data can serve as a prognostic criterion of the emergence of<br />
postoperative complications and the course of treatment.<br />
2107<br />
STUDY oF il-8 inDiCES in ElDErlY PEoPlE WiTH FEmoral nECK FraCTUrES<br />
Popova, O. 1 and nurpeisov , t. 2<br />
1 2 laboratory, research institute of traumatology and Orthopedy, Astana, Kazakhstan, Astana, Kazakhstan. research institute of<br />
Cardiology, Almary, Kazakhstan.<br />
this study the dynamics of il-8 rate in patients with osteoporotic femoral neck fractures (a group of patients with subcapital and<br />
pertrochanteric fractures).<br />
the level of il-8 has been studied in 112 patients with osteoporotic fractures of proximal one-third of femoral neck. in the group<br />
with subcapital fractures we have revealed a high concentration of il- 8, which exceeded the controlling group indices by 1.2 times.<br />
il-8 indices in the group of patients with pertrochanteric fractures have not reached statistically significant distinctions.<br />
During the first 24 post-operation hours we have observed in the group of patients with subcapital fractures a growth of il- 8 rate<br />
by 1,2 times (p > 0,05) in comparison with that before the operation. no significant difference with its content was revealed in<br />
patients with pertrochateric fractures as compared with the controlling group.<br />
By the 14th day there was registered a tendency to the further growth of il–8 indices up to 4,2 pg / ml, which was by 1,8 times<br />
higher than the level before the operation (p > 0,05). On the contrary, there was an il-8 decline to the lower level registered in the<br />
group with pertrochanteric fractures as compared to the controlling group indices (1,7 pg / ml).<br />
According to our research, patients with subcapital fractures of the neck of the femur proved to be the most vulnerable elderly<br />
patients. We have also registered the highest percentage of post-operation complications and a more lingering rehabilitation period<br />
in this group of patients. it should be noted that women showed higher il-8 indices (2,15 pg/ml), which were by 1,1 times higher<br />
than those of the controlling group.<br />
it has been determined that during the first post-operation day the il-8 level exceeded the indices of the controlling group by 1,6<br />
times and on the 14-th day the elevation was by 2,2 times higher, which amounted 2,93pg/ml and 4,2pg/ml accordingly. the fact<br />
in question may serve as a diagnostic criterion for the development, diagnosing and treatment of osteoporotic fractures in older and<br />
senile patients.<br />
www.worldallergy.org 121<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
2108<br />
EXPrESSion oF il-17a anD il-17F CYToKinES in B lYmPHoCYTES<br />
Vazquez tello, A. 1 , Halwani, r. 2 , li, r. 3 , Bar-Or, A. 4 , mazer, B. 5 , Al-muhsen, s. 6 and Hamid, Q. 7<br />
1College of medicine, Asthma research Chair and Prince naif center for immunology research, King saud University, riyadh, saudi<br />
Arabia. 2Asthma research Chair and Prince naif Center for immunological research, College of medicine, King saud University.,<br />
riyadh, saudi Arabia. 3montreal neurological institute and mcgill University, montreal, QC, Canada. 45 montreal neurological institute<br />
and mcgill University, montreal, QC, Canada. 5meakins-Christie laboratories and respiratory Division, Department of medicine,<br />
mcgill University, montreal, QC, Canada. 6Department of Pediatrics, College of medicine, King saud University. 7mcgill University,<br />
meakins-Christie laboratories, montreal, QC, Canada.<br />
introduction. il-17A and F cytokines are regarded as promoters of autoimmune conditions such as inflammatory bowel disease,<br />
rheumatoid arthritis, and multiple sclerosis. there is a body of evidence suggesting that il-17A and F are produced primarily by<br />
CD4 + th-17 lymphocytes. However, recent reports suggest that other cells including CD8+, nKt and treg cells also express il-17A<br />
and il-17F and may contribute to the production of these cytokines in immunologically-mediated diseases. B lymphocytes are<br />
known to be important cytokine sources in inflammation and play a significant role in a number of chronic immunological diseases<br />
including allergic and autoimmune diseases. We therefore investigated the potential of human B lymphocytes to produce il-17A and<br />
il-17F.<br />
methods. Highly purified B cells were obtained from tonsils or peripheral blood by using a multiple-step separation procedure<br />
which included rosette depletion, adherence depletion, CD3+ cell magnetic-activated depletion and CD19+ magnetic-activated<br />
positive cell selection. CD20+ purity was verified by flow cytometry. in these cells fractions, the percentage of double-labeled<br />
CD3+CD4+ cells (t lymphocytes) was negligible (0.2%); CD14+ cells (macrophages/monocytes) were also very low (
ABstrACts<br />
result<br />
the patient was diagnosed as relapsing polychondritis (rP) and treated with prednison 2 mg/kg of bodyweight/day. the next<br />
bronchoscopy showed that the patient’s airway became narrowed, so we added immunosupressive agent (methotrexate), started<br />
from 10 mg/week. After the patient got methotrexate for 6 weeks, there was a clinical improvement and the tracheoscopy<br />
examination showed that the karina, the right and left prime bronchus was opened, and no evidence of granulation.<br />
Conclusion<br />
steroids alone did not give good result as expected, but the combination with methotrexate in this patient was proved useful and<br />
gave better clinical improvement.<br />
Key word: Collagen type ii, laryngotracheomalacia, methotrexate, relapsing polychondritis<br />
2110<br />
PEriPHEral EoSinoPHilia<br />
restrepo, m. 1 , Diez, s. 1 , sanchez, J. 1 , Chinchilla, C. 2 and Cardona, r. 3<br />
1 2 Allergology, Universidad de Antioquia, medellín, Colombia. University of Antioquia - grupo de Alergología Clínica y Experimental<br />
(gACE), medellin, Colombia. 3University of Antioquia, medellin, Colombia.<br />
Background: the accumulation of eosinophils in a variety of tissues is not unique to host defense or as result of immune<br />
dysregulation, this buildup occurs as a strategy to maintain homeostasis in both states: health and disease. Eosinophilia is<br />
considered to occur when the total number of eosinophils in the periphery is significantly higher than considered normal for the<br />
general population<br />
objective: to present the clinical case of a patient with peripheral eosinophilia, which one did not show apparent trigger.<br />
medical history and monitoring: 5 years old male patient, evaluated by our allergy group for 3-month history of cervical<br />
lymphadenopathy associated with fever, current edema in hands and feet and itchy, his laboratory test revealed eosinophils<br />
between 1860 and 9500cell/ml. studies were conducted to rule out to rule out causes of peripheral eosinophilia. HiV, toxocara, CmV,<br />
toxoplasma antibodyes has done , cerebrospinal fluids cytology, igE, bone marrow biopsy, echocardiography, upper gastrointestinal<br />
endoscopy, colonoscopy and biopsies all within normal ranges.<br />
By peripheral eosinophilia, recurrent fever and swelling hands gleich syndrome was thought , which is characterized by recurrent<br />
episodes of angioedema, urticaria, itchy, fever, weight gain, elevated igm and leukocytosis with marked eosinophilia. requested<br />
to continue with the studios vit B12 levels, igm, skin biopsy with immunohistochemistry and serum levels of tryptase, Finding<br />
high levels of Vit B12: 1018 pg / ml, normal tryptase and igm. skin biopsy was not carried out because the skin symptoms and<br />
eosinophilia resolved.<br />
it highlights the need for diagnostic studies in patients with hypereosinophilia in order to reach an etiological diagnosis. in our<br />
patient suspected gleich syndrome, but the normalization of the eosinophil count four months after without drug treatment and<br />
the absence of physical signs, now ruled out the diagnosis and force us to make periodic checks.<br />
Bibliography: the eosinophilias, including the idiopathic hypereosinophilic syndrome. Briito Babapulle. J Haematol 2003.<br />
Eosinophilia and Eosinophil-related Disorders Peter F. Weller middleton’s <strong>Allergy</strong>: Principles and Practice, 7th ed.n<br />
PoSTEr SESSion 2-2: Drug and food allergy<br />
2200<br />
PoTEnTial aDVErSE rEaCTionS From ComPlEmEnTarY anD alTErnaTiVE mEDiCinE (Cam) anD DiETarY SUPPlEmEnT<br />
(DS) in norTH amEriCa<br />
Wong, H. g.<br />
Department of medicine, University of British Columbia & Vancouver general Hospital, Vancouver, BC, Canada.<br />
Background: Complementary and alternative medicine (CAm) and dietary supplement (Ds) being natural products, are usually<br />
considered harmless. Potential adverse reactions in four preparations are presented.<br />
method: Visits were made to Chinese herbal shops and health food stores in Vancouver, Canada, and new York, UsA. the<br />
ingredients of some CAm and Ds were carefully examined.<br />
results: Four preparations, two from Vancouver (1,2) and two from new York (3,4) were noted to have potential adverse reactions.<br />
1. ArtHO-ACE “pill for pain relief” with a label stating “this product is made from [ten] selected natural herbal [sic] and contains no<br />
toxin [sic] & chemicals.” Does it mean it may contain heavy metal or pharmaceutical product?<br />
www.worldallergy.org 123<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
2. rAPiDCUts “a rapid fat burning catalyst”, to take 1 pack BiD, with ingredients in each pack including (i) magnolia bark extract<br />
(known to contain turbocurarine) and (ii) caffeine 298mg (less than 400mg of caffeine per day from all sources, recommended by<br />
Health Canada).<br />
3. CHinA tUng sHUEH Pills “pill for blood thinning”, containing “radix salvine miltiorrhizae [sic]” with potential herb-drug<br />
interaction with warfarin.<br />
4. FU Zi li ZHOng WAn “nausea extract for gastric bloating”, containing prepared aconite root (Aconitum carmichaeli) with potential<br />
adverse cardiac side effect.<br />
Conclusions: there are potential adverse reactions in CAm and Ds purchased in Chinese herbal shops and health food stores in<br />
north America. Physicians should inquire the use of CAm and Ds by patients. there should be higher standard in regulation in CAm<br />
and Ds in north America.<br />
2201<br />
inTErim FinDingS From ESTaBliSHing THE EFFECTiVEnESS, CoST-EFFECTiVEnESS anD SaFETY oF oral anD<br />
SUBlingUal immUnoTHEraPY For FooD allErgY: a SYSTEmaTiC rEViEW<br />
nurmatov, U. 1 , Devereux, g. 2 and sheikh, A. 1<br />
1<strong>Allergy</strong> & respiratory research group, Centre for Population Health sciences, the University of Edinburgh, Edinburgh, United<br />
Kingdom. 2Department of Child Health, royal Aberdeen Children’s Hospital, the University of Aberdeen, Aberdeen, United Kingdom.<br />
Background: the prevalence of food allergy in children has increased in recent decades. Oral and sublingual immunotherapy<br />
aims to desensitise people and induce immunological tolerance, enabling igE-mediated food allergic patients to consume increased<br />
quantities of the food(s) in question. this is a promising new therapeutic approach and a careful critique and synthesis of the<br />
literature will be an important contribution towards establishing the safety, effectiveness and cost-effectiveness of this approach.<br />
objectives: to identify and critically review the published and unpublished evidence for the effectiveness and safety of oral and<br />
sublingual immunotherapy in people with igE-mediated food allergy.<br />
methods: systematic review and meta-analysis of all interventional studies i.e. randomised controlled trials (rCts), quasi-rCts<br />
and controlled clinical trials (CCts) were identified from searching 11 electronic databases. the primary outcomes of interest are<br />
the recovery rate from food allergy as assessed by the ability to consume increased amount of the offending food allergen whilst<br />
on treatment (i.e. desensitisation) and success rates for complete tolerance to the causative food. secondary outcomes of interest<br />
include the frequency and severity of local/systematic adverse events, quality of life, health services use including emergency<br />
department contacts and hospital admissions, and data on cost-effectiveness both from the perspectives of patients/families and<br />
healthcare providers.<br />
interim findings: Our searches identified 721 potentially relevant papers; after de-duplication, 626 potentially eligible papers were<br />
included for screening. 606 studies were excluded for not meeting review criteria and another 20 potentially appropriate abstracts<br />
reviewed, of which 11 satisfied our inclusion criteria. there were seven rCts and four CCts; nine of these trials relate to oral<br />
immunotherapy and the remaining two are concerned with assessing sublingual therapy. Analyses are underway and results will be<br />
presented at the conference.<br />
implications: this work will clarify the evidence base for the use of oral and sublingual immunotherapy in people with igEmediated<br />
food allergy and will inform national and international deliberations on service provision.<br />
2202<br />
CiSPlaTin aDminiSTraTion FolloWing aCUTE HYPErSEnSiTiViTY To oTHEr PlaTinUm ComPoUnDS: a PHaSE ii STUDY<br />
syrigou, E. , makrilia, n. , Politi, K. , Kaklamanos, g. , manolopoulos, l. and syrigos, K. n.<br />
Oncology Unit, 3rd Department of medicine, sotiria general Hospital, Athens school of medicine, greece, Athens, greece.<br />
Platinum compounds are antineoplastic agents widely used in numerous malignancies. A high percentage of patients exhibit<br />
carboplatin-associated hypersensitivity, especially after their seventh course of chemotherapy. the purpose of this study was to<br />
determine how useful skin tests are in ruling out cross-reaction to cisplatin, especially when treating physicians wish to continue<br />
platinum-based chemotherapy in patients responsive to these drugs. Prick tests were performed on three patients with medium<br />
and severe hypersensitivity to carboplatin. these tests were followed by intradermal tests with a series of carboplatin and cisplatin<br />
dilutions. Prick tests were negative for both carboplatin and cisplatin, whereas, in all patients, intradermal tests were positive with<br />
carboplatin and negative with cisplatin. Cisplatin was administered instead of carboplatin and was well tolerated by all patients<br />
without administering premedication. We reach the conclusion that intradermal skin tests can be used to detect cross-reaction<br />
between platinum compounds in order that platinum-based therapy is safely continued with a different platinum agent. this method<br />
requires neither desensitization nor premedication.<br />
www.worldallergy.org 124<br />
FinAl PrOgrAm
ABstrACts<br />
2203<br />
FooD allErgY anD aToPiC DErmaTiTiS<br />
Hekmatdoost, Jr., A.<br />
Dep Clinical nutrition and Dietetics, shahid Beheshti University of medical sciences, tehran, iran.<br />
Food allergy is one of the most important factor in children with atopic dermatitis (AD). in this study, we have measured any<br />
association existed between AD severity, quality of life, total igE, eosinophil counts, and the number of food items sensitized.<br />
specific igE of ten common food items was measured for a group of consecutive AD patients (n = 105) enrolled during a<br />
randomized trial and correlated the findings with eczema severity. twenty-nine patients were negative for any of the ten common<br />
food items. the most commonly sensitized foods were caw milk (51%), fish (49%), egg white (41%), and wheat (38%). Atopy to<br />
beef as a protein and orange as a fruit were least common among the food items studied, even among patients positive for 8-9<br />
igE items. Patients with severe AD (objective sCOrAD > 40) were more likely to be positive for at least one of the food items (Yates<br />
corrected p = 0.024 for >/=1 food-specific igE in severe vs. moderate AD, Or 3.42 and 95% Ci 1.15-10.32); and for at least seven<br />
of the food items (p = 0.001 for >/=7 food-specific igE vs. nil with Or 11.67 and 95% Ci 2.29-67.77), respectively. the spearman<br />
coefficients between the number of positive food-specific igE and total sCOrAD, objective sCOrAD, area of AD involvement,<br />
Children’s Dermatology life Quality index (CDlQi), total igE levels, and eosinophil counts were 0.42 (p < 0.001), 0.45 (p < 0.001),<br />
0.50 (p < 0.001), 0.17 (p = 0.116), 0.80 (p < 0.001), and 0.22 (p = 0.043), respectively. specific igE levels for beef correlated with<br />
all the other food-specific igE levels, including cow’s milk (rho = 0.061, p < 0.001) and soy (rho = 0.70, p < 0.001). the number of<br />
common food items sensitized correlated with disease severity, extent, and total igE levels. it seems that many atopic children could<br />
be treated by food limitations.<br />
2204<br />
CliniCal CHaraCTEriSTiCS oF raniTiDinE inDUCED HYPErSEnSiTiViTY<br />
Cho, Y. J.<br />
<strong>Allergy</strong> and Clinical immunology, internal medicine, Ewha Womans University mockdong Hospital, seoul, south Korea.<br />
Purpose: ranitidine is a widely used drug for gastrointestinal problem and is usually associated with a low incidence of adverse<br />
reactions. there have been only a few cases of immediate type hypersensitivity reactions to ranitidine. to see the characteristics of<br />
ranitidine induced hypersensitivity, we analyzed 10 cases of ranitidine induced hypersensitive reaction<br />
methods: Patient who is suspicious of ranitidine induced hypersensitivity was evaluated. skin test and oral provocation were<br />
performed. We also evaluated the cross reactivity of other drugs (cimetidine, famotidine and proton pump inhibitor) used for gastric<br />
protection.<br />
results: Eighty percent of patient was positive in ranitidine skin test and oral provocation test. mean age of these patients was<br />
35 ± 7 years old. male: female ratio was 4:6. two cases illustrates a severe anaphylactic reaction after a single intravenous dose<br />
of 50 mgs of ranitidine and three cases showed anaphylactic reaction after oral intake of dose of 150mg of ranitidine. Five cases<br />
illustrated only skin eruption after oral intake of 150mg of ranitidine. All of five cases who illustrated anaphylactic reaction showed<br />
positive reaction with skin prick test and/or intradermal skin tests. three patients who showed only skin reactions were positive in<br />
intradermal skin test with ranitidine. two of cases were negative for skin test with ranitidine and they showed mild skin eruption<br />
with itching sense in 2 hours and 3 hours each with 75mg of ranitidine of oral provocation test. All of the 10 cases showed<br />
negative reaction in skin test and oral provocation test with cimetidine, famotidine and proton pump inhibitor.<br />
Conclusion: Our case suggests that ranitidine may induce immunoglobulin E-mediated anaphylaxis but also non-immunological<br />
mechanisms may be involved in hypersensitivity reactions.<br />
ranitidine may have very rare cross-reactivity with other gastric protective drugs. Clinicians should therefore be aware of possible<br />
life-threatening adverse reactions to commonly used H2-receptor antagonists such as ranitidine.<br />
2205<br />
PangaSiUS HYPoPHTHalmUS HYPErSEnSiTiViTY<br />
Palomeque, sr., m. t. 1 , torrecillas, m. 1 , Bartolome, B. 2 , martínez Borque, n. 1 , gonzález mendiola, m. r. 1 , martín Casáñez, E. 1 , lara<br />
de la rosa, P. 1 , soto Vargas, g. 1 and martínez Bohigas, D. 1<br />
1 2 Alergología, Complejo Hospitalario Universitario Albacete, Albacete, spain. Departamento i+D, Bial-Arístegui, Bilbao, spain.<br />
introduction: Fish is a relatively common source of food allergens and its ingestion may cause fatal anaphylactic reactions. Fish<br />
allergic subjects usually present igE antibody to several fish species, although clinical cross reactivity may be more limited. We<br />
report a patient allergic to Pangasius hypophthalmus (Panga fish) but no to other fish. this exclusive sensitivity was confirmed by in<br />
www.worldallergy.org 125<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
vivo and in vitro tests, and a unique Pangasius hypophthalmus allergen was detected. Panga is a fish from Vietnam rivers which is<br />
being exported to many countries (included spain) in the last years.<br />
Clinical case: A 18-year-old man reported five reactions a few minutes after eating panga fish; he had upper and lower respiratory<br />
tract dyspnea, laryngeal oppression, wheezing and heartburn. He declared that he did not suffer allergic symptoms with the<br />
ingestion of any other kind of fish or seafood.<br />
results: Prick-test with Anisakis simplex, seafood, panga fish and thirteen different commercial fish extracts (hake, cod, salmon,<br />
sole, trout, tuna, bream, bass fish, sardine, herring, south African Anchovy, anglerfish and bonito) was positive only to octopus,<br />
panga and bass fish. Prick-prick with panga fish was positive (cooked: 10x7; raw: 12x9) and negative with sardine, cod, hake,<br />
salmon, south African Anchovy, swordfish, sole, guilthead bream, squid, cuttlefish, octopus and shrimp. the open oral challenge test<br />
was negative with salmon, sole, trout, bass fish, guilthead bream, squid, cuttlefish, octopus and shrimp.<br />
specific igE against extracts from panga (cooked: 4.3 kU/l ; raw: 3.1 kU/l), sardine (2.1 kU/l), hake (0.7 kU/l), cod (0.6 kU/l)<br />
and shrimp (0,9 kU/l) was detected by means of EAst method (Enzyme Allergosorbent test). igE-immunoblotting with panga<br />
extracts (cooked and raw) revealed igE-binding bands of 14 kDa and 12 kDa, the same molecular mass as the ones appeared after<br />
incubation with a rabbit serum anti-sardine parvalbumin.<br />
Conclusion: We report a patient who is allergic exclusively to panga fish. Probably the allergen involved is parvalbumin.<br />
2206<br />
FiXED DrUg ErUPTion inDUCED BY iBUProFEn anD aCETaminoPHEn<br />
torrecillas, sr., m. , Palomeque, m. t. , martín, E. , martínez, n. , lara, P. , soto, g. , martínez, D. and gonzález, m. r.<br />
Alergología, Complejo Hospitalario Universitario Albacete, Albacete, spain.<br />
Fixed Drug Eruption is considered the only pathognomonic drug hypersensitivity dermatosis. the most frequently drugs involved are<br />
sulfonamides, pyrazolones, barbiturates, chemotherapeutic agents, psychotropic drugs, penicillins and tetracyclines, but it also has<br />
been reported for ibuprofen, paracetamol and other nsAiDs, usually with only one drug involved.<br />
We report the case of a 62 years old man, hypertensive, treated with amlodipine + valsartan who complains about having<br />
presented pruritic violaceous macules on the back of hands, face and abdomen 24 hours after taking ibuprofen or paracetamol<br />
which lasted four weeks.<br />
Patch test were performed with a battery of nsAiDs, ibuprofen 5% and acetaminophen 10% in vaseline in healthy skin, and<br />
ibuprofen and acetaminophen also in back of hands, with negative results.<br />
single-blind, placebo controlled oral challenge (sBPCOC) with acetaminophen was positive, reappearing the lesions on the back<br />
of hands at 45 minutes after administration of 500 mg (cumulative dose 1000 mg). sBPCOC with ibuprofen also was positive with<br />
lesions at two hours into the test (cumulative dose 600 mg).<br />
single-blind, placebo controlled oral challenge to therapeutic doses of aspirin (1000 mg) and metamizol (575 mg) was well<br />
tolerated<br />
We present a case of fixed drug eruption by ibuprofen and acetaminophen with good tolerance to other groups of nsAiDs,<br />
diagnosted by controlled exposure test, having been negatived patch testing with them.<br />
2207<br />
FrEQUEnCY oF immEDiaTE, laTE anD DElaYED TYPE FooD HYPErSEnSiTiViTY in ProVoCaTion TEST For Egg allErgY<br />
anD iTS CorrElaTion WiTH Egg-WHiTE igE raST SCorE<br />
noma, t. 1 , Ogawa, n. 1 , Ogawa, n. 2 , mikami, K. 2 , saeki, t. 1 , isozaki, A. 3 , Kawano, Y. 3 and Oshiba, H. 4<br />
1 2 3 Pediatrics, Kitasato Univ, sagamihara, Japan. Pediatrics, Chiba Aiyukai memorial Hospital, Japan. Pediatrics, Yokohama City<br />
minato red Cross Hospital, Japan. 4Pediatrics, tokyo Kousei-nenkin Hospital, Japan.<br />
in egg allergy the method to determine the serum level of a specific igE is associated with shortcomings such as a frequent lack<br />
of correlation between the symptoms and the presence of a specific igE ; furthermore, in an attempt to find an antigen responsible<br />
for food hypersensitivity, the development of symptoms in a provocation test does not necessarily guarantee test values that signify<br />
positivity (a low sensitivity). in the present study where the egg provocation test was conducted, the correlation of the time required<br />
for the symptoms to develop, with the egg white rAst score in egg allergy were examined.<br />
subjects: included 125 children with atopic dermatitis (AD), (mean 2 y 10 m, from 3 m to 15 y in age).<br />
the oral provocation test and result: Approximately 0.1 ml of the raw egg was given first, followed by several spoonfuls (0.15ml/<br />
sp), until the entire quantity. in a one-week observation of the patients who were subjected to the egg-loading test, 75 among 125<br />
suffered immediate (type i, 1h>), late (type l, 24h>), or a delayed-type (typed, 1-7d) skin eruption or exacerbation of eczema, while<br />
50 exhibited negative responses to the test. For type i , the positivity and the rAst score was 50.7%, 1.71+/-0.36(95%Ci), 12.0%,<br />
www.worldallergy.org 126<br />
FinAl PrOgrAm
ABstrACts<br />
1.11+/- 0.81 for type i alone out of them, 2.7%, 1.5+/-2.08 for type il, 4.0%, 0.33+/- 0.50% for type Di, and 32.0%, 2.17+/- 0.37<br />
for type ilD which is the higher value (P=0.049). 55.6% of type i alone exhibited negative- rAst score.<br />
in conclusion: the type ilD shows higher value of the rAst score, which likely reflects the pathogenesis of the disease such as<br />
allergic inflammation and the severity in the higher value group.<br />
2208<br />
anTi-igE anTiBoDY anD FooD igE-mEDiaTED DiSEaSES in SEVErE aSTHmaTiC PaTiEnTS<br />
Florio, g. 1 , Oricchio, C. 2 , Palmieri, m. 1 , marone, g. 3 and Patella, V. 1<br />
1 2 Division of <strong>Allergy</strong> and Clinical immunology, Agropoli general Hospital, Department of medicine Asl salerno, salerno, italy. Unit of<br />
transfusion medicine, Agropoli general Hospital, Asl salerno, salerno, italy. 3Division of <strong>Allergy</strong> and Clinical immunology and Center<br />
for Basic and Clinical immunology research (Cisi), University of naples Federico ii, naples, italy.<br />
BaCKgroUnD: it is now recognized that immunoglobulin E (igE) plays a central role in mediating the allergic response.<br />
Omalizumab, a recombinant humanized monoclonal antibody (Xolair®), has been currently used in the treatment of patients with<br />
allergic asthma with moderate to severe persistent allergic asthma with a serum igE.<br />
oBJECTiVE: to investigate the efficacy of anti-igE to treat igE-mediated hypersensitivity to foods.<br />
mETHoDS: in a court of 12 patients (9 females, 3 males; range 6-46 years old; mean 32 years) with severe attacks asthma and<br />
food allergy to igE-mediated, they were treated with omalizumab and monitored during the treatment. the appropriate dose and<br />
frequency of administration of Xolair® was determined by levels of igE basal (iU / ml), measured before starting treatment, and<br />
body weight (kg).<br />
rESUlTS: seven female patients and one male patient with severe attacks of igE-mediated asthma and food allergy to milk, while<br />
three female patients and two male patients with severe asthma and food allergy to egg proteins. All patients experienced allergic<br />
food reactions based on history of Anaphylaxis and Dermatitis. Before treatment with Omalizumab, they had asthma with a mean<br />
of symptom scores of 7.2 ± 2.1 [scale from 0 (least) to 9 (severe)]. the total igE concentrations were a mean 1046 ± 84.3 iU/ml.<br />
After 16 weeks of treatment with Xolair®, total igE were decreased with a mean of 440 ± 92.7 lU/ml. no access to intensive care<br />
unit was needed during the treatment and the asthma symptom score decreased with a mean of 3.7 ± 2.4 and peak expiratory<br />
flow (PEF) of the morning increased each four weeks in all patients. Whereas the introduction (after challange test), in their diet,<br />
after 16 weeks of treatment with Xolair®, of cow’s milk, egg and its derivatives: in nine patients no reactions (anaphylaxis and<br />
dermatitis); in one patient a mild reaction with angioedema;in two patients a episode of hives it was registered.<br />
ConClUSion: these new features suggest further prospective regarding the use of this biological drug for patients suffering of<br />
severe allergies such as the food allergy.<br />
2209<br />
EFFECTS oF DiETarY CoUnSElling on ProTEin inTaKE anD PlaSmaTiC ProTEin ProFilE in CHilDrEn WiTH FooD<br />
allErgY<br />
D’Auria, E. , mandelli, m. , Cagnoli, g. , lammardo, A. m. , Zuvadelli, J. , salvatici, E. and giovannini, m.<br />
Department of Pediatrics, san Paolo Hospital-University of milan, italy, milan, italy.<br />
Background: Elimination diet in children with food allergy (FA) could be responsible for inadequate dietary intake and protein<br />
imbalance.<br />
aim: to investigate the protein intake and plasmatic protein profile in children with FA on elimination diet.<br />
methods: the study included 40 children (19 boys and 21 girls, 3-36 months of age), all affected by FA on elimination diet for at<br />
least 30 days. measurement of total protein, albumin, prealbumin, plasma nonessential to essential amino acid ratio was carried out<br />
at enrollment (t ) and after 6 months (t ) of dietary counselling by registered dietician.<br />
0 1<br />
results: Protein intake in FA children exceeded the recommended intake, according to national dietary recommendations, as<br />
in non allergic children. the ratio between the mean value of protein intake (g/kg) in our children, assessed by a 3-day diary,<br />
and the recommended protein intake (g/kg) decreased significantly from t to t [t =1,60 (0,7-3), t =1,31 (0,9-2); p=0,05] after<br />
0 1 0 1<br />
nutritional counselling. the comparison of the measurements of plasmatic protein profile [mean (min-max)] observed in the study<br />
population during the 2 times of valutation showed no significative difference (significance with p
ABstrACts<br />
ABstrACts<br />
Conclusions: An unbalanced diet is a frequent feature in allergic children. this condition could be prevented and resolved by an<br />
adequate nutritional counselling. in particular, in our population the dietary intervention improved the quality of protein intake.<br />
Plasmatic non essential/essential aminoacids may be an useful marker of protein status.<br />
2210<br />
THE rolE oF SKin PriCK TEST in DiagnoSiS oF CroSS –allErgY<br />
Bartuzi, Z. 1 and napiórkowska, K. 2<br />
1Department Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University,<br />
Bydgoszcz, Poland. 2Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University,<br />
Bydgoszcz, Poland.<br />
Background: Patients with birch pollen allergy frequently develop hypersensitive reactions to certain food e.g. apples, celery and<br />
carrots due to cross-reactivity reactivity between these allergens. these reactions result from the similarity of allergen proteins<br />
structure, which are sometimes unbound phylogenetically. the aim of this study was to investigate the role of cross-reactivity and<br />
the diagnostic value of skin prick test (using commercial and native extracts of allergens), total and specific igE in diagnosis such<br />
kind of allergy.<br />
material and methods: Fifty eight patients at the age above 16 were included in the study. the clinical history and the positive<br />
result of the skin prick test with the birch extract were the condition for qualifications. Patients were divided into two groups.<br />
Patients included in the first group were birch allergic without any symptoms after eating food (23 persons). Patients in the other<br />
group had birch pollen allergy and they had reported clinical symptoms after eating foods such as: apple, celery, carrot, tomato,<br />
banana, peach, peanut and hazelnut. (35 persons). the skin prick tests with pollen and food commercial extract and with native<br />
food allergens were determined for all individuals.<br />
results: All patients showed positive skin prick test with other pollen allergen extracts. Particularly a high percentage of positive<br />
skin reaction was find for hazel (78,3% in the first group vs. 97,1% in the second group) alder (82,6% vs. 97,1%). Patients included<br />
in the first group had positive skin reaction more often for grass and cereals (61% vs. 48,6%) and poplar (30,4% vs. 11,4%).<br />
Patients from the other group were characterized by a significantly higher percentage of positive skin tests with weeds. generally,<br />
skin prick tests with native allergens showed more positive skin reaction and a better agreement with clinical history than skin<br />
prick tests with commercial extracts.<br />
Conclusions: the skin prick tests with native allergens seems to be the method of verifying and supplementing other diagnostic<br />
tests in patients with food allergy.<br />
2211<br />
THE EFFECTiVEnESS oF THE mEaSUrEmEnT oF ToTal anD SPECiFiC igE in DiagnoSiS oF CroSS allErgY<br />
Bartuzi, Z. 1 and napiórkowska, K. 2<br />
1Department Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University,<br />
Bydgoszcz, Poland. 2Allergology, Clinical immunology and internal Diseases, Collegium medicum nicolaus Copernicus University,<br />
Bydgoszcz, Poland.<br />
Background: some patients with birch pollinosis frequently develop hypersensitive reactions to certain plant food (i.e. apples,<br />
celery and carrots). this phenomenon is caused by cross-reactivity between inhalant and food allergens. Exposure to inhalant<br />
allergens causes hypersensitivity to the other allergens. the aim of this study was to investigate the diagnostic value of<br />
measurement total and specific igE in diagnostic such kind of allergy.<br />
material and methods: Fifty eight patients at the age above 16 were included in the study. the clinical history and the positive<br />
result of the skin prick test with the birch extract were the condition for qualifications. Patients were divided into two groups.<br />
Patients included in the first group were birch allergic without any symptoms after eating food (23 persons). Patients in the other<br />
group had birch pollen allergy and they reported clinical symptoms after eating foods such as: apple, celery, carrot, tomato, banana,<br />
peach, peanut and hazelnut (35 persons). igE concentration (total and specific) were determined for all individuals.<br />
results: no difference in total igE levels was found between the two groups (271,5+/-403,8 iU/ml vs 242,5+/- 340,9 iU/ml).<br />
Patients with birch allergy and hypersensitivity to food allergens showed significantly higher birch pollen specific igE levels and it<br />
might be the predictive factor of developing cross allergy to distinct plant food which may develop later (11,8 +/- 14,1 iU/ml vs 4,1<br />
+/- 6,6 iU/ml). the measurement of total and specific igE was characterized by the lowest effectiveness in diagnostic of allergy in<br />
comparison with skin tests (with commercial and native extracts of allergens).<br />
Conclusions: the measurement of total and specific igE seems to be the valuable method of verifying and supplementing other<br />
diagnostic tests in patients with food allergy. igE may be an alternative in case of questionable or negative skin prick tests and<br />
when the sPt cannot be performed.<br />
www.worldallergy.org 128<br />
FinAl PrOgrAm
ABstrACts<br />
2212<br />
aSSESSing PoTEnTial DETErminanTS oF PoSiTiVE ProVoCaTion TESTS in SUBJECTS WiTH nSaiD HYPErSEnSiTiViTY<br />
Viola, m. , rumi, g. , Valluzzi, r. l. , gaeta, F. , Caruso, C. and romano, A.<br />
<strong>Allergy</strong> Unit, Complesso integrato Columbus, rome, italy.<br />
Background: Provocation tests (Pts) with the suspected compounds are considered the “gold standard” for establishing or<br />
excluding a diagnosis of hypersensitivity to nonsteroidal anti-inflammatory drugs (nsAiDs) [1]. However, only a few studies have<br />
evaluated the potential determinants of positive responses to Pts.<br />
the aims of this study are to asses the reliability of clinical histories as indicators of nsAiD hypersensitivity, as well as the risk<br />
factors for a positive Pt.<br />
methods: 275 subjects with an unequivocal history of nsAiD hypersensitivity reactions underwent Pts with the suspected drugs.<br />
to establish the potential determinants of positive Pts, we examined the following variables: gender, age at the time of reaction<br />
(12 months), and inclusion in a category of the stevenson et al. classification [2].<br />
results: 214 (77.8%) subjects tolerated the suspected drugs and 61 (22.2%) reacted. Age
ABstrACts<br />
ABstrACts<br />
2214<br />
EPiDEmiologiCal STUDY oF FooD allErgY in THE ToWn oF ConSTanTinE (algEria)<br />
Boughellout, H. and Zidoune, m. n.<br />
nutrition and Food tECHnOlOgY institute, UniVErsitY mEntOUri COnstAntinE, Constantine, Algeria.<br />
the epidemiological study of food allergy was performed by a questionnaire at three centers of maternal and child health care in<br />
the town of Constantine. it involved 770 children aged between 0-3 years.<br />
the study involved two different components: the first involves studying food allergy : symptomatology, age of onset of the<br />
disorder, confirmatory tests, atopic history of parents and type of feedings. the second part concerns the study of diet followed, the<br />
substitutes, tolerance to these products and the development of allergy.<br />
the prevalence of food allergy has reached a cumulative rate of 7.14%.<br />
the major allergen is cow’s milk 47.45% 11.86% followed by eggs and finally the olive oil and strawberries (8.47%). the allergic<br />
reaction has been in the cow’s milk, eggs and canned foods.<br />
the most noticed clinical manifestations are : skin symptoms 57.14%, 46.42% digestive and respiratory symptôms 25%. the rate<br />
of anaphylaxis is 14.28%.<br />
the family history represents a rate of 46.42%, mothers are more affected 28.57%.<br />
Food allergy (especially cow’s milk protein) usually appears during the first month of life 42.85% of cases, this rate reached 75%<br />
during the first 3 months.<br />
<strong>Allergy</strong> is a health problem, particularly in the absence of care centers for allergic children.<br />
2215<br />
anaPHYlaCTiC rEaCTion inDUCED BY HomEoToXiC DrUg<br />
naime, m. , sofia, m. and Elizabeth, P.<br />
Escuela De Ciencias De la salud, Universidad de oriente, Puerto la Cruz, Venezuela.<br />
Female patient, 57 years old, with nsAiDs allergy history, who after the homeopathic drug administration (reumatric®) presented:<br />
laryngeal stridor, generalized skin rash, severe respiratory distress which needed cardiopulmonary resuscitation, sphincter<br />
relaxation and loss of consciousness; she is moved by her family on 16/08/1910 to santa Ana medical center, the patient was<br />
admitted in poor general conditions, swollen, facial erythema, acrocyanosis and chest pain treated with sublingual isordil, with<br />
blood pressure: 159/89 mmHg, heart rate: 110 bpm, respiratory rate: 18 bpm, with paraclinical tests: Hb: 13,6 gr/dl, Wbc: 22400<br />
cells/μl, Het: 45%, lym: 55%, Plt: 182000, Pt and Ptt within normal limits, pH:7,44; PCo: 29,7; PO2: 150; HCO3: 20,5; satO2:<br />
99% (with O2 by mask to 6 l/min); fibrinogen: 291 mg/l; Urea: 47,6 mg/l; Creatinine: 1,23 mg/l; troponins: i: 0,06; t: 0,03. she was<br />
admitted to intensive care unit with this diagnosis: 1) anaphylactic shock, 2) hypersensitivity reaction, 3) ischemic cardiopathy.<br />
Advanced supportive measures were applied for 48 hours with satisfactory evolution. Paraclinical tests 18/08/10: Hb: 11,6 gr/dl,<br />
Wbc: 14100 cells/μl, Het: 81%, lym: 18%, Plt: 212000, Pt and Ptt within normal limits, Urea: 43,5 mg/l; Creatinine: 0,91 mg/l,<br />
glucose: 150,9 mg/dl, CK: 535 U/l; CKmB: 48 U/l; tgO: 79,6 U/l; tgP: 51,4 U/l; na: 131,5 mmol/l; K: 5,59 mmol/l; Cl: 106,2 mmol/l;<br />
troponins: i: 10,17; t: 0,40. she was under hospitalization for 3 days. 21/08/10 is discharged later to cardiology and immunology<br />
evaluation with this diagnosis: severe anaphylactic shock for homeotoxic drug (reumatric®), complicated with ischemic<br />
myocardial injury in recovery.<br />
2216<br />
anaPHYlaXiS aFTEr naSal ProVoCaTion TEST WiTH alTErnaria alTErnaTa EXTraCT<br />
gomez-garcia, C. 1 , sus-Carrizosa, s. 1 , Olivares, m. 1 , Chinchilla, C. 1 , ramirez, r. 1 , Cardona-Villa, r. 1 and restrepo, m. 2<br />
1 2 University of Antioquia - grupo de Alergología Clínica y Experimental (gACE), medellin, Colombia. Allergology, Universidad de<br />
Antioquia, medellín, Colombia.<br />
Background<br />
Alternaria alternata is an ascomycete mold. it is predominantly an outdoor allergen, even though it can be found indoor, mostly<br />
derived from outdoor sources. in sensitized individuals, exposure to Alternaria alternata can exacerbate respiratory (asthma, rhinitis)<br />
and cutaneous (atopic dermatitis) symptoms. For the diagnosis of allergic rhinitis, nasal provocation test (nPt) can be used in<br />
clinical practice, since it helps to determine a correct therapy. incidence of anaphylaxis after nPt is not known.<br />
Case report<br />
55 years old woman, retired school teacher, with moderate-severe persistent rhinitis since childhood. she had been receiving<br />
www.worldallergy.org 130<br />
FinAl PrOgrAm
ABstrACts<br />
regular treatment with beclometasone dipropionate and an antihistaminic, with some relief of her symptoms. Frequently she<br />
required antibiotics for the treatment of bacterial sinusitis. negative family history for atopy.<br />
method<br />
skin prick test to aeroallergens was positive only to Alternaria alternata (4 mm – positive control 7 mm). We decided to perform a<br />
nPt in order to demonstrate clinical relevance of this allergen.<br />
Alternaria alternata extract used in this nasal provocation was provided at a concentration of 30 HEP/ml. Vital signs, peak nasal<br />
inspiratory flow and peak expiratory flow were normal. Challenge was initiated with placebo (0.9% saline solution), and after 30<br />
minutes Alternaria dilution 1:1000 was delivered into each nostril with a spray bottle.<br />
results<br />
thirty minutes later after dilution 1:1000 had been delivered, the patient presented with severe naso-ocular symptoms and wheals<br />
in the neck. Although she had moderate dry cough, pulmonary auscultation and pulse oximetry were normal. Blood pressure, peak<br />
nasal inspiratory flow and peak expiratory flow were also within normal range. standard treatment was administered, and the<br />
patient was admitted for inpatient observation and treatment period. After 24 hours the patient was discharged asymptomatic.<br />
SYmPTomS BaSal<br />
30 min<br />
aFTEr 0,9%<br />
SS<br />
Pruritus 1 2 5<br />
rhinorrhea 1 1 6<br />
obstruction 1 1 5<br />
Sneezing 0 0 1<br />
ToTal 3 4 17<br />
30 min<br />
aFTEr<br />
1:1000<br />
DilUTion<br />
Table 1. nasal symptoms score test.<br />
Conclusion<br />
We present a patient with anaphylaxis due to Alternaria alternata extract during a nPt. Although blood pressure remained normal,<br />
both upper respiratory tract and skin were compromised. standard treatment was successful.<br />
2217<br />
PaTiEnT WiTH PEanUT allErgY WiTH nEgaTiVE CUTanEoUS anD in ViTro TESTS, ConFirmED BY oral ConTrollED<br />
FooD CHallEngE<br />
Diez, s. 1 , restrepo, m. 1 , sanchez, J. 1 and Cardona, r. 2<br />
1 2 Allergology, Universidad de Antioquia, medellín, Colombia. University of Antioquia, medellin, Colombia.<br />
Background: the peanut allergy and dry fruit allergy in general is not very frequent in our country and its prevalence is ignored,<br />
being this more important in developed countries as United states where an increment is reported in the last years (1). their<br />
manifestations generally debut in the childhood what differs of the case that will be presented next, where the symptoms began to<br />
the 50 years of age.<br />
objective: to present the case of a 58 years-old woman with history of two previous episodes of angioedema caused by peanut<br />
consumption with negative cutaneous and in vitro tests whose clinical condition was confirmed by means of a oral controlled food<br />
challenge with peanut and whose has like comorbidity aspirin allergy.<br />
method: For the patient’s diagnostic approach was conducted a skin prick test with food extracts that included the peanut extract,<br />
we also did a prick by prick test with peanut. specific igE for peanut was requested, and finally we carry out a controlled oral food<br />
challenge.<br />
For the study of the reactions to the nsAiD a nasal challenge with aspirin and an oral controlled challenge with meloxicam was<br />
carried out to offer the patient an anti-inflammatory option in the event of needing it.<br />
results: the skin prick test, prick by prick test with peanut and specific igE in vitro test for peanut allergy was all negative, the<br />
controlled oral food challenge with peanut caused an episode of urticaria and angioedema, with an accumulated dose of 9 grams<br />
of peanut. the controlled nasal aspirin challenge was positive and in the controlled drug challenge with meloxicam the patient<br />
tolerated a total dose of 15 mg of medication without presenting adverse reactions.<br />
Conclusion: the most interesting fact in this case is that although it has been described a sensibility and negative predictive values<br />
www.worldallergy.org 131<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
for peanut prick test over 95% (2) and a lower but not worthless diagnostic accuracy for in vitro test, we suggest that according<br />
with our patient, if there is a positive causal relationship in the medical interview a controlled oral food challenge must be carried<br />
out as the gold standard for food allergy diagnosis.<br />
references<br />
1. Scott H. Sicherer, mD,a anne muñoz-Furlong, Ba,c James H. godbold, PhD,b and Hugh a. Sampson, mDa . US<br />
prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up JaCi 2010; 125(6): 1322<br />
2. Saleh al-muhsen, ann E. Clarke, rhoda S. Kagan. Peanut allergy: an overview. CmaJ 2003; 168(10): 1529<br />
2218<br />
ECZEma inDUCED BY FooD allErgY: CoUlD iT mimiC an immUnE DEFiCiEnCY?<br />
Arshi, s. , nabavi, m. , Babaie, D. and ghalehbaghi, B.<br />
<strong>Allergy</strong> and Clinical immunology, hazrat-e rasool Hospital, iran University of medical sciences, tehran, iran.<br />
Absrtract: Food allergy occurs in 4–6% of young children, it is a major cause of life-threatening hypersensitivity reactions. A 19<br />
month girl was admitted to our hospital because of recurrent infections and ulcerative skin lesions on trunk, hands and legs<br />
predominantly on creases and diaper, which has been started since 2 month of age. she was born by nVD and went on formula<br />
after 2 month. she was febrile and ill. she was admitted for several times in Baku because of sever eczema and 2 episodes of<br />
infections and received iVig.On lab evaluations there were leukocytosis and neutrophilia. immunologic study (CD flowcytometery,<br />
immunoglubolones, phagocytosis, opsonozation, and chemotaxis ) was performed which was unremarkable. Although she received<br />
full doses of H1 and H2 blockers, suffered from sever pruritis. so the skin prick test wasn’t reliable . in history she drink a kind<br />
of herbal tea since 4 months of age and major foods of her diet were bread and potato. riDA test was performed and sever<br />
food allergy was detected. the child was hospitalized and went on appropriate treatment include restrict avoidance, hydration,<br />
moisturizing, local and systemic steroid, local and systemic antibiotic. After a few days of treatment his condition became so far<br />
better. this case report highlights the possible benefit exclusive breast feeding for infants under 6 months especially in atopic<br />
families. Considering the immunodeficiency syndromes in cases of sever eczema with infections is obviously necessary. Key words:<br />
food allergy, eczema,<br />
PoSTEr SESSion 2-3: Skin and other diseases<br />
2300<br />
ComParaTiVE EValUaTion oF EPiDEmiologiCal FaCTorS anD ComPliCaTionS oF CaTaraCT SUrgErY in DiaBETiC<br />
PaTiEnTS VErSUS non DiaBETiC PaTiEnTS<br />
fayyaz Jahani, sr., F. and sA.madani, A.<br />
medical, tonekabon Azad Univevercity of medical seinces, tonekabon, iran.<br />
introduction: in attention to prevalence of cataract as one of the most common disease in ophthalmology, also extraction with<br />
intraocular lens implantation as the most common surgery in ophthalmic surgery .this study was designed for comparison of<br />
epidemiologic factors and rupture of posterior capsule during surgery between diabetic and non diabetic patients.<br />
methods: the manner of this study was retrospective and information was prepared by extraction from the files of operated<br />
patients during of three years in tonekabon teaching hospital and information analyzed by sPss 11 software.<br />
results: from 199 patients that had been undergone cataract extraction and i.O.l implantation, 32 patients had diabetes (16/1℅)<br />
that 29 patients type 1 and 3 patients type 2 ,and 167 patients were non diabetic .factor of sexuality had not any role for producing<br />
of cataract in diabetic patients. tearing of posterior capsule during surgery was more common in diabetic patients versus non<br />
diabetic patients, and on the chi-square exam and Pierson coefficient equal to 0.000, meaningful relation was existed between<br />
diabetes and post capsular rupture .there was no meaningful relation between kind of sexuality and post capsular rupture.<br />
Conclusion: due to more chance of post capsular rupture in diabetic patients versus non diabetic patient .its better that cataract<br />
surgery in diabetic patients to be done with the best controls and equipments (vitrectomy machine).also prospective study for<br />
further evaluation of other complication of cataract surgery in diabetic patients to be proposed<br />
Key words : cataract ,posterior capsule rupture<br />
www.worldallergy.org 132<br />
FinAl PrOgrAm
ABstrACts<br />
2301<br />
EFFECT oF a SYnBioTiC miXTUrE on aToPiC DErmaTiTiS in CHilDrEn: a ranDomiZED-ConTrollED Trial<br />
Ahanchian, ii, H. 1 , Farid, r. 2 , Jabbari, F. 2 and moghiman, t. 2<br />
1 2 Pediatric <strong>Allergy</strong> and immunology, mashhad University of medical sciences, mashhad, iran. mashhad University of medical<br />
sciences, mashhad, iran.<br />
Background: Atopic dermatitis (AD) is the most common chronic relapsing skin disease seen in infancy and childhood. the<br />
intestinal microbiota plays an important role in immune development and may play a role in the development of allergic disorders.<br />
manipulation of the intestinal microbiota by synbiotics may therefore offer an approach to the prevention or treatment of allergic<br />
diseases.<br />
objective: We studied the clinical and immunologic effects of a new symbiotic(a mixture of seven probiotic strains of bacteria and<br />
Fructooligosaccharide) in infants and children with AD.<br />
method: in a randomized, double-blind, placebo-controlled study, 40 infants and children aged 3months to 6 years with AD<br />
received either a synbiotic or placebo for 8 weeks. the severity scoring of Atopic Dermatitis (sCOrAD) index was recorded at<br />
baseline and also at 4 and 8 weeks of treatment..<br />
results: the synbiotic group showed a significantly greater reduction in sCOrAD than did the placebo group (P= 0.001).no specific<br />
effect was demonstrated of the probiotics employed on cytokine profile.<br />
Conclusion: this study provides evidence that a mixture of seven strains of probiotics and Fructooligosaccharide can clinically<br />
improve the severity of AD in young children. Further studies are needed to investigate the effects on underlying immune responses<br />
and the potential long term benefits for patients with AD.<br />
Keywords: Atopic Dermatitis, synbiotic, Cytokine, Children<br />
2302<br />
EFFiCaCY oF omaliZUmaB monoTHEraPY in THE managEmEnT oF aToPiC DErmaTiTiS<br />
syrigou, E. 1 , sinaniotis, A. 1 , Paraskevopoulos, J. 2 and Psarros, P. 3<br />
1 2 Department of <strong>Allergy</strong>, “sotiria” general Hospital, Athens, greece. Department of <strong>Allergy</strong>, 401 Army Hospital, Athens, greece.<br />
3Department of <strong>Allergy</strong>, naval Hospital, Athens, greece.<br />
Background:Omalizumab is a unique biological therapeutic drug licensed for the treatment of atopic patients with moderate to<br />
severe persistent allergic asthma with a serum igE ranging from 30 to 700 iU/ml. this study was performed to examine the efficacy<br />
of omalizumab for the treatment of atopic dermatitis, a disease with significant morbidity.<br />
methods:We report the case of three young Caucasian men (16, 18 and 24 years old) who presented with chronic severe atopic<br />
dermatitis that only responded to oral corticosteroids. Failed treatments for these patients included topical corticosteroids,<br />
topical tacrolimus, oral prednisone, oral antibiotics and oral antihistamines. Only oral corticosteroids provided significant relief.<br />
All three patients had also moderate to severe persistent allergic asthma. All three patients had increased serum immunoglobulin<br />
E (igE) levels: 532 iU/ml, 11.860iU/ml and 13.340iU/ml respectively (reference range, 11-210 iU/ml). All three patients received<br />
omalizumab a humanized monoclonal anti-igE antibody currently indicated for patients 12 years and older with moderate to severe<br />
persistent asthma, administered suncutaneously, in a total dose of 450mg every 15 days. Atopic dermatitis severity was assessed<br />
at 0, 1, 3, 6 months with sCOrAD.<br />
results:All the three patients responded to a 12-week course of omalizumab, with significant improvement of their atopic<br />
dermatitis symptoms. no adverse events were reported throughout the course of treatment.<br />
Conclusion:We suggest that omalizumab may have a role in the treatment of atopic dermatitis in the adult population and further<br />
studies are needed to establish its therapeutic effect.<br />
2303<br />
EFFECTiVEnESS oF omaliZUmaB in THE TrEaTmEnT oF ColD UrTiCaria<br />
sinaniotis, A. 1 , Psarros, P. 2 , Paraskevopoulos, g. 3 and syrigou, E. 1<br />
1 2 Department of <strong>Allergy</strong>, “sotiria” general Hospital, Athens, greece. Department of <strong>Allergy</strong>, Athens naval Hospital, Athens, greece.<br />
3Department of <strong>Allergy</strong>, 401 Army Hospital, Athens, greece.<br />
Background: the effectiveness of the humanized monoclonal antibody omalizumab in the treatment of physical urticaria has been<br />
demonstrated by a number of small studies and case reports. in this case study we sought to assess the effects of omalizumab in<br />
www.worldallergy.org 133<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
patients with acquired cold urticaria (ACU), unresponsive to standard treatment with high doses of antihistamines, montelukast and/<br />
or corticosteroids.<br />
methods: Four patients with ACU (three males, one female, median age = 34 years) with a critical stimulation time threshold (Cstt)<br />
at 3 minutes. three out of the four cold urticaria patients had a history of systemic anaphylactic reactions after exposure to cold<br />
environment and episodes of urticaria-angioedema several times a week during the winter, spring and autumn.<br />
results: treatment with omalizumamb, resolved symptoms in three out four patients with cold urticaria (time to clinical response<br />
1.5 months). Only the patient with the lowest total igE (4.1 iU/ml) had a mild response to treatment, although the Csst became<br />
negative on the second month of treatment. Conclusion:treatment with omalizumab can be beneficial in selected patients with cold<br />
urticaria refractory to standard treatment with antihistamines and /or corticosteroids. Patients with low levels of total igE may not<br />
respond adequately to treatment with Omalizumab.<br />
2304<br />
THE aCTiVE Form oF D ViTamin, CalCiTriol 1,25(oH)2D3 anD naTUral PPrgamma agoniST, -3 PolYUnSaTUraTED<br />
FaTTY aCiDS (PUFaS) migHT SErVE aS a nEgaTiVE FEEDBaCK looP To PrEVEnT EXCESSiVE inFlammaTion in PaTiEnTS<br />
WiTH SEVErE aToPiC DErmaTiTiS<br />
Zaharov, t. 1 , Chaynava, A. 2 , Kamenov, B. A. 3 and Kamenov, s. 4<br />
1 2 3 Pediatrics, regional Hospital næstved, naestvad, Denmark. Pediatrics, regional Hospital næstved, naestved, Denmark. Pediatric<br />
Clinic, Clinical Centre of nis, nis, serbia and montenegro. 4Pediatric, Helth Centre of nis, nis, serbia and montenegro.<br />
the function of vitamin D is promoting cell differentiation, cell maturation and inhibiting (uncontrolled) cell proliferation. VDr is<br />
expressed by almost all immune cells, including activated CD4+ and CD8+ t cells, B cells, neutrophils, and APCs . 1,25(OH)2D<br />
inhibits th-1 type immune function in adult (memory) cells, induces t regulatory cells, and enhances phagocytosis by white blood<br />
cells. Vitamin D inhibits the activation of t cells, and promotes tolerance in dendritic cells.39,40 VDr has also been implicated in<br />
toll-like-receptor (tlr) signaling and regulation of the innate immune response in macrophages. Current evidence indicates that<br />
PUFAs can prevent the development of inflammatory diseases by affecting different steps of the immune response.<br />
Case reports:<br />
14 months old girl, known with severe atopic dermatitis, debuted at first days of life, had relapsed several staphylococci cutaneous<br />
infections, vasculitis like syndrome without positive verification of PCr/Antibody of Herpes family virus and was many times in<br />
treatment with per os and i.v. antibiotics. in the first 9 months of age exclusive breastfeedings, but due to event stimulation after<br />
mothers diet, stopped. started with diet restriction, only specific milk formula neocat, PUFAs , calcitriol and probiotics(lgg).<br />
results: 1) before immunomodulatory therapy, only with skin care and topical Cs, intermittent topical calcineurin inhibitors and<br />
pruritis control: very high igE over 5000, over 100 for cows milk, eggs and cross reaction almost of all, one that was normal was<br />
fish and shrimps igE, high Eo counts, 1.68, thrombocytosis and neu-peni. Calcitrol 204, normal levels of immunoglobulin’s, C1q<br />
concentration 77%, slightly below ref. intervals, reduced activity of complement via the mBl pathway and decreased concentration<br />
of B cells. 2) After: normalization of le and tr counts, especially nice response in Eo are decreasing to 0.53, reduction in igE level<br />
to 2500.EDtA blood for t, B and nK cell: normal proportions and concentrations of t and B / nK lymphocytes, nice response of<br />
virgin tcell, normal exposure of adhesions molecules, normal t cell proliferation by polyclonal stimulation, normal value of somatic<br />
mutation. there are no signs of maternal engraftment on the CD4/CD8 separated cells. there is not sign of stAt3 deficiency.<br />
Clinical benefit, much better without signs of acute infections and severe itching, almost normal skin without lesions, normal<br />
growth.<br />
2305<br />
mETHoTrEXaTE For UrTiCarial VaSCUliTiS anD angioEDEma WiTH CrYogloBUlinEmia<br />
Butt, A. , Alkhalil, m. , ledford, D. and lockey, r. F.<br />
Division of <strong>Allergy</strong> & immunology, University of south Florida and James A. Haley Veterans’ Hospital, tampa, Fl.<br />
Background: Cryoglobulinemia (Cg) is associated with a leukocytoclastic vasculitis primarily affecting the kidneys, skin and<br />
peripheral nerves. Urticaria, but not usually angioedema, is a potential presentation for Cg. Cryoglobulins are usually associated<br />
with infectious, autoimmune and lymphoproliferative disorders; therefore, treatment options are varied. We report a patient with<br />
corticosteroid (Cs)-dependent urticaria and angioedema (U/AE) who was able to discontinue Cs therapy following weekly oral<br />
methotrexate (mtX).<br />
results: 57-year- old Caucasian male presented with a seven month history of recurring symptoms of generalized urticaria and<br />
facial angioedema. the symmetrical rash initially developed after a dental procedure requiring penicillin therapy. the findings<br />
were attributed to penicillin, but persistence of the rash prompted a skin biopsy which demonstrated a leukocytoclastic vasculitis.<br />
Prednisone, 10 mg twice daily, resulted in minimal improvement of the rash, but arthritic pain in the hands and knees developed.<br />
An immunologic and rheumatologic evaluation showed type 3 mixed Cg without monoclonal protein, 2+ urinary protein, decreased<br />
www.worldallergy.org 134<br />
FinAl PrOgrAm
ABstrACts<br />
C3 (50 mg/dl; normal 90 – 180 mg/dl) and CH50 (13 U/ml; normal 31-66 U/ml). negative studies included serum rheumatoid<br />
factor, hepatitis antibodies, anti-nuclear antibody, anti-neutrophil cytoplasmic antibody and Ct scan of the abdomen.<br />
treatment with daily doxepin, 100 mg, meloxicam, 7.5 mg, hydroxycloroquine, 400 mg, and prednisone, 20 mg, was ineffective for<br />
the U/AE. Exacerbations occurred when the dose of prednisone was reduced. Oral mtX, 25 mg weekly, facilitated a prednisone<br />
taper, which was discontinued completely within 6 months without U/AE exacerbations. the cryoglobulin quantification remained<br />
unchanged.<br />
Conclusion: the differential diagnosis of U/AE includes a variety of less common immunologic conditions. the mechanism of<br />
action of weekly, oral mtX is not completely understood. suppression of cell replication is probably not the primary mechanism of<br />
action. Weekly mtX is a minimally immunosuppressive therapy that may be effective for U/AE associated with Cg. Evaluation for<br />
Cg should be considered in subjects with U/AE requiring chronic Cs therapy or with features of leukocytoclastic vasculitis.<br />
2306<br />
anTi-igE (omaliZUmaB) EFFECTiVE aS SinglE-DrUg THEraPY For CHroniC iDioPaTHiC UrTiCaria<br />
gonzález-Cervera, J. 1 , rodríguez-Domínguez, sr., B. 1 , Antolín-Amérigo, D. 2 , Henríquez-santana, A. 2 , ruiz Hornillos, F. 2 and<br />
manzano, D. 1<br />
1 2 <strong>Allergy</strong>, Hospital general de tomelloso, tomelloso, spain. <strong>Allergy</strong>, Hospital de Valdemoro (madrid), madrid, spain.<br />
objective: report a clinical case in which Anti-IgE (omalizumab) effectiveness and security are pointed out evidencing omalizumab<br />
as a suitable alternative medication for Chronic idiopathic urticaria in non-responders to recommended conventional therapy<br />
(Antihistamines and corticosteroids).<br />
methods and material: *Case report: A 35 year-old caucasian male suffering from generalized and extremely pruritic<br />
erythematous infiltrative hives during the previous 6 years on a daily basis together with facial angioedema fortnightly was referred<br />
to our <strong>Allergy</strong> Division. Daily Levocetirizine, Hydroxicine and Ranitidine were insufficient to relieve his cutaneous lesions, requiring<br />
systemic corticosteroids monthly resulting in lack of effectiveness. Cutaneous eruption and swelling is not clearly related either to<br />
food/drug intake or physical agents. Complementary tests: Blood cell count, Biochemistry, total igE and specific igE to Anisakis,<br />
milk, egg, peanut and haddock, antithyroid autoantibodies, HBV, HCV and HIV serology; Urine analysis, stool ova and parasites exam<br />
as well as thorax radiography were performed.<br />
results: Blood Cell Count and Biochemistry taken from peripheral blood sample were both within normal range. total igE was<br />
115,2 Ui/ml. specific igE to Anisakis Simplex, milk, egg,peanut and haddock was
ABstrACts<br />
ABstrACts<br />
antihistamines, antileukotriene and immunomodulators like cloroquine, azatioprine, colchicine and steroids, the cyclosporine was<br />
contraindicated by its malignant hypertension.<br />
therefore we decided to begin treatment with omalizumab at doses of 150 mg monthly (total igE 18 Ui/ml) associated to<br />
antihistamine and antileukotriene.<br />
result: After 3 doses of this therapy hives and angioedema remission was obtained and lasted for two months.<br />
Conclusion: the omalizumab can be an option in patients with vasculitic, pressure and autoimmune urticaria resistant to others<br />
management lines, being even safer than steroids and immunomodulators. the low levels of our patient’s total igE make to think<br />
that the effect of this medication is not only ig E dependent as has been suggested by several authors.<br />
2308<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE TrEaTmEnT oF HErEDiTarY angioEDEma<br />
(HaE) aTTaCKS<br />
Craig, t. J. 1 , Zuraw, B. 2 , lumry, W. 3 , Baker, J. 4 , levy, r. 5 , Hurewitz, D. 6 , White, m. 7 , riedl , m. 8 , Busse, P. 9 , Bielory, l. 10 , grant, J. A.<br />
11 12 13 13 13 13 , Kalfus, i. , Broom, C. , Villano, s. , Uknis, m. , tillotson, g. and the Cinryze study group<br />
1 2 3 Penn state University, Hershey, PA. the scripps research institute, la Jolla, CA. <strong>Allergy</strong> and Asthma specialists, Dallas, tX.<br />
4 5 6 University of michigan, Ann Arbor, mi. Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, gA. <strong>Allergy</strong> Clinic of tulsa, inc., tulsa, OK.<br />
7 8 9 institute for Asthma and <strong>Allergy</strong>, Wheaton, mD. UClA medical Center, los Angeles, CA. mount sinai school of medicine, new York,<br />
nY. 10UmDnJ - new Jersey medical school, newark, nJ. 11University texas medical Branch, galveston, tX. 12lev Pharmaceuticals,<br />
Plymouth meeting, PA. 13ViroPharma incorporated, Exton, PA.<br />
introduction: nf-C1 inH (Cinryze) is approved in the Us for routine prophylaxis against angioedema attacks in adolescent and adult<br />
patients with HAE. this study evaluated the efficacy and safety of repeat use of nf-C1 inH for the treatment of HAE attacks.<br />
methods: this open-label, multicenter (29 sites) study enrolled 113 subjects with a diagnosis of HAE. Approval was obtained<br />
from WirB and informed consent obtained from all subjects. subjects were eligible to receive nf-C1 inH 1000U iV for attacks of<br />
angioedema at any anatomic location. subjects could receive a second dose of nf-C1 inH 1000U if they had not improved by 60<br />
minutes. Documentation of attack occurred every 15 minutes by diary card. the presence of three consecutive assessments of<br />
improvement constituted relief. safety was monitored by recording AEs, vital signs, virology (HBV, HCV, HiV) and anti-C1 inhibitor<br />
antibody.<br />
results: Of the 113 subjects (aged 2-80 years) in this study, 101 received nf-C1 inH for an acute attack, and were included in the<br />
efficacy analysis. twelve received nf-C1 inH for short-term prophylaxis only. A total of 609 attacks in 101 subjects were treated.<br />
median time to beginning of relief of the first attack was 45 minutes. Of 84 laryngeal attacks, none required intubation after receipt<br />
of nf-C1 inH. no difference was observed in subject response between children and adults. in subjects treated for >1 attack the<br />
efficacy of nf-C1 inH was not reduced; of 15 subjects who had ≥ 10 attacks, the median time to beginning of relief of their 10th<br />
attack was 30 minutes. Adverse events were reported in 41% (46/113) of subjects. the majority (87%) were of mild or moderate<br />
intensity. the most common (3%-5% of subjects) were sinusitis, nasopharyngitis, streptococcal pharyngitis, HAE, constipation,<br />
cough, rash, and bronchitis. there were no severe hypersensitivity reactions, including anaphylaxis, related to nf-C1 inH. HBV, HCV,<br />
and HiV testing revealed no evidence of viral transmission. there was no evidence of development of clinically relevant anti-C1 inH<br />
antibodies.<br />
Conclusion: nf-C1 inH was safe and effective for the treatment of all HAE attacks. For subjects with >1 attack, the efficacy of nf-C1<br />
inH for the treatment of HAE did not diminish with subsequent repeated administration.<br />
2309<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) For THE ProPHYlaXiS oF HErEDiTarY<br />
angioEDEma (HaE) aTTaCKS<br />
Zuraw, B. 1 , Baker, J. 2 , Hurewitz, D. 3 , White, m. 4 , Vegh, A. 5 , Bielory, l. 6 , lumry, W. 7 , riedl , m. 8 , Davis-lorton , m. 9 , levy, r. 10 ,<br />
grant, J. A. 11 , Busse, P. 12 , Banerji, A. 13 , li, H. H. 14 , Kalfus, i. 15 , Broom, C. 16 , Villano, s. 16 , Uknis, m. 16 , tillotson, g. 16 and the Cinryze<br />
study group<br />
1 2 3 4 the scripps research institute, la Jolla, CA. University of michigan, Ann Arbor, mi. <strong>Allergy</strong> Clinic of tulsa, inc., tulsa, OK. institute<br />
for Asthma and <strong>Allergy</strong>, Wheaton, mD. 5Puget sound <strong>Allergy</strong> Asthma and imm., tacoma, WA. 6UmDnJ - new Jersey medical school,<br />
newark, nJ. 7<strong>Allergy</strong> and Asthma specialists, Dallas, tX. 8UClA medical Center, los Angeles, CA. 9Winthrop - University Hospital,<br />
mineola, nY. 10Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, gA. 11University texas medical Branch, galveston, tX. 12mount sinai<br />
school of medicine, new York, nY. 13massachusetts general Hospital, Boston, mA. 14institute for Asthma & <strong>Allergy</strong>, Chevy Chase, mD.<br />
15 16 lev Pharmaceuticals, Plymouth meeting, PA. ViroPharma incorporated, Exton, PA.<br />
www.worldallergy.org 136<br />
FinAl PrOgrAm
ABstrACts<br />
introduction : HAE is a genetic disease characterized by recurrent, painful and potentially life-threatening swelling episodes. this<br />
study evaluated the safety and efficacy of nf-C1 inH for routine prophylaxis of HAE attacks.<br />
methods: this open-label, multicenter study (47 sites) enrolled 146 subjects aged ≥1 year with HAE and ≥1 attack per month or<br />
history of laryngeal edema. Approval was obtained from WirB and informed consent obtained from all subjects. nf-C1 inH was<br />
administered prophylactically at 1000 U iV every 3 to 7 days. subjects were also eligible to receive treatment with nf-C1 inH for<br />
acute attacks. subjects were instructed to document all attacks on a daily basis. safety was monitored through the recording of<br />
AEs, vital signs, virology and anti-C1 inH antibody assessments.<br />
results: mean age was 37 years (range 3-82). Pre-enrollment, subjects had a median HAE attack rate of 3.0 per month (range:<br />
0.08-28.0). On nf-C1 inH prophylaxis, the median number of HAE attacks per month was 0.2 (range: 0 4.6) and 86% experienced<br />
an average of ≤1 attack per month; 35% reported no attacks during the study. Exposure to nf-C1 inH varied (range: 8 to 959 days),<br />
73% received nf-C1 inH over a period of at least 6 months. For subjects receiving therapy for at least one year, the median attack<br />
rate was consistently low at 0.3 per month (range 0-4.0). irrespective of age, laboratory analysis demonstrated persistent rise in<br />
C1 inH antigenic and functional levels following nf-C1 inH therapy. Of 74 subjects tested, there were no detectable anti-C1 inH<br />
antibodies following C1 inH administration. Adverse events most frequently reported related to nf-C1 inH were: headache 5.5%,<br />
nausea 4.1%, rash 2.7%, erythema 2.1% and diarrhea 2.1%. the most commonly reported sAE was HAE attack (11.6%). Five<br />
subjects experienced thrombotic sAEs: mi, DVt, PE, and 2 CVA; none of these was considered to be related to nf-C1 inH. there were<br />
no severe hypersensitivity reactions related to nf-C1 inH. there was no evidence of transmission of HBV, HCV, or HiV during this<br />
study.<br />
Conclusions: Administration of nf-C1 inH reduced the median monthly HAE attack rate. the distribution of monthly attack rates<br />
per subject over a 1-year period showed persistent effects of prophylactic nf-C1 inH. these data support the safety and efficacy of<br />
nf-C1 inH for routine prophylaxis of HAE attacks.<br />
2310<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1inH) For TrEaTmEnT oF aCUTE aTTaCKS oF<br />
HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS<br />
Craig, t. J. 1 , lumry, W. 2 , Baker, J. 3 , Davis-lorton , m. 4 , manning , m. 5 , Kalfus, i. 6 , Broom, C. 7 , Villano, s. 7 , Uknis, m. 7 , tillotson, g. 7<br />
and the Cinryze study group<br />
1 2 3 4 Penn state University, Hershey, PA. <strong>Allergy</strong> and Asthma specialists, Dallas, tX. University of michigan, Ann Arbor, mi. Winthrop -<br />
University Hospital, mineola, nY. 5<strong>Allergy</strong> and immunology Associates, scottsdale, AZ. 6lev Pharmaceuticals, Plymouth meeting, PA.<br />
7ViroPharma incorporated, Exton, PA.<br />
introduction: HAE is an autosomal dominant disease of deficient functional C1 inhibitor (nf-C1 inH) manifested by attacks of<br />
angioedema commonly involving the gastrointestinal lining, extremities, face, larynx, and genitalia. HAE typically begins in childhood<br />
and worsens around puberty. Children have smaller airways complicating intubation during laryngeal attacks and are likely to suffer<br />
from upper respiratory infections which can trigger attacks, emphasizing the importance of appropriate treatment options for this<br />
age group.<br />
methods: Overall, this open-label, multicenter study evaluated subjects aged ≥1 year with a diagnosis of HAE; this subset analysis<br />
presents data on subjects aged
ABstrACts<br />
ABstrACts<br />
2311<br />
oPEn-laBEl USE oF nanoFilTErED C1 ESTEraSE inHiBiTor (HUman) (nF-C1 inH) For THE ProPHYlaXiS oF aTTaCKS oF<br />
HErEDiTarY angioEDEma (HaE) in PEDiaTriC SUBJECTS<br />
Hurewitz, D. 1 , grant, J. A. 2 , Busse, P. 3 , Davis-lorton , m. 4 , Baker, J. 5 , riedl , m. 6 , Banerji, A. 7 , levy, r. 8 , Craig, t. J. 9 , Kalfus, i. 10 ,<br />
Broom, C. 11 , Villano, s. 11 , Uknis, m. 11 , tillotson, g. 11 and the Cinryze study group<br />
1 2 3 <strong>Allergy</strong> Clinic of tulsa, inc., tulsa, OK. University texas medical Branch, galveston, tX. mount sinai school of medicine, new York,<br />
nY. 4Winthrop - University Hospital, mineola, nY. 5University of michigan, Ann Arbor, mi. 6UClA medical Center, los Angeles, CA.<br />
7 8 9 massachusetts general Hospital, Boston, mA. Family <strong>Allergy</strong> and Asthma Center, PC, Atlanta, gA. Penn state University, Hershey,<br />
PA. 10lev Pharmaceuticals, Plymouth meeting, PA. 11ViroPharma incorporated, Exton, PA.<br />
introduction: HAE is an autosomal dominant disease of deficient functional C1 inhibitor (nf-C1 inH) manifested by attacks of<br />
angioedema commonly involving the gastrointestinal lining, extremities, face, larynx, and genitalia. symptoms of HAE typically begin<br />
in childhood and worsen around puberty. stanozolol is FDA approved for pediatric prophylaxis but has undesirable AEs, such as<br />
masculinization, premature puberty, and premature epiphyseal plate closure. this subset analysis evaluates the use of nf-C1 inH for<br />
routine prophylaxis in pediatric subjects with HAE
ABstrACts<br />
PoSTEr SESSion 3-1: immune mechanisms of allergy<br />
3100<br />
an UnUSUal PrESEnTaTion oF PUlmonarY maSS liKE lESionS SEConDarY To an allErgiC CaUSE<br />
rafique, m. and mahboub, B.<br />
Department of Pulmonary medicine, rashid Hospital, <strong>Dubai</strong>, United Arab Emirates.<br />
Background:31yr old male referred for evaluation of pulmonary masses presents with symptoms of cough with expectoration<br />
for 3yrs,intermittent dyspnoea & hemoptysis.H/o use of frequent antibiotics.loss of appetite& weight present methodsCXr show<br />
perihilar & central pulmonary masses.Ct sugg of large nodular bilateral opacities in upper lobes,middle lobe,lingula close<br />
to hilum,few small nodules in both lower lobes with no adenopathy. Bronchoscopy (FOB) showed features of dilatation of rt<br />
Upper lobe,middle lobe bronchi with extrusion of impacted mucus balls sugg of Bronchiectasis with inspissated mucus with no<br />
endobronchial growth resultsBroncho alveolar lavage & washings grew pseudomonas & aspergillus fumigatus,negative for<br />
malignancy and negativeAFB smear & cultures,total igE70 iU/ml,Absolute eosinophil count 200,mantoux negative,allergy skin<br />
tests positive for A.fumigatus,High A.fumigatus Ab 2560,specific igE m3asp39,50 Kua/l.Pulmonary function showed moderate<br />
obstruction with significant reversibility sugg of asthma. treated with levofloxacin 2wk, Oral steroids 0.5mg/kg 2mth with tapering<br />
doses.Formeterol & Budesonide inhaler 160mcg 2puffs BD with Chest physiotherapy .His CXr& Ctscan showed complete clearance<br />
of pulmonary nodular masses in 2mths timeConclusion An Unsual presentation of Allergic Bronchopulmonary aspergillosis ABPA,<br />
which mimic tumour like opacities due to mucus plugging ,revealing underlying central bronchiectasis after clearance of mucus<br />
balls with background of undiagnosed asthma reference Allergic bronchopulmonary aspergillosis.Patterson strekmE Dept of<br />
medicine, section of Pulmonary and Critical Care medicine, the University of Chicago, Chicago, il 60637, UsA: 2010 may;7(3):237-<br />
44 Proc American thoracic society<br />
3101<br />
ForgoTTEn ParaSiTES in allErgY PraCTiCE<br />
Kumar, P.<br />
medicine, louisiana state University Health sciences Center, new Orleans, lA.<br />
BaCKgroUnD<br />
in UsA and other western countries, parasitic infestations are often overlooked as a cause of allergic diseases. in order to heighten<br />
awareness, the following three patients are being presented.<br />
PaTiEnTS mETHoDS & rESUlTS<br />
Case i: 26 year old female presented with two year history of generalized urticaria and periorbital angioedema. travel history<br />
included trip to india 6 months prior to onset of symptoms. she had elevated eosinophil count (518/mm3), elevated total igE<br />
(1376 K U/l). specific igE antibodies to ascaris were elevated at 9.29 K U/l (normal
ABstrACts<br />
ABstrACts<br />
3102<br />
CHaraCTEriSTiCS oF rHinoVirUS-inDUCED PBmC immUnE rESPonSES in aSTHmaTiCS, From inFanCY To aDUlTHooD<br />
Katsuhito, i. 1 , Katsunuma, t. 1 , saito, H. 2 and matsumoto, K. 2<br />
1 2 Pediatrics, Jikei University, school of medicine, tokyo, Japan. laboratory for allergy, Department of <strong>Allergy</strong> and immunology,<br />
national research institute for Child Health and Development, tokyo, Japan, tokyo, Japan.<br />
Background: Asthmatic patients have higher susceptibility to rhinovirus (rV) infection, the most common trigger of asthma<br />
exacerbations in children and adults. impaired iFn-alpha and lambda production in bronchial epithelial cells from asthmatic adults<br />
upon exposure to rV has been demonstrated in vitro. However, the mechanisms underlying the increased susceptibility to rV<br />
infection in asthmatic patients are not fully understood. the aim of the present study was to investigate the characteristics of the<br />
immune responses of peripheral blood mononuclear cells (PBmCs) from asthmatic patients to rV stimulation.<br />
methods: PBmCs obtained from three different age groups (1-6y: young children group; 7-19y: youth group; 20-y: adult group)<br />
of asthmatic patients and non-asthmatic control subjects were stimulated with rV14 for 72 h. Healthy adults with a history of<br />
childhood asthma were also enrolled. the concentrations of iFn-alpha, il-6, tnF-alpha, il-10 and soluble Fas ligand (sFasl) in the<br />
supernatant were measured by ElisA.<br />
results: When compared with age-matched control subjects, the level of iFn-alpha protein was significantly lower in the asthmatic<br />
youth group. the levels of il-6, tnF-alpha, il-10 and sFAsl proteins were significantly lower in both the asthmatic youth and adult<br />
groups. such impaired responses were not found in healthy adults with a history of childhood asthma. no significantly different<br />
responses were found between the asthmatic and control young children groups, whereas young asthmatic children with persistent<br />
wheeze after 2 years of follow-up showed significantly lower il-10 production than those without persistent wheeze.<br />
Conclusions: impaired production of both anti-viral and inflammatory cytokines by PBmCs upon rV stimulation may be involved in<br />
the higher susceptibility to rV infection that is seen in asthmatic patients. in addition, such immune responses–especially regulatory<br />
cytokine production–may play important roles in the development or disappearance of persistent wheeze in children with asthma.<br />
3103<br />
CUrCUmin maY inHiBiTS T CEll aCTiVaTion THroUgH STorE-oPEraTED Ca2+ EnTrY CHannElS anD K+ CHannElS<br />
Kim, W. K. 1 and nam, J. H. 2<br />
1 2 Asthma & <strong>Allergy</strong>, Dongguk University ilsan Hospital, goyang, south Korea. Physiology, Dongguk University collage of medicine,<br />
Kyung Ju, south Korea.<br />
Ca2+ -release activated Ca2+ channel (CrAC)-mediated increase in cytoplasmic Ca2+ concentration (D[Ca2+ ] ) is a critical early step of<br />
c<br />
signals for the activation of lymphocytes. Also, the voltage-gated K + channel (K ) and intermediate-conductance Ca v 2+ -activated K +<br />
channel (iKCa1/sK4) draw attention as pharmacological targets for regulating immune responses. since polyphenolic agents have<br />
various ranges of anti-inflammatory or immunomodulatory effects, here we compared the effects of curcumin, rosmarinic acid,<br />
resveratrol and epigallocatechin gallate on the ionic currents through CrAC (i ), Kv (i ), sK4 (i ), and on the D[Ca CrAC Kv sK4 2+ ] in Jurkat-t<br />
c<br />
cells, using fura-2 spectrofluorimetry and patch clamp technique. Curcumin (10 mm) inhibited both anti-CD3 Ab-induced D[Ca2+ ]<br />
c and thapsigargin-induced store-operated Ca2+ entry (sOCE) via CrAC. Ferulic acid and vanillin, the metabolites of curcumin,<br />
had no effect on sOCE. Dose-dependent inhibition of i by curcumin was confirmed in Jurkat t (iC , 5.9 mm) and the HEK-293<br />
CrAC 50<br />
cells overexpressing Orai1 and stim1 (iC , 0.6 mm). Also, curcumin potently inhibited both i (iC , 11.9 mm) and i (iC , 4.2<br />
50 Kv 50 sK4 50<br />
mm). the other polyphenols (rosmarinic acid, resveratrol and epigallocatechin gallate at 10 – 30 mm) had no effect on sOCE, and<br />
showed only a partial inhibition of the K + currents. in summary, among the tested polyphenolic agents, curcumin showed prominent<br />
inhibition of major ion channels in lymphocytes, which might contribute to the anti-inflammatory effects of curcumin when<br />
sufficient concentration is reached in vivo.<br />
3104<br />
nano-SiZED WElDing FUmE inCrEaSES inFlammaTorY CYToKinES, aPoPToSiS anD g2 arrEST in HUman T CEll linE<br />
Chiung, Y. m. 1 , liu, P. s. 2 , Chen, Y. Y. 2 , lin, J. B. 1 and tsai, C. J. 3<br />
1 2 Division of medicine, institute of Occupational safety & Health, taipei County, taiwan. Department of microbiology, soochow<br />
University, taipei, taiwan. 3institute of Environmental Engineering, national Chiao tung University, Hsinchu.<br />
the impact on inflammatory cytokine Production, apoptosis and g /g phases of human t lymphocyte induced by welding fume<br />
1 2<br />
was investigated to discuss the effects of different ranges of particle size. the on-site dusts were collected by micro orifice uniform<br />
deposition impactor (mOUDi). Human t cell line, Jurkat cell were treated by different sized dust particles which were classified to<br />
ten ranges of 8hr collected welding fumes under Pm , prepared as 0.2 % buffered solutions, respectively. inflammatory cytokine<br />
10<br />
il-6 and tnF-a production were measured at 24 hours by ElisA, and found both of the two were much higher by the particles<br />
www.worldallergy.org 140<br />
FinAl PrOgrAm
ABstrACts<br />
smaller than 100 nm. Cell cycle and apoptosis were performed by flow cytometry. After 72hrs treatment, the viability decreased<br />
slightly related with the increasing ranges of size of the metal fume particles, counted by trypan Blue stain and Propidium iodide<br />
(Pi) uptake, and apoptosis was estimated by cytosolic caspase 3 activation. the rates of apoptosis in each treatment were about<br />
7~12% of the control. the increase rate of caspase 3, is according to the order of particle size reduction. Different size of welding<br />
fume particles also affect sub g cell cycle from 1~9 %, and 23~26% of g /m stage of the total cells. With the reduction of particle<br />
1 2<br />
size, we observed a decrease tendency of sub g1 phase and an increase tendency of g /m phase in total cell percentages.<br />
2<br />
We conclude nano-sized particles in metal fume increases the production of inflammatory cytokines of t cell in a short term<br />
treatment, and makes cells arrested at g /m phase and increases cell apoptosis in a long term exposure. statistical results support<br />
2<br />
the ultra-fine and nano-scale particles in welding fume cause larger effects on inflammatory cytokine production, Caspase 3 and<br />
g /m arrest (r = -0.425, P= 0.019). some metals, such as manganese, Copper (Cu) and nickel were analyzed by Atomic Absorption,<br />
2<br />
only the concentrations of smaller sized Cu particles exhibited significant correlation with Pi (r=-0.20, P=0.04). the mechanisms<br />
induce production of cytokines; apoptosis and g2 arrest with nano-sized welding fume remain to be clarified in future.<br />
3105<br />
THE EFFiCaCY oF a naSal anTiHiSTaminE oloPaTaDinE For THE TrEaTmEnT oF SEroUS oTiTiS mEDia in CHilDrEn<br />
nsouli, s.<br />
Asthma and <strong>Allergy</strong>, DAnVillE AstHmA AnD AllErgY CliniC, DAnVillE, CAliFOrniA, UsA, Danville, CA.<br />
Previously we have shown that the combination of a nasal Corticosteroid mometasone with an oral antibiotic may be more<br />
efficacious than monotherapy with an oral antibiotic in the treatment of serous otitis media in children.<br />
since chronic inflammation is the histopathologic landmark of otitis media with effusion, clinical observations have led us to believe<br />
that the combination of a nasal Antihistamine Olopatadine with an oral antibiotic may be more effective than monotherapy with an<br />
oral antibiotic in the treatment of serous otitis media.<br />
We studied forty pediatric patients (age 6 years to 11 years) in a randomized open labeled 2-week trial to compare the efficacy of<br />
the combination nasal Olopatadine 665 mcg/nostril twice daily with an oral antibiotic Amoxicillin/Clavulanate potassium (90mg/kg/<br />
day in 2 divided doses every 12 house) for the treatment of otitis media with effusion<br />
the efficacy of the treatment options was assessed using pneumatic otoscopy, impedance tympanometry, and audiometry to<br />
monitor the clinical course of the middle ear effusion in both treatment groups.<br />
in the combination group nasal Olopatadine and oral antibiotic a resolution of otitis media with effusion occurred at the 7th day. in<br />
contrast in the group treated with monotherapy with the oral antibiotic the resolution of otitis media with effusion occurred on the<br />
14th day.<br />
in conclusion, the combination of nasal antihistamine Olopatadine plus an oral antibiotic is more effective than monotherapy with an<br />
oral antibiotic. the combination nasal antihistamine Olopatadine plus an oral antibiotic may be a safer and shorter therapy given the<br />
safety issues with long term use of system antibiotics.<br />
3106<br />
ComBinaTion oF a naSal anTiHiSTaminE oloPaTaDinE anD a naSal CorTiCoSTEroiD, momETaSonE For THE<br />
TrEaTmEnT oF SEaSonal allErgiC rHiniTiS PaTiEnTS noT CUrrEnTlY ConTrollED on monoTHEraPY inTranaSal<br />
anTiHiSTaminE or inTranaSal CorTiCoSTEroiD<br />
nsouli, s.<br />
Asthma and <strong>Allergy</strong>, DAnVillE AstHmA AnD AllErgY CliniC, CAliFOrniA, UsA, Danville, CA.<br />
For seasonal Allergic rhinitis (sAr) patients that remain symptomatic on an intranasal antihistamine, Olopatadine or intranasal<br />
corticosteroid, mometasone furoate, the combination of intranasal antihistamine, Olopatadine with an intranasal cortiscosteroid<br />
mometasone may provide additional efficacy in sub-optimally controlled seasonal Allergic rhinitis Patients.<br />
in this open labeled 8-week trial 40 patients with symptomatic sAr currently using Olopatadine 1330 mgc/nostril BiD or<br />
mometasone furoate, 100 mcg/nostril QD were randomized to receive the combination Olopatadine 1330 mcg/nostril BiD +<br />
mometasone, 100 mcg/nostril QD. the end points of the trial include: rhinomanometry, nasal symptom score (composite score of<br />
nasal congestion, rhinorrhea, sneezing post nasal drip and itching) and flexible rhinopharyngolaryngoscopy examination.<br />
mean efficacy measurements at the end of the 8-week trial revealed significant improvements in all parameters examined in the<br />
combination treatment group as compared to baseline measurements.<br />
in conclusion, the combination nasal Olopatadine plus nasal mometasone is more effective than monothereapy nasal Olopatadine<br />
or nasal mometasone. it appears that in the combination treatment Olopatadine and mometasone, the primary end points<br />
(rhinomanometry and symptom scores) are significantly improved.<br />
www.worldallergy.org 141<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
3107<br />
EXPErimEnTallY UnraVEling THE aToPiC marCH<br />
Wilson, m. s.<br />
molecular immunology, nimr, mrC, london, United Kingdom.<br />
Experimentally Unraveling the atopic march.<br />
mark s. Wilson. molecular immunology Division. national instiutes for medical research, mrC. mill Hill. london. UK.<br />
the sequential progression of allergic symptoms from atopic eczema, food allergy, rhinitis and asthma have been widely reported<br />
and referred to as ‘the Atopic march’. Co-morbidities of allergic conditions and the over-dispersed distribution of allergic diseases<br />
within few individuals have also been identified. these data suggest that allergic diseases may be linked; however the relationships<br />
between allergic symptoms are unclear. to separate cause from consequence, we are investigating the immunological interactions<br />
between these disease phenotypes and have developed experimental models of allergic asthma, allergic rhinitis and food allergy.<br />
these models are used to ask whether food allergy, and/or upper airway rhinitis influence the development of lower airway<br />
asthma. mice sensitized and orally challenged with crude peanut antigen (CPA) are subsequently sensitized and challenged, in the<br />
lower airways, with house dust mite (HDm). A cohort of peanut-allergic mice will also be sensitized and challenged in the upper<br />
airways with ragweed (rW) prior to lower airway HDm challenge. We hypothesize that peanut allergy and rW-induced rhinitis will<br />
exacerbate HDm-sensitization (igE) and HDm-induced airway inflammation. the molecular mechanisms of such interactions will<br />
be investigated and tested. Our studies and latest observations will be presented. This work is supported by the Medical Research<br />
Council (MRC), UK.<br />
3108<br />
a noVEl rolE For THE ComPlEmEnT rEgUlaTor CD46 in EPiTHElial TigHT JUnCTion FormaTion/rEgUlaTion<br />
Al-shouli, s. t. 1 and Kemper, C. 2<br />
1 2 Clinical immunology and <strong>Allergy</strong>., King’s College london guy’s and s’t thomas’ Hospital, london, United Kingdom. mrC Centre for<br />
transplantation, london, United Kingdom.<br />
Background: the complement regulator CD46 has been shown to play a role in epithelial cell polarization and is overexpressed on<br />
epithelial tumor cells. it is clear that our understanding of the many functions of the complement system in health is growing but<br />
still not complete. it is therefore to be expected that complement will be connected in the future with additional human diseases.<br />
this research project focuses on just such a prediction: We have obtained data suggesting a novel role for CD46 in epithelial cell<br />
tight junction regulation and growth induction or restriction. these data suggest that complement may also play a previously<br />
unacknowledged role in another important human disease, colon cancer. Colon cancer is the third most common cancer in the<br />
UK with a poor prognosis because of a high mortality and recurrence rate, thus, there is a need to develop better treatments.<br />
methods: 1-Culture PtECs or Caco-2 cells for several days on 24 wells-plates to measure E-cadherin expression, CD46 expression,<br />
Cell-proliferation assessed and apoptosis induced in cells. 2- Culture the human kidney proximal tubular epithelial cells (PtECs)<br />
or the human intestinal cell line (Caco-2) for several days on transwells to measure transepithelial resistance (tEr) and Beads<br />
dextran. results: we found that CD46 interacts with E-cadherin and sPAK, both vital proteins in the maintenance of epithelial cell<br />
layer integrity. mutations in either protein cause colon cancer or iBD, respectively. Further, we observed that CD46 regulates tight<br />
junctions and by this transepithelial resistance and paracellular permeability. Based on these data we hypothesize that complement/<br />
CD46 communicates with the E-cadherin/catenin network in epithelial cells (via interaction/activation of sPAK) and contributes to<br />
normal epithelial cell barrier integrity. Further, defects in CD46-mediated signals leading to disturbance in its crosstalk with the<br />
E-cadherin/catenin network may be a factor in malignant transformation. Conclusion: our study was conducted to ascertain the<br />
biological properties of CD46 in a cell-cell adhesion network. We believe that this study helped to further solidify this idea and set<br />
the ground for more detailed future studies.<br />
3109<br />
THE rolE oF EXTErnal PHYSiCal ForCES in TriggEring THE allErgiC rEaCTionS<br />
Athota, r. r. 1 , reddy, r. r. K. 2 , neerupudi, K. B. 1 and sam, r. A. 3<br />
1 2 3 Biochemsitry, Andhra University, Visakhapatnam, india. Department of Physics, s K University, Anantapur, india. internal medicine,<br />
Christian medical College, Vellore, india.<br />
Background: in the era of scientific advancements, the allergic population is increasing at an alarming rate in modern urban<br />
society. in this context, the influence of the external forces like humidity and other physical forces in triggering the allergic<br />
symptoms is investigated.<br />
methods: the humidity has been measured in two cities namely Visakhapatnam, a coastal city and Anantapur, a non-coastal<br />
www.worldallergy.org 142<br />
FinAl PrOgrAm
ABstrACts<br />
and dry weather city of Andhra Pradesh state in india, and the number of allergic population has been determined basing on the<br />
appearance of allergic symptoms, and measuring the absolute esinophil count, peak expiratory flow rate and estimation of igE<br />
antibody.<br />
results: Visakhapatnam city with ~70% humidity is found to trigger about 30% migrants to develop allergic symptoms to that of<br />
Anantapur city with ~40% humidity to 10% migrants to be allergic. Physical forces/non-immunogenic agents like rainy season,<br />
onslaught of monsoon, dampness, odors, exposure to sun light at certain angles or direct exposure to air conditioned breeze could<br />
trigger the spontaneous allergic rhinitis/asthma. Furthermore, a small variation in humidity from room to room in the same building<br />
can trigger allergic reactions in susceptible individuals. these allergic symptoms can be prevented by regulating the fan speed, or<br />
air-conditioned breeze. And also, it is observed that allergic symptoms appear more frequently in indoors rather than in outdoors,<br />
this is due to humidity, soiled robes, the other agents like house dust mite, unhygienic conditions or combination of other facts.<br />
Conclusion: there are certain kinds of physical agents which can induce allergic symptoms and also certain perfumes can relieve<br />
off existing asthmatic symptoms.<br />
3110<br />
THE STaTiSTiCS TaKE iT all: ComParaTiVE analYSiS oF THE gEnomiC BaCKgroUnD oF CHilDHooD aSTHma in<br />
CaUCaSian PoPUlaTion<br />
Hadadi, E. 1 , Ungvari, i. 1 , Virag, V. 1 , nemeth, Z. 2 , Hullam, g. 3 , Antal, P. 3 , Falus, A. 1 and szalai, C. 1<br />
1 2 3 genetics, Cell and immunbiology, semmelweis University, Budapest, Hungary. Csertex Kft, Budapest, Hungary. Department of<br />
measurement and information systems, Budapest University of technology and Economics, Budapest, Hungary.<br />
Asthma is a complex pulmonary disease with genetic and environmental components.<br />
Our purpose with this work was to identify new genes and snPs implicated in pathomechanism of asthma.<br />
in this study we selected candidate genes described in the literature and from our previously completed whole genome gene<br />
expression microarray analysis of OVA induced mouse model of asthma. For further analysis we selected 308 genes. For the<br />
selection of snPs, we created a new web-based data-mining and data-analyzing platform with the integration of public datastores.<br />
the program performs model-based analysis on results of text and data mining processes, previous measurements and<br />
Bayesian statistical analyses. Out of the 2643 snPs in these genes 399 snPs were chosen and used for panel design. We designed<br />
four 48plex panels with Autoprimer software and the determination of snPs was carried out with single base extension assays<br />
(genomelab snPstream, Beckman Coulter).<br />
genotyping was performed in 349 asthmatic children and 461 controls. statistical analysis was carried out by conventional<br />
frequentist analysis (chi-square test and logistic regression) and a new method developed by our team for the Bayesian analysis<br />
of relevant variables based on Bayesian model averaging (using markov Chain monte Carlo methods) and complex properties of<br />
Bayesian networks such as markov Blanket sets and markov Blanket graphs. the developed methodology of “Bayesian, four-level,<br />
sequential analysis of relevance” is capable of incorporating diverse priors to facilitate knowledge-rich data analysis, effecting more<br />
reliable results on multidimensional genomic studies.<br />
According to conventional analyses (logistic regression and c2 test) 36 snPs appeared to be associated with asthma in Hungarian<br />
population while by Bayesian multilevel analysis (BmlA) only 16 snPs came to the front and from these 8 showed association<br />
with asthma. According to our understanding a multifactorial genetic background can be revealed only by complex and aggregate<br />
method which can filter out essential and cardinal elements and alleviate the ‘noise’ /statistical faults. in our further studies we<br />
would like to test and confirm this conception.<br />
3111<br />
PrEValanCE oF HUman-mETaPnUEmoVirUS inFECTion in WHEEZY aDmiTTED CHilDrEn<br />
Alyasin, Jr., s. 1 and moatari, A. 2<br />
1 2 Pediatric, shiraz University of medical science, shiraz, iran. influenza research Center, shiraz University of medical science,<br />
shiraz, iran.<br />
introduction: Viral infections such as para- influenza, influenza and respiratory syncitial virus (rsV) contribute to the most of<br />
respiratory infections in children less than 5 year-old, yet causes for some 15-35% of children respiratory infections remained to be<br />
unknown. in recent years newly discovered human-metapnuemovirus (hmPV) showed to be one of the major causes for upper as<br />
well as lower respiratory tract infections especially in children. this virus also showed to be one of contributors in infants asthma<br />
exacerbation.<br />
method: in the present study, in one year, we examined 120 nasopharyngeal swaps from hospitalized children affected by<br />
wheezing for the presence of hmPV by rt-PCr technique. the datas are recorded in questionnaires.<br />
result: mean age for admitted children was 16 month-old .twenty out of 120 (16.6%) of<br />
www.worldallergy.org 143<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
cases were positive for hmPV. HmVP prevalence among male was three times greater than female. All of the positive hmPV children<br />
were affected by wheezing. more over 31.3% were simultaneously affected by wheezing and asthma. significant correlation<br />
between clinical manifestation and more than 2 days of hospitalization and positivity of hmPV were detected.<br />
Conclusion: HmPV prevalence in children with asthma and wheezing was almost the same in shiraz in compare with the other part<br />
of the world. recent findindgs suggest a probable role of hmPV in asthma exacerbation and wheezing onset.<br />
3112<br />
SEroPrEValEnCE oF aniSaKiaSiS analiSYS rESiDEnTS From “alDEa DE PESCaDorES” ToWn, PUErTo la CrUZ,<br />
anZoaTEgUi 2010<br />
naime, m. , sofia, m. and Elizabeth, P.<br />
Escuela De Ciencias De la salud, Universidad de oriente, Puerto la Cruz, Venezuela.<br />
Anisakiosis is a zoonosis caused by nematodes Anisakidae family, of which there are many genres distinguished by their public<br />
health concern as: Pseudoterranova, Contracaecum, Hysterothylacium and Anisakis. Furthermore, there are four species recognized<br />
from Anisakis: A. simplex, A. physeris, A. typical and A. schupakovi. Anisakis simplex is being the most studied parasite in clinical<br />
practice, parasitizing marine mammals in its adult form, and in different larval stages affects fish and cephalopods. the humans,<br />
being an accidental host, it is acquired through the consumption of raw or undercooked fish. Anisakiosis could be a public health<br />
problem, especially in areas where the economy and feeding depend on fishing, causing health problems for the whole community.<br />
objectives: analyze the seroprevalence of anisakiasis in residents from “Aldea de Pescadores” town, sector i, Puerto la Cruz,<br />
Anzoátegui state. materials and methods: it was conducted an exploratory, field, prospective, cross-sectional research. there<br />
were taken samples of 93 local people from “Aldea de Pescadores” which were tested by Prick test and specific igE determination<br />
in order to detect positive Anisakiosis cases, to carried out a hypothesis test, analyzed by sPss 17.0. results: there was a (8.6%)<br />
of positive prick test to Anisakis simplex; 6.5% for the specific igE determination to the same parasite. However, verified the null<br />
hypothesis there were no differences in the prevalence of gastrointestinal, dermatological and/or breathing symptoms in those with<br />
skin and serological positive tests for Anisakis simplex. Conclusions: the results indicate that the Anisakis simplex infection is not<br />
a public health problem in “Aldea de Pescadores” town. nevertheless, there are a positive percentage of Anisakiasis cases in this<br />
town. For this reason, it is necessary the spread of information, and the application of prophylactic measures to avoid the increasing<br />
number of people affected by this disease.<br />
Keywords: Anisakiasis, Prick test, igE, Anisakis simplex.<br />
3113<br />
EFFECTS oF VarioUS rESPiraTorY VirUSES on DEr F-SEnSiTiZED moUSE moDEl oF aSTHma<br />
Kim, H. H. , Chun, Y. H. , Yoon, J. , Kim, J. t. and lee, J. s.<br />
Pediatrics, the Catholic University of Korea, Pucheon-si, south Korea.<br />
Purpose: respiratory viral infection is the main cause of acute asthma exacerbation in children and can be a confirmed viral<br />
infection in 85% of children who visit a hospital because of asthma exacerbation. Viruses related to acute asthma exacerbation are<br />
rhinovirus (rV), respiratory syncytial virus (rsV), parainfluenza virus (PiV), human metapneumovirus (hmPV) and influenza virus.<br />
Among the viruses, rV is the most well-known frequent cause virus of acute asthma exacerbation for children 2 years or more.<br />
some in vitro studies showed the immunologic responses after rV infection were different from other respiratory viruses. this<br />
may refer that the response to rV infection can be different to other respiratory viruses in patients with asthma. in this experiment,<br />
we determined cell counts and the level of cytokines in bronchoalveolar lavage fluid (BAlF) of asthma mouse model after being<br />
infected by rV, rsV, or influenza virus in order to evaluate that there are differences in the kind of virus.<br />
methods: Asthma mouse model is made by sensitizing BAlB/c mouse to house dust allergen Der f. the asthma mouse model is<br />
confirmed by measuring the airway resistance caused by methacholin inhalation, the eosinophil counts, interleukin (il)-4, il-5 and<br />
il-13 in BAlF, and by observing peribronchial eosinophilic inflammation of lung tissue through a microscope. After the prepared<br />
asthma mouse model is infected by rV, rsV, and the influenza virus respectively, the rt-PCr is used to confirm the existence of<br />
virus genes in lung tissue. We determined the number of eosinophils, neutrophils, lymphocytes and macrophages in BAlF and<br />
measured rAntEs and inF-γ in BAlF of the mice infected by the viruses.<br />
results in the case of the Der f-sensitized mouse model with rV infection, the airway resistance and eosinophil counts in BAlF<br />
increased, and inF-γ level did not increase by the virus. these findings were different from in the case of rsV or influenza virus<br />
infection.<br />
Conclusion: in the case of infecting a respiratory virus to the developed asthma mouse model with the sensitized house dust mite<br />
allergen, increased airway resistance and eosinophilic inflammation with no increase in th1 response were shown only with rV.<br />
these findings can be related to the phenomenon that rV is most frequently found to be the cause of acute asthma exacerbation.<br />
www.worldallergy.org 144<br />
FinAl PrOgrAm
ABstrACts<br />
3114<br />
igg4 aS THE PrEDominanT aUToanTiBoDY in SEra From PaTiEnTS WiTH aCTiVE STaTE oF PEmPHigUS VUlgariS<br />
Entezam, m. 1 and Ayatollahi, m. 2<br />
1 2 genetic Department, shiraz University of medical sciences, shiraz , iran. transplant research Center, shiraz University of medical<br />
sciences, shiraz, iran.<br />
Background: Pemphigus vulgaris (PV) is an autoimmune blistering disease of the skin and mucous membranes caused by<br />
pathogenic antibodies. the aim of this study was to determine the antigen-specific subclasses of igg present in the sera of<br />
iranian patients with the active form of the disease and those in remission. methods: serum samples from 75 patients with<br />
the clinical presentation of PV and 50 normal healthy subjects were investigated after informed consent to use these samples<br />
for investigational use. Distribution of the igg subclass autoantibody was studied by using specific monoclonal antibodies to<br />
igg1, igg2, igg3 and igg4 in 17 patients with active form of disease, and 20 patients in remission with an indirect ElisA based<br />
method. results: the mean optical densities (OD) for igg1−igg4 (1.22, 0.63, 0.55, 1.11) versus the controls (0.38, 0.26, 0.37,<br />
0.41) showed significant differences (P = 0.0001) for igg1 and igg4 in all PV patients. the mean OD of specific igg1 autoantibody<br />
(0.52) compared with normal controls (0.38) was found to be significant in patients in remission (P = 0.02), while the titres of<br />
igg4 autoantibody were not significantly different between patients in remission and control individuals (OD = 0.46 versus 0.41)<br />
(P = 0.37). Conclusion: Elevated levels of igg4 in patients with active disease, and of igg1 in patients in remission, point to an<br />
important finding regarding the pathogenesis of autoantibodies in PV patients. the finding concludes that the detection of igg4 in PV<br />
patients is pathogenic and should be considered as a clinical marker, while elevated igg1 autoantibody may be produced within the<br />
repertoire of natural and non-pathogenic autoantibodies.<br />
Keywords: Autoimmune disease, Pemphigus vulgaris, igg4<br />
PoSTEr SESSion 3-2 immunotherapy<br />
3200<br />
EFFiCaCY oF SUB-lingUal immUnoTHEraPY in PollEn allErgiC aSTHma<br />
Khoury, A. , Al-Fadel, r. and sawas, K.<br />
Chest Diseases, Aleppo Faculty of medicine, Aleppo, syria.<br />
objective: the aim of this paper is to studying the efficacy of pollen sublingual immunotherapy in allergic asthmatic patients due to<br />
grass pollens in two consecutive seasons .methods: A randomized, double-blind, placebo-controlled search was done to evaluate<br />
the efficacy, carry-over effect and safety of grasses pollens with (slit).We enrolled 41 patients and 14 placebo patient with age<br />
rang was between ( 18 – 50 ) years . During a 11- day dose progression phase, the patients received a daily successively increased<br />
doses ( 10 – 20 – 40 – 60 – 80 – 100 – 300 – 600 – 1200 – 1800 – 2400 ir ) followed by 2400 ir three times every week in two<br />
consecutive seasons. Primary efficacy variables were symptoms and medication scores, and secondary variables included global<br />
evaluation of efficacy. results: there was a statistically improvement in slit treated patent in comparison with placebo group<br />
P(0,001).side effects were mainly local without any systemic side effects, five patients had sublingual itching and one patient had<br />
sneezing which was resolved with continuing therapy. Conclusion: sublingual swallow immunotherapy seems to be safe and<br />
efficacious for allergic asthmatic patients due to grass pollen even when started immediately or during pollen season.<br />
Key Words : Pollen , grasses . immunotherapy , treatments<br />
3201<br />
SaFETY anD EFFiCaCY oF CarBamYlaTED monomEriC DErmaToPHagoiDES allErgoiD DEPoT FormUlaTion giVEn BY<br />
SUBCUTanEoUS roUTE<br />
Fancello, P. 1 , Atzeni, i. 1 , Bruno, m. 2 and Falagiani, P. 3<br />
1 2 Allergology service, “san gavino monreale” Hospital - Asl 6, sanluri (Cr), italy. medical service, lofarma s.p.A., milan, italy.<br />
3scientific Direction, lofarma s.p.A., milan, italy.<br />
Background: immunotherapy with monomeric allergoid proved to be well tolerated, safe and effective in patients with respiratory<br />
allergy. Aim of this study was to assess the tolerability of a carbamylated monomeric allergoid given by subcutaneous route to<br />
patients with allergic rhinitis with or without asthma. method: We evaluated, in a prospective open-label phase ii study, lasting<br />
about 8 months, 15 patients (8m/7F, age: 15 - 45 years, mean age: 30 years), suffering from allergic rhinitis with (5) or without<br />
(10) asthma mainly due to house dust mites. the patients were given subcutaneously, during the first 5 weeks of the study, an<br />
increasing dose (0.1, 0.2, 0.4, 0.6 ml at 10,000 BU/ml) of the carbamylated monomeric allergoid (lofarma s.p.A., italy) and then,<br />
www.worldallergy.org 145<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
during the 7 maintenance months, a dose of 0.8 ml (at 10,000 BU/ml) with a monthly cadence. the amount of major allergen<br />
was 4 μg of group 1 per ml. At each visit, they were evaluated for any local and/or systemic adverse reaction (Ar) related to the<br />
administration of the product. At baseline and at the end of the study a visual analogue scale (VAs) was performed as well. results:<br />
no Ars were observed in 7 out of 15 patient (46.6%). Eight patients (53.3%) showed Ars. they were nearly all local and all mild:<br />
pain at the arm (2 patients), local itching (3 patients), local reaction of the dimension of a walnut (2 patient) and fever the day after<br />
the injection (1 patient). none of these Ars caused either the interruption of the treatment or the hospitalisation of the patient. there<br />
was an improvement of VAs score from 2.8 ± 1.6 to 6.8 ± 2.4 (p
ABstrACts<br />
Conclusion: Our study demonstrates that after a 3-year course of treatment; both modalities for administering immunnotherapy,<br />
i.e: slit and sCit, result in a significant decrease in mean wheal size for pollen relevant to our desert country. this can be a<br />
confirmation for the role of both forms of sit in modifying the nature of igE-mediated diseases.<br />
Key words: sit= Allergen-specific immunotherapy, slit = sublingual immunotherapy, sCit= subcutaneous immunotherapy, sAr=<br />
seasonal allergic rhinitis.<br />
3204<br />
KinD oF SEnSiTiZaTion in SUBJECTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE STUDY<br />
(ParT i)<br />
simone, P. 1 and Amboni, P. 2<br />
1 2 UsC Pneumologia, Ospedali riuniti di Bergamo, Bergamo, italy. UsC Patologia Clinica e laboratorio Analisi, Ospedali riuniti di<br />
Bergamo, Bergamo, italy.<br />
Background and method<br />
234 subjects living in a subalpine region underwent allergoid sublingual immunotherapy (lofarma s.p.A., italy) (slit) during 5<br />
years for allergic oculorinitis and/or asthma unresponsive to pharmacologic treatments. We describe relationships between sex<br />
(m–F), age, average prick tests (PK) antigens (Ag) reactivity, Ag)/histamine wheal (1+2), for perennial (Pr) or<br />
seasonal (ss) Ag, mono (ms) or polysensitivity (Ps), and formulations in tablets (tB) or drops (DP). results<br />
19 Ag were tested (mean 16; range 9-19) always including 7: birch, grass mix (gr), mugwort, Parietaria mix (PAr), Alternaria<br />
alternata, Dermatophagoydes farinae (DF) and cat dander (Ct).<br />
the 145 m (61.9%) and 89 F had similar age (28.3-29.8; range 6-56; ds12.6) and ms (20-14) (13.8-5.7%) (p>0.38).5 Ag reacted<br />
the more, average gr 2.5 + DF-Dermatophagoides pteronyssinus (DErm) (1.9-1.7+), hazelnut-birch (BEt) (1.3-1.4+), the same in<br />
m and F (p>0.05). BEt-PAr reactivity increases with age, DErm-gr decreases, lower only for gr in ms (0.7+) than in Ps (2.9+)<br />
(p0,05) too ; m-ms increases with age (odds 5.6; p=0.05), not F-ms or m-F Ps (p=0.7). reflecting PK reactivity ms-Ag (Pr) slit<br />
were higher, 19 DErm (55.9%), than (ss), 9 BEt (26.5%) and 6 gr (17.6%); but Ps-Ag (Pr) slit lower (p=0.2): 81 DErm (40.5%)<br />
and 4 Kt (2%), 93 gr (46.5%), including 40 (43%) BEt associations and 9 PAr (9.7%); BEt alone 16 (8%), 3 PAr, 2 Cupressus and<br />
1 each mugwort and ragweed. the total slit were 130 ss slit (55.6%), 114 (48.7%) gr and/or BEt, BEt globally 56 (23.9%), 100<br />
DErm slit (42.7%). tB-slit were 173 (73.9%): 98 DErm (56.6%), 46 gr (26.6%), 21 BEt (12.1%), 4 Kt (1.2%), than 2 PAr, and 1<br />
each mugwort and ragweed. the 61 DP slit were 40 associations: gr+BEt (65.6%), 9 gr+PAr (14.7%), 2 Cupressus (3.28%) and<br />
10 gr, BEt, DErm or PAr. Conclusions<br />
in a subalpine region trees and DErm are important antigens. the high need for gr+BEt slit lead to think to common antigens.<br />
tB are often prescribed while DP imply particular antigens or associations.<br />
3205<br />
CliniCal CHaraCTEriSTiCS oF PaTiEnTS UnDErgoing allErgoiD SUBlingUal immUnoTHEraPY. a rETroSPECTiVE<br />
STUDY (ParT ii)<br />
simone, P. 1 and Amboni, P. 2<br />
1 2 UsC Pneumologia, Ospedali riuniti di Bergamo, Bergamo, italy. UsC Patologia Clinica e laboratorio Analisi, Ospedali riuniti di<br />
Bergamo, Bergamo, italy.<br />
Background and method<br />
235 subjects underwent allergoid sublingual immunotherapy (lofarma s.p.A., italy) (slit) for rhinitis (ri), asthma (As) with or<br />
without conjunctivitis (OC+/-). We describe relationships between sex (m–F), pathology, mono (ms) or polysensitivity (Ps), seasonal<br />
(ss) or perennial (Pr) slit. results<br />
slit regarded 230 ri (98.3%) including 151 As (ri+As) (65.6%), and 4 As (1.7%): so 155 As (66.2%), 97.4 % ri+, 86 (ri+As) were<br />
OC+ (57%), 45 ri ( 57%) and 1 As (25%): OC links to ri. the 145 m (61.9%) and F, the 200 Ps (85.4%) and 34 ms, had similar<br />
age (28.3-32.3 ) and also similar ms in m-F (20-14;13.8-15.7%) (p>0.38). Considering casual the 4 As, 3 m Ps (OC-) and 1 F<br />
ms (OC+), higher m prevailed also in pathology and (ss) or (Pr) slit: 44/79 ri (55.7%), 98/151 (ri+As) (64.9%) being m-ri 4/8<br />
ms (50%) and 40/71 Ps (56.3%) and m-(ri+As), 16/25 ms (64%) and 82/126 Ps (65.1%). in the 235 slit, 1 double in a m Ps,<br />
m were 146/235 (62.1%), 20/34 ms (58.8%) and 126/201 Ps (62.7%) (p=0,68) being m ss slit, total or ms or Ps, respectively<br />
84/131(64.1%), 9/15 (60%) and 75/116 (64.6%) and m Pr-its respectively 62/104 (59.6%), 11/19 (57.9%) e 51/85 (60%). in<br />
ss slit were 131 (55,7%): 84/146 m (57.5%) and 47/89 F (52.8%); higher in Ps 116/201 (57.7%), m 75/126 (59.5%), F 41/75<br />
(54.7%), whereas in ms prevailed Pr slit, total 19/34 (55.9%), if m 11/20 (55%) or F 8/14 (57.1%) (p=0,2). Higher prevalence of<br />
ri+As interested both sexes: in 145 m, 20 ms e 125 Ps, respectively 98 (67.6%), 16 (80%) and 82 (65.6%), where ri was 44<br />
www.worldallergy.org 147<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
(30.3%), 4 (20%) e 40 (32%); in 89 F, 14 ms e 75 Ps, respectively 53 (67.6%), 44 ( 80%) and 9 (65.6%), with ri 35 (39.3%), 4<br />
(38.6%) and 31 (41.3%): globally a little higher prevalence of m (ri+As), and of F ri particularly if ms. similar findings were found<br />
relating (ri+As) to ss or Pr slit if ms and Ps. Conclusions<br />
slit selection seems independent from sex, pathology and kind of sensitivity and is suitable for all seasonal antigens.<br />
3206<br />
a SUrVEY oF allErgEn SPECiFiC immUnoTHEraPY in KorEa<br />
Hur, g. 1 , Kim, t. 2 , Han, m. Y. 3 , nahm, D. 4 and Park, J. 5<br />
1 2 internal medicine, Korea University College of medicine, seoul, south Korea. Department of <strong>Allergy</strong> and Clinical immunology,<br />
Asan medical Center, University of Ulsan College of medicine, seoul, south Korea. 3Pediatrics, Pochon CHA University College of<br />
medicine, seoul, south Korea. 4<strong>Allergy</strong> & rheumatology, Ajou University school of medicine, seoul, south Korea. 5Division of <strong>Allergy</strong><br />
& immunology Department of internal medicine, Yonsei University College of medicine, seoul, south Korea.<br />
Background; Allergen-specific immunotherapy (sit) has been used as the only curative and specific treatment for allergic<br />
diseases. there have been no data on sit in Korea. therefore, we carried out a survey to observe the prescription pattern of allergy<br />
specialists in Korea.<br />
methods; All 690 members of the Korean Academy of Asthma, <strong>Allergy</strong>, and Clinical immunology received an e-mail attaching a<br />
questionnaire on sit, and were required to return the answers. All returned answers were recruited between August 2009 and<br />
september 2009.<br />
results; the response rate was 21.0%. Among them, 42.8% was physicians, 32.4% was pediatricians, and 20.7% was<br />
otolaryngologists. Only 69% of respondents performed sit in practice. the methods used to detect causative allergens were skin<br />
prick test (46.1%) and serologic tests (44.1%) such as immunoCAP and mAst. the limitations to to start sit in their own practice<br />
were lack of equipment (21%) and practical experience (15.8%), no necessary because pharmacotherapy alone was enough to<br />
treat (14.5%), no good profit (14.5%), and its risks for adverse reactions (13.2%). the target diseases for sit were allergic rhinoconjunctivitis<br />
(46%), allergic asthma (38%), and atopic dermatitis (10%). ninety-two allergic specialists (82%) performed sit via<br />
subcutaneous route (sCit) and 18% via sublingual route (slit). the allergens used for sCit were house dust mites (42.5%), pollens<br />
(31.3%), and animal dander (10.2%). twenty-eight (30%) doctors have experienced anaphylactic reaction during sCit. About 40%<br />
of doctors have experienced any adverse reaction including local reactions during slit.<br />
Conclusion; in Korea, 69% of allergy specialists performed sit in practice. the prevalence of sCit was 82% and slit was 18%.<br />
lack of equipment and practical education were critical barrier to performing sit in doctors. therefore, proper practical educations<br />
to update information on sit will be necessary for allergy specialists.<br />
3207<br />
SUCCESSFUl gamma-inTErFEron THEraPY in a CaSE oF rEFraCTorY VaCCinE-aSSoCiaTED aBSCESS in a CgD<br />
PaTiEnT<br />
nabavi, m. 1 , maherbanai, s. 1 and Bemanian, m. H. 2<br />
1 2 semnan medical University, tehran, iran. Yazd medical university, Yazd, iran.<br />
CgD is a rare phagocyte defect with an incidence of four to five per million individuals, caused by genes affecting one X-linked and<br />
three autosomal recessive chromosomes. it is associated with recurrent abscesses of different size and locations. We present an 8<br />
year old girl who developed large abscesses at her thigh since 2 years of age.<br />
Case report:<br />
the patient is an 8 year old girl who developed a large abscess at her thigh just at the site of childhood vaccinations when she was<br />
2 years of age. the large 4×5-sized abscess contained voluminous yellow-greenish pus which led to persistent drainage. many<br />
topical and systemic antibiotics were used without any result and multiple courses of hospitalizations with intravenous use<br />
of wide-spread antibiotics had no benefits. gram stain and smear always showed a mixture of microbial agents for instance<br />
staphylococcus, either s. alba or s.aureus. the abscess had 2 to 4 stoma apart from each other and sometimes locolation of pus<br />
posed the need to incision and drainage of mutiple sites. Once acid fast bacilli were grown and anti tubercolosis medications<br />
were prescribed and used for at least 9 months without any significant relief. Because of refractoriness of abscesses , phagocyte<br />
defect were sugessted and an immunological consultation performed when she was 6 years of age. immunoglobulines were within<br />
normal limits. nitro Blue tetrazolium (nBt) and Di Hydro rhodamine test (DHr) was performed and showed a significant defect<br />
of respiratory burst and the patient regarded as “ Chronic granulomatous Disease”. long term therapeutic doses of trimetoprimsulfisoxazole<br />
followed by continous prophylaxis, resulted to some relief. introduction of gamma- interferon as an every-other-day<br />
schedule were terminally led to closure of abscess stoma and terminated the discharge. multiple scars of previously draining<br />
www.worldallergy.org 148<br />
FinAl PrOgrAm
ABstrACts<br />
abscesses are visible at her thigh. there was no other site of local or systemic infection and the general status remained good<br />
during and after gamma- interferon therapy.<br />
3208<br />
FloW CYTomETrY aS a Tool For DElaYED DrUg allErgY rEaCTionS DiagnoSiS: oUr EXPEriEnCE<br />
Ardito, s. 1 , De Donno, m. 2 , Aiello, V. 2 , iaia, m. l. 1 and maietta, g. 2<br />
1 2 <strong>Allergy</strong> Department, Perrino Hospital, Brindisi, italy. Cellular immunology, Pignatelli institute, lecce, italy.<br />
introduction.<br />
the lymphocyte transformation test (ltt) is the only test to detect a sensitization of t cells to drugs in the peripheral blood of drugallergic<br />
patients, but it is often considered more of a research than a diagnostic tool. in a pilot study, Pichler et al. evaluated surface<br />
molecule CD69 expression as a marker of t-cell activation in a group of patients with t-cell-mediated drug allergic reactions. CD69<br />
was detectable after 48 hrs by flow cytometry in all patients tested.<br />
Aim of the study.<br />
We analysed 11 clinical cases of adverse drug reactions we observed in our department of allergy. in all cases clinical patterns and<br />
the time of reaction indicated a delayed type of immune mechanism.<br />
the patients underwent clinical evaluation, skin tests for the suspected drug and CD69 analysis with flow cytometry.<br />
methods.<br />
Clinical evaluation was made by allergy specialist doctor in agreement with the questionnaire of EAACi interest group on drug<br />
hypersensitivity. 8 patients experienced maculo-papular rush or generalized urticaria after amoxicillin intake, 1 patient after<br />
levofloxacin and 2 patients after ibuprofen or ketoprofen administration<br />
skin test were performed as described by torres mJ et al. (1).<br />
CD69 analysis were performed with flow cytometry by using monoclonal antibodies anti CD3, CD4, CD69, as described from<br />
Pichler et al. (2) and results were expressed as s.i. (stimulation index).<br />
results.<br />
in the group of 8 patients with delayed adverse reactions after amoxicillin intake, 3 patients showed positive intradermal skin tests<br />
with the drug, while 5 patients were negative. CD69 analisys was positive in 6 of the 8 patients.<br />
the patient with maculo-papular rush after levofloxacine intake showed positive patch tests and positive CD69 analisys.<br />
the 2 patients with adverse reactions to nsAiDs showed negative patch tests, but positive CD69 analisys.<br />
Conclusions.<br />
On the basis of our clinical experience, CD69 measurement seems to be a promising tool to detect drug-reactive t cells in the<br />
peripheral blood of drug allergic patients.<br />
references.<br />
(1) m.J. torres , m. Blanca, J. Fernandez , A. romano, A. Weck, W. Aberer , et al. Diagnosis of immediate allergic reactions to betalactam<br />
antibiotics. <strong>Allergy</strong>. 2003: 58(10):961-72.<br />
(2) A. Beeler, l. Zaccaria,t. Kawabata, B.O. gerber, W.J. Pichler CD69 upregulation on t cells as an in vitro marker for delayed-type<br />
drug hypersensitivity. <strong>Allergy</strong> 2008: 63: 181–188<br />
3209<br />
CliniCal CHaraCTEriSTiCS oF oral TolEranCE inDUCTion oF non-igE mEDiaTED FooD allErgY USing iFn-gamma<br />
lee, sr., J. H. and noh, g.<br />
Department of Pediatrics, school of medicine, Chungnam national University, taejeon, south Korea.<br />
Background: Food allergies are classified as igE-mediated (iFA)and non-igE-mediated (nFA). late eczematous reactions of the skin<br />
were found to be one of typical and diagnostic symptoms of nFA. Clinically, oral immunotherapy for food allergy has been tried to<br />
induce oral tolerance.<br />
Objective: recently, oral immunotherapy for food allergy has been successful in nFA using subcutaneous iFn-gamma injection.<br />
We are to characterize the clinical findings of nFA and the induction of the oral tolerance to food allergen in nFA after oral<br />
immunotherapy using iFn-gamma.<br />
methods: non-igE-mediated food allergies were diagnosed by food challenge, skin prick test and food-specific igE. total 77 nFA<br />
patients with atopic dermatitis that is characterized by late eczematous skin reaction were selected in this study. 37 subjets were<br />
www.worldallergy.org 149<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
treated with a relevant Oit protocol for nFA. As a control group 10 subjets received only iFn-gamma without allergenic food. 10<br />
subjets receive only food without iFn-gamma, and 20 subjets with nFA did not receive treatment. Patients were evaluated clinically<br />
after treatment using subcutaneous iFn-gamma injection.<br />
results: All patients became successfully tolerized to previously offensive foods (changes in clinical severity scores by food<br />
challenge from 15.9 ± 3.6 to 1.8 ± 1.0 points, p 0.05) in a group of only iFn-gamma treatment<br />
without food, from 14.6 ± 3.6 to 14.1 ± 3.0 points (p>0.05) in a group of only food challenge without iFn-gamma treatment, and<br />
from 15.9 ± 3.7 to 15.4 ± 4.3 points (p >0.05) in a untreated group with neither iFn-gamma nor food.<br />
Conclusions: non-igE-mediated food allergy can be successfully treated by relevant oral immunotherapy using iFn-gamma. iFngammaƒnseemed<br />
to be necessary for the tolerance induction.<br />
3210<br />
THE rolE oF immUnoTHEraPY in aSTHma anD rHiniTiS<br />
Hwejeh, l.<br />
Chest Department, AlAsAD UniVErsitY HOsPitAl in DAmAsCUD, Damascus, syria.<br />
immunotherapy (sit ) is the only currently available treatment that deals with the main cause of allergic disease by modifying the<br />
immune response<br />
Our study is a retrospective study in alasad university hospital in Damascus syria to identify the causative allergens and to evaluate<br />
the efficacy of immunotherapy .<br />
We studied 345 patients with well-documented history of rhinitis(68%) , or asthma (47%).<br />
140 patients received either sublingual or subcutaneous immune therapy and followed the protocol of sit.<br />
results showed 65.9% improvement in asthmatic patients with pollen allergy ,<br />
And 78% improvement in asthmatic patients with mites allergy.<br />
Patients with rhinitis due to mites allergy had 76.4% improvement<br />
While patients with rhinitis allergic to pollen had 70.1% improvement<br />
3211<br />
CHroniC aSTHma in aDUlTS<br />
Aguilar, D.<br />
mEDiCinE DiVisiOn, JUArEZ HOsPitAl, mexico DF, mexico.<br />
Alterations of forced vital capacity (FVC) and one-second forced expiratory volume (FEV1) forms part of the alterations present<br />
in chronic asthma. in an area that is aggressive for the health of the asthmatic patients as the city of mexico for its height, air<br />
pollution, overpopulation and migratory flows, the evolution of this disease to be different to other people living in other places<br />
with characteristics less damaging their environment. We used spirometry system to study 50 patients staying more than 5 years<br />
in the Valley of mexico<br />
with diagnosis of moderate persistent asthma. measurmenet made to that end of the values of FVC and FEVi in early morning<br />
without using bronchodilators and steroids systemic or topical. statistic : missing system. results: 35 females and 15 males,<br />
aged between 18 and 81 years old standard dev, in female 12.91, mean 39, standard dev. in male: 13.44, mean 35.5. He won<br />
the following most common pattern: Bronchial Hyperreactivity+ normal spirometry 39% in females. male sex in the peripheral<br />
moderate obstruction+ bronchial hyrresponsiveness in 33%. Conclusion: in both sexes the prevalence is the obstruction from mild,<br />
moderate and severe. most patients had bronchial hyperreactivity.<br />
3212<br />
SUBCUTanEoUS immUnoTHEraPY For TrEE PollEn allErgY WiTH a PrEParaTion WiTH oPTimiSED allErgEn<br />
alUminiUm HYDroXiDE raTio: an oPEn laBEl oBSErVaTional STUDY inVESTigaTing TolEraBiliTY anD<br />
EFFECTiVEnESS in THE roUTinE USE in DailY PraCTiSE<br />
neumann, U. 1 , Wolf, H. 2 , schnitker, J. 3 and Wuestenberg, E. g. 4<br />
1 2 3 Ent-Physician, Wolmirstedt, germany. Clinical Development, AlK-Abelló, Wedel, germany. institut für angewandte statistik,<br />
Bielefeld, germany. 4medical and regulatory Affairs, AlK-Abelló, Wedel, germany.<br />
Background: For subcutaneous immunotherapy (sCit) allergens usually are adsorbed to aluminium hydroxide (alum) for slow<br />
www.worldallergy.org 150<br />
FinAl PrOgrAm
ABstrACts<br />
allergen release (depot effect). in addition alum also acts as an adjuvant that enhances the immunological effect. therefore, a sCit<br />
product with an optimised allergen/alum ratio allows reducing the maximum dose applied for maintenance therapy and shorter updosing<br />
schedules. in this open observational study the tolerability and effectiveness in the routine use in daily practise of a product<br />
with an optimised allergen/alum ratio with a five-injection up-dosing schedule was investigated.<br />
methods: Patients with rhinoconjunctivitis with/without asthma induced by birch/tree pollen were treated with a sCit depot<br />
preparation (Birch or tree-mix, AVAnZ, AlK-Abelló, Hørsholm, Denmark) containing 15% of the allergen content and 50% of the<br />
alum content compared with the widely used AlK allergen product for sCit (Alutard sQ, AlK-Abellò, Hørsholm, Denmark). therapy<br />
was initiated by up-dosing with 5 injections (300, 600, 3.000, 6.000, 15.000 sQ+) in weekly intervals and was continued by<br />
maintenance injections of 15.000 sQ+ with 14 and 28 days intervals.<br />
results: in total 409 patients were documented (Birch: 81, tree mix: 328 patients). the effectiveness of the treatment was rated as<br />
good or very good by 88.2% of the patients (Birch 85.1%, tree-mix 88.8%) and 90.7% by the investigators (Birch 87.2%, tree-mix<br />
91.5%). Adverse events were in general mild to moderate local reactions and occurred in 22.7% of the patients mostly at up-dosing<br />
(18.8% of patients). serious adverse events were reported in 5 patients (1.2%). Among them, the causality was rated as ‘possible’<br />
in 3 patients. Overall the tolerability was assessed as good or very good by 96.8% of the patients (Birch 100.0%, tree-mix 96.1%)<br />
and 97.1% by the investigators (Birch 98.1%, tree-mix 96.6%).<br />
Conclusion: A sCit product with an optimised allergen/adjuvant ratio (AVAnZ) routinely used in the daily practise with 5 injections<br />
up-dosing was evaluated by patients and physicians to be effective and well tolerated.<br />
3213<br />
immUnomoDUlaTorY PoTEnTial oF mESEnCHYmal STEm CEll ProViDE a PromiSing alTErnaTiVE For TrEaTmEnT oF<br />
liVEr TranSPlanTaTion<br />
Ayatollahi, m. 1 , Entezam, m. 2 and geramizadeh, B. 3<br />
1 2 transplant research Center, stem Cells & transgenic research Center, shiraz University of medical sciences, shiraz, iran. genetic<br />
Department, shiraz University of medical sciences. 3transplant research Center, shiraz University of medical sciences.<br />
introduction: liver transplantation is the final treatment for the end stage of liver failure due to the hepatic dysfunction.<br />
Considering several limitations in this approach and based on the fact that mesenchymal stem cell (msC) do not elicit alloreactive<br />
lymphocyte to response due to immune modulations, this project was design to improve isolation, culture, characterization and in<br />
vitro differentiation of human msC into hepatocyte like-cell using different protocols and culture conditions. methods: Bone marrow<br />
of healthy donors was aspirated from the iliac crest after obtaining approval of Ethic Committee and informed consent to use<br />
these samples for investigational use. the adherent cells expanded rapidly and maintained with periodic passages until a relatively<br />
homogeneous population was established. the identification of these cells was carried out by differentiation potential into osteocyte<br />
and adipocyte. transdifferentiation of human msCs into hepatocyte-like cells was undertaken in response to a novel specific culture<br />
condition. results: the differentiation of msCs into osteoblast is determined by deposition of a mineralized extracellular matrix.<br />
Adipocytes are identified by their morphology and staining. Hepatic cells were demonstrated in vitro functions characteristic of liver<br />
cells. Conclusion: We have defined conditions under which human msCs can be isolated and expanded from human bone marrow.<br />
these cells can be amplified about 108-fold in 6 weeks, and were capable of transdifferentiation into liver-like cells. Understanding<br />
the cellular and molecular biology of msCs may be new insights into their clinical applications.<br />
Keywords: immunomodulatory Potential, Human mesenchymal stem cells, Clinical applications, liver transplantation<br />
PoSTEr SESSion 3-3: Pediatric allergies<br />
3300<br />
STUDY oF THE rElaTionSHiP BETWEEn ToTal anD SPECiFiC igE in SCHool agE aSTHmaTiC CHilDrEn<br />
Al Janabi, O. A.<br />
<strong>Allergy</strong>, <strong>Allergy</strong> And Asthma Center Baghdad, Baghdad, iraq.<br />
Asthma is a common and heterogeneous respiratory disease, usually associated with increased levels of total igE, even in subjects<br />
negative for specific igE to common aeroallergens.<br />
to identify the relationship between total and specific igE levels in school age Asthmatic children, determine the frequency of<br />
total igE in related to age, family history and gender in asthmatic children, clarify the relationship between specific igE levels and<br />
asthma, residence, and age, furthermore ; determine the frequency of asthmatic children in relation to family history, age, gender<br />
and residence.<br />
this study was conducted at the <strong>Allergy</strong> and Asthma Center – Baghdad, 499 children with mild intermitted asthma of both genders<br />
www.worldallergy.org 151<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
included in this study, divided into 3 age groups (6-10, 11-14, and 15-19) years submitted to a questionnaire with evaluation of<br />
both total igE and specific igE antibodies to House Dust mite levels.<br />
the results were arranged in figures and tables and given as mean ± sD, values and data were analyzed using sPss version 14.<br />
the differences between the study’s groups were tested by using (AnOVA). P < 0.05 was accepted as statistically significant.<br />
male children were 270 (54%), 229 (46%) were female children, 290 of them live in urban area while only 209 live in rural area,<br />
there is a significant relationship between sD of specific igE levels and total igE in asthmatic children with a P value (0.000) and<br />
this relationship were significant in relation to positive family history with a p value= 0.003.<br />
Even many Population studies have shown an association between prevalence of asthma and total serum immunoglobulin E (igE)<br />
levels independent of specific reactivity to common allergens, this study found that there is a significant relationship between the<br />
total igE levels and the specific igE levels in asthmatic children and both total igE and specific igE levels are high in asthmatic<br />
children with positive family history of asthma.<br />
3301<br />
a STaTiSTiCal STUDY oF THE moST Common allErgEnS in CHilDrEn, WHo SUFFEr From DiSEaSES or allErgiC<br />
rEaCTionS in THE CiTY oF laTaKia (SYrian CoaST)<br />
Did, g. s.<br />
department of pediatric – faculty of medicine – tishreen University – lattakia - syria, lattakia, syria.<br />
this study was carried out in group of 639 children (298 girls and 341 boys), children aged 2 to 18 years .<br />
they were divided into 3 groups:<br />
1- (2 – 5 years old: 205 children)<br />
2- (> 5 – 13 years old: 289 children)<br />
3- (> 13 – 18 years old: 145 children)<br />
A sPt* used 6 aeroallergens: domestic moth, rot fungus (mould mixing**), grass mix pollen, cat dander, olive pollen, grain pollen***.<br />
521 (81.53 %) were reactive to at least one of the aeroallergens. Among the sPt-positive patients, a positive prick-test reaction to<br />
the house dust mites (87.33 %) was most common followed by mould (42.80 %) , 5 grasses mixing (34.35 %) , olive pollen (32.82<br />
%) , cat dander (30.13 %) , 4-cereals pollen (21.88 %).<br />
therefore, it appears that the prevelance of sPt reactivity to common aero allergens is high among lattakian allergic children,<br />
particularly in those with asthma and in all age groups.<br />
Dr. ghazal Dib: Assistant professor - department of pediatric – faculty of medicine – tishreen University – lattakia - syria<br />
* sPt: skin Prick test<br />
** mould mixing: Alternaria alternata, cladosporium, penicillium.<br />
3302<br />
ConnECTionS oF aSTHma anD rESPiraTorY inFECTionS in BoSnian CHilDrEn<br />
Bajraktarevic, A. 1 , Hadzimurtezic, A. 1 , Pavlovic, V. 1 , miokovic, m. 1 , mahinic, A. 1 , selimovic, A. 2 , suljevic, i. 3 , Hadzimurtezic, Z. 4 and<br />
sporisevic, l. 5<br />
1 2 Pediatrics Department, Public Health insitution of Canton sarajevo, sarajevo, Bosnia. Pulmonology Pediatrics Department,<br />
Pediatrics Clinic sarajevo, sarajevo, Bosnia. 3Department for Biochemistry, Clinical medical Center sarajevo, sarajevo, Bosnia.<br />
4 5 Asthma Department, UmC sarajevo- Clinic for Pulmology, sarajevo, Bosnia. Pediatrics Department, First medical Aid<br />
BACKgrOUnD: asthma is the most common chronic childhood illness. the kids patient exhibits prolonged expirations, increased<br />
use of accessory muscles for breathing, barrel chest, tachypnea, cyanosis, wheezing, exertional dyspnea, scattered rhonchi, coarse<br />
crackles and late-stage clubbing.Colds are caused by many types of viruses causing virtually the same symptoms.<br />
mEtHODs: the main issue in diagnosis is differentiating respiratory viruses, which cause most cases, from bacterial infection such<br />
as pneumonia comparing with asthma , which would benefit from treatment with antibiotics, and from influenza, for which antivirals<br />
are effective. gram stain of the sputum is necessary in all but the most severe cases of asthma and other respiratory diseases such<br />
as upper and lower respiratory infection .<br />
rEsUlts: the severity of the asthma will depend on the amount of lung tissue involved and type of pneumonia or severity chronic<br />
obstructive lung disease in children. During period 2005-2009, 8864 children with respiratory syncytial virus, 625 with influenza<br />
virus, 1813 with parainfluenza virus, and 1902 with adenoviruses were evaluated in connection with asthma at Primary Children’s<br />
medical Center sarajevo, First medical Aid and Pediatrics Clinic sarajevo.<br />
DisCUssiOn: the diagnostic labeling of presumed nonbacterial upper and lower respiratory tract infection is unclear.<br />
www.worldallergy.org 152<br />
FinAl PrOgrAm
ABstrACts<br />
COnClUsiOns: Empiric treatment with antibiotics is to be considered only for critically ill kids asthmatic patients.. treatment<br />
is often empiric and based on history and examination. the rapid spread of antibiotic resistance in community pathogens has<br />
underscored the urgency for reducing unnecessary antibiotic use. Childhood asthma is a heterogeneous disease, which can start<br />
early or late in childhood and be transient or persistent.<br />
KEY WOrDs: Asthma , respiratory infections, Children, Diagnostic.<br />
3303<br />
CHilDHooD aSTHma anD oPPorTUniSTiC inFECTionS oF HiV PoSiTiVE CHilDrEn in BoSnia anD HErZEgoVina<br />
Bajraktarevic, A. 1 , Hadzimurtezic, A. 1 , Omerovic, m. 1 , mahinic, A. 1 , Hadzimurtezic, Z. 2 , Djurdjevic Djulepa, A. 3 , sporisevic, l. 4 ,<br />
selimovic, A. 5 , Vranic, B. 6 and suljevic, i. 7<br />
1 2 Pediatrics Department, Public Health insitution of Canton sarajevo, sarajevo, Bosnia. Asthma Department, UmC sarajevo- Clinic<br />
for Pulmology, sarajevo, Bosnia. 3Perinatology Department, general Hospital sarajevo, sarajevo, Bosnia. 4Pediatrics Department,<br />
First medical Aid sarajevo, sarajevo, Bosnia. 5Pulmonology Pediatrics Department, Pediatrics Clinic sarajevo, sarajevo, Bosnia.<br />
6 7 Pulmonology Pediatrics Department, infectious Clinic sarajevo, sarajevo, Bosnia. Department for Biochemistry, Clinical medical<br />
Center sarajevo, sarajevo, Bosnia.<br />
intrODUCtiOn: Opportunistic infections are the most common complication of AiDs. increased understanding of the pathogenesis<br />
of HiV and associated opportunistic pathogens has led to effective prophylaxis for many of these infections. asthma (ginA)<br />
guidelines (modification for children) also recommend a measure of severity that is based on daily medication regimen and<br />
response to treatment.<br />
mEtHODs: HiV is present in body fluids especially blood and semen especially in the early and late phases of the disease in<br />
children. this was a randomized, double-blind controlled trial conducted between 2005 and 2009 in a primary, secondary and<br />
tertiary care pediatric pulmonology departments.<br />
rEsUlts: the rate of new HiV infections has fallen in our country. When CD4 + t cells drop below about 400 per μl, the kids patients<br />
immunity is sufficiently weakened that opportunistic infections begin. these are infections caused by organisms that ordinarily do<br />
not cause disease symptoms in immunocompetent children.<br />
DisCUssiOn: the epidemic of AiDs in Bosnia and Herzegovina is stabilizing but at an unacceptably high level.<br />
COnClUsiOns: asthma is the most common chronic childhood illness. the following opportunistic infections and conditions can<br />
frequently occur in children with AiDs as viral infections like herpes simplex virus, lymphoid interstitial pneumonia , shingles<br />
, cytomegalovirus infection , parasitic infections such as a pneumonia caused by Pneumocystis carinii, toxoplasmosis, serious<br />
bacterial infections such as bacterial meningitis, tuberculosis, salmonellosis and fungal infections.<br />
KEY WOrDs: HiV, Children, Opportunistic infections, treatment, Asthma.<br />
3304<br />
THE EFFECT oF CEllUloSE PoWDEr (naSalEZE) on THE CoUrSE oF SEaSonal allErgiC rHiniTiS<br />
Kherkheulidze, m. , Kavlashvili, n. , Kandelaki, E. and Adamia, n.<br />
Pediatrics, state medical University, tbilisi, georgia.<br />
the aim of the study was to assess the effectiveness of cellulose powder extract on prophylactic treatment of seasonal allergic<br />
rhinitis in children. We studied 38 patients with mean age 13,3±3,7 years, already diagnosed seasonal allergic rhinitis according<br />
to the isAAC and AriA criteria and at least double value of total igE immunoglobulin. All children received nasaleze inhaled powder<br />
once or twice a day based on symptom severity during one month. Before starting and at the end of the treatment all children had<br />
clinical examination. We evaluated nasal symptom score (0-4) according to their symptoms (nasal obstruction, rhinorrea, sneezing,<br />
itching), total igE, eosinophils of nasal secretion and quality of life (PrQlQ, published by E. Juniper). the study reveals that relief of<br />
symptoms was obtained within 0.1-3 hours after taking medication. the mean of the clinical nasal symptom score was 3,02±0,8<br />
at the beginning and 1,23±0,9 at the end of the treatment (p
ABstrACts<br />
ABstrACts<br />
3305<br />
EPiDEmiologY oF rHiniTiS in SEConDarY SCHool CHilDrEn USing mSYPQ (moDiFiED Sino-naSal oUTComE TEST-20<br />
YoUng PErSon QUESTionnairE) anD ComPariSon WiTH moDiFiED SnoT-20 USED in aDUlT CommUniTY BaSED SUrVEY<br />
sami, A. s.<br />
Ent, royal national throat, nose and Ear Hospital, london, United Kingdom.<br />
Background:<br />
rhinitis is significantly prevalent in the adult community but this research aimed to explore the prevalence of nasal and paranasal<br />
symptoms within the age group of 11-16 years while also assessing, within the same student population, the prevalence of<br />
impaired sleep, social and emotional function, time off school and visits to the family doctor.<br />
the sino-nasal Outcome test -20 (snOt-20) questionnaire, a valid disease related quality of life instrument, was modified for use<br />
on secondary school children for this project. the modified snOt-20 for Young Person Questionnaire, msYPQ was used in secondary<br />
school children in east london with the result compared to a similar adult survey.<br />
method<br />
the pilot project tested msYPQ according to EPOs criteria. EPOs positive showed significantly high score on msYPQ confirming the<br />
presence of the disease (rhinitis/rhinosinusitis), while EPOs negative had very low to zero score on msYPQ. this confirmed that<br />
msYPQ can identify subjects with rhinitic symptoms and is a good instrument to assess the effect on quality of life.<br />
the msYPQ was used in a face-to-face interview and postal survey for children aged between 11-16 years in three large east<br />
london schools. the data was collected and analysed for the prevalence of rhinitis, associated symptoms and effects on quality of<br />
life.<br />
results:<br />
the results showed that over 32% of secondary school children suffered rhinitic symptoms (cough was identified as one of the<br />
most significant symptoms). A similar prevalence of 30% was found in adults.<br />
more than 21% of secondary school students had their quality of life affected by rhinitis and more than 47% took between 2-15<br />
days off school due to rhinitic symptoms. in adults these values were 25% and 10% respectively. Conclusion:<br />
this analysis confirmed that rhinitis is a common problem in the 11-16 year age group. it affects quality of life and performance at<br />
school, as students have to take days off from the school and are frustrated by their symptoms.<br />
this study also confirms that msYPQ is a good tool for identifying the prevalence of rhinitis symptoms in 11-16 age group and their<br />
effect on quality of life.<br />
3306<br />
SEVErE aToPiC DErmaTiTiS ComPliCaTED WiTH FooD ProTEin-inDUCED gaSTroinTESTinal SYnDromE, CaSE rEPorT<br />
oF 5 inFanTS<br />
Yamamoto, K. , nomura, i. , shoda, t. , tsumura, Y. , Yoshida, K. , Horimukai, K. , Fukuie, t. , Futamura, m. , narita, m. and Ohya, Y.<br />
Division of <strong>Allergy</strong>, national Center for Child Health and Development, tokyo, Japan.<br />
Objective:sPlAD (severe Protein loss in Atopic Dermatitis), is an extreme form of atopic dermatitis in infants and their serum<br />
protein is lost through inflamed skin (Pediatr <strong>Allergy</strong> immunol 2002, 13(4):287-94). Food Protein-induced gastrointestinal syndrome<br />
(FPigs) is cell-mediated food allergy mainly involves gastrointestinal tract (Curr Opin <strong>Allergy</strong> Clin immunol. 2009;9(4):371-7). the<br />
prevalence of both sPlAD and FPigs has been increasing since the 1990’s in Japan. Co-existence of these two conditions in an<br />
infant may become a serious impact on health and growth. As we experienced 5 patients, we would like to clarify clinical features<br />
of these patients.<br />
method:A diagnosis of sPlAD was made if the patient showed; (1) severe atopic dermatitis, (2) total serum protein less than -2 sD<br />
of the normal value. FPigs was suspected if their gastrointestinal symptoms were stopped by the avoidance of offending food and<br />
confirmed by food challenge test. Five patients were enrolled and evaluated clinical features and biological markers (serum total<br />
protein, peripheral eosinophil count, total igE, specific igE antibodies, and stool cytology).<br />
result:two girls and 3 boys aged 4~6 months old showed severe AD (100%), serous skin discharge (100%), diarrhea (100%),<br />
bloody stool (100%) and vomiting (20%). Body weight was -3.2 ~ -1.6sD at the diagnosis. their serum total protein was 3.7 ~<br />
4.9g/dl. Peripheral blood eosinophil count was 6~29 %. total igE was 32 ~ 1163kU/l. Dermatitis was treated with proper skin care<br />
and topical steroid therapy and responded well. serum total protein was recovered promptly. But diarrhea was persisted and food<br />
elimination was performed. Food challenge test revealed that wheat, rice and soy were the offending food. their body weight was<br />
recovered after treatment of both conditions.<br />
www.worldallergy.org 154<br />
FinAl PrOgrAm
ABstrACts<br />
Conclusion:sPlAD and FPigs, both rare forms of allergic diseases, coexisted in 5 infants. this leads to an idea that there may be<br />
common factors concerning pathogenesis of those 2 conditions.<br />
3307<br />
THE PrEValEnCE oF CHilDHooD aSTHma, allErgiC rHiniTiS anD aToPiC DErmaTiTiS in YErEVan<br />
gambarov, s. s. , Kostanyan, l. V. and Zakharyan, A.<br />
Clinical immunology and <strong>Allergy</strong>, Yerevan state medical University after m. Heratsi, Yerevan, Armenia.<br />
aim-the aim of this research was to explore the prevalence of childhood asthma, allergic rhinitis and atopic dermatitis via<br />
standardized methods in Yerevan, which allow comparing our results with the international data.<br />
methods- We have delivered standardized questionnaires of ‘the international study of Asthma and Allergies in Childhood’ (isAAC)<br />
to 3079 parents of 6-7 years old pupils (73% response rate) and 3002 13-14 years old pupils (94% response rate) from a random<br />
sample of 52 schools of Yerevan in october-december 2008. During the second phase we have also investigated the respiratory<br />
function in the current wheezing group (98 and 105 pupils in 6-7 and 13-14 age groups respectively), transient wheezing group<br />
(122 and 116) and control group (30 in each age group) with the use of portable spirometer and bronchial reversibility test (two<br />
puffs of salbutamol àerosol were used to measure the reversibility).<br />
results-the lifetime prevalence of wheezing was 9% in 6-7 years old children and 8.4% in 13-14 years old children. Current<br />
wheezing (i.e. wheezing in past 12 months) was observed in 3.7% and 4% first and ninth grade schoolchildren, and self-reported<br />
doctor diagnosed asthma was observed in 0.5 and 0.8% respectively.<br />
in the younger age group the prevalence of lifetime rhinitis was 6.2%, current rhinitis-4.3%, and doctor diagnosed allergic<br />
rhinitis-1%.For the older group the data were-11.7%, 8.5% and 1.9% respectively.<br />
the prevalence of atopic eczema in the 6-7 old age group was 2.4% current eczema-1.4%, and diagnosed atopic eczema 0.6%. in<br />
the older age group the lifetime prevalence of eczema was 4.4%, current eczema-3.2% and diagnosed atopic eczema-1.1%.<br />
the spirometry results show that there is no statistically significant difference of forced expiratory volume in 1 second (FEV1)<br />
between the wheezing and control groups, but the bronchial reversibility was statistically higher in wheezing group (both age<br />
groups p=0.001 and p< 0.0005 for 6-7 and 13-14 age groups respectively).<br />
Conclusion-Our data conclude that Yerevan is a region of low prevalence of asthma and other atopic disorders, but since the<br />
prevalence of the symptoms of these diseases is several times higher than diagnosed diseases, we can conclude that allergies are<br />
underdiagnosed in Yerevan.<br />
3308<br />
PrEVEnTaBlE imPaCT oF SUPlaTaST ToSilaTE DoSagE on aSTHma onSET in inFanTS<br />
norifumi, O. 1 , norifumi, O. 2 , Kentaro, m. 3 , Hiroaki, O. 4 , Atsushi, i. 5 , Yutaka, K. 5 , toshiaki, s. 2 and takeshi, n. 2<br />
1 2 3 Pediatrics, Chiba Aiyukai memorial Hospital, Chiba, Japan. Pediatrics, Kitasato University school of medicine, Japan.. Department<br />
of Pediatrics, Chiba Aiyukai memorial Hospital, Chiba, Japan. 4Department of Pediatrics, tokyo Kousei-nenkin Hospital, Japan.<br />
5Department of Pediatrics, Yokohama City minato red Cross Hospital, Japan.<br />
Background: recent epidemiology suggests the increasing prevalence of allergic diseases including asthma in the industrialized<br />
countries, which necessitates the analysis of the mechanisms of allergic diseases and development of the effective treatment.<br />
suplatast tosilate (iPD) has been shown to be clinically effective for the treatment of hypersensitivity and childhood asthma, and it<br />
is a novel antiallergic agent that suppresses several processes, including the synthesis of il-4 and il-5 in both human and murine<br />
th2 cells. However, the effect of iPD to restrain the bronchial asthma onset of an infant having an established allergic factor has not<br />
been examined. Hence influence on asthma onset by the iPD dosage in patients who repeated 1-3 times wheeze after the life that a<br />
shift to the childhood asthma was observed.<br />
Objective and methods: the object is 39 patients who accepted 1-3 times wheeze after birth ranging from 6 months to 3 years in<br />
age. After an observation period of two weeks, they were divided into 3 groups; theophyline treated group (group A), theophyline +<br />
iPD group (group B), and iPD alone (group C). the clinical evaluation was performed concerning frequency of coughing and wheeze,<br />
and that of the β2-receptor agonist inhalation consumption in every four months with an asthma diary. in addition, allergic tests;<br />
peripheral blood eosinophile count and serum igE value were determined in every four months.<br />
results and Discussion: As for the coughing, the frequency fell not significantly 12 months later (the last four months) as compared<br />
to the first four months in all groups. Concerning the wheeze, the significant decrease in particular was examined in group B, C. As<br />
for the frequency of the β2-receptor agonist inhalation consumption, the significant decrease was observed in group B and C, but<br />
not in group A. the meaningful change of the peripheral blood eosinophile count was not observed in group A and C. However it<br />
increased 8 and 12 months later significantly in group B. the serum igE value increased 12 months later in group A and B, whereas<br />
such a meaningful increase was never recognized in group C. iPD likely restrains an increase of serum igE value. Conclusion: iPD<br />
www.worldallergy.org 155<br />
FinAl PrOgrAm<br />
ABstrACts
ABstrACts<br />
ABstrACts<br />
regulates igE production and eosinophile count in patients who show 1-3 times wheeze after life, and has likely action to improve<br />
wheeze expression clinically.<br />
3309<br />
EValUaTion oF Small airWaYS oF JaPanESE CHilDHooD aSTHma BY HrCT anD iTS aSSoCiaTion WiTH SnPS<br />
tomikawa, m. 1 , Oguma, t. 2 , niimi, A. 2 , matsui, E. 3 , Kondo, n. 3 and Ebisawa, m. 1<br />
1 2 Pediatrics, sagamihara national Hospital, sagamihara, Japan. respiratory medicine, graduate school of medicine, Kyoto<br />
University, Kyoto, Japan. 3Pediatrics, graduate school of medicine gifu University, gifu, Japan.<br />
Objectives: the purposes of these studies were to evaluate small airways in childhood asthma by high-resolution computed<br />
tomography (HrCt) and to examine the association of single nucleotide polymorphisms (snPs) with small airways’ obstruction.<br />
methods: ten asthmatic patients (6 males & 4 Females) treated with iCs were recruited to the evaluation of small airways. By<br />
using HrCt, low attenuation area (lAA) % and mean lung density (mlD) % were examined. ninety three patients (70 males & 23<br />
females) were recruited to snPs study and were divided into %FEF50%≥80% group (n=34) and %FEF50%
ABstrACts<br />
autumn only in 13% of cases in spring and summer in 12 % of cases. the Pt was positive in 93% of cases, sensitization to dust<br />
mites is in first place (67%) followed by the olive tree (32%), cypress (29%), Parietaria (22%), 5 grasses (21%) , Alternaria (25%),<br />
dog (20%), cat (15%) and cockroach (15%). the monsensibisation was found in 20% of cases, the majority were polysensitized<br />
with mites.<br />
Discussion - comments: the mites are the main aero-allergen, in accordance with literature data. sensitization to pollen<br />
occupies the second place, this may be related with age bracket included in the study (children over 4 years). We note an important<br />
awareness to mold. Polysensitization is often encountered in older children. in some cases, there was a discrepancy between the<br />
history and results of skin prick tests based research to discuss specific igE.<br />
Conclusion: the diagnosis is mainly clinical allergy. the examination and skin tests constitute the cornerstone. they are sufficient<br />
in most cases to diagnose the cause. Clinical common sense and prudence of the findings are required in the interpretation of<br />
results.<br />
3312<br />
THE rolE oF CHiTinaSE-liKE ProTEinS in allErgiC inFlammaTion on PEDiaTriC aDEnoiD TiSSUE<br />
shin, s. 1 , Ye, Y. 2 , lee, K. 1 , Kim, s. 1 , Cho, J. 1 and Park, H. 2<br />
1 2 Otorhinolaryngology-Head and neck surgery, Kyung Hee University, seoul, south Korea. Department of <strong>Allergy</strong> & rheumatology,<br />
Ajou University school of medicine, suwon, south Korea.<br />
Chitin is an essential structural component of the fungal cell wall and is present in the exoskeleton of arthropods and the<br />
microfilarial sheath of nematodes. recent findings have not only demonstrated that mammals produce chitinases, but also that<br />
increased secretion of chitinases is closely associated with th2-dominated pathophysiological conditions including infection,<br />
fibrosis, allergy and asthma. the purpose of this study is to measure the level of chitinase-like proteins (ClPs) in adenoid tissues<br />
from atopic children, and to know its role in allergic inflammation on pediatric adenoid tissues. Forty atopic subjects, who were<br />
sensitized to more than one common aeroallergen, and 40 non-atopic subjects undergoing adenotonsillectomy, were recruited.<br />
the level of ClPs was measured by ElisA. immunoassays using adenoid tissue homogenate were performed to quantify the levels<br />
of total igE, eosinophil cationic protein (ECP), mast cell tryptase and Alternaria-specific igE. median level of ClPs was tend to be<br />
higher in atopics than in non-atopics (p = 0.056). median level of ECP was significantly higher in atopics than in non-atopics (p <<br />
0.001), while no difference was seen in tryptase. the level of ClPs in adenoid tissues strongly correlated with ECP or tryptase level.<br />
in addition, median level of ClPs was significantly higher in children showing positive response for Alternaria-specific igE than in<br />
children with negative response. in conclusion, chitinase showed close relationships with ECP or tryptase in allergic inflammation<br />
on pediatric adenoid tissues, and increased locally in fungal allergen sensitized children.<br />
3313<br />
PaSSiVE SmoKing iS a maJor DETErminanT oF EXHalED niTriC oXiDE lEVElS in allErgiC aSTHmaTiC CHilDrEn<br />
laoudi, Y. 1 , nikasinovic, l. 2 , sahraoui, F. 1 , grimfeld, A. 1 , momas, i. 2 and Just, J. 1<br />
1 2 Department of Asthma and Allergic Diseases, Armand trouseau Children University Hospital, Paris, France. laboratory of Public<br />
health and Environment, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris-Descartes, EA 4064, Paris, France.<br />
Background: Fraction of exhaled nitric oxide (FenO), as a reflection of allergic bronchial inflammation, is considered to be a<br />
treatment follow-up parameter in allergic asthmatics. Factors such as active smoking can, however, influence FenO measurement<br />
and are thus taken into account in the interpretation of this parameter. in children, the evidence in favor of an impact of passive<br />
smoking (Ps) on FenO measurement is controversial.<br />
objective: to evaluate the impact of Ps on measurement of FenO in allergic asthmatic children.<br />
methods: 70 non-treated allergic asthmatic children over the age of 5 years underwent phenotype characterisation by<br />
measurement of on-line FenO, spirometry, and allergic tests (skin prick tests, total and specific igE levels, blood eosinophilia).<br />
Children were considered to be exposed to Ps when at least 5 cigarettes per day were declared by the family to be smoked at<br />
home.<br />
results: mean FenO in 48 children unexposed to Ps was 62.3 ± 29.1 ppb versus 30.3 ±17.6 ppb in 22 exposed children (p
ABstrACts<br />
ABstrACts<br />
3314<br />
PrEValEnCE oF allErgiC rHiniTiS in SCHool CHilDrEn PoPUlaTion oF TBiliSi anD WESTErn gEorgia<br />
Kherkheulidze, m. , Adamia, n. , Kandelaki, E. and Kavlashvili, n.<br />
Pediatrics, state medical University, tbilisi, georgia.<br />
the aim of the study was assessment of prevalence of allergic rhinitis in schoolchildren population of tbilisi and Western georgia<br />
region. the cross sectional research was conducted through questioning of the random and representative groups of population.<br />
schools and groups for study were selected by simple randomization.<br />
First stage of research covered 5569 children 53.7 % boys and 46.3 % girls aged from 6 to 16, who were divided into 2 groups –<br />
i group consist with 1049 child aged 6-10 years and ii group (1651 children ) aged 11-16 years. statistical data processing was<br />
provided by software package sPssv12.<br />
According to questioning, repeated sneezing episodes were identified in 14, 2 % of i group and 18, 7 % in elder group. the study<br />
reviled that most frequent symptom of allergic rhinitis is rhinorea and pruritus, while most disturbing symptom is nasal obstruction.<br />
Pruritus was indicated in 15.7 % elder group 20, 1 % in younger group. rhinorrhea was stated in 16.4, mostly among older<br />
schoolchildren. nasal obstruction was identified in 15.9 of respondents, with high frequency in younger schoolchildren.<br />
spread of the symptoms of Ar was reliably higher among boys (p
ABstrACts<br />
mEtHODs: ninety-six children aged 3 to 17 years old were recruited, including 80 with perennial Ar and 16 with non-Ar as<br />
controls. medical history was taken and physical examination, serum specific igE, total igE, peripheral blood eosinophil count,<br />
nasal smear were conducted. the nasal symptom score was calculated for each patient from a questionnaire and correlated with<br />
laboratory data. Bivariate correlation analysis and multiple linear regression analysis were done to compare the correlation among<br />
clinical markers and symptom score.<br />
rEsUlts: levels of all allergic markers in children with Ar were significantly different from those in non-allergic children. All of<br />
the markers were related to the severity of Ar in Pearson correlation analysis. On logistic regression analysis, only serum allergenspecific<br />
igE were independent predictors.<br />
COnClUsiOn: these results suggest that serum allergen-specific igE is correlated with the severity of perennial Ar in children.<br />
3317<br />
rolE anTEnaTal anD PoSTnaTal FaCTorS in oCCUrrEnCE oF an allErgiC DiaTHESiS aT CHilDrEn WHo HaVE BEEn<br />
Born in CiTY loCaTED nEar To nUClEar EnTErPriSE<br />
Petrushkina, n.<br />
Departament of physiology, Ural state Univercity Physical Culture, Chelyabinsk, russia.<br />
the purpose of research has consisted in an establishment antenatal and postnatal factors in occurrence of an allergic diathesis at<br />
children who have been born in city located near to nuclear enterprise.<br />
research included 335 children (the main group) at which parents worked at the nuclear enterprise and 466 children - the control.<br />
We applied a method logistic regression which have allowed to choose from set of attributes the most significant for occurrence of<br />
an allergic diathesis.<br />
Frequency of an allergic diathesis in the basic group was 12,6 on 100 children, in the control - 11,9 (distinctions are doubtful). the<br />
early sensitization on the first year of a life and to development of attributes of an allergic diathesis was promoted by such factors<br />
as medicamentous treatment in second half of pregnancy (0,65), threat of interruption (0,72 (0,84) and early placentation, and<br />
also mixed (0,72) and artificial feeding (0,73). For occurrence of this pathology significant there was a residing at adverse social<br />
conditions (0,71). the role of a parental professional irradiation is not established.<br />
thus occurrence of an allergic diathesis at children does not depend on a professional irradiation of parents and is defined<br />
(determined) by known non- radiation factors which promote early specialization.<br />
3318<br />
an ESTimaTion oF THE rESPTaTorY’S FUnCTion CHilDrEn WHo liVE nEar aTomiC PlanT<br />
Petrushkina, ii, n.<br />
Departament of Physiology, Ural state Physical Culture, Chelyabinsk, russia.<br />
Diseases of respiratory system one of conducting places in a pathology of children’s age. in this connection with the purpose of<br />
an estimation of a condition of respiratory system research of function of external breath at practically healthy 420 children is<br />
executed.<br />
investigation was carried out with use of the automated microprocessor a method of registration of parameters curve “stream -<br />
volume” of the forced exhalation. For an estimation of a condition of function of external breath studied the following parameters:<br />
frequency of breath 1 minute, vital volume of lungs (VVl), minute volume of breath (mVB), respiratory volume (rV), volume of the<br />
forced exhalation for 1 secund (VFE), the maximal volumetric speed at a level of 75%, 50%, 25% and 25-75% forced VVl, peak<br />
volumetric speeds of an exhalation and breath (ÏÎÑ), test tiffno attitude forced VVl for 1 s to VVl (%), resistance of respiratory ways.<br />
Absolute values of volume-speed parameters increase with the years. relative sizes did not depend on age and were above the<br />
bottom border of physiological norm. so VVl were within the limits of 90-107%. Parameters of bronchial passableness at a level<br />
75, 50, 25% FVVl laid from 96 up to 131%. With the years the increase on the average on 200-510 sm3 at boys is marked (higher<br />
than at girls). so, at girls of 9 years VVl it is equal 1950 sm3 , and 15 years - 3650 sm3 , at boys – 2320 and 4190 sm3 accordingly<br />
(Ð
ABstrACts<br />
ABstrACts<br />
3319<br />
PUlmonarY FUnCTion TEST in HEalTHY CHilDrEn 7 To 9 YEarS aFTEr rESPiraTorY Viral inFECTionS<br />
Kartasasmita, iV, C. B. , sudarwati, s. , Wulandari, D. A. , suwardi, A. U. , saptaputra, W. , nuradi, i. , Kuswandewi, m. and simoes, E.<br />
A.<br />
Department of Child Health, Hasan sadikin/school of medicine Padjadjaran University, Bandung, indonesia, Bandung, indonesia.<br />
Background. Pulmonary function test (PFts) provides an assessment of airflow limitation. it can be used for diagnosis of asthma in<br />
children over 6 years of age. Viral infections during infancy can cause wheezing (roberg et al. 2007) and abnormal lung function<br />
at 6 years of age (Anderson et al. 2008). the aim of this study is to determine the PFts in children 7 to 9 years after viral respiratory<br />
infections.<br />
materials and methods. this study is a part of a nested case control study entitled “rsV and recurrent wheezing in indonesia:<br />
7 – 9 year follow-up study with lung function studies”. the PFts were obtained from December 2009 to July 2010. All the<br />
children were healthy when the PFts were performed. to determine the obstructive impairment we analyzed FEV1 and FEV1/<br />
FVC ratio. reversibility was measured in children with % predictive FEV1 < 80%, before and after administration of a short acting<br />
bronchodilator.the FEV1/FVC ratio > 80% showed normal lung function.<br />
results. A total 218 children, age 8.4 to 13.4 years old (mean 10.5 ± 1.05 years), consisted of 111 boys and 107 girls, were<br />
enrolled in the study. Fifty two cases with history of viral respiratory infections, and 166 controls. the viral pathogens found were:<br />
rsV (25), rV (19), mix rsV and rV (6), and hmPV (2). the mean ± sD of FEV1 in cases (2.12 ± 0.42) was slightly higher than<br />
control (2.04 ± 0.39), however, the difference was statisticaly not significant. the mean ± sD FEV1/FVC ratio in cases (90.76 ±<br />
9.15) and in control (92.28 ± 6.5) were also statisticaly no difference. in 14 out of 218 (6.4%) children the reversibility test were ><br />
12%.<br />
Conclusion: the PFts in children with history of viral respiratory infections are within normal limit, 7 to 9 years later. the rate of<br />
asthma is low.<br />
3320<br />
CliniCal ProFilE anD riSK FaCTorS in HoSPiTaliZED CHilDrEn WiTH BronCHioliTiS<br />
Kirovski, i. , nikolovski, l. , sazdovski, A. , micevska, V. and seckova, l.<br />
Department of Pulmonology and Allergology, University Children’s Hospital, skopje, macedonia.<br />
Bronchiolitis, potentially life-threatening respiratory condition is the most common reason for hospitalization in infancy.<br />
the aim of the study was to determine the risk factors and to describe the clinical profile in children who were admitted to the<br />
hospital with a diagnosis of bronchiolitis.<br />
methods: We studied 153 children, the analysis we conducted was restricted to first hospitalizations within the first 18 months. Data<br />
from their medical records were entered in a specially designed questionnaire. the following data were analyzed: age on admission,<br />
gender, gestational age, association of bronchiolitis with children’s nutritional status. Clinical factors such as chronic lung disease<br />
and congenital heart disease (CHD) were investigated. socioeconomic status, possible exposure to passive smoking, family history<br />
of atopy, number of siblings were also investigated. the respiratory rate, oxygen saturation, presence of chest wall retractions and<br />
cyanosis upon admission were noted.<br />
results: Of the 153 patients 85 were males and 68 females, giving a male to female ratio of 1,25:1. sixty-six percent were<br />
under 9 months of age and were previously healthy children. We could not find significant association between bronchiolitis and<br />
nutritional status. shorter or lack of exclusive breastfeeding was a risk factor for the hospitalization. 37% of the children were<br />
passive smokers. socioeconomic status was a factor in increasing the risk of hospital admission in our patients. Prevalence rate<br />
for bronchiolitis was higher in rural areas compared to urban ones. Other factors, such as a diagnosis of bronchodysplasia, CHD,<br />
and prematurity were not significantly associated with being hospitalized for bronchiolitis. the best method for initial assessment of<br />
bronchiolitis was oxygen saturation.<br />
Conclusion: the youngest infants and those who have been exposed to cigarette smoke after birth have the highest risk of<br />
bronchiolitis. the association between socioeconomic factors and hospitalization indicates that these factors may have a significant<br />
influence on the hospitalization rate in bronchiolitis during infancy. the promoting of exclusive breastfeed ing is for prevention of<br />
infectious diseases and also because of the lesser aggressive course of bronchiolitis in breastfed children.<br />
www.worldallergy.org 160<br />
FinAl PrOgrAm
ABstrACts<br />
3321<br />
aSSoCiaTion BETWEEn THE oVErWEigHT anD allErgiC DiSEaSES in SCHool agE CHilD PoPUlaTion oF TBiliSi<br />
Kherkheulidze, m. , Kavlashvili, n. , Kandelaki, E. and Adamia, n.<br />
Pediatrics, state medical University, tbilisi, georgia.<br />
the study aims evaluation of relationship between Bmi indices and allergic disorders. Cross-sectional study was conducted<br />
through questioning of the random and representative groups of school age child population in tbilisi. in addition spirometry and<br />
measurement of weight was conducted. A written, self-completed questionnaire modified from the isAAC core questionnaire<br />
concerning symptoms and Bmi-per-age cut-off points based on WHO standard reference were used. Overweight status was<br />
defined as a Bmi greater than the age- and gender-specific 85th percentile. At all 1026 children from 10-14 years old were involved<br />
in study. the study reveled that Bmi was more then 85 % in 28, 1 % cases. 19.3% children reported a physician-diagnosed allergic<br />
disease, and 28.6% reported undiagnosed allergic symptoms the Overweight subjects more frequently reported ever having<br />
wheezing (27.7 vs. 16.2%, p
ABstrACts<br />
ABstrACts<br />
Conclution: our study confirmed that familial atopic diseases and exposure to smoking were significant predictors of childhood<br />
Asthma.<br />
3324<br />
EValUaTion oF USing VBg inSTEaD oF aBg in aSTHma EXaCErBaTion<br />
Fatemi Khorasgani, m. 1 , niazi, E. 1 and Farzaneh, s. 2<br />
1 2 Pediatrics, islamic Azad University-najafabad branch, isfahan, iran. Anesthesiology, islamic Azad University-najafabad branch,<br />
isfahan, iran.<br />
Background- Arterial blood gas (ABg) is the gold standard for blood gas analysis. in asthma exacerbation severity evaluation,<br />
ABg is important; however, it is somehow difficult and potentially dangerous. Using venous blood gas (VBg) sampling is easier for<br />
less expert personnel, with minimal damage for patient. in this research, we want to compare aBg & VBg indexes in asthma<br />
exacerbation.<br />
method-this prospective diagnostic study was done with convenience sampling of 50 admitted children, 36 boys and 14 girls,<br />
between 3 and 6 years (mean 4.18) in pediatric emergency ward in shariati hospital in isfahan with asthma exacerbation during<br />
2009 spring. they were normotensive and their temperature between 36-38.5. ABg sampling as routine in asthma management<br />
and VBg sampling along other venous tests were done without any excessive cost for patient. For both ABg and VBg test, we used<br />
an AVl compact1 analyzer few minutes after sampling. For data analysis, we utilized sPss ver. 14.<br />
results-From 17 patient with PO < 60 in ABg, 100% had PO 60, 80.77% had PO >60 in VBg<br />
2 2 2 2<br />
and for seven with normal PO in ABg 57.14% had normal value in VBg. For relationship between PO in ABg and VBg P-value was<br />
2 2<br />
0.04.<br />
From nine patients with PCO > 45 in ABg, 66.67% had PCO >45 in VBg.For 22 patients with PCO
sPEAKEr AnD CHAirPErsOn inDEX<br />
last name First name Session Page number<br />
Ababneh Hani PO2-1 45<br />
Ababneh Hani Ps5 49<br />
Ababneh Hani sY15 51<br />
Abdul rahman Hussain sY3 39<br />
Agarwal mK Ps5 49<br />
Al Ameri Hatem Pg11 35<br />
Al Frayh Abdulrahman Ps3 43<br />
Al Hammadi suleiman Pg7 34<br />
Al Hammadi suleiman PO2-2 45<br />
Al Kendi Hussain sY15 50<br />
Al nuaimi Asma sY9 44<br />
Al rawas Omar Pg1 33<br />
Al tamemi salem Pg13 35<br />
Al tamemi salem PO2-3 45<br />
Al Zaaibi Ashraf sY5 41<br />
Al-Ahmad mona sY5 41<br />
Al-Ahmed nasser PO3-2 49<br />
Al-Dhekri Hasan sY12 48<br />
Al-Dhekri Hasan sY16 51<br />
Al-Harfi Harb Kn3 51<br />
Al-Herz Waleed Ps3 43<br />
Al-muhsen saleh sY5 41<br />
Alrayes Hassan Ps1 38<br />
Al-sayegh mirza Ps6 52<br />
Alsowaidii shirina Ps2 40<br />
Ansotegui ignacio J. Pg9 34<br />
Arifhodzic nermina sY5 41<br />
Awad Zeinab sY2 39<br />
Baena-Cagnani Carlos E. Pg13 35<br />
Baena-Cagnani Carlos E. sY7 43<br />
Baena-Cagnani Carlos E. Css 46<br />
Bahna sami Pg16 36<br />
Bahna sami Pg22 37<br />
Baratawidjaja Karnen Ps4 46<br />
Barnes neil Pg6 34<br />
Barnes neil sY4 41<br />
Barnes neil sY12 48<br />
Barnes neil sY16 51<br />
Bateman Eric Pg11 35<br />
Bateman Eric sY1 38<br />
Bateman Eric PO1-2 42<br />
Bateman Eric sY9 44<br />
Bateman Eric Kn2 45<br />
Baz Zeina sY5 41<br />
Benyounes Abdenour sY15 50<br />
Blaiss michael s. Pg12 35<br />
Blaiss michael s. Pg13 35<br />
Blaiss michael s. sY13 49<br />
Blaiss michael s. Ps6 52<br />
Bonini sergio Pg15 35<br />
Bonini sergio sY2 39<br />
Bonini sergio sY13 50<br />
Bork Konrad special session 37<br />
Boulet louis-Philippe Pg6 34<br />
Boulet louis-Philippe sY4 41<br />
Boulet louis-Philippe sY12 48<br />
Boulet louis-Philippe sY14 50<br />
Boulet louis-Philippe Ps6 52<br />
Braido Fulvio Pg10 34<br />
Braido Fulvio Pg18 36<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
last name First name Session Page number<br />
Braido Fulvio sY6 42<br />
Braido Fulvio sY13 50<br />
Canonica g. Walter Pg8 34<br />
Canonica g. Walter Pg23 37<br />
Canonica g. Walter Ps2 40<br />
Canonica g. Walter Css 46<br />
Canonica g. Walter sY10 47<br />
Canonica g. Walter Kn3 51<br />
Casale thomas B. Pg1 33<br />
Casale thomas B. Pg24 37<br />
Casale thomas B. Ps4 46<br />
Chikhladze manana V. sY13 49<br />
Craig timothy J. special session 37<br />
Cua-lim Felicidad Ps4 46<br />
Custovic Adnan sY9 44<br />
Custovic Adnan sY12 48<br />
Custovic Adnan Ps5 49<br />
Douagui Habib sY2 39<br />
Ebisawa motohiro Pg16 36<br />
Ebisawa motohiro sY8 44<br />
Ehlayel mohamad sY1 38<br />
Elbousify Ahmed sY10 47<br />
El-gamal Yehia sY15 51<br />
Fiocchi Alessandro Pg16 36<br />
Fiocchi Alessandro sY11 47<br />
Fiocchi Alessandro PO3-3 49<br />
Fiocchi Alessandro Ps5 49<br />
Fiocchi Alessandro sY14 50<br />
gonzález-Díaz sandra Pg7 34<br />
gonzález-Díaz sandra Pg22 37<br />
gonzález-Díaz sandra sY8 44<br />
gonzález-Díaz sandra PO2-2 45<br />
gorski Pawel sY16 51<br />
greenberger Paul Pg12 35<br />
greenberger Paul PO1-3 42<br />
greenberger Paul Ps3 43<br />
greenberger Paul sY8 44<br />
Haahtela tari Pg9 34<br />
Haahtela tari Pg21 36<br />
Haahtela tari sY1 39<br />
Haahtela tari sY7 44<br />
Halwani rabih sY9 44<br />
Hanna Kamal sY12 48<br />
Hasnain syed m. sY5 41<br />
Hasnain syed m. PO1-1 42<br />
Holgate stephen t. Ps1 38<br />
Holgate stephen t. sY4 41<br />
Hossny Elham sY3 39<br />
Husain maitham sY13 49<br />
Hwejeh lubna sY8 44<br />
ibrahim Abdulla Pg4 33<br />
idrees majdi sY15 50<br />
irani Carla PO1-3 42<br />
irani Carla sY6 42<br />
Jee Young-Koo sY4 41<br />
Joo Cho Young Ps3 43<br />
Kalayci Omer Pg8 34<br />
Kalayci Omer Pg20 36<br />
Kalayci Omer sY11 47<br />
Kaliner michael A. Pg8 34<br />
KEY: Css – Company sponsored symposium Kn – Keynote lunch symposium Pg – Postgraduate Course<br />
PO – Poster session Ps – Plenary session sY – symposium<br />
www.worldallergy.org 163<br />
FinAl PrOgrAm
sPEAKEr AnD CHAirPErsOn inDEX<br />
last name First name Session Page number<br />
Kaliner michael A. Pg21 36<br />
Kaliner michael A. sY3 39<br />
Kaliner michael A. Ps2 40<br />
Kaliner michael A. PO1-4 42<br />
Kelkar Pramod Pg7 34<br />
Kelkar Pramod Pg17 36<br />
Kelkar Pramod sY16 51<br />
Khadadah mousa Kn2 45<br />
Kheder Ali Ben Ps1 38<br />
Kherallah nizar Pg9 34<br />
Kherallah nizar Pg24 37<br />
Kherallah nizar PO3-3 49<br />
Kherallah nizar sY14 50<br />
Kowalski marek l. Pg5 33<br />
Kowalski marek l. Pg24 37<br />
Kowalski marek l. sY3 40<br />
ledford Dennis Pg4 33<br />
ledford Dennis Pg14 35<br />
ledford Dennis sY2 39<br />
ledford Dennis sY6 42<br />
ledford Dennis Ps3 43<br />
ledford Dennis sY8 44<br />
lemanske robert Ps3 43<br />
lemanske robert sY7 43<br />
lemanske robert PO3-1 49<br />
lemanske robert sY14 50<br />
lockey richard F. Pg14 35<br />
lockey richard F. Pg19 36<br />
lockey richard F. Ps1 38<br />
lockey richard F. Kn1 40<br />
lockey richard F. sY6 42<br />
lockey richard F. Ps5 49<br />
lockey richard F. sY15 50<br />
lötvall Jan sY11 47<br />
mahboub Bassam Pg3 33<br />
makoto nagata sY10 47<br />
masjedi mohammad reza sY15 50<br />
mohamed Yousser sY4 41<br />
nelson Harold Pg18 36<br />
nelson Harold Pg23 37<br />
nelson Harold Ps3 43<br />
nelson Harold sY10 47<br />
nizam iqubal mohammed PO1-2 42<br />
O’Byrne Paul Pg6 34<br />
O’Byrne Paul Pg15 35<br />
O’Byrne Paul sY1 38<br />
O’Byrne Paul Ps4 46<br />
Park Hae-sim Pg5 33<br />
Park Jung-Won sY1 38<br />
Park Hae-sim sY3 40<br />
Park Jung-Won PO3-1 49<br />
Park Hae-sim sY16 51<br />
Pawankar ruby Pg4 33<br />
Pawankar ruby sY3 39<br />
Pawankar ruby Kn1 40<br />
Pawankar ruby Ps2 40<br />
Peters stephen Pg1 33<br />
Peters stephen Pg11 35<br />
Peters stephen sY9 45<br />
Peters stephen Ps4 46<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
last name First name Session Page number<br />
Polosa riccardo Pg3 33<br />
Polosa riccardo Pg17 36<br />
Polosa riccardo sY12 48<br />
reda shereen sY7 43<br />
rodriguez-Perez noel sY3 39<br />
rodriguez-Perez noel PO1-1 42<br />
rogala Barbara PO2-3 45<br />
rogala Barbara sY13 49<br />
rosenwasser lanny Pg20 36<br />
rosenwasser lanny special session 37<br />
rosenwasser lanny Ps1 38<br />
rosenwasser lanny sY2 39<br />
rosenwasser lanny PO2-1 45<br />
rosenwasser lanny Ps4 46<br />
rouadi Philip PO1-4 42<br />
saleh Fadhel sY4 41<br />
sallam Anwar Ps2 40<br />
sallam Anwar sY14 50<br />
sanchez-Borges mario Pg18 36<br />
sanchez-Borges mario Css 46<br />
sanchez-Borges mario Ps6 52<br />
sayah Zineb sY15 50<br />
scadding glenis Ps2 40<br />
scadding glenis sY10 47<br />
scadding glenis PO3-2 49<br />
sepiashvili revaz i. sY2 39<br />
shah Ashok Ps1 38<br />
singh meenu sY7 43<br />
slavyanskaya tatiana Pg21 36<br />
tadros Faheem Css 46<br />
Viegi giovanni Pg3 33<br />
Viegi giovanni Ps1 38<br />
Viegi giovanni Ps6 52<br />
Virchow Christian sY11 47<br />
Yoon Ho Joo sY6 42<br />
Zaitoun Fares Pg22 37<br />
Zitt myron Pg2 33<br />
Zitt myron Pg19 36<br />
KEY: Css – Company sponsored symposium Kn – Keynote lunch symposium Pg – Postgraduate Course<br />
PO – Poster session Ps – Plenary session sY – symposium<br />
www.worldallergy.org 164<br />
FinAl PrOgrAm
POstEr AUtHOr inDEX<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
author Poster # Session author Poster # Session author Poster # Session<br />
Adamia, n 3304 PO 3-3<br />
Adamia, n 3310 PO 3-3<br />
Adamia, n 3314 PO 3-3<br />
Adamia, n 3321 PO 3-3<br />
Afifi, m 1203 PO 1-2<br />
Afifi, m 1308 PO 1-3<br />
Agarwal, m 1106 PO 1-1<br />
Agondi, rC 1306 PO 1-3<br />
Agondi, rC 1324 PO 1-3<br />
Agondi, rC 1217 PO 1-2<br />
Aguilar, D 3211 PO 3-2<br />
Ahanchian, ii, H 2301 PO 2-3<br />
Ahmad, nEQ 1326 PO 1-3<br />
Ahmed, F 1205 PO 1-2<br />
Ahmed, s 1302 PO 1-3<br />
Aiello, V 3208 PO 3-2<br />
Akiyama, K 1305 PO 1-3<br />
Al Frayh, A 1118 PO 1-1<br />
Al Hammadi, s 1303 PO 1-3<br />
Al Janabi, OA 3300 PO 3-3<br />
Al Qerem, W 1317 PO 1-3<br />
Al shammari, nH 1215 PO 1-2<br />
Al sini, H 1118 PO 1-1<br />
Al-Ahmad, m 3203 PO 3-2<br />
Al-Ahmad, ms 1304 PO 1-3<br />
Al-Ahmed, n 1304 PO 1-3<br />
Al-Ahmed, n 3203 PO 3-2<br />
Al-Enezi, A 3203 PO 3-2<br />
Al-Fadel, r 3200 PO 3-2<br />
Al-Jahdali, H 1322 PO 1-3<br />
Al-muhsen, s 1320 PO 1-3<br />
Al-muhsen, s 1321 PO 1-3<br />
Al-muhsen, s 1322 PO 1-3<br />
Al-muhsen, s 1323 PO 1-3<br />
Al-muhsen, s 2108 PO 2-1<br />
Al-Onizi, A 1304 PO 1-3<br />
Al-Qassim, A 1118 PO 1-1<br />
Al-sheyab, nA 1209 PO 1-2<br />
Al-shouli, st 3108 PO 3-1<br />
Al-tamemi, sH 1116 PO 1-1<br />
Alaiya, A 1118 PO 1-1<br />
Alkhalil, m 2305 PO 2-3<br />
Alyasin, Jr., s 3111 PO 3-1<br />
Amboni, P 3204 PO 3-2<br />
Amboni, P 3205 PO 3-2<br />
Amin, D 1408 PO 1-4<br />
Anıl, B 1214 PO 1-2<br />
Angino, A 1309 PO 1-3<br />
Angino, A 1312 PO 1-3<br />
Antal, P 3110 PO 3-1<br />
Antolín-Amérigo, D 2306 PO 2-3<br />
Ar, Ks 2100 PO 2-1<br />
Arafa, E 1216 PO 1-2<br />
Aranda, A 1109 PO 1-1<br />
Ardito, s 3208 PO 3-2<br />
Arici, m 2104 PO 2-1<br />
Arifhodzic, n 1304 PO 1-3<br />
Arifhodzic, n 3203 PO 3-2<br />
Arifhodzic, nA 3202 PO 3-2<br />
Arshi, s 1402 PO 1-4<br />
Arshi, s 2218 PO 2-2<br />
Athota, rr 3109 PO 3-1<br />
Atsushi, i 3308 PO 3-3<br />
Atzeni, i 3201 PO 3-2<br />
Aun, mV 1324 PO 1-3<br />
Aun, mV 1217 PO 1-2<br />
Ayatollahi, m 3213 PO 3-2<br />
Ayatollahi, m 3114 PO 3-1<br />
Aynacı, E 1214 PO 1-2<br />
B g, P 1108 PO 1-1<br />
B m, r 1307 PO 1-3<br />
B m, r 1108 PO 1-1<br />
B.Kartasasmita, C 1117 PO 1-1<br />
Babaie, D 2218 PO 2-2<br />
Bae, Y 2102 PO 2-1<br />
Bae, Y 1316 PO 1-3<br />
Baghali, Z 1113 PO 1-1<br />
Bajraktarevic, A 3302 PO 3-3<br />
Bajraktarevic, A 3303 PO 3-3<br />
Baker, J 2308 PO 2-3<br />
Baker, J 2309 PO 2-3<br />
Baker, J 2310 PO 2-3<br />
Baker, J 2311 PO 2-3<br />
Baker, J 2312 PO 2-3<br />
Baldacci, s 1309 PO 1-3<br />
Baldacci, s 1312 PO 1-3<br />
Banerji, A 2309 PO 2-3<br />
Banerji, A 2311 PO 2-3<br />
Banerji, A 2312 PO 2-3<br />
Bansal, s 1106 PO 1-1<br />
Bar-Or, A 2108 PO 2-1<br />
Bartolome, B 2205 PO 2-2<br />
Bartuzi, Z 2210 PO 2-2<br />
Bartuzi, Z 2211 PO 2-2<br />
Batpenov , n 2106 PO 2-1<br />
Bemanian, mH 3207 PO 3-2<br />
Bennert, J 1109 PO 1-1<br />
Bennert, J 1112 PO 1-1<br />
Benyounes, sr., A 3311 PO 3-3<br />
Bielory, l 2308 PO 2-3<br />
Bielory, l 2309 PO 2-3<br />
Bisaccioni, C 1306 PO 1-3<br />
Bisaccioni, C 1324 PO 1-3<br />
Blagbrough, s 1211 PO 1-2<br />
Blaiss, ms 1408 PO 1-4<br />
Bodi, sg 1325 PO 1-3<br />
Boesoerie, sF 2109 PO 2-1<br />
Borbotti, m 1309 PO 1-3<br />
Borbotti, m 1312 PO 1-3<br />
Borges, DB 1217 PO 1-2<br />
Borick, m 2213 PO 2-2<br />
Boughellout, H 2214 PO 2-2<br />
Bousquet, J 1213 PO 1-2<br />
Britton, m 1211 PO 1-2<br />
Broom, C 2308 PO 2-3<br />
Broom, C 2309 PO 2-3<br />
Broom, C 2310 PO 2-3<br />
Broom, C 2311 PO 2-3<br />
Broom, C 2312 PO 2-3<br />
Bruno, m 3201 PO 3-2<br />
Busse, P 2308 PO 2-3<br />
Busse, P 2309 PO 2-3<br />
Busse, P 2311 PO 2-3<br />
Butt, A 2305 PO 2-3<br />
C r, sB 1108 PO 1-1<br />
Cagnoli, g 2209 PO 2-2<br />
Camacho, n 1120 PO 1-1<br />
Camci, g 2104 PO 2-1<br />
Cardona, r 2307 PO 2-3<br />
Cardona, r 2217 PO 2-2<br />
Cardona, r 2110 PO 2-1<br />
Cardona-Villa, r 2216 PO 2-2<br />
Carrozzi, l 1312 PO 1-3<br />
Caruso, C 2212 PO 2-2<br />
Castro-Coelho, AP 1324 PO 1-3<br />
Castro-Coelho, AP 1217 PO 1-2<br />
Cavdar, g 2104 PO 2-1<br />
Cerrai, s 1309 PO 1-3<br />
Cerrai, s 1312 PO 1-3<br />
CH, Cm 1401 PO 1-4<br />
Chang, Y 1314 PO 1-3<br />
Chang, Y 1218 PO 1-2<br />
Chao, ss 1407 PO 1-4<br />
Chaynava, A 2304 PO 2-3<br />
Chehregani, A 1113 PO 1-1<br />
Chen, YY 3104 PO 3-1<br />
Chikhladze, mV 1111 PO 1-1<br />
Chinchilla, C 2216 PO 2-2<br />
Chinchilla, C 2110 PO 2-1<br />
Chisholm, A 1210 PO 1-2<br />
Chiung, Ym 3104 PO 3-1<br />
Chkhaidze, i 3310 PO 3-3<br />
Cho, J 3312 PO 3-3<br />
Cho, s 1314 PO 1-3<br />
Cho, s 1218 PO 1-2<br />
Cho, Ys 2102 PO 2-1<br />
Cho, Ys 1314 PO 1-3<br />
Cho, Ys 1316 PO 1-3<br />
Cho, Ys 1218 PO 1-2<br />
Cho, YJ 2204 PO 2-2<br />
Cho, YJ 1314 PO 1-3<br />
Cho, YJ 1218 PO 1-2<br />
Choi, B 1314 PO 1-3<br />
Choi, B 1218 PO 1-2<br />
Choi, D 1220 PO 1-2<br />
Choi, i 1110 PO 1-1<br />
Chudasama, J 1109 PO 1-1<br />
Chudasama, J 1112 PO 1-1<br />
Chun, YH 3113 PO 3-1<br />
Corrigan, CJ 1313 PO 1-3<br />
Craig, tJ 2308 PO 2-3<br />
Craig, tJ 2310 PO 2-3<br />
Craig, tJ 2311 PO 2-3<br />
Craig, tJ 2312 PO 2-3<br />
Crisp, J 1209 PO 1-2<br />
D’Auria, E 2209 PO 2-2<br />
Daneshvar, n 3322 PO 3-3<br />
Daneshvar, n 3323 PO 3-3<br />
Danzig, m 1409 PO 1-4<br />
Das, AB 1109 PO 1-1<br />
Das, AB 1112 PO 1-1<br />
Davis-lorton , m 2309 PO 2-3<br />
Davis-lorton , m 2310 PO 2-3<br />
Davis-lorton , m 2311 PO 2-3<br />
De Donno, m 3208 PO 3-2<br />
Della torre, E 1204 PO 1-2<br />
Della torre, F 1204 PO 1-2<br />
Devereux, g 2201 PO 2-2<br />
Di Pede, F 1309 PO 1-3<br />
Di Pede, F 1312 PO 1-3<br />
Did, gs 3301 PO 3-3<br />
Diez, s 2307 PO 2-3<br />
www.worldallergy.org 165<br />
FinAl PrOgrAm
POstEr AUtHOr inDEX<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
author Poster # Session author Poster # Session author Poster # Session<br />
Diez, s 2217 PO 2-2<br />
Diez, s 2110 PO 2-1<br />
Djordjevic, Dr 3315 PO 3-3<br />
Djurdjevic Djulepa, A 3303 PO 3-3<br />
Dr, g 1307 PO 1-3<br />
Dr, g 1108 PO 1-1<br />
Eatemadi, A 1403 PO 1-4<br />
Eatemadi, A 1404 PO 1-4<br />
Eatemadi, A 1101 PO 1-1<br />
Ebisawa, m 3309 PO 3-3<br />
El Hassan, E 1413 PO 1-4<br />
Elizabeth, P 3112 PO 3-1<br />
Elizabeth, P 2215 PO 2-2<br />
Ellis, s 1210 PO 1-2<br />
Entezam, m 3213 PO 3-2<br />
Entezam, m 3114 PO 3-1<br />
Fakim, n 1304 PO 1-3<br />
Falagiani, P 3201 PO 3-2<br />
Falus, A 3110 PO 3-1<br />
Fancello, P 3201 PO 3-2<br />
Farid, r 2301 PO 2-3<br />
Farrokhi, sr., s 1402 PO 1-4<br />
Farzaneh, s 3324 PO 3-3<br />
Fatemi<br />
Khorasgani, m 3324 PO 3-3<br />
Fayyaz Jahani, sr., F 2300 PO 2-3<br />
Florio, g 2208 PO 2-2<br />
Forutan, H 3323 PO 3-3<br />
Fukuie, t 3306 PO 3-3<br />
Futamura, m 3306 PO 3-3<br />
gaarder, Pi 1313 PO 1-3<br />
gad-El-rab, mO 1118 PO 1-1<br />
gaeta, F 2212 PO 2-2<br />
gaffuri riva, V 1204 PO 1-2<br />
gallagher, r 1209 PO 1-2<br />
gambarov, ss 3307 PO 3-3<br />
gates, D 1409 PO 1-4<br />
gemou-Engesaeth, V 1313 PO 1-3<br />
gendlin, gE 1202 PO 1-2<br />
geramizadeh, B 3213 PO 3-2<br />
ghalehbaghi, B 2218 PO 2-2<br />
ghosh, n 1109 PO 1-1<br />
ghosh, n 1112 PO 1-1<br />
ghrahani, r 1327 PO 1-3<br />
giavina-Bianchi, P 1306 PO 1-3<br />
giavina-Bianchi, P 1324 PO 1-3<br />
giavina-Bianchi, P 1217 PO 1-2<br />
giovannini, m 2209 PO 2-2<br />
gomez-garcia, C 2216 PO 2-2<br />
gonzález, mr 2206 PO 2-2<br />
gonzález<br />
mendiola, mr 2205 PO 2-2<br />
gonzález-Cervera, J 2306 PO 2-3<br />
gopalan, g 1409 PO 1-4<br />
grant, JA 2308 PO 2-3<br />
grant, JA 2309 PO 2-3<br />
grant, JA 2311 PO 2-3<br />
grimfeld, A 3313 PO 3-3<br />
grogaard, JB 1313 PO 1-3<br />
grønnerød, C 1201 PO 1-2<br />
Hadadi, E 3110 PO 3-1<br />
Hadzimurtezic, A 3302 PO 3-3<br />
Hadzimurtezic, A 3303 PO 3-3<br />
Hadzimurtezic, Z 3302 PO 3-3<br />
Hadzimurtezic, Z 3303 PO 3-3<br />
Halvorsen, s 1313 PO 1-3<br />
Halwani, r 1320 PO 1-3<br />
Halwani, r 1321 PO 1-3<br />
Halwani, r 1322 PO 1-3<br />
Halwani, r 1323 PO 1-3<br />
Halwani, r 2108 PO 2-1<br />
Hamed, mn 1219 PO 1-2<br />
Hameed, WA 1308 PO 1-3<br />
Hamid, Q 1313 PO 1-3<br />
Hamid, Q 1320 PO 1-3<br />
Hamid, Q 1321 PO 1-3<br />
Hamid, Q 1322 PO 1-3<br />
Hamid, Q 1323 PO 1-3<br />
Hamid, Q 2108 PO 2-1<br />
Han, mY 3206 PO 3-2<br />
Harun, r 1326 PO 1-3<br />
Hasegawa, m 1305 PO 1-3<br />
Hasnain, sm 1118 PO 1-1<br />
Hassan, m 1219 PO 1-2<br />
Haughney, J 1210 PO 1-2<br />
Havstad, s 1302 PO 1-3<br />
Heier, HE 1313 PO 1-3<br />
Hekmatdoost, Jr., A 2203 PO 2-2<br />
Henríquez-santana, A 2306 PO 2-3<br />
Higashi, n 1305 PO 1-3<br />
Hiroaki, O 3308 PO 3-3<br />
Hong, C 1110 PO 1-1<br />
Horimukai, K 3306 PO 3-3<br />
Hossny, E 2213 PO 2-2<br />
Howarth, DP 1216 PO 1-2<br />
Hukutomi, Y 1305 PO 1-3<br />
Huliraj, n 1307 PO 1-3<br />
Huliraj, n 1108 PO 1-1<br />
Hullam, g 3110 PO 3-1<br />
Hur, g 3206 PO 3-2<br />
Hur, J 1107 PO 1-1<br />
Hurewitz, D 2308 PO 2-3<br />
Hurewitz, D 2309 PO 2-3<br />
Hurewitz, D 2311 PO 2-3<br />
Hurewitz, D 2312 PO 2-3<br />
Hwejeh, l 3210 PO 3-2<br />
iaia, ml 3208 PO 3-2<br />
ibrahim, A 1303 PO 1-3<br />
irwan, n 1117 PO 1-1<br />
irwan, n 1327 PO 1-3<br />
ishii, t 1305 PO 1-3<br />
isozaki, A 2207 PO 2-2<br />
Jabbari, F 2301 PO 2-3<br />
Jahromi, mm 1310 PO 1-3<br />
Jang, mK 1316 PO 1-3<br />
Jee, Y 1107 PO 1-1<br />
Jeong, W 1107 PO 1-1<br />
Jin, H 1102 PO 1-1<br />
Jin, H 1104 PO 1-1<br />
Johnson, C 1302 PO 1-3<br />
Joukaji, A 1100 PO 1-1<br />
Jung, s 1107 PO 1-1<br />
Just, J 3313 PO 3-3<br />
Kajiwara, K 1305 PO 1-3<br />
Kaklamanos, g 2202 PO 2-2<br />
Kalfus, i 2308 PO 2-3<br />
Kalfus, i 2309 PO 2-3<br />
Kalfus, i 2310 PO 2-3<br />
Kalfus, i 2311 PO 2-3<br />
Kalfus, i 2312 PO 2-3<br />
Kalil, J 1306 PO 1-3<br />
Kalil, J 1324 PO 1-3<br />
Kalil, J 1217 PO 1-2<br />
Kamenov, BA 2304 PO 2-3<br />
Kamenov, BA 3315 PO 3-3<br />
Kamenov, s 2304 PO 2-3<br />
Kandelaki, E 3304 PO 3-3<br />
Kandelaki, E 3310 PO 3-3<br />
Kandelaki, E 3314 PO 3-3<br />
Kandelaki, E 3321 PO 3-3<br />
Kang, H 1314 PO 1-3<br />
Kapalczynski, W 1400 PO 1-4<br />
Kartasasmita, iV, CB 3319 PO 3-3<br />
Kartasasmita, CB 1327 PO 1-3<br />
Kashwani , m 1215 PO 1-2<br />
Katsuhito, i 3102 PO 3-1<br />
Katsunuma, t 3102 PO 3-1<br />
Kausar, mA 1106 PO 1-1<br />
Kavlashvili, n 3304 PO 3-3<br />
Kavlashvili, n 3310 PO 3-3<br />
Kavlashvili, n 3314 PO 3-3<br />
Kavlashvili, n 3321 PO 3-3<br />
Kawano, Y 2207 PO 2-2<br />
Kemper, C 3108 PO 3-1<br />
Kentaro, m 3308 PO 3-3<br />
Khare, m 1325 PO 1-3<br />
Kherkheulidze, m 3304 PO 3-3<br />
Kherkheulidze, m 3310 PO 3-3<br />
Kherkheulidze, m 3314 PO 3-3<br />
Kherkheulidze, m 3321 PO 3-3<br />
Khouqeer, r 1105 PO 1-1<br />
Khoury, A 1100 PO 1-1<br />
Khoury, A 3200 PO 3-2<br />
Khoury, A 1205 PO 1-2<br />
Kim, D 1107 PO 1-1<br />
Kim, HH 3113 PO 3-1<br />
Kim, J 1102 PO 1-1<br />
Kim, J 1104 PO 1-1<br />
Kim, Jt 3113 PO 3-1<br />
Kim, JY 1110 PO 1-1<br />
Kim, J 1102 PO 1-1<br />
Kim, J 1104 PO 1-1<br />
Kim, J 2103 PO 2-1<br />
Kim, K 1107 PO 1-1<br />
Kim, K 1315 PO 1-3<br />
Kim, m 3316 PO 3-3<br />
Kim, s 1314 PO 1-3<br />
Kim, s 1218 PO 1-2<br />
Kim, s 1114 PO 1-1<br />
Kim, s 1314 PO 1-3<br />
Kim, s 1218 PO 1-2<br />
Kim, s 1102 PO 1-1<br />
Kim, s 1314 PO 1-3<br />
Kim, s 3312 PO 3-3<br />
Kim, t 2102 PO 2-1<br />
Kim, t 3206 PO 3-2<br />
Kim, t 1314 PO 1-3<br />
Kim, t 1316 PO 1-3<br />
Kim, t 1218 PO 1-2<br />
Kim, t 1314 PO 1-3<br />
Kim, WK 3103 PO 3-1<br />
Kim, Y 1107 PO 1-1<br />
www.worldallergy.org 166<br />
FinAl PrOgrAm
POstEr AUtHOr inDEX<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
author Poster # Session author Poster # Session author Poster # Session<br />
Kimura, s 1412 PO 1-4<br />
Kirovski, i 3320 PO 3-3<br />
Kleiner, m 1413 PO 1-4<br />
Knowles, V 1211 PO 1-2<br />
Kondo, n 3309 PO 3-3<br />
Kose, s 2104 PO 2-1<br />
Kostanyan, lV 3307 PO 3-3<br />
Kovacevic, sP 3315 PO 3-3<br />
Krzych-Falta, Jr., E 1400 PO 1-4<br />
Kumar, P 3101 PO 3-1<br />
Kurbacheva, Om 1202 PO 1-2<br />
Kuswandewi, m 3319 PO 3-3<br />
lammardo, Am 2209 PO 2-2<br />
laoudi, Y 3313 PO 3-3<br />
lara, P 2206 PO 2-2<br />
lara de la rosa, P 2205 PO 2-2<br />
latysheva, EA 1202 PO 1-2<br />
ledford, D 2305 PO 2-3<br />
lee, B 1220 PO 1-2<br />
lee, sr., JH 3209 PO 3-2<br />
lee, J 1220 PO 1-2<br />
lee, Js 3113 PO 3-1<br />
lee, K 3312 PO 3-3<br />
lee, mK 1114 PO 1-1<br />
lee, sJ 1114 PO 1-1<br />
lee, sn 1114 PO 1-1<br />
lee, s 1314 PO 1-3<br />
lee, t 2102 PO 2-1<br />
lee, WY 1114 PO 1-1<br />
lee, Y 1314 PO 1-3<br />
lee, Ys 2102 PO 2-1<br />
lee, Ys 1316 PO 1-3<br />
levy, r 2308 PO 2-3<br />
levy, r 2309 PO 2-3<br />
levy, r 2311 PO 2-3<br />
levy, r 2312 PO 2-3<br />
li, HH 2309 PO 2-3<br />
li, r 2108 PO 2-1<br />
limonta, A 1204 PO 1-2<br />
lin, JB 3104 PO 3-1<br />
liu, Ps 3104 PO 3-1<br />
lockey, rF 2305 PO 2-3<br />
lumry, W 2308 PO 2-3<br />
lumry, W 2309 PO 2-3<br />
lumry, W 2310 PO 2-3<br />
lusawa, A 1400 PO 1-4<br />
mahboub, B 1303 PO 1-3<br />
mahboub, B 1200 PO 1-2<br />
mahboub, B 3100 PO 3-1<br />
maherbanai, s 3207 PO 3-2<br />
mahinic, A 3302 PO 3-3<br />
mahinic, A 3303 PO 3-3<br />
maietta, g 3208 PO 3-2<br />
maio, s 1309 PO 1-3<br />
maio, s 1312 PO 1-3<br />
majangsari, rgD 2109 PO 2-1<br />
majangsari, rgD 1117 PO 1-1<br />
majd, A 1113 PO 1-1<br />
makrilia, n 2202 PO 2-2<br />
mandelli, m 2209 PO 2-2<br />
manning , m 2310 PO 2-3<br />
manolopoulos, l 2202 PO 2-2<br />
manzano, D 2306 PO 2-3<br />
marone, g 2208 PO 2-2<br />
martín, E 2206 PO 2-2<br />
martín Casáñez, E 2205 PO 2-2<br />
martínez, D 2206 PO 2-2<br />
martínez, n 2206 PO 2-2<br />
martínez Bohigas, D 2205 PO 2-2<br />
martínez Borque, n 2205 PO 2-2<br />
martini, F 1309 PO 1-3<br />
martini, F 1312 PO 1-3<br />
mascarenhas, l 1211 PO 1-2<br />
masumoto, A 1206 PO 1-2<br />
matsui, E 3309 PO 3-3<br />
matsumoto, K 3102 PO 3-1<br />
mazer, B 2108 PO 2-1<br />
mcgarry, K 1317 PO 1-3<br />
meltzer, EO 1409 PO 1-4<br />
merrawi, m 1100 PO 1-1<br />
micevska, V 3320 PO 3-3<br />
mikami, K 2207 PO 2-2<br />
min, K 1314 PO 1-3<br />
miokovic, m 3302 PO 3-3<br />
mita, H 1305 PO 1-3<br />
mitsui, C 1305 PO 1-3<br />
mn, J 1325 PO 1-3<br />
moatari, A 3111 PO 3-1<br />
moghiman, t 2301 PO 2-3<br />
mohamed, n 1200 PO 1-2<br />
mohamed, r 1200 PO 1-2<br />
mohd Ashari, ns 1401 PO 1-4<br />
mohd Ashari, ns 2100 PO 2-1<br />
momas, i 3313 PO 3-3<br />
montenegro, Fg 1324 PO 1-3<br />
montenegro, Fg 1217 PO 1-2<br />
monterrey, C 1120 PO 1-1<br />
moon, H 2102 PO 2-1<br />
moon, H 1314 PO 1-3<br />
moon, H 1316 PO 1-3<br />
moon, H 1218 PO 1-2<br />
moon, K 1316 PO 1-3<br />
mori, A 1305 PO 1-3<br />
mori, s 1412 PO 1-4<br />
mousavi, t 1402 PO 1-4<br />
mutyara, K 1327 PO 1-3<br />
mösges, r 1413 PO 1-4<br />
n, s 1411 PO 1-4<br />
n, s 1221 PO 1-2<br />
n r, rm 1307 PO 1-3<br />
n r, rm 1108 PO 1-1<br />
nabavi, m 2218 PO 2-2<br />
nabavi, m 3207 PO 3-2<br />
nagaraju, mK 1411 PO 1-4<br />
nagaraju, mK 1221 PO 1-2<br />
nagata, m 1206 PO 1-2<br />
nageotte, C 1302 PO 1-3<br />
nahm, D 3206 PO 3-2<br />
nahm, D 1218 PO 1-2<br />
naime, m 3112 PO 3-1<br />
naime, m 2215 PO 2-2<br />
nakagome, K 1206 PO 1-2<br />
nam, JH 3103 PO 3-1<br />
napiórkowska, K 2210 PO 2-2<br />
napiórkowska, K 2211 PO 2-2<br />
narita, m 3306 PO 3-3<br />
neerupudi, KB 3109 PO 3-1<br />
nemeth, Z 3110 PO 3-1<br />
neshat, l 1317 PO 1-3<br />
neumann, U 3212 PO 3-2<br />
niazi, E 3324 PO 3-3<br />
niimi, A 3309 PO 3-3<br />
nikasinovic, l 3313 PO 3-3<br />
nikolovski, l 3320 PO 3-3<br />
nirsen, g 1120 PO 1-1<br />
nishihara, F 1206 PO 1-2<br />
noh, g 3209 PO 3-2<br />
noma, t 2207 PO 2-2<br />
nomura, i 3306 PO 3-3<br />
norifumi, O 3308 PO 3-3<br />
norifumi, O 3308 PO 3-3<br />
nsouli, s 1410 PO 1-4<br />
nsouli, s 3105 PO 3-1<br />
nsouli, s 3106 PO 3-1<br />
nuradi, i 3319 PO 3-3<br />
nurmatov, U 2201 PO 2-2<br />
nurpeisov , t 2106 PO 2-1<br />
nurpeisov , t 2107 PO 2-1<br />
Ogawa, n 2207 PO 2-2<br />
Ogawa, n 2207 PO 2-2<br />
Oguma, t 3309 PO 3-3<br />
Ohri, m 1325 PO 1-3<br />
Ohya, Y 3306 PO 3-3<br />
Olivares, m 2216 PO 2-2<br />
Omerovic, m 3303 PO 3-3<br />
Ono, E 1305 PO 1-3<br />
Oricchio, C 2208 PO 2-2<br />
Oshiba, H 2207 PO 2-2<br />
Othman, r 1326 PO 1-3<br />
Ownby, D 1302 PO 1-3<br />
Palmieri, m 2208 PO 2-2<br />
Palomeque, sr., mt 2205 PO 2-2<br />
Palomeque, mt 2206 PO 2-2<br />
Panicker, r 1304 PO 1-3<br />
Paraskevopoulos, g 2303 PO 2-3<br />
Paraskevopoulos, J 2302 PO 2-3<br />
Parasuramalu, Bg 1307 PO 1-3<br />
Park, Cs 1316 PO 1-3<br />
Park, H 1102 PO 1-1<br />
Park, H 1104 PO 1-1<br />
Park, H 3312 PO 3-3<br />
Park, H 1314 PO 1-3<br />
Park, H 1218 PO 1-2<br />
Park, J 1107 PO 1-1<br />
Park, J 1110 PO 1-1<br />
Park, J 3206 PO 3-2<br />
Park, J 1314 PO 1-3<br />
Park, J 1218 PO 1-2<br />
Park, sW 1314 PO 1-3<br />
Park, sW 1218 PO 1-2<br />
Patella, V 2208 PO 2-2<br />
Pauk, n 2101 PO 2-1<br />
Pavlovic, V 3302 PO 3-3<br />
Pawankar, r 1303 PO 1-3<br />
Pawankar, r 1412 PO 1-4<br />
Petrushkina, n 3317 PO 3-3<br />
Petrushkina, ii, n 3318 PO 3-3<br />
Piegaia, B 1309 PO 1-3<br />
Pinnock, H 1210 PO 1-2<br />
Politi, K 2202 PO 2-2<br />
Popova, O 2106 PO 2-1<br />
Popova, O 2107 PO 2-1<br />
www.worldallergy.org 167<br />
FinAl PrOgrAm
POstEr AUtHOr inDEX<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
author Poster # Session author Poster # Session author Poster # Session<br />
Pourpak, Z 1113 PO 1-1<br />
Prakash rao, m 1207 PO 1-2<br />
Pratt, C 1112 PO 1-1<br />
Price, D 1210 PO 1-2<br />
Price, D 1211 PO 1-2<br />
Price, D 1212 PO 1-2<br />
Price, D 1319 PO 1-3<br />
Price, D 1213 PO 1-2<br />
Psarros, P 2302 PO 2-3<br />
Psarros, P 2303 PO 2-3<br />
r, D 1221 PO 1-2<br />
r, g 1411 PO 1-4<br />
r, g 1221 PO 1-2<br />
r, iii, m 1411 PO 1-4<br />
rafique, m 1303 PO 1-3<br />
rafique, m 3100 PO 3-1<br />
raj, s 1301 PO 1-3<br />
ramirez, r 2216 PO 2-2<br />
randa, O 1215 PO 1-2<br />
reddy, rrK 3109 PO 3-1<br />
rengganis, i 1115 PO 1-1<br />
restrepo, m 2216 PO 2-2<br />
restrepo, m 2307 PO 2-3<br />
restrepo, m 2217 PO 2-2<br />
restrepo, m 2110 PO 2-1<br />
rezaei, n 1402 PO 1-4<br />
rha, YH 3316 PO 3-3<br />
ribeiro, m 1306 PO 1-3<br />
riedl , m 2308 PO 2-3<br />
riedl , m 2309 PO 2-3<br />
riedl , m 2311 PO 2-3<br />
riedl , m 2312 PO 2-3<br />
rodríguez-<br />
Domínguez, sr., B 2306 PO 2-3<br />
roedland, EA 1313 PO 1-3<br />
roh, s 1107 PO 1-1<br />
rojek, B 1400 PO 1-4<br />
romano, A 2212 PO 2-2<br />
roongrotwattanasiri,<br />
K 1412 PO 1-4<br />
rosifah, D 2109 PO 2-1<br />
ruiz Hornillos, F 2306 PO 2-3<br />
rumi, g 2212 PO 2-2<br />
ryan, D 1210 PO 1-2<br />
s P, PK 1307 PO 1-3<br />
s P, PK 1108 PO 1-1<br />
sA.madani, A 2300 PO 2-3<br />
saad, s 2213 PO 2-2<br />
saadeh, C 1109 PO 1-1<br />
sabry, EY 1300 PO 1-3<br />
saeki, t 2207 PO 2-2<br />
sah, s 1401 PO 1-4<br />
saha, gK 1103 PO 1-1<br />
ahin, F 1214 PO 1-2<br />
sahraoui, F 3313 PO 3-3<br />
saito, H 3102 PO 3-1<br />
salekmoghadam, A 1402 PO 1-4<br />
salvatici, E 2209 PO 2-2<br />
sam, rA 3109 PO 3-1<br />
sami, As 1405 PO 1-4<br />
sami, As 1406 PO 1-4<br />
sami, As 3305 PO 3-3<br />
samoliñski, B 1400 PO 1-4<br />
sanchez, J 2307 PO 2-3<br />
sanchez, J 2217 PO 2-2<br />
sanchez, J 2110 PO 2-1<br />
sapartini, g 2109 PO 2-1<br />
sapartini, g 1117 PO 1-1<br />
sapartini, g 1327 PO 1-3<br />
saptaputra, W 1117 PO 1-1<br />
saptaputra, W 3319 PO 3-3<br />
saptaputra, W 1327 PO 1-3<br />
saranac, lm 3315 PO 3-3<br />
sarno, g 1309 PO 1-3<br />
sarno, g 1312 PO 1-3<br />
sawas, K 3200 PO 3-2<br />
sazdovski, A 3320 PO 3-3<br />
schiavino, D 1119 PO 1-1<br />
schnitker, J 3212 PO 3-2<br />
seçik, F 1214 PO 1-2<br />
seckova, l 3320 PO 3-3<br />
sekiya, K 1305 PO 1-3<br />
selimovic, A 3302 PO 3-3<br />
selimovic, A 3303 PO 3-3<br />
senevirathne, K 1328 PO 1-3<br />
sepiashvili, ri 1311 PO 1-3<br />
sepiashvili, ri 1111 PO 1-1<br />
setiabudiawan, B 2109 PO 2-1<br />
setiabudiawan, B 1117 PO 1-1<br />
setiabudiawan, B 1327 PO 1-3<br />
shah, r 1301 PO 1-3<br />
shah, s 1209 PO 1-2<br />
shamssain, m 1317 PO 1-3<br />
shamssain, m 1318 PO 1-3<br />
sharef, sW 1116 PO 1-1<br />
shehab, A 2213 PO 2-2<br />
sheikh, A 2201 PO 2-2<br />
shin, KC 1114 PO 1-1<br />
shin, s 3312 PO 3-3<br />
shoda, t 3306 PO 3-3<br />
siddiqui, W 1106 PO 1-1<br />
silva, nA 1120 PO 1-1<br />
silvi, P 1309 PO 1-3<br />
simoes, EA 3319 PO 3-3<br />
simoes, EA 1327 PO 1-3<br />
simone, P 3204 PO 3-2<br />
simone, P 3205 PO 3-2<br />
simoni, m 1309 PO 1-3<br />
sims, EJ 1211 PO 1-2<br />
sinaniotis, A 2302 PO 2-3<br />
sinaniotis, A 2303 PO 2-3<br />
siribaddana, A 1328 PO 1-3<br />
slavyanskaya, tA 1311 PO 1-3<br />
sliem, H 1219 PO 1-2<br />
sofia, m 3112 PO 3-1<br />
sofia, m 2215 PO 2-2<br />
soto, g 2206 PO 2-2<br />
soto Vargas, g 2205 PO 2-2<br />
sporisevic, l 3302 PO 3-3<br />
sporisevic, l 3303 PO 3-3<br />
sudarwati, s 3319 PO 3-3<br />
sulaiman, n 1303 PO 1-3<br />
suljevic, i 3302 PO 3-3<br />
suljevic, i 3303 PO 3-3<br />
sus-Carrizosa, s 2216 PO 2-2<br />
suwardi, AU 3319 PO 3-3<br />
syrigos, Kn 2202 PO 2-2<br />
syrigou, E 2202 PO 2-2<br />
syrigou, E 2302 PO 2-3<br />
syrigou, E 2303 PO 2-3<br />
szalai, C 3110 PO 3-1<br />
takaku, Y 1206 PO 1-2<br />
takeshi, n 3308 PO 3-3<br />
takzare, A 3323 PO 3-3<br />
takzare, n 3323 PO 3-3<br />
takzaree, A 3322 PO 3-3<br />
takzaree, n 3322 PO 3-3<br />
tamayo, l 2307 PO 2-3<br />
taniguchi, m 1305 PO 1-3<br />
tanimoto, H 1305 PO 1-3<br />
thomas, m 1210 PO 1-2<br />
tillotson, g 2308 PO 2-3<br />
tillotson, g 2309 PO 2-3<br />
tillotson, g 2310 PO 2-3<br />
tillotson, g 2311 PO 2-3<br />
tillotson, g 2312 PO 2-3<br />
tn, B 1325 PO 1-3<br />
tomikawa, m 3309 PO 3-3<br />
torrecillas, m 2205 PO 2-2<br />
torrecillas, sr., m 2206 PO 2-2<br />
tort, m 1408 PO 1-4<br />
toshiaki, s 3308 PO 3-3<br />
tsai, CJ 3104 PO 3-1<br />
tsuburai, t 1305 PO 1-3<br />
tsumura, Y 3306 PO 3-3<br />
Uknis, m 2308 PO 2-3<br />
Uknis, m 2309 PO 2-3<br />
Uknis, m 2310 PO 2-3<br />
Uknis, m 2311 PO 2-3<br />
Uknis, m 2312 PO 2-3<br />
Ungvari, i 3110 PO 3-1<br />
Vafa, A 1208 PO 1-2<br />
Valluzzi, rl 2212 PO 2-2<br />
Varasteh, A 1402 PO 1-4<br />
Vatanchian, m 1113 PO 1-1<br />
Vazquez tello, A 1323 PO 1-3<br />
Vazquez tello, A 2108 PO 2-1<br />
Vegh, A 2309 PO 2-3<br />
Vermani, m 1106 PO 1-1<br />
Viegi, g 1309 PO 1-3<br />
Viegi, g 1312 PO 1-3<br />
Vijayan, V 1106 PO 1-1<br />
Villano, s 2308 PO 2-3<br />
Villano, s 2309 PO 2-3<br />
Villano, s 2310 PO 2-3<br />
Villano, s 2311 PO 2-3<br />
Villano, s 2312 PO 2-3<br />
Viola, m 2212 PO 2-2<br />
Virag, V 3110 PO 3-1<br />
Virchow, C 1319 PO 1-3<br />
Vranic, B 3303 PO 3-3<br />
Wah, WZ 2100 PO 2-1<br />
Wang, DY 1407 PO 1-4<br />
Wanigasekara, PC 1328 PO 1-3<br />
Wegienka, g 1302 PO 1-3<br />
White, m 2308 PO 2-3<br />
White, m 2309 PO 2-3<br />
Wilson, ms 3107 PO 3-1<br />
Wm, Wm 1401 PO 1-4<br />
Wolf, H 3212 PO 3-2<br />
Wong, Hg 2200 PO 2-2<br />
Wuestenberg, Eg 3212 PO 3-2<br />
www.worldallergy.org 168<br />
FinAl PrOgrAm
POstEr AUtHOr inDEX<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
author Poster # Session author Poster # Session author Poster # Session<br />
Wulandari, DA 3319 PO 3-3<br />
Y, nK 1401 PO 1-4<br />
Yıldırım, E 1214 PO 1-2<br />
Yıldız, P 1214 PO 1-2<br />
Yagi, t 1412 PO 1-4<br />
Yamaguchi, t 1206 PO 1-2<br />
Yamamoto, K 3306 PO 3-3<br />
Yavas, s 2104 PO 2-1<br />
Ye, Y 1102 PO 1-1<br />
Ye, Y 1104 PO 1-1<br />
Ye, Y 3312 PO 3-3<br />
Yong, sJ 1114 PO 1-1<br />
Yoon, HJ 1314 PO 1-3<br />
Yoon, HJ 1218 PO 1-2<br />
Yoon, J 3113 PO 3-1<br />
Yoshida, K 3306 PO 3-3<br />
Yun, is 1110 PO 1-1<br />
Yutaka, K 3308 PO 3-3<br />
Zaharov, t 2304 PO 2-3<br />
Zakharyan, A 3307 PO 3-3<br />
Zhang, H 2105 PO 2-1<br />
Zhu, X 2105 PO 2-1<br />
Zidoune, mn 2214 PO 2-2<br />
Zivanovic, ss 3315 PO 3-3<br />
Zoratti, E 1302 PO 1-3<br />
Zuraw, B 2308 PO 2-3<br />
Zuraw, B 2309 PO 2-3<br />
Zuvadelli, J 2209 PO 2-2<br />
www.worldallergy.org 169<br />
FinAl PrOgrAm
nOtEs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
www.worldallergy.org 170<br />
FinAl PrOgrAm
nOtEs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
www.worldallergy.org 171<br />
FinAl PrOgrAm
nOtEs<br />
WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE<br />
Asthma and Co-morbid Conditions: Expanding the Practice of <strong>Allergy</strong> for Optimal Patient Care<br />
www.worldallergy.org 172<br />
FinAl PrOgrAm
Q411-10<br />
Allergic disease is a growing health issue in the world<br />
today compounded by environmental and socioeconomic<br />
problems and medical management.<br />
The <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> Journal (WAO<br />
Journal)—the official publication of the <strong>World</strong><br />
<strong>Allergy</strong> <strong>Organization</strong>, the only global umbrella<br />
organization for national and regional allergology<br />
and clinical immunology societies—provides a<br />
dynamic platform for the exchange of ideas and<br />
knowledge among researchers and practitioners<br />
from different regions of the world.<br />
<strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong> Journal TM<br />
Official publication of the <strong>World</strong> <strong>Allergy</strong> <strong>Organization</strong><br />
A Forum for Global<br />
Scientific Interactions<br />
Keep up with new advances in allergy, asthma and clinical immunology worldwide.<br />
EDITOR-IN-CHIEF<br />
Lanny J. Rosenwasser, MD<br />
Dee Lyons/Missouri Endowed Chair in<br />
Pediatric Immunology Research<br />
Professor of Pediatrics,<br />
<strong>Allergy</strong>-Immunology Division<br />
Children’s Mercy Hospital<br />
Professor of Pediatrics, Medicine<br />
and Basic Science<br />
University of Missouri-Kansas City<br />
School of Medicine<br />
Monthly ISSN: 1939-4551<br />
Free access for members of current WAO Member Societies<br />
Go to www.<strong>World</strong><strong>Allergy</strong>.org. Click “Members Only” then “WAO Journal”<br />
Not a WAO member? Visit us at www.WAOJournal.org<br />
www.WAOJournal.org<br />
Visit www.WAOJournal.org and…<br />
✔ Examine new information that extends our<br />
understanding of pathogenesis and disease<br />
function<br />
✔ Learn new approaches for evaluation of disease<br />
and outcomes concerning treatments and<br />
interventions<br />
✔ Publish clinical reviews and editorials on basic<br />
and clinical translational science in allergy and<br />
clinical immunology<br />
✔ Sign up for eAlerts and receive the linked table<br />
of contents as soon as a new issue is posted<br />
Encompassing both translational research and<br />
clinical issues, the WAO Journal is dedicated to<br />
providing quality, up-to-date science to its readers,<br />
and a quick production schedule and worldwide<br />
recognition for its contributors.
DiAmOnD sPOnsOrs<br />
PlAtinUm sPOnsOrs<br />
gOlD sPOnsOr<br />
COllABOrAting PArtnErs<br />
sUPPOrting PArtnErs<br />
SMALL AIRWAYS<br />
WORKING GROUP<br />
sUPPOrting gOVErnmEnt PArtnErs<br />
Merck Sharp & Dohme (Italia) S.p.A.<br />
Via G. Fabbroni, 6 00191 Roma<br />
www.msd-italia.it www.univadis.it info@univadis.it<br />
Realizzato con il supporto non condizionato di Merck Sharp & Dohme (Italia) S.p.A.<br />
<strong>World</strong> allergy organization<br />
555 East Wells street, suite 1100 • milwaukee, Wi 53202 UsA<br />
Phone: +1 414 276 1791 • Fax: +1 414 276 3349<br />
WAO-1010-344
2010 WAO IntErnAtIOnAl ScIEntIfIc cOnfErEncE <strong>Final</strong> Program